Metabolic alterations in prostate cancer pathogenesis by Arruabarrena Aristorena, Amaia
 Metabolic Alterations in Prostate 
Cancer Pathogenesis
Doctoral Thesis
2016
Amaia Arruabarrena-Aristorena
Director: Arkaitz Carracedo Pérez
Metabolic Alterations in Prostate 
Cancer Pathogenesis 
Doctoral Thesis 
Amaia Arruabarrena Aristorena 
2016 
Supported by: 
Report of the experimental work to apply for the grade of Doctor in 
Biological Sciences, into the Doctorate Programme of Molecular 
Biology and Biomedicine of the University of the Basque Country, The 
work herein has been performed by Amaia Arruabarrena Aristorena 
at the Center for Cooperative Research in Biosciences (CIC 
bioGUNE) under the mentorship of Dr. Arkaitz Carracedo Pérez. 
(c)2016 AMAIA ARRUABARRENA ARISTORENA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
"Lo que sabemos es una gota, 
 lo que ignoramos un inmenso océano" 
(Isaac Newton) 
 
 
 
 
 
 
 
 
 
 
 
Zuei aita ta ama, 
Zuri bruja, 
Zuri poxoki,  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
 
 
 
 
 
-Dox: non-induced 
+ Dox: induced with doxycycline 
µg: microgram 
µM: microMolar 
1,3-DAP: 1,3-diaminopropane  
1C: one carbon  
3PG: 3-phosphoglycerate  
4E-BP: Eukaryotic Translation Initiation 
Factor 4E-binding Protein  
a.u.: arbitrary units 
aa: amino acid 
AAALAC: Association for Assessment and 
Accreditation of Laboratory Animal Care 
International 
ABC: Avidin/Biotin Complex 
ABD: ATP-binding cassette  
ACF: Aberrant Crypt Foci  
ACN: Acetonitrile  
AD: Alzheimer´s disease  
AGC: cAMP-dependent, cGMP-dependent 
and protein kinase C protein kinase family 
AKT: Protein Kinase B, PKB 
AMD1/Amd1: Human/Murine S-
adenosylmethionine decarboxylase  
Amp: Ampicillin 
AP: Anterior Prostate 
APAO: Acetylpolyamine Oxidase  
APC: Adenomatous Polyposis Coli  
AR: Androgen Receptor  
Arg, R: Arginine 
ATCC: American Type Culture Collection 
Atg13: Autophagy-related protein 13 
ATG5: Autophagy related 5 homolog 
ATG7: Autophagy related 7 
ATM: Ataxia telangiectasia mutated protein 
kinase 
ATP: Adenosine Triphosphate 
AZ: antizyme  
AZi: antizyme inhibitor 
BAD: Bcl-2-associated death promoter 
protein 
BCAA: Branched Chain Amino Acids  
BCKA: Branched Chain Ketoacids  
bHLH-LZ: basic Helix-Loop-Helix-Leucine 
Zipper  
Bhmt: Betaine-homocysteine S-
methyltransferase  
BIOEF: Basque biobank for research  
BPE: Bovine Pituitary Extract  
BPH: Benign Prostatic Hyperplasia 
BRRS: Bannayan-Riley-Ruvalcaba 
syndrome  
Cad: Cadaverine  
CAD: Carbamoyl-Phosphate Synthetase 2 
CBS/Cbs: Human/Murine Cystathionine β 
Synthase  
CDK-4: Cyclin-dependent kinase 4 
cDNA: complementary DNA  
CEIC: Clinical Research Ethics Committee 
Chow: regular diet 
CHX: Cyclohexamide  
CI: Confidence Interval 
CID:Collision Induced Dissociation 
c-MYC: Myc proto-oncogene protein 
Cre: recombinase  
CRPC: Castration-Resistant Prostate 
Cancer  
CS: Cowden syndrome 
Cth: Murine Cystathionase 
Cys: Cysteine, C 
CZ: Central Zone 
dcSAM: decarboxylated S-
adenosylmethionine  
DEPTOR: DEP domain containing mTOR-
interacting protein  
DFMO: α-difluoromethylornithine  
DG: Diglyceride  
DHS: Deoxyhypusine Synthase  
DLP: Dorso-Lateral Prostate 
Abbreviations 
 
 
 
 
 
DMSO: Dimethyl Sulfoxide 
DNA: Desoxyribonucleic Acid  
DOHH: Deoxyhypusine Hydroxylase  
DRE: Digital Rectal Examination  
DTT: Dithiothreitol 
DU145MYC-AMD1-HA WT: DU145 cells 
overexpressing AMD1 fused to HA and 
myctags 
EGF 1-53: Epidermal Growth Factor 1-53 
EGFR: Epidermal Growth Factor Receptor 
eIF2α: eukaryotic translation initiation factor 
2 complex 
eIF4G: eukaryotic Initiation Factor 4G 
eIF5A: eukaryotic translation initiation 
factor 5A  
EMT: Epithelial-Mesenchymal Transition 
ES: Embryonic Stem  
ETBF: enterotoxigenic Bacteroidesfragilis 
ETC: Electron Transport Chain 
FA: Formaldehyde 
FAD: Flavin Adenine Dinucleotide  
FAO: Fatty Acid Oxidation 
FAP: Familial Adenomatous Polyposis  
FAT: FRAP (FKBP12–rapamycin-
associated protein)-ATM (ataxia 
telangiectasia mutated)-TRRAP 
FATC: C terminus of FRAP-ATM-
TRRAPcomplex 
FBS : Fetal Bovine Serum  
FDR: False Discovery Rate 
FI-ToF-MS: Flow Injection-Time-of-Flight 
Mass Spectrometry  
FKBP12: Peptidyl-prolyl cis-trans 
isomerase FKBP12 
flox: loxP recognition sequences  
FOXO: Forkhead Box Family of 
Transcription Factors  
FRAP: Fluorescence recovery after 
photobleaching 
FRB: FKBP12-rapamycin binding  
GEMM: Genetic Engineered Mouse Model  
GlcNAc: N-acetylglucosamine  
GLDC: Glycine decarboxylase 
Gln: glutamine, Q  
Glu: Glutamate, E 
Gly: Glycine, G 
Gnmt -/-: Whole body Gnmt knockout 
GNMT/Gnmt: Human/Murine Glycine N-
methyltransferase  
Gnmt+/+: Whole body Gnmt wild-type 
GPCR: G-protein-coupled receptor 
GSK3: Glycogen Synthase Kinase 3  
H&E: Haematoxylin and Eosin  
h: hour 
H2O2: Hydrogen Peroxide 
HBP: Hexosamine Biosynthetic Pathway  
HBS: HEPES-Buffered Solution 
HCC: Hepatocellular Carcinoma  
HCys: Homocysteine  
HEPES: 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
HGPIN: High Grade Prostatic Intraepithelial 
Neoplasia 
HPLC: High-Performance Liquid 
Chromatography 
H-Ras: GTPase HRas 
IARC:  International Agency for Research 
in Cancer 
IGF-1R: Insulin-like growth factor 1 receptor 
IHC: Immunohistochemistry 
Ile: Isoleucine, I 
INPP4B: Inositol Polyphosphate 4-
phosphatase type II  
IPA: Ingenuity Pathway Analysis  
IRES: Internal Ribosome Entry Sites 
IRS1: Insulin Receptor Substrate 1  
JNK: c-Jun N-terminal kinase 
KDa: Kilodalton 
KFSD: Keratosis Follicularis Spinulosa 
Decalvans  
Abbreviations 
 
 
 
 
 
Kg: kilogram 
Km: Michaelis constant 
KRAS: GTPase KRas 
LBE: LST8-bindingelement 
LC/MS: Liquid Chromatography / Mass 
Spectrometry  
LDD: Lhermitte-Duclos disease 
Leu: Leucine, L 
m/z: mass to charge ratio 
Mat2: Methionine adenosyltransferase II 
MAX: Protein max 
MDM2: Mouse Double Minute 2 homolog 
Met Def: methionine restricted 
Met: methionine, M 
MFA: Metabolic Flux Analysis  
mg: miligram 
MGBG: methylglyoxal-bis 
(guanylhydrazone)  
MK: MK2206 
mLST8: mammalian lethal with sec-13 
protein 8  
mM: milli Molar 
mm3: cubic milimeters 
Mo: Month 
Mock: empty vector 
mRNA: messenger RNA 
MS/Ms: Human/Murine Methionine 
Synthase  
mSin1: mammalian stress-activated map 
kinase-interacting protein 1  
MTA: Methylthioadenosine 
MTD: Maximum-Tolerated Dose  
m-THF: methyl-tetrahydrofolate  
Mthfr: Murine Methylenetetrahydrofolate 
reductase  
mTOR: Mechanistic Target of Rapamycin  
mTORC1: Mechanistic Target of 
Rapamycin Complex 1 
mTORC2: Mechanistic Target of 
Rapamycin Complex 2 
NAD: Nicotinamide Adenine Dinucleotide 
FC: Fold Change 
NADPH: Nicotinamide Adenine 
Dinucleotide Phosphate 
NAFLD: Non-alcoholic fatty liver disease 
NCI: National Cancer Institute 
NE: Neuroendocrine 
nM: nano Molar 
N-MYC: N-myc proto-oncogene protein 
NNMT: Nicotinamide N-Methyltransferase  
NP: Nanoparticle 
ODC1/Odc1: Human/Murine Ornithine 
Decarboxylase 1  
OGT: O-GlcNAc Tranferase  
ORF: Open Reading Frame  
OXPHOS: Oxidative Phosphorylation  
p21Cip1/WAF1: Cyclin-dependent kinase 
inhibitor 1 
p27Kip1: Cyclin-dependent kinase inhibitor 
p27 
p53: Tumor protein p53 
PA: Polyamine 
Paox: Murine Peroxisomal N1-Acetyl-
Spd/Spm Oxidase  
PB: Probasin  
PB-Cre: Probasin-Cre  
PC: Phosphatidylcholine  
PCa: Prostate Cancer 
PCR: Polymerase Chain Reaction 
PD: Parkinson´s disease  
PDK1: Phosphoinositide-dependent kinase 
1  
PDs: pharmacodynamics  
PDTX: Patient Derived Tumor Xenograft 
PE: Phosphatidylethanolamine 
PEG: Polyethylene glycol 
PEMT/Pemt: Human/Murine 
Phosphatidyletanolamine N 
methyltransferase  
PET: Positron Emission Tomography 
Abbreviations 
 
 
 
 
 
PFA: Paraformaldehide 
PH: Pleckstrin-homology 
PHTS: PTEN hamartoma tumor syndromes  
PI: Propidium Iodide 
PI3K: Phosphoinositide 3-kinase 
PICS: Pten-loss induced cellular 
senescence 
PIKK: PI3K-related kinase  
PIN: Prostatic Intraepithelial Neoplasia 
PIP2: Phosphatidylinositol-4,5-
bisphosphate, PI(4,5)P2 
PIP3: Phosphatidylinositol-3,4,5-
trisphosphate, PI(3,4,5)P3 
PKCα: Protein Kinase C-α 
PKR: IFN-induced double-stranded RNA-
dependent protein kinase 
PKs: pharmacokinetics  
PLP: Pyridoxal Phosphate 
PPARγ: Peroxisome Proliferator-activated 
Receptor gamma 
PPP: Pentose Phosphate Pathway  
PPRE: PPAR response element  
PRAS40: Proline-Rich AKT Substrate 40 
kDa  
PRE: Polyamine-responsive element 
proAMD1/proAmd1: Human/Murine AMD1 
proenzyme 
protor1/2: protein observed with rictor 1 
and 2  
PSA: Prostate-Specific Antigen  
PSVs: polyamine-sequestering vesicles  
Pten +/-: Pten heterozygosity, Pten 
heterozygousç 
PTEN C124S: catalytically inactive PTEN 
Pten Hy/-: hypomorphic Pten mutant 
Pten pc-/-: Pten prostate-specific knockout 
Pten pc+/+: Pten prostate-specific wild-type 
PTEN WT: PTEN wild-type 
PTEN: Phosphatase and tensin homolog  
Put: Putrescine  
PZ: Peripheral Zone 
RAD001: Everolimus  
RAFT: rapamycin and FKBP12 target  
Rapa, R: Rapamycin  
RAPTOR: Regulatory-associated protein of 
mammalian Target Of Rapamycin  
REDD1: Damage-inducible transcript 4 
protein (DDIT4) 
RICTOR: Rapamycin-insensitive 
Companion of mammalian Target Of 
Rapamycin  
RIPA: RadioImmunoPrecipitation Assay 
buffer 
RNA: Ribonucleic Acid  
ROS: Reactive Oxygen Species 
RP: Radical Prostatectomy 
RT: Retention Time  
RT: Room Temperature 
RTK: Receptor Tyrosine Kinase 
RT-QPCR: Real Time-Quantitative-
Polymerase Chain Reaction 
S6K: Ribosomal Protein S6 Kinase  
SAH: S-adenosylhomocysteine 
Sahh: Murine S-adenosylhomocysteine 
hydrolase  
SAM: S-adenosylmethionine 
SAM486A: (E)-2-(4-carbamimidoyl-2,3-
dihydro-1H-inden-1-ylidene) 
hydrazinecarboximidamide dihydrochloride 
Sardh: Sarcosine dehydrogenase  
SCD1: stearoyl-CoA desaturase 1  
Ser: Serine, S 
SGK1: Glucocorticoid-induced Protein 
Kinase 1  
SH2: Src-homology 2 
SHIP1: Src-homology 2 (SH2)-containing 
phosphatase 1 
SHIP2: Src-homology 2 (SH2)-containing 
phosphatase 2 
shRNA: short-hairpin RNA 
Abbreviations 
 
 
 
 
 
shSC: short-hairpin Scramble 
SLC: solute carrier  
Slc3a2: Murine Solute Carrier Family 3 
Member 2 
SMO: Spermine Oxidase 
SN: Supernatant 
SNP: Single-nucleotide Polymorphism  
Spd: Spermidine, N-(3-
aminopropyl)butane-1,4-diamine 
SpdS: Spermidine Synthase 
Spm: Spermine, N,N′-bis(3-
aminopropyl)butane-1,4-diamine 
SpmS: Spermine Synthase  
SRS: Snyder-Robinson syndrome  
SSAT1/Ssat1: Human/Murine 
Spermidine/spermine N1-acetyltransferase  
Std Er: Standard Error 
T: Torin-1 
TBS-T: Tris-Buffered Saline solution 
containing Tween-20 
TCA (solution): Trichloroacetic acid 
TCA: Tricarboxylic Acid Cycle  
TCEP: tris(2-carboxyethyl)phosphine  
TG: Triglyceride  
THF: Tetrahydrofolate  
Thr: Threonine, T 
TNM: Tumor, Node, Metastasis 
ToF-MS: Time-of-Flight Mass Spectrometry  
TRAMP: transgenic adenocarcinoma of the 
mouse prostate  
TRRAP: Transformation/Transcription 
Domain Associated Protein 
TSC2: Tuberous Sclerosis 2 Protein 
t-SSAT1: truncated SSAT1  
TURP: Trans-Urethral Resection of the 
Prostate  
TZ: Transition Zone 
ULK1/2: serine/threonine-protein kinase 
ULK1/2  
uORF: upstream Open Reading Frame 
UPLC-MS: Ultra-high Performance Liquid-
Cromatography coupled to Mass 
Spectrometry 
UPR: Unfolded Protein Response 
UTR: Untranslated Region  
V: Vehicle 
Val: Valine, V 
VP: Ventral Prostate 
WHO: World Health Organization 
WT: Wild-Type 
XIC: Extracted Ion Chromatogram 
 
 
 
  
 
 
Index 
 
 
 
SUMMARY ..................................................................................................................................... 37 
INTRODUCTION ............................................................................................................................ 37 
I CANCER ................................................................................................................................... 39 
I.1 CANCER HALLMARKS AND TUMOR PROGRESSION ........................................................................ 39 
II PROSTATE CANCER ............................................................................................................... 41 
II.1 HUMAN AND MURINE PROSTATE PHYSIOLOGY .......................................................................... 41 
II.2 PROSTATE CANCER PROGRESSION MODEL ................................................................................ 43 
II.3 PROSTATE CANCER PATHOLOGY AND TREATMENT ...................................................................... 44 
II.3.1 PROSTATE CANCER PATHOLOGY ................................................................................................. 44 
II.3.2 PROSTATE CANCER TREATMENT ................................................................................................. 46 
III PI3K PATHWAY AND CANCER .............................................................................................. 46 
III.1 PI3K PATHWAY ................................................................................................................ 46 
III.1.1 STRUCTURAL AND BIOCHEMICAL CHARACTERISTICS OF CLASS I PI3K ............................................... 46 
III.1.2 SIGNALING DOWNSTREAM CLASS I PI3K .................................................................................... 47 
III.1.3 KEY MEDIATORS DOWNSTREAM PI3K ........................................................................................ 48 
III.1.3.1 AKT.................................................................................................................................. 48 
III.1.3.2 mTOR .............................................................................................................................. 49 
III.1.3.3 PTEN ............................................................................................................................... 50 
III.2 PI3K PATHWAY DEREGULATION IN CANCER ............................................................................. 51 
III.3 GENETIC MODELS OF PTEN LOSS IN VIVO ................................................................................. 52 
III.3.1 GENETIC MODELS OF PTEN GERMLINE MUTATIONS ...................................................................... 53 
III.3.2 GENETIC MODELS OF PROSTATE-SPECIFIC PTEN DELETION ............................................................. 53 
IV METABOLIC DEREGULATION AND CANCER ...................................................................... 55 
IV.1 WARBURG EFFECT ............................................................................................................. 55 
IV.2 1C METABOLISM ............................................................................................................... 56 
IV.3 OTHER METABOLIC ALTERATIONS .......................................................................................... 56 
V POLYAMINES ........................................................................................................................... 57 
V.1 DEFINITION OF POLYAMINES ................................................................................................. 57 
V.2 POLYAMINE FUNCTIONS ....................................................................................................... 58 
V.2.1 REGULATION OF GENE EXPRESSION ............................................................................................ 58 
V.2.2 CONTROL OF CELL PROLIFERATION ............................................................................................. 58 
Index 
 
 
 
 
 
V.2.3 IMPLICATION IN CELLULAR STRESS ............................................................................................. 60 
V.3 POLYAMINE METABOLISM ................................................................................................... 60 
V.3.1 POLYAMINE SYNTHESIS ............................................................................................................ 60 
V.3.2 POLYAMINE CATABOLISM ........................................................................................................ 61 
V.3.3 POLYAMINE TRANSPORT .......................................................................................................... 62 
V.4 RATE LIMITING ENZYMES OF THE PATHWAY ............................................................................. 63 
V.4.1 ODC1 .................................................................................................................................. 63 
V.4.2 AMD1 ................................................................................................................................. 64 
V.4.2.1 AMD1 regulation ............................................................................................................ 65 
V.4.2.1.1 AMD1 processing ......................................................................................................... 65 
V.4.2.1.2 AMD1 transcription ..................................................................................................... 65 
V.4.2.1.3 AMD1 translation ........................................................................................................ 65 
V.4.2.1.4 AMD1 degradation ...................................................................................................... 66 
V.5 POLYAMINES AND DISEASE .................................................................................................. 67 
V.5.1 POLYAMINES AND CANCER ....................................................................................................... 68 
OBJECTIVES ................................................................................................................................ 72 
MATERIALS AND METHODS ...................................................................................................... 75 
I IN VIVO AND EX VIVO ASSAYS ............................................................................................. 77 
I.1 ANALYSIS OF TISSUE SAMPLES ................................................................................................ 77 
I.1.1 ANALYSIS OF MURINE SAMPLES .................................................................................................. 77 
I.1.1.1 Genetically engineered mouse models (GEMM) ............................................................. 77 
I.1.1.2 Xenograft models in nude mice ....................................................................................... 77 
I.1.1.2.1 AMD1 OE in vivo ........................................................................................................... 78 
I.1.1.2.2 AMD1 Silencing in vivo.................................................................................................. 78 
I.1.1.3 Preclinical trials ................................................................................................................ 78 
I.1.1.3.1 RAD001 treatment in vivo ............................................................................................. 78 
I.1.1.3.2 SAM486A treatment in vivo .......................................................................................... 79 
I.1.1.3.3 Methionine restriction in vivo....................................................................................... 79 
I.1.2 ANALYSIS OF HUMAN SPECIMENS ............................................................................................... 80 
I.2 METHODS ......................................................................................................................... 81 
I.2.1 GENOTYPING .......................................................................................................................... 81 
I.2.1.1 Genomic DNA purification from mouse tail .................................................................... 81 
I.2.1.2 Polymerase Chain Reaction (PCR) for genotyping ........................................................... 82 
I.2.2 PATHOLOGICAL ANALYSIS OF PROSTATE TISSUES ............................................................................ 83 
I.2.2.1 Tissue processing, paraffin embedding and sectioning ................................................... 83 
I.2.2.2 Slide processing for immunohistochemistry ................................................................... 83 
I.2.2.2.1 Haematoxylin and Eosin (H&E) staining ....................................................................... 84 
I.2.2.2.2 Ki67 and RpS6S235-236 staining ........................................................................................ 84 
I.2.2.2.3 AMD1 staining and scoring ........................................................................................... 84 
I.2.3 MOLECULAR ANALYSIS OF PROSTATE TISSUES ............................................................................... 85 
Index 
 
 
 
I.2.3.1 Gene expression analysis of murine prostate tissues ...................................................... 85 
I.2.3.2 Protein expression analysis of murine prostate tissues ................................................... 85 
I.2.4 METABOLOMIC ANALYSIS OF MURINE PROSTATE TISSUES ................................................................ 85 
I.2.4.1 Time of Flight-Mass Spectometry (ToF-MS) ..................................................................... 85 
I.2.4.2 Liquid Cromatography-Mass Spectometry (LC/MS) ......................................................... 86 
I.2.4.3 Targeted metabolomics by UPLC-MS ............................................................................... 86 
I.2.4.4 Metabolic Flux Analysis (MFA) ......................................................................................... 86 
II IN VITRO ASSAYS ................................................................................................................... 87 
II.1 MATERIALS ....................................................................................................................... 87 
II.1.1 CELL LINES AND CULTURE CONDITIONS ........................................................................................ 87 
II.1.2 DRUGS .................................................................................................................................. 88 
II.2 METHODS ......................................................................................................................... 89 
II.2.1 CLONING ............................................................................................................................... 89 
II.2.2 VIRUS PRODUCTION AND TARGET CELL LINE INFECTION .................................................................. 91 
II.2.2.1 Transient transfection in HEK293 cells ............................................................................ 92 
II.2.2.2 Lentivirus production and target cell-line infection ........................................................ 93 
II.2.2.2.1 Second Generation Lentivirus production ................................................................... 93 
II.2.2.2.2 Third Generation Lentivirus production ....................................................................... 94 
II.2.2.2.3 Constitutive Silencing of AMD1 .................................................................................... 96 
II.2.2.2.4 Inducible AMD1silencing .............................................................................................. 96 
II.2.2.3 Retrovirus production and target cell-line infection ....................................................... 96 
II.2.3 CELLULAR ANALYSIS ................................................................................................................. 98 
II.2.3.1 Cell-growth analysis by crystal violet staining ................................................................. 98 
II.2.3.2 Anchorage-independent growth (Soft agar) ................................................................... 98 
II.2.3.3 Foci formation assay........................................................................................................ 98 
II.2.3.4 DNA synthesis rate analysis by bromo deoxyurdine (BrdU) ........................................... 99 
II.2.3.4.1 BrdU Incorporation ...................................................................................................... 99 
II.2.3.4.2 BrdU exposure and detection by immunofluorescence (IF) ........................................ 99 
II.2.3.5 Cell cycle analysis ............................................................................................................ 99 
II.2.4 MOLECULAR ASSAYS ............................................................................................................. 100 
II.2.4.1 Gene expression analysis .............................................................................................. 100 
II.2.4.1.1 RNA extraction and retrotranscription ...................................................................... 100 
II.2.4.1.2 Real time quantitative PCR (RT-Q-PCR) ...................................................................... 100 
II.2.4.2 Protein expression analysis ........................................................................................... 101 
II.2.4.2.1 Protein extraction ....................................................................................................... 101 
II.2.4.2.2 Western Blotting (WB) ............................................................................................... 102 
II.2.4.2.3 Protein Immunoprecipitation (IP) Assay .................................................................... 102 
II.2.4.2.4 AMD1 translation rate by 35S-Met labelling ............................................................... 103 
II.2.4.2.5 Polysome Profiling ...................................................................................................... 103 
II.2.4.2.5.1 Sample extraction ................................................................................................... 104 
II.2.4.2.5.2 Sample processing ................................................................................................... 105 
II.2.4.2.6 Phosphoproteomics ................................................................................................... 105 
II.2.4.2.6.1 Sample Preparation ................................................................................................. 105 
Index 
 
 
 
 
 
II.2.4.2.6.2 LC-MS/MS analysis .................................................................................................. 106 
II.2.4.2.6.3 Data analysis ........................................................................................................... 106 
II.2.4.3 In-House targeted metabolomic approaches ............................................................... 107 
II.2.4.3.1 One carbon Metabolism and Polyamine Pathway analysis by LC/MS in vitro .......... 107 
II.2.4.3.2 dcSAM and polyamine quantification in vitro ........................................................... 107 
II.2.4.3.3 MFA in vitro ............................................................................................................... 107 
III STATISTICAL ANALYSIS...................................................................................................... 108 
RESULTS AND DISCUSSION .................................................................................................... 133 
I INTEGRATIVE METABOLIC STUDY TO UNCOVER METABOLIC ALTERATIONS 
UNDERLYING PROSTATE CANCER (PCA) ............................................................................. 111 
I.1.1 TOF-MS METABOLOMICS. ...................................................................................................... 114 
I.1.1.1 Tricarboxylic Acid Cycle (TCA) ........................................................................................ 115 
I.1.1.2 Amino Sugar Synthesis Pathway .................................................................................... 117 
I.1.1.3 Branched Chain Amino Acid (BCAA) Metabolism .......................................................... 117 
I.1.1.4 Serine, Glycine (Gly) and one-carbon (1C) Metabolism ................................................ 117 
I.1.2 LC/MS METABOLOMIC STUDY TO QUANTIFY METABOLIC ALTERATIONS IN PCA ................................ 121 
I.1.2.1 LC/MS metabolomics in murine samples ...................................................................... 121 
I.1.2.1.1 Branched chain amino-acid metabolism .................................................................... 121 
I.1.2.1.2 Urea cycle.................................................................................................................... 121 
I.1.2.1.3 Methionine cycle ........................................................................................................ 121 
I.1.2.1.4 Trans-sulphuration reactions ...................................................................................... 123 
I.1.2.1.5 Polyamine synthesis and catabolism pathways .......................................................... 123 
I.1.2.2 LC/MS metabolic study to validate GEMM findings in human prostate cancer specimens
 124 
I.1.3 IN VIVO13C-LABELED METHIONINE MFA .................................................................................... 127 
I.1.3.1 Pilot experiment of13C5 labeled metabolic flux analysis (MFA) to establish the 
experimental settings for in vivo analysis .................................................................................... 127 
I.1.3.2 In vivo 13C-labeled methionine MFA demonstrates the increased flux of methionine 
towards polyamine metabolism in PCa ....................................................................................... 128 
RESULTS AND DISCUSSION .................................................................................................... 133 
II ELUCIDATION OF THE MECHANISM OF ACTION UNDERLYING THE METABOLIC 
ALTERATIONS OBSERVED IN PCA ......................................................................................... 135 
II.1 EVALUATION OF TRANSCRIPTIONAL CHANGES AS DRIVERS OF THE POLYAMINE METABOLIC SWITCH .....135 
II.1.1 TRANSCRIPT ANALYSIS OF GENES WITHIN THE METHIONINE/POLYAMINE AND RELATED PATHWAYS .... 135 
II.1.1.1 Gene expression of polyamine metabolism-related enzymes ..................................... 135 
II.1.1.2 Gene expression of enzymes implicated in polyamine catabolism .............................. 136 
II.1.1.3 Gene expression of folate metabolism related enzymes ............................................. 138 
Index 
 
 
 
II.1.1.4 Gene expression of enzymes implicated in trans-sulphuration reactions .................... 138 
II.1.1.5 Gene expression of methionine metabolism related enzymes .................................... 138 
II.1.2 EVALUATION OF GNMT AS A CANDIDATE GENE TO MEDIATE THE METABOLIC SWITCH ...................... 139 
II.1.2.1 In vivo ............................................................................................................................ 139 
II.1.2.1.1 Gnmt-loss as a single event. ....................................................................................... 140 
II.1.2.1.2 Compound deletion of Pten and Gnmt ...................................................................... 141 
II.1.2.2 In vitro ........................................................................................................................... 143 
II.1.2.2.1 GNMT over-expression to characterize its role in PCa ............................................... 143 
II.2 EVALUATION OF POST-TRANSCRIPTIONAL CHANGES AS DRIVERS OF THE POLYAMINE METABOLIC SWITCH
 146 
II.2.1 ANALYSIS OF AMD1 PROTEIN LEVELS IN PTEN PC+/+ VS. PTEN PC-/-MICE ............................................. 146 
II.2.2 REGULATION OF AMD1 DOWNSTREAM PTEN .......................................................................... 147 
II.2.3 DECONSTRUCTION OF PI3K CASCADE BY PHARMACOLOGICAL INHIBITION ....................................... 148 
II.2.4 PRECLINICAL TRIAL OF RAD001 TO VALIDATE MTORC1 REGULATION OF AMD1 IN VIVO ................. 152 
II.2.5 MOLECULAR MECHANISM OF REGULATION OF AMD1 DOWNSTREAM MTORC1 ............................. 153 
II.2.5.1 Regulation through ODC1 upregulation and putrescine increase ................................ 154 
II.2.5.2 Regulation through increased autophagy ..................................................................... 156 
II.2.5.3 Regulation through translation initiation control ......................................................... 157 
II.2.5.4 Regulation of proAMD1 stability ................................................................................... 158 
II.2.5.5 mTORC1 regulation of AMD1 levels through direct phosphorylation .......................... 159 
II.2.6 TARGETS DOWNSTREAM AMD1 .............................................................................................. 161 
RESULTS AND DISCUSSION ..................................................................................................... 168 
III ANALYSIS OF THE THERAPEUTIC POTENTIAL OF TARGETING AMD1 AND 
EVALUATION OF PROSPECTIVE THERAPIES ........................................................................ 169 
III.1 ANALYSIS OF THE THERAPEUTIC POTENTIAL OF TARGETING AMD1 ............................................. 169 
III.1.1 GENETIC MODULATION OF AMD1 LEVELSIN VITRO .................................................................... 169 
III.1.1.1 Ectopic expression of AMD1 by lentiviral transduction ............................................... 169 
III.1.1.2 AMD1 silencing by lentiviral transduction. .................................................................. 170 
III.1.1.3 Pharmacological modulation of AMD1 levelsin vitro ................................................... 174 
III.1.2 AMD1 MODULATION IN VIVO ................................................................................................ 175 
III.1.2.1 AMD1 ectopic expression in vivo ................................................................................. 175 
III.1.2.2 AMD1 silencing in vivo ................................................................................................. 176 
III.2 EVALUATION OF POTENTIAL THERAPIES ................................................................................. 178 
III.2.1 NUTRITIONAL MODULATION .................................................................................................. 178 
III.2.2 SAM486A PRECLINICAL TRIAL .............................................................................................. 184 
III.2.3 ANALYSIS OF AMD1 LEVELS IN A CLINICAL TRIAL OF RAD001 ..................................................... 188 
GENERAL DISCUSSION ............................................................................................................. 193 
I THE REVOLUTION OF OMICS: MILESTONESAND REMAINING CHALLENGESIN 
CANCER RESEARCH ................................................................................................................. 195 
Index 
 
 
 
 
 
OMICS DEVELOPMENT AND CANCER RESEARCH ................................................................................195 
CHALLENGES AND FUTURE PROSPECTS OF METABOLOMICS IN EUKARYOTES.............................................196 
II THE INTERPLAY OF MTORC1 SIGNALING AND POLYAMINE METABOLISM IN CANCER 
AND BEYOND ............................................................................................................................. 198 
THE CROSSTALK BETWEEN SIGNALING AND METABOLISM IN CANCER .....................................................198 
SIGNALING-METABOLISM CROSSTALK BEYOND CANCER ......................................................................200 
III AMD1 AS A PREDICTIVE BIOMARKER AND TARGET IN PROSTATE CANCER ............ 202 
CONCLUSIONS ........................................................................................................................... 206 
BIBLIOGRAPHY .......................................................................................................................... 210 
   Figure Index 
 
 
 
 
INTRODUCTION 
FigureI1........................................................................................................................................39
Representation of the multi-step tumor progression model. 
FigureI2.........................................................................................................................................40
Schematic representations showing the revisited hallmarks of cancer by Hanahan and 
Weinberg, 2011. 
FigureI3.........................................................................................................................................42
Anatomy and histology of male human and murine reproductive system. 
FigureI4.........................................................................................................................................43
Schematic showing the prostate cancer progression model. 
FigureI5.........................................................................................................................................45
Grading systems employed for histopathological evaluation of prostate cancer. 
FigureI6.........................................................................................................................................47
Schematic depicting domain structure of the catalytic and regulatory subunits of class I 
PI3Ks. 
FigureI7.........................................................................................................................................48
Signaling downstream class I PI3Ks. 
FigureI8.........................................................................................................................................50
mTOR forms two distinct complexes 
FigureI9.........................................................................................................................................54
Prostate-specific Pten knockout mouse model. 
FigureI10.......................................................................................................................................59
Role of polyamines in cell physiology 
FigureI11.......................................................................................................................................61
Methionine cycle and polyamine pathway connection. 
FigureI12.......................................................................................................................................62
Putative mechanism models for polyamine uptake, accumulation and sequestration into 
vesicles in mammalian cells. 
FigureI13......................................................................................................................................64
Ornithine decarboxylase 1 (ODC1) and antizyme (AZ) regulation. 
FigureI14......................................................................................................................................65
AMD1 processing mechanism. 
FigureI15......................................................................................................................................66
Different levels of AMD1 regulation 
 
MATERIALS AND METHODS 
FigureM1.....................................................................................................................................78 
Schematic showing the experimental design of the RAD001 preclinical trial. 
FigureM2.......................................................................................................................................79 
Schematic showing the experimental design of the SAM486A preclinical trial. 
Figure Index 
 
 
 
 
 
FigureM3......................................................................................................................................79
Schematic showing the experimental design of the methionine restriction preclinical trial 
for four weeks. 
FigureM4......................................................................................................................................80
Schematic showing the experimental design of the methionine restriction preclinical trial 
for four months. 
FigureM5......................................................................................................................................82
PCR programs followed for mouse tail DNA amplification and genotyping. 
FigureM6......................................................................................................................................84
Schematic of immunohistochemistry procedures 
FigureM7......................................................................................................................................92
Schematic showing the experimental design followed for virus production. 
FigureM8......................................................................................................................................93
Representative image showing packaging system and lentivirus production in HEK293 
cells. 
FigureM9.......................................................................................................................................93
Informative image showing the fragmentation of the lentiviral genome into a second 
generation packaging system 
FigureM10.....................................................................................................................................94
Informative image showing the fragmentation of the lentiviral genome into a third 
generation packaging system. 
FigureM11.....................................................................................................................................95
Illustrative image explaining the third generation lentiviral production in HEK283 cells and 
posterior infection of target cells 
FigureM12.....................................................................................................................................97
Informative image showing the fragmentation of the retroviral genome into the packaging 
system. 
FigureM13.....................................................................................................................................97
Informative image showing different retroviral packaging methods. 
FigureM14...................................................................................................................................104
Schematic of the protocol followed to analyze AMD1 protein synthesis rate. 
 
RESULTS AND DISCUSSION I 
FigureR1....................................................................................................................................112
General experimental design of in vivo experiments. 
FigureR2....................................................................................................................................113
Experimental design of the integrative metabolomic study. 
Figure Index 
 
 
 
 
FigureR3......................................................................................................................................116
ToF-MS study unraveled increasing number of metabolic alterations through PCa 
development. 
FigureR4......................................................................................................................................118
ToF-MS enrichment analysis uncovered alterations in amino sugar synthesis pathway, 
BCAA metabolism, TCA and Ser and Gly metabolism in PCa pathogenesis. 
FigureR5......................................................................................................................................120
The inclusion criteria established narrowed the number of consistently altered 
metabolites. 
FigureR6......................................................................................................................................122
LC/MS analysis confirmed the altered metabolic pathways detected by ToF-MS. 
FigureR7......................................................................................................................................123
Diagram summarizing the main metabolic alterations observed by LC/MS. 
FigureR8......................................................................................................................................125
LC/MS analysis of PCa patients´ specimens compared to BPH samples confirmed the 
metabolic alterations observed in the PCa GEMM. 
FigureR9......................................................................................................................................126
Diagram summarizing the main metabolic alterations observed by LC/MS in PCa patients´ 
specimens 
FigureR10....................................................................................................................................127
Experimental design of in vivo MFA pilot experiment. 
FigureR11....................................................................................................................................128
In vivo flux pilot experiment to set up optimal conditions. 
FigureR12....................................................................................................................................129
Experimental design of in vivo metabolic flux experiment. 
FigureR13....................................................................................................................................130
The in vivo metabolic flux experiment confirmed in a dynamic setting the increased flux 
towards polyamine synthesis pathway through SAM decarboxylation. 
FigureR14....................................................................................................................................130
The fractional labeling data from the in vivo MFA experiment reinforces the rewiring 
towards SAM decarboxylation and polyamine synthesis. 
FigureR15...................................................................................................................................131
Diagram summarizing the main metabolic alterations observed in the in vivo U-13C5-
methionine MFA experiment by LC/MS. 
 
RESULTS AND DISCUSSION II 
FigureR16....................................................................................................................................137
Transcript analysis of the expression levels of enzymes involved in 1C metabolism and 
polyamine synthesis pathways. 
Figure Index 
 
 
 
 
 
FigureR17....................................................................................................................................140
Evaluation of Gnmt loss single event as a mediator in the metabolic switch 
FigureR18....................................................................................................................................142
Evaluation of compound deletion of Pten and Gnmt and its implication in the metabolic 
switch. 
FigureR19..................................................................................................................................143
GNMT overexpression reduces cell-growth in AR expressing prostate cancer cells. 
FigureR20....................................................................................................................................144
GNMT over-expression in vitro did not recapitulate the metabolic wiring observed in Pten 
pc-/-mice. 
FigureR21....................................................................................................................................146
Amd1 protein, but not RNA, levels dramatically increase upon Pten loss in vivo. 
FigureR22....................................................................................................................................147
PTEN expression in Pten deficient cells decreases AMD1 protein levels. 
FigureR23....................................................................................................................................149
PI3K/mTOR pathway targeting. 
FigureR24………………………………………………………………………………………………..150
mTORC1 regulates AMD1 protein expression. 
FigureR25....................................................................................................................................151
mTORC1 regulates dcSAM production. 
FigureR26....................................................................................................................................152
mTORC1 downstream PI3K regulates AMD1 at protein levels. 
FigureR27....................................................................................................................................153 
mTORC1 regulation of AMD1 is conserved in vivo. 
FigureR28....................................................................................................................................154 
Hypothetical means of AMD1 regulation downstream mTORC1. 
FigureR29....................................................................................................................................155
mTORC1 regulation of AMD1 does not depend on ODC1 nor on putrescine levels. 
FigureR30....................................................................................................................................156
mTORC1 does not regulate AMD1 through autophagy induction. 
FigureR31....................................................................................................................................158
mTORC1 does not regulate initiation of AMD1 translation. 
FigureR32....................................................................................................................................159
mTORC1 regulates stability of proAMD1. 
FigureR33....................................................................................................................................160 
proAMD1 phosphorylation in S298 residue is decreased upon mTORC1 inhibition. 
FigureR34....................................................................................................................................161
Phosphorylation of residue S298 in proAMD1 decreases its stability and processing. 
Figure Index 
 
 
 
 
FigureR35....................................................................................................................................161 
mTORC1 phosphorylates proAMD1 in residue S298 increasing its stability and allowing its 
processing. 
FigureR36....................................................................................................................................162
Proteomic study to elucidate the mechanistic program induced downstream AMD1. 
FigureR37....................................................................................................................................163 
AMD1 inhibition and silencing induce a proteomic profile regulated by MYC, which shows 
similarity with profiles obtained upon mTORC1 inhibition. 
FigureR38....................................................................................................................................164  
MYC levels correlate with AMD1 levels. 
FigureR39..................................................................................................................................165
AMD1 under the regulation of mTORC1 might induce a transcriptional program controlled 
by c-MYC. 
 
RESULTS AND DISCUSSION III 
FigureR40....................................................................................................................................170 
Impact of AMD1 over-expression in PCa growth. 
FigureR41................................................................................................................................... 171  
Impact of constitutive AMD1 silencing in PCa growth in DU145 cells. 
Figure R42. ................................................................................................................................ 171   
Impact of constitutive AMD1 silencing in PCa growth in PC3 cells. 
FigureR43....................................................................................................................................172 
Impact of inducible AMD1 silencing in PCa growth. 
FigureR44....................................................................................................................................173 
Rescue experiment to revert the phenotype upon inducible AMD1 silencing. 
FigureR45....................................................................................................................................174 
Impact of pharmacological AMD1 inhibition with SAM486A in PCa growth. 
FigureR46....................................................................................................................................175
Impact of AMD1 over-expression in PCa oncogenicity in vivo. 
FigureR47....................................................................................................................................177
Impact of inducible AMD1 silencing in PCa oncogenicity in vivo. 
FigureR48....................................................................................................................................180
Impact of short-term methionine restriction in PCa metabolism in vivo. 
FigureR49....................................................................................................................................181
Impact of short-term methionine restriction in PCa metabolism in vivo. 
FigureR50....................................................................................................................................182
Impact of long-term methionine restriction in PCa metabolism in vivo. 
FigureR51....................................................................................................................................183
Impact of long-term methionine restriction in PCa metabolism in vivo. 
Figure Index 
 
 
 
 
 
FigureR52....................................................................................................................................185
Impact of pharmacological AMD1 inhibition with SAM486A in PCa oncogenicity in vivo. 
FigureR53....................................................................................................................................186
Impact of pharmacological AMD1 inhibition with SAM486A in PCa metabolism. 
FigureR54....................................................................................................................................189
Impact of pharmacological mTORC1 inhibition with RAD001 on AMD1 levels in a clinical 
trial. 
FigureR55....................................................................................................................................190
Impact of pharmacological mTORC1 inhibition with RAD001 on AMD1 levels in a clinical 
trial. 
 
GENERAL DISCUSSION 
FigureD1...................................................................................................................................................197
Schematic representation of polyamine pools according to the observed in Pten pc-/- mice 
and upon AMD1 inhibition with SAM486A. 
FigureD2......................................................................................................................................197
Schematic representation of the hypothesis postulating increased flux through polyamine 
pathway in prostate cancer. 
FigureD3...................................................................................................................................................199
Scheme depicting the anabolic processes regulated downstream mTORC1, including 
AMD1 regulation and polyamine production. 
FigureD4......................................................................................................................................201
Interplay between PI3K-mTORC1 signaling and polyamine levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Summary 
 
 
 
37 
 
SUMMARY 
 
 Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that 
sustain cell growth, proliferation and promote cancer initiation and progression. In this thesis work 
we describe a novel molecular mechanism by which mTORC1 regulates polyamine dynamics, a 
metabolic route that is essential for oncogenicity. Through the integrative metabolomics analysis 
of a mouse model and human biopsies of prostate cancer, we identified alterations in tumors 
impacting on the production of decarboxylated S-Adenosylmethionine (dcSAM) and polyamine 
synthesis. Mechanistically, we demonstrate that this metabolic rewiring stems from mTORC1-
mediated post-transcriptional control of S-Adenosylmethionine decarboxylase 1 (AMD1). This 
novel molecular regulation was pharmacologically validated in samples from murine pre-clinical 
and human clinical trials with Everolimus. Importantly, we demonstrate that manipulation of AMD1 
levels and activity dictates prostate cancer oncogenicity. The results in this thesis provide 
fundamental information about the complex regulatory landscape controlled by mTORC1 to 
integrate and translate growth signals into an oncogenic metabolic program. 
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I CANCER 
Cancer refers to the uncontrolled proliferation of cells that leads to the formation of an abnormal 
cellular mass, denominated tumor. This term encompasses more than 100 different forms of the 
disease, as virtually every tissue can spawn one or more cancer types (Weinberg, 1996). 
Importantly, each of them requires unique diagnosis and treatment. Nevertheless, a common 
shared feature of tumors is the aberrant proliferation of malignant or transformed cells (Hanahan 
and Weinberg, 2000). 
 According to the World Health Organization (WHO, data collected by the International 
Agency for Research in Cancer (IARC) on the last Globocan 2012 report), cancer is one of the 
leading causes of morbidity and mortality worldwide. Indeed, more than 8 million people die from 
cancer every year, which covers 13% of all deaths worldwide. Of note, new cancer cases are 
estimated to increase in a 70% over the next two decades (http://www.who.int/cancer/en/). In 
Europe, 3.5 million new cases were estimated in 2012. The most common cancer types were 
breast (13.5%), colorectal (13%), prostate (12.1%) and lung (11.9%), representing 50.5% of the 
overall estimated burden of cancer in Europe in 2012 (Ferlay et al., 2013). All these key facts 
underscore the need and relevance for cancer research. 
 
I.1 Cancer hallmarks and tumor progression 
After decades of research, cancer is widely accepted as a primarily genetic disease (Vogelstein 
and Kinzler, 2004). Cancer development is a sequential, multistep and complex process of 
mutations that accumulateleading to transformation and clonal expansion of cells (3 to 7 
mutagenic events are suggested to be required) (Vogelstein and Kinzler, 1993; Hahn and 
Weinberg, 2002). Multiple studies performing comparative analysis of genetic alterations in early 
versus late stage tumors support this notion (Yokota, 2000). Subsequent genetic and epigenetic 
alterations would convert normal cells into premalignant cells, premalignant cells into transformed 
cells and transformed cells into metastatic cells (Fig. I1). Thus, this progressive accumulation of 
(Metastasis)
Adapted from StrattonMR, Campbell PJ and Futreal PA, Nat Rev 2009
Figure I1. Representation of the multi-step tumor progression model. 
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alterations would imply increasing malignancy and aggressiveness of the tumor (Nowell, 2002). 
The cumulative nature of this process and the monoclonal and polyclonal expansion of 
transformed cells, in turn supports the heterogeneity of primary and metastatic tumors (Yokota, 
2000). 
 There are three type of genes whose alteration is considered relevant to tumorigenesis: 
oncogenes, tumor-suppressor genes and genomic stability genes. Both gain of function 
alterations of oncogenes and loss of function alterations of tumor-suppressor genes lead to 
uncontrolled proliferation of cells driving the neoplastic process. Alterations in the third group of 
geneslead to increased mutation rate, which can affect the function of oncogenes and tumor 
suppressors (Nowell, 2002; Vogelstein and Kinzler, 2004). 
 
  
 In an effort to unify and identify common features of cancer cells, Hanahan and Weinberg 
proposed, more than a decade ago, six capabilities that a cell must acquire to engage malignant 
growth: i) self-sufficiency of growth signals, ii) insensitivity to growth-inhibitory signals, iii) evasion 
of apoptosis, iv) limitless replicative potential, v) sustained angiogenesis and vi) tissue invasion 
and metastasis (Hanahan and Weinberg, 2000). In order to acquire these capabilities, it was 
postulated that cells would need to acquire an enabling characteristic: genome instability 
(consequence of the malfunction of genomic integrity control mechanisms), hence increasing 
mutation rate (Nowell, 2002). With the intense research in the field during the following decade, 
increased knowledge regarding tumor initiation, progression and dissemination led to revisiting 
Adapted from Hanahan D and  Weinberg  RA, Cell Rev 2011
Figure I2. Schematic representations showing the revisited hallmarks of cancer by Hanahan and 
Weinberg, 2011. 
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these hallmarks. Together with the aforementioned genomic instability, the inflammatory state of 
premalignant and malignant cells arose as a second enabling characteristic. Indeed, cells of the 
immune system were suggested to act as promoters of tumor progression by producing growth, 
survival and angiogenic factors, extracellular matrix-modifying enzymes, epithelial-mesenchimal 
transition (EMT)-inducing signals and reactive oxygen species (ROS) in the tumor 
microenvironment (Hanahan and Weinberg, 2011). Importantly, two other capabilities of cancer 
cells were introduced in the list of cancer hallmarks due to their relevance in the development of 
the disease: avoiding immune destruction and reprogramming energy metabolism. Increasing 
evidence supports the notion that deregulation of metabolism is a directresponse to growth factor 
signaling (Ward and Thompson, 2012) (Fig. I2). 
 
II PROSTATE CANCER 
II.1 Human and murine prostate physiology 
The prostate is part of the male reproductive system, and is the largest accessory gland in the 
body (Bhavsar et al., 2014).The glandular tissue of the prostate secretes an alkalinefluid that 
helps maintain sperm motility. The smooth muscle of the prostate gland contracts during 
ejaculationto contribute to the expulsion of semen from the urethra (Scandalon VC and Sanders 
T, 2007). For further comprehension of this work we will describe in depth the anatomic and 
histological characteristics of human and murine prostate.  
 The human prostate gland is about 3 cm high by 4 cm wide by 2 cm deep, about thesize 
of a walnut, and it is located just below the urinary bladder. It is conical in shape and surrounds 
the first 2,5 cm of the urethra as it emerges from the bladder (Scandalon VC and Sanders T, 
2007) (Fig. I3A-B). The human prostate is a single organ that forms a pseudocapsule consisting 
of glandular and stromal elements (Bhavsar et al., 2014). In humans, this gland is organized in 
four zones following the branching pattern of the prostate ducts: the central (CZ), which surrounds 
the urethra; the transition zone (TZ), anterior to the urethra, the peripheral (PZ), posterior to the 
urethra and the fibromuscular stroma that separates the prostate from the rectum (Knoblaugh and 
True, 2012) (Fig. I3C). The PZ is relatively accessible for transrectal biopsies to sample the 
prostate for prostatic adenocarcinoma. The PZ is the largest of the zones, encompassing 
approximately 70% of the glandular tissue, while the CZ and the PZ account for approximately 
25% and 5% of the glandular tissue, respectively (Bhavsar et al., 2014).  
 The mouse prostate gland is divided into three distinct lobes: the dorsolateral lobe (DLP), 
which has butterfly shape and surrounds the urethra; the ventral (VP), leaf-shaped, gelatinous 
and located above the urethra and toward midline; and the anterior lobes (AP), located cranial to 
the other lobes and attached to the lesser curvature of the seminal vesicles (Knoblaugh and True, 
2012) (Fig. I3D). Histologically, each of the lobes is surrounded by a thin mesothelium-lined 
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delicate capsule. The glandular prostate is separated from the capsule by loose fibroadipose 
tissue containing major vessels, nerves, and ganglia. The individual mouse prostate lobes are 
composed of a series of branching ducts, which are formed by few layers of spindle cells and 
eosinophilic collagen (Shappell et al., 2004). The individual murine prostate lobes show distinctive 
histological features. The DLP is lined by cuboidal and columnar epithelium, with moderate 
infolding, granular cytoplasm with eosinophilic secretions and basally located uniform nuclei. The 
VP is mostly lined by cuboidal epithelium, with spare infolding, abundant homogeneous pale 
secretions and small basally located nuclei. The AP lobes are lined by cuboidal to columnar 
epithelium with a papillary pattern, contain granular cytoplasm with homogeneous eosinophilic 
secretions and centrally located nuclei (Knoblaugh and True, 2012). 
 Similarly, the human prostate ducts are constituted of cuboidal to columnar epithelium 
composed of a layer of basal cells and a luminal layer of differentiated secretory cells, with small 
subpopulations showing differentiated neuroendocrine (NE) phenotype, which represent less than 
1% of prostate epithelial cells (Shappell et al., 2004; Knoblaugh and True, 2012) (Fig. I3E). 
  
Prostate
Adapted from: http://www.cancer.gov/types/prostate/patient/prostate-
treatment-pdq
Adapted from Knoblaugh S and True L, 
Comparative Anatomy and Histology: A Mouse and 
Human Atlas, Elsevier 2012
Adapted from Shen MM and Abate-ShenC,Genes and Dev 2010
(AP)(VP)
(DLP)
(AP)
(VP)
A B
C ED
Figure I3. Anatomy and histology of male human and murine reproductive system. A, Picture of 
human anatomy showing the localization of the prostate gland. B, Picture of murine anatomy showing the 
different organs constituting the male reproductive system. C-D, Schematics of the anatomy of the different 
zones and lobes of human (C) and murine (D) prostates. E, Schematic depicting the different cellular types 
in a histological section of a human prostate duct. 
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 Importantly, the individual prostate zones or lobes have different embryologic origins and 
can be distinguished not only by the appearance and anatomic features, but by the biological 
functions and susceptibility to pathology (Bhavsar et al., 2014). Of note, although the mouse DLP 
has sometimes been assessed as the most homologous to the human PZ, the developing lobes 
are identifiable only in the embryo in humans. Thus there is no supporting evidence nor 
consensus agreement among pathologists for a direct correlation between the specific mouse 
prostate lobes and the human prostate zones (Shappell et al., 2004). Furthermore, overall, the 
mouse prostate has a modest stromal component compared to that of the human prostate 
(Knoblaugh and True, 2012). Hence, there are fundamental anatomic differences between the 
human and murine prostates that should be considered when studying the neoplastic 
development of this organ. 
 
II.2 Prostate cancer progression model 
In spite of the anatomic and histological differences between the human and murine prostate 
structures, prostate cancer progression occurs in a strikingly similar manner in mice and humans 
(Nardella et al., 2010a).  
 Prostate cancer starts from the accumulation of genetic alterations in the epithelium of the 
prostatic gland, which leads to prostatic intraepithelial neoplasia (PIN) and can progress to high-
grade prostatic intraepithelial neoplasia (HGPIN). The progressive accumulation of further genetic 
insults leads to more aggressive and malignant lesions, which thereby disrupt the basement 
membrane and invade the surrounding stroma, leading to an invasive carcinoma (Nardella et al., 
2010). This carcinoma can stay confined in the prostate or invade other organs, causing 
metastasis and ultimately resulting in lethality (Abate-Shen and Shen, 2002) (Fig. I4). 
  
PIN is characterized by cellular proliferating foci within preexisting ducts and acini with 
cytologic changes, such as nuclear and nucleolar enlargement. In this kind of premalignant 
neoplasia, inversion of the normal epithelial proliferation orientation occurs, cells proliferating from 
the basal cell compartment to the luminal space. PIN progresses into HGPIN, which is usually 
Figure I4. Schematic showing the prostate cancer progression model. 
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multicentric and is commonly found in the PZ. Early stromal invasion, which is the earliest 
evidence of carcinoma, occurs at sites with basal cell disruption in ducts with HGPIN (Bostwick et 
al., 2004). Cancer cells require the acquisition of another capability in order to survive upon loss 
of contact with the basement membrane, evasion of anoikis signals. Anoikis is a programmed cell 
death induced upon cell detachment from extracellular matrix. Resistance to this type of cell death 
is of vital importance in cancer progression (Paoli et al., 2013). Prostate cancer invariably 
metastasizes to bone, although lung, liver and pleura are secondary metastasis sites (Bubendorf 
et al., 2000). 
 
II.3 Prostate cancer pathology and treatment 
II.3.1 Prostate cancer pathology 
According to the last Globocan 2012 report of the IARC, 1.1 million men were diagnosed of 
prostate cancer in 2012 worldwide and the disease caused 307,000 deaths 
(http://www.who.int/cancer/en/). This cancer type is the second most frequent and the fifth cause 
of death from cancer in men worldwide. In Europe it represents the most frequent cancer type in 
men, with 417,000 new cases and 92,000 deaths in 2012 (Ferlay et al., 2013). 
 Age is the main risk factor for prostate cancer. Indeed, it is estimated that approximately 
95% of men older than 70 present benign prostatic hyperplasia (BPH) (Valkenburg and Williams, 
2011). In the same line, PIN and HGPIN incidence positively correlate with age. Indeed, PIN 
shows a frequency of 9% and 22% in men in their 20s and 30s respectively (Bostwick et al., 
2004). However, the etiologic factors related to prostate cancer are various and encompass, apart 
from the age, familiar history, race, diet, lifestyle factors and hormonal influences (Isaacs et al., 
2002). 
 BPH usually arises from the TZ. In contrast, PIN and HGPIN are rarely seen in this zone 
(Shappell et al., 2004) and commonly occur in the PZ. Indeed, the PZ  harbors the majority of 
prostate carcinomas (70%) (Abate-Shen and Shen, 2002). Based on the zonal difference in the 
incidence of BPH and prostate carcinoma and the fact that stromal cell proliferation is a major 
feature of BPH, this benign lesion is not contemplated as the precursor of prostatic invasive 
carcinoma. Instead, PIN is considered the precursor lesion of this disease (Isaacs et al., 2002). 
BPH histological alterations are very common in the TZ and show increasing incidence with age. 
Actually, BPH lesions have been observed in 80-90% of radical prostatectomies (RP) performed, 
while only 20% of significant prostate cancers (PCas) have their origin in the TZ (Shappell et al., 
2004). 
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Prostate cancer is suspected on the basis of digital rectal examination (DRE) and/or 
prostate-specificantigen (PSA) levels (http://uroweb.org/individual-guidelines/oncology-
guidelines/). PSA is a kallikrein-related serine protease produced in normal prostatic tissue with 
the physiological role of liquefying seminal fluid. However, this peptidase is also produced in BPH 
and PCa and is thought to be released into the blood due to disruption of normal prostate 
architecture, especially in PCa where basal layer of cells is lost (Lilja et al., 2008). However, 
definitive diagnosis depends on histological verification of carcinoma in prostate biopsies obtained 
by trans-urethral resection of the prostate (TURP) or prostatectomy (http://uroweb.org/individual-
guidelines/oncology-guidelines/). These biopsies are histopathologically evaluated and classified 
according to two different methods, the Gleason Score and the TNM (Tumor, Node, Metastasis) 
system(Shen and Abate-Shen, 2010). The Gleason Score classifies the tumors according to the 
differentiation level (from 1 to 5) of their most prevalent architecture and assigns a combined 
score, calculated from the sum of the two most common patterns (Mellinger et al., 1967; 
Humphrey, 2004) (Fig. I5). The TNM system encompasses evaluation of the primary tumor 
status, from prostate-confined to invasive (T1-4), absence or presence of lymph node involvement 
(N0 or 1) and absence or presence and degree of metastasis (M0-1a-c) (Ohori et al., 1994; Shen 
and Abate-Shen, 2010) (Fig. I5). 
 
A B
 
Figure I5. Grading systems employed for histopathological evaluation of prostate cancer. A, 
Schematic picture depicting the histological patterns for prostate cancer grading according to Gleason Score 
system.B, Table describing the extent of primary tumor (T), lymph node involvement (N) and 
presence/absence of metastasis according to TNM grading system. 
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II.3.2 Prostate cancer treatment 
Based on the DRE, PSA analysis and the histopathological evaluation of the biopsies, different 
therapeutic options are proposed to the patient following the Guidelines on Prostate Cancer, 
assessed by Urology Associations, and the treatment election is reached in agreement. 
 In general, the treatment options for prostate cancer comprise surgical excision of the 
prostate (RP), radiotherapy (irradiation through externalbeam therapy or implantation of 
radioactive “seeds” - brachytherapy), hormonal therapy (androgen deprivation therapy or 
chemical castration) and chemotherapy (docetaxel) (Shen and Abate-Shen, 2010). 
 In patients with low and intermediate risk PCa, RP or brachytherapy are normally the first-
line therapy. Biochemical recurrence is considered when a gradual increase of PSA is observed 
after first line treatment. Then, chemical castration (androgen deprivation therapy) is suggested. 
In high risk PCa, RP or radiotherapy in combination with hormonal therapy is recommended. If the 
patient exhibits an increase of PSA or appearance of Fluorodeoxyglucose-PET (positron emission 
tomography) positive masses after androgen deprivation, alternative hormonal therapies or 
chemotherapy are recommended. Chemotherapy is usually the therapy of choice when cancer 
develops into metastasis. However, the therapeutic alternatives are subject to individual and 
personalized consideration. For those patients with low risk indolent prostate cancer, active 
surveillance is emerging as the main recommendation, with the aim of minimizing over-treatment 
and treatment-related side-effects (Wadman, 2015). According to this option, patients remain 
under close surveillance to decide on the therapeutic strategy if the cancer progresses 
(http://uroweb.org/individual-guidelines/oncology-guidelines/). Nevertheless, the lack of 
information on long-term outcome and biomarkers for eligibility criteria seeds uncertainty 
regarding this strategy (Chamie et al., 2015). 
 
III PI3K PATHWAY AND CANCER 
III.1 PI3K Pathway 
Phosphoinositide 3-kinases (PI3Ks) are a family of conserved lipid kinases that catalyze the 
phosphorylation of  the 3´-hydroxyl group of phosphatidylinositol and phosphatidylinositides 
(Katso et al., 2001). This reaction unleashes an array of intracellular signaling pathways 
implicated in the control of cellular proliferation, growth, survival, motility and metabolism (Thorpe 
et al., 2015).  
III.1.1 Structural and biochemical characteristics of class I PI3K 
PI3Ks are classified into three classes (I-III) according to substrate specificity and structure. Little 
is known about the functional role of class II and III PI3Ks. In mammals, class I PI3Ks are divided 
into two subfamilies depending on the receptor they respond to. Class IA PI3Ks are activated by 
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growth factor receptor tyrosine kinases (RTKs), while class IB PI3Ks are activated by G-protein-
coupled receptors (GPCRs). We will focus on class IA PI3Ks for in-depth description. 
 Class IA PI3Ks areheterodimers composed of two subunits, the catalytic subunit p110 
and the regulatory subunit p85, which maintains p110 with low-activity in basal conditions and 
functions as an adaptor to couple it to activated protein tyrosine kinases (Hiles et al., 1992). There 
are three highly homologous catalytic subunit isoforms, p110α, p110β and p110δ, which 
associate with any of the five regulatory subunit isoforms: p85α, p55α, p50α, p85β and p55γ (Fig. 
I6). 
 
III.1.2 Signaling downstream class I PI3K 
Growth factors signal through receptor tyrosine kinases, which recruit scaffold and signaling 
proteins (including PI3K) through autophosphorylation of their C-terminal tail. p85-p110 
heterodimer interacts with phosphorylated tyrosines in RTKs, gets activated and converts plasma 
membrane lipid phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2; PIP2] into phosphatidylinositol-
3,4,5-trisphosphate [PI(3,4,5)P3; PIP3]. This lipid phosphorylation is the signal for proteins that 
contain pleckstrin-homology (PH) domains, to be recruited to the plasma membrane and bind to 
PIP3 (Cantley, 2002). Examples of these proteins are serine-threonine kinase AKT (Protein kinase 
B, PKB) and phosphoinositide-dependent kinase 1 (PDK1). Once AKT is phosphorylated by 
PDK1 and mechanistic target of rapamycin (mTOR) complex 2 (mTORC2) and activated, it 
phosphrylates multiple downstream targets, including glycogen synthase kinase 3 (GSK3) and the 
forkhead box family of transcription factors (FOXOs). AKT also activatesmTORC1 through 
phosphorylation of its upstream regulatorsproline-rich AKT substrate40 KDa (PRAS40, activatory 
regulation) and tuberous sclerosis 2 protein (TSC2, inhibitory regulation) (Liu et al., 2009b). The 
control of the intensity and duration of this signaling pathway is controlled by three type of 
phosphatases. Src-homology 2 (SH2)-containing phosphatases (SHIP1 and SHIP2), inositol 
polyphosphate 4-phosphatase type II (INPP4B) and Phosphatase and tensin homolog (PTEN) 
dephosphorylate position 5, 4 or 3 of the inositol ring; respectively (Fig. I7). 
A
B
Adapted from Vanhaesebroeck B, et al, Nat Rev Mol Cell Bio 2010 
Figure I6. Schematic depicting domain structure of the catalytic and regulatory subunits of class I 
PI3Ks. 
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III.1.3 Key mediators downstream PI3K 
We will focus in key effectors downstream PI3K for the correct understanding of this work. 
III.1.3.1 AKT 
AKT or PKBα was first discovered in the genome of the retrovirus AKT-8 in murine T-cell 
lymphoma (Alessi et al., 1996). There are three AKT isoforms (AKT1/PKBα, AKT2/PKBβ and 
AKT3/PKBγ), all belonging to the cAMP-dependent, cGMP-dependent and protein kinase C 
(AGC) kinase family (Lawlor and Alessi, 2001). The three distinct isoforms are ubiquitously 
expressed in all cell and tissue types, although AKT3 seems to have a more restricted expression 
pattern (Toker and Yoeli-Lerner, 2006). 
 Upon binding to PIP3, AKT gets phosphorylated and activated by PDK1 and mTORC2, in 
turn phosphorylating a variety of downstream targets to regulate many different cellular processes 
(Cantley, 2002) (Fig. I7). AKT is known to promote cell survival by inhibiting pro-apoptotic 
proteins, such as Bcl-2-associated death promoter protein (BAD) (Datta et al., 1997), or by 
inhibiting the transcription factors FOXO1/3/4 and tumor protein p53 (p53) (Tran et al., 2003). In 
the same line, an important role has been attributed to AKT in cell growth and proliferation 
(Manning and Cantley, 2007). AKT was reported to activate mTORC1 (through the inhibition of 
the negative regulator TSC2 (Inoki et al., 2002; Manning et al., 2002)), as well as to inhibit cyclin-
dependent kinase inhibitors Cyclin-dependent kinase inhibitor p27 (p27Kip1) (Liang et al., 2002) 
Adapted from Engelman JA, Nat Rev Cancer 2009
Figure I7. Signaling downstream class I PI3Ks. Schematic representation of PI3K signaling cascade 
highlighting key downstream kinases and phosphatases. 
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and Cyclin-dependent kinase inhibitor 1 (p21Cip1/WAF1cell) (Zhou et al., 2001), to promote cell growth 
and proliferation. Through the regulation of the aforementioned and other targets, AKT has been 
also implicated in the regulation of angiogenesis, cellular metabolism and cell migration and 
invasion (Manning and Cantley, 2007). Importantly, germline deletion of AKT1 or AKT3 have been 
reported to result in growth defects in vivo (Engelman et al., 2006). 
III.1.3.2 mTOR 
mTOR was first discovered as the target complex of the immunosuppressant rapamycin, in 
complex with peptidyl-prolyl cis-trans isomerase FKBP12 (FKBP12), and it was therefore named 
rapamycin and FKBP12 target (RAFT) (Brown et al., 1994; Sabatini et al., 1994). This complex 
contains two components of 245KDa and 35KDa, which were designated RAFT1 and RAFT2 
respectively. RAFT1 was found to show high homology with yeast proteins TOR1 and TOR2 and 
thereby it was considered the mammalian homolog of yeast TOR proteins (Sabatini et al., 1994). 
 mTOR is a serine/threonine protein kinase that belongs to the PI3K-related kinase (PIKK) 
family and forms two distinct complexes, mechanistic target of rapamycin complex 1 (mTORC1) 
and mTORC2 by interacting with some shared and other specific proteins (Abraham and 
Gibbons, 2007). The shared components of both complexes are the catalytic mTOR subunit, 
mammalian lethal withsec-13 protein 8 (mLST8), DEP domain containing mTOR-interacting 
protein (DEPTOR) and the Tti1/Tel2 complex. However, while mTORC1 specifically interacts with 
regulatory-associated protein of mammalian target of rapamycin (RAPTOR) and proline-rich Akt 
substrate40 KDa (PRAS40), mTORC2 is formed of rapamycin-insensitive companion of mTOR 
(RICTOR), mammalian stress-activated map kinase-interacting protein 1 (mSin1) and protein 
observed with rictor 1 and 2 (protor1/2) (Laplante and Sabatini, 2012) (Fig. I8). 
 This kinase shows a phylogenetically conserved amino acidic sequence that consists of: 
up to 20 HEAT motifs repeated in tandem, a FAT [FRAP (FKBP12–rapamycin-associated 
protein)-ATM (ataxiatelangiectasiamutated)-TRRAP (transactivation/transformation-domain-
associated protein) complex] domain and the catalytic kinase domain, which contains a FKBP12-
rapamycin binding (FRB) domain, a LST8-binding element (LBE) and a FATC (C terminus of 
FRAP-ATM-TRRAP complex) domain (Bjornsti and Houghton, 2004; Saran et al., 2015). 
 Contrary to mTORC1, the knowledge regarding the function and signaling cascade of 
mTORC2 is scarce. While insensitive to nutrients, this mTOR complex responds to growth factors 
through PI3K (Laplante and Sabatini, 2012). mTORC2 regulates cellular processes such us 
growth, proliferation, survival, metabolism, apoptosis, ion transport and cytoskeletal 
rearrangements through the direct phosphorylation of several AGC kinase subfamily members, 
including AKT, serum- and glucocorticoid-induced protein kinase 1 (SGK1) and protein kinase C-α 
(PKCα) (Saran et al., 2015). Although originally thought to be rapamycin insensitive, long term 
treatments have been shown to inhibit mTORC2 in a cell type-dependent fashion (Laplante and 
Sabatini, 2012). 
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 The identification of rapamycin has allowed a deeper characterization of the functions and 
regulation of mTORC1 (Saran et al., 2015). mTORC1 is considered a master sensor of 
extracellular and intracellular nutrient and energy status, capable of translating multiple signals 
into the coordination and regulation of anabolic and catabolic processes to sustain cell growth 
(Dibble and Manning, 2013a). Through transcriptional, translational (Ma and Blenis, 2009) and 
post-translational mechanisms mediated by its downstream targets ribosomal protein S6 kinase 
(S6K) and eukaryotic translation initiation factor 4E-binding protein (4E-BP), mTORC1 stimulates 
the synthesis of macromolecules (lipids, proteins and nucleic acids), promotes the production of 
adenosine triphosphate (ATP), nicotinamide adenine dinucleotide phosphate (NADPH) and 
macromolecule precursors and inhibits degradative processes, such as lipolysis, β-oxidation and 
autophagy (Dibble and Cantley, 2015). 
III.1.3.3 PTEN 
PTEN is a dual lipid and protein phosphatase and one of the phosphatases known to degrade 
PIP3 by dephosphorylating the phosphate group on position D3 of the inositol ring (Blanco-
Aparicio et al., 2007) (Fig. I7). Due to its biochemical function, it plays a primordial role in the 
regulation of the PI3K-AKT-mTORC1 axisand it is involved in multiple cellular processes. Indeed, 
through many of the aforementioned mechanisms, PTEN activity has been related to cell 
metabolism, motility and polarity, self-renewal capacity, tumor microenvironment regulation and 
senescence (Song et al., 2012). Regarding this last mentioned function, Pten loss was reported to 
result in a distinct type of senescence, referred to as Pten-loss-induced cellular senescence 
(PICS) (Alimonti et al., 2010). Importantly, PTEN has been demonstrated to exert relevant 
phosphatase-independent functions in the nucleus (Serra H, 2015; Song et al., 2011a). PTEN has 
been also attributed PI3K-AKT-mTORC1 pathway independent roles. PTEN was shown to exert 
its tumor suppressive effect through c-jun N-terminal kinase (JNK) and IFN-induced double-
stranded RNA-dependent protein kinase (PKR)-eukaryotic translation initiation factor 2 complex 
mTORC1
mTORC2Adapted from Saran U, Foti M and Dufour JF Clin Sci 2015 
Figure I8. mTOR forms two distinct complexes. Schematic representation of mTOR structure and shared 
and specific components of each particular complex. 
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(eIF2α) phosphorylation in an AKT-independent manner (Mounir et al., 2009; Vivanco et al., 
2007). 
 
 
III.2 PI3K Pathway deregulation in cancer 
Hyperactivation of the PI3K pathway is known to contribute to human cancer (Cantley, 2002). 
Human cancer genomic studies revealed that many components of the PI3K pathway are 
frequently affected by germline or somatic mutations in a wide variety of human tumors, 
underscoring the relevance of this signaling cascade in the disease (Liu et al., 2009b). Indeed, 
deregulation of this oncogenic cascadecommonly occurs by activating mutations in growth factor 
receptors, the PIK3CA gene coding for the catalytic subunit p110α or AKT, as well as loss of 
function of the tumor suppressor PTEN or TSC1/2 (Marone et al., 2008). 
 As aforementioned, activating alterations (mutations and amplification) in PI3K are 
frequent in multiple cancer types (Samuels et al., 2004). The oncogenic capacity of class I PI3K 
was first demonstrated in the late 1990s (Thorpe et al., 2015). However, the high incidence of 
mutations of this kinase in human cancers was discovered in 2004, when Samuels and 
colleagues found it to be altered in 32% of colorectal cancers, 27% of glioblastomas and 25% of 
gastric cancers, among others. Furthermore, these mutations were reported to arise late in 
tumorigenesis, suggesting a role in invasiveness (Samuels et al., 2004). Although missense 
mutations have been reported in all p110α domains, mutations in each domain lead to different 
mechanisms of aberrantly activating the pathway. In turn, mutations in the helical domain prevent 
p110α inhibition by p85 or facilitate its interaction with insulin receptor substrate 1 (IRS1), 
mutations in the kinase domain enhance the interaction with lipid membranes, and other 
mutations mimic conformational changes of active PI3K (Thorpe et al., 2015). 
 AKT is also amplified and mutated in cancer (Carracedo and Pandolfi, 2008). In fact, the 
activating mutation E17K in the PH domain of AKT makes it growth factor-independent, leading to 
its aberrant localization to the membrane and the stimulation of downstream signaling (Carpten et 
al., 2007). However, distinct AKT isoforms may show tumor-specific alterations. Indeed, while 
AKT1 amplification has mainly been detected in gastric cancer, somatic mutations on AKT1 have 
been described in breast, colorectal, ovarian, lung, and bladder cancers (Martini et al., 2014). In 
contrast, AKT2 amplification has been frequently detected in ovarian, breast, colorectal, and 
pancreatic tumors, while AKT3 appears amplified in breast and prostate cancers (Agarwal et al., 
2013). Finally, the activating mutation E17K has been identified on AKT3 in melanoma (Davies et 
al., 2008). 
 Importantly, few cancer-related somatic mutations in MTOR have been functionally 
characterized, recently some mutations leading to mTOR hyperactivation and nutrient signaling 
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and resistancehave been reported. In addition, hyperactivation of upstream kinases (PI3K, AKT) 
or growth factor receptors, as well as loss of upstream negative regulators (PTEN, TSC1/2) can 
lead to hyperactivation of mTOR (Dancey, 2010). Oncogenic PI3K-mTORC1 overactivation 
confers addiction to the pathway. Indeed, PTEN loss driven prostate cancer has been reverted by 
tissue-specific mTOR deletion in the mouse prostate (Guertin et al., 2009). 
 Nevertheless, the most common mechanism triggering hyperactivation of PI3K pathway is 
somatic loss of PTEN due to genetic or epigenetic alterations (Thorpe et al., 2015).In fact, when 
PTEN is deleted, mutated or otherwise inactivated, PI3K effectors, in particular AKT, are activated 
in the absence of any other stimulus (Cully et al., 2006). Sequencing of PTEN revealed that it is 
one of the most commonly mutated and deleted tumor suppressors among human cancers 
(Carracedo et al., 2011). In the same line, multiple tumors show alterations in its protein 
expression, in PTEN locus methylation or loss of heterozygosity (Marone et al., 2008). Genetic 
alterations in PTEN encompass from point mutations to large chromosomal deletions (Nardella et 
al., 2010a). These mutations are mostly missense and non-sense localized in exons 5,7 and 8, 
that encode the phosphatase domain (Marone et al., 2008). Of note, PTEN mutations can either 
affect both alleles (specially in endometrial cancer and glioblastoma) or only one allele, as 
observed in glioma, prostate, breast or lung, among others (Nardella et al., 2010a). 
 In prostate cancer, approximately 30% of patients withcastration-resistant prostate cancer 
(CRPC) harbor mutations in PIK3CA (Sarker et al., 2009). However, the relevance of PTEN loss 
of function is better described. In fact, approximately 25% of prostate HG-PINs and 70% of 
prostate cancers at early stage show heterozygous alterations in PTEN (Yoshimoto et al., 2006). 
Of note, prostate tumors tend to select for PTEN heterozygous inactivation at presentation and 
loss the other allele later in the progression of the disease (Carracedo and Pandolfi, 2008). 
  
III.3 Genetic models of Pten loss in vivo 
In line with its implication in a plethora of cellular processes, mutations in PTEN have been 
identified in multiple sporadic malignancies and in cancer-susceptibility syndromes (Nardella et 
al., 2010a). Germline mutations and deletions of PTEN are associated with the development of 
several autosomal dominant syndromes collectively named as PTEN hamartoma tumor 
syndromes (PHTS). PHTS include Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba 
syndrome (BRRS), Lhermitte-Duclos disease (LDD), Proteus syndrome, and Proteus-like 
syndrome (Hollander et al., 2011). These patients suffer from hamartomas with cancer 
predisposition in different organs. Macrocephaly development has also been described in the first 
two syndromes (Nardella et al., 2010a). The relevance of the tumor-suppressor role of PTEN led 
to the development of multiple Pten knockout mouse models with the aim of studying the effects 
of its loss of function in vivo. 
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III.3.1 Genetic models of Pten germline mutations 
In the last decade of the twentieth century, mouse engineering experienced important advances, 
including the development of the genetargetingtechnology. Gene targeting brought the possibility 
of introducing specific mutations by homologous recombination into endogenous genes of 
embryonic stem (ES) cells,and transmitting these changes in the germline through mice breeding 
(Jonkers and Berns, 2002).  
 Homozygous Ptenloss is lethal at day E7.5 post-fertilization, which highlights an essential 
role of Pten in embryonic development (Di Cristofano et al., 1998). In the same line, hypomorphic 
Pten mutants (PtenHy/-) showed a partial rescue of embryonic lethality, leading to some viable 
mice albeit at a lower frequency than expected according to Mendelian ratios (Trotman et al., 
2003). Pten heterozygosity (Pten+/-) was reported to cause dysplastic and hyperplastic alterations 
in prostate, skin and colon resembling CS, BRRS and LDD features. Furthermore, spontaneous 
development of tumors of various histological origins was described in Pten+/- mice (Di Cristofano 
et al., 1998). Importantly, Pten hypomorphic mice showed increased aggressiveness, with 
massive prostatic hyperplasia and invasive PCa (Trotman et al., 2003). In conclusion, these 
“hypomorphic Pten allelic series” revealed that subtle variations in Pten expression levels result in 
dose-dependent pathological alterations (Nardella et al., 2010a). 
 
III.3.2 Genetic models of prostate-specific Pten deletion 
Germline knockouts have been widely employed for the study of gene function in vivo. Although 
these conventional knockouts are useful to ascertain gene function during development, they 
exhibit intrinsic limitations to model postnatal pathologies, mostly due to their whole body range of 
action (Wu et al., 2001). To circumvent the consequence of losing Pten in all cells of the body, 
and to study the impact of Pten loss in a given tissue, conditional tissue-specific Pten knockout 
mouse models were employed (Jonkers and Berns, 2002). Conditional gene knockout 
techniques, such us the Cre-loxP recombination system, bypass some of the limitations of 
conventional gene-targeting. This technique combines the use of the bacteriophage P1 site-
specific DNA recombinase (Cre) and the creation of conditional target alleles in mice expressing 
Cre under the control of cell type-specific or inducible promoters (Wu et al., 2001). Cre excises 
DNA sequences located between two unidirectional loxP recognition sequences ("flox"), leaving 
one loxP site on the linear DNA. 
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 To achieve specific deletion of Pten in the prostate, PtenloxP/loxP mice were crossed with 
Probasin-Cre (PB-Cre) transgenic mice. In PB-Cre transgenic mice Cre recombinase is 
expressed specifically in the prostate epithelium post-puberty due to its regulation by the rat 
Probasin (PB) gene promoter, which is an androgen responsivepromoter (Nardella et al., 2010a). 
Two distinct versions of the PB promoter have been utilized to perform these crosses, PB-Cre 
and PB-Cre4, where in PB-Cre4 mice Cre expression is driven by a composite promoter, 
ARR2PB, which is a more potent derivative of the original rat PB. Indeed, Cre expression under 
ARR2PB promoter led to widespread Pten deletion in the prostate epithelium, prostate 
enlargement and more aggressive invasive PCa with multifocal origin compared to original PB 
promoter driven phenotype (Trotman et al., 2003). We will focus on PB-Cre4 mice phenotype for 
further considerations regarding prostate-specific deletion driven models, which is the model that 
was employed in this thesis work. Homozygous prostate-specific Pten deletion leads to HG-PIN 
development at 9 weeks of age. Moreover, after bypassing Pten loss induced senescence at 11 
weeks of age, these HG-PIN lesions further progress into full penetrance invasive PCa by 6 
months. Although disease aggressiveness increased with time, these mice did not show 
metastatic lesions (Chen et al., 2005) (Fig. I9). 
PbCre+/PbCre, 
Pten Lox/+
Heterozygous
Model
PbCre+/PbCre,
Pten Lox/Lox
Homozygous
Model
IndolentPIN with
only focal lesions
PIN Invasive PCa
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PbCre+/PbCre+
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3 Mo 6 Mo
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prostate
Prostatic
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Figure I9. Prostate-specific Pten knockout mouse model. Representation of the genotype (wild-type, 
heterozygous or homozygous)-phenotype (PIN or PCa) correlation at early (3Mo) and late (6 Mo) stages of 
the disease. 
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IV METABOLIC DEREGULATION AND CANCER 
IV.1 Warburg effect 
The first evidence reporting the deregulation of metabolism in cancer were provided by Otto 
Warburg in the early 1920s (Warburg et al., 1927). This German physiologist observed that tumor 
cells consumed more glucose than normal tissues, which suggested a relevant differential 
characteristic of normal versus cancerous cells (Warburg, 1956a). However, this data was left 
aside for many years in cancer research until the beginning of twenty first century, when reports 
claiming the importance of alterations in metabolic enzymes in cancer pathogenesis started to 
arise (Possemato et al., 2011; Reitman et al., 2011). Increasing evidence claim that oncogenic 
alterations in metabolic enzymes can directly trigger the deregulation of cancer cell metabolism 
(Ward and Thompson, 2012), but it is widely accepted that metabolism in cancer is regulated at 
large by signaling alterations. The consolidation of this field has led to the consideration of the 
deregulation of metabolism in cancer as a hallmark of the disease (Hanahan and Weinberg, 
2011).  
 Normal cells uptake glucose, they convert it into pyruvate and incorporate it in the 
Tricarboxylic Acid Cycle (TCA) to obtain 36 molecules of ATP from a single molecule of glucose 
through oxidative phosphorylation. However, tumoral cells or cells with high proliferation rates 
uptake higher amounts of glucose and convert it into lactate even in the presence of oxygen, 
yielding 4 ATP in a process defined as aerobic glycolysis or “Warburg effect” (Vander Heiden et 
al., 2009). Recently, more information about how the Warburg effect can be energetically 
sustained has been provided. Lactate production from glucose in cancer cells occurs 10-100 
times faster than complete glucose oxidation through oxidative phosphorylation in the 
mitochondria (Shestov et al., 2014). Hence, this inherent difference in kinetics would explain the 
choice for anaerobic glycolysis of cancer cells (Liberti and Locasale, 2016). It is worth noting that 
cells with a higher metabolic rate would also exhibit a selective advantage under limited nutrient 
and energy availability conditions (such as the tumor microenvironment) and conditions of high 
rapid ATP demand (Epstein et al., 2014). 
 Aerobic glycolysis has also been proposed as an adaptation to use glucose for the 
production of anabolic intermediates and NADPH (Vander Heiden et al., 2009). In fact, glycolytic 
intermediates in cancer cells are diverted into branching pathways, such as, pentose phosphate 
pathway (PPP), hexosamine biosynthesis pathway or thede novo serine synthesis (50% of 
glucose) and one carbon (1C) metabolism, in order to obtain biosynthetic precursors (Pavlova 
and Thompson, 2016). 
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IV.2 1C metabolism 
1C metabolism accepts inputs, such as glucose or amino acids and processes them to produce 
outputs for anabolic processes. Thus, this pathway is considered a nutrient status integrator 
(Locasale, 2013).1C metabolism encompasses folate and methionine (Met) cycle. This cyclic 
metabolic network is fueled by a carbon unit from serine (Ser) conversion to glycine (Gly) and 
subsequent glycine cleavage, which then is tranferred through biochemical reactions to other 
metabolic pathways. Folate is reduced by a number of enzymes, leading to the production of 
methyl-tetrahydrofolate (m-THF), which couples folate cycle to Met cycle, and further 
tetrahydrofolate (THF) generation(Amelio et al., 2014). Importantly, virtually all biomolecules 
require substrates from 1C metabolism for their synthesis. 1C metabolism is also connected to 
trans-sulphuration pathway through an intermediate of Met cycle, homocysteine,and is implicated 
in the maintainance of cellular Redox balance, through the NADPH/NADP ratio balance and 
glutathione production, and in the methylation capacity of the cell, throught the regulation of S-
adenosylmethionine (SAM) levels (Locasale, 2013). 
 Ser, one of the fuels of this pathway, can be synthesized de novo, from a glycolisis 
intermediate, 3-phosphoglycerate (3PG) (Locasale, 2013). Importantly, this pathway has been 
shown to correlate with tumorigenesis (Snell, 1984). Indeed, Ser and not Gly, was demonstrated 
to selectively support 1C metabolism and proliferation of cancer cells (Labuschagne et al., 2014). 
Likewise, glycine metabolism, glycine decarboxylase (GLDC) and the glycine-cleavage system 
have also been implicated in cell tranformation and tumorigenesis (Zhang et al., 2012; Wang et 
al., 2009). 
 
IV.3 Other metabolic alterations 
Recent advances in cancer research have proven that deregulation of metabolism in cancer 
extends beyond the previously thought unique objective of adapting to the enhanced anabolic 
processes required for proliferation (Ward and Thompson, 2012). Cancer cells exhibit increased 
uptake of other growth-supporting substrates, like glutamine, which was observed more than 50 
years ago (Eagle, 1955). The transcription factor myc proto-oncogene protein (c-MYC) (often 
amplified in tumors) induces glutamine utilization (Wang et al., 2011), providing nitrogen for purine 
and pyrimidine synthesis, non-essential amino acids and polyamines (Pavlova and Thompson, 
2016), as well as carbons for anaplerosis (a process through which the activity of the tricarboxylic 
acid cycle is sustained by providing additional alpha ketoglutarate).  
 Some cancer cells also exhibit opportunistic modes of nutrient acquisition (Pavlova and 
Thompson, 2016). In fact, mutant RAS-transformed cells recover free amino acids from 
extracellular proteins, through internalization by macropinocytosis and lysosomal degradation 
(Commisso et al., 2013). Remarkably, this mode of aminoacid uptake is inhibited by mTORC1 
(Palm et al., 2015). In the same line, mutant GTPase KRas (KRAS)-expressing cells are more 
prone to elicit entosis, the engulfment and digestion of entire living cells,as a means of amino acid 
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recovery (Krajcovic et al., 2013). Furthermore, upon inhibition of stearoyl-CoA desaturase (SCD)1 
in hypoxic conditions, these cells are able to scavenge serum fatty acids (Kamphorst et al., 2013). 
 Metabolic reprogramming of cancer cells leads to the production of metabolites such as 
acetyl-CoA, that are substrate for histone acetyl transferases, resulting in increased acetylation of 
growth-related genes and subsequent increased growth (Cai et al., 2011). Thus, the metabolic 
reprogramming in cancer allows the direct transmission of growth signals to metabolic enzymes 
(Pavlova and Thompson, 2016). 
 
V POLYAMINES 
Polyamine metabolism is a physiologically relevant pathway that has been extensively related to 
proliferation. Owing to their multiple roles in essential cellular processes, their concentrations are 
strictly controlled at several levels, by regulation of the enzymes implicated in their synthesis and 
catabolism. This fact underscores the importance of fine-tuning the availability of polyamines. The 
deregulation of these enzymes has been therefore implicated in multiple diseases, and especially 
in cancer pathogenesis. 
V.1 Definition of polyamines 
Polyamines are ubiquitous essential small polycationic molecules derived from amino acids. 
Since Antonie Van Leewenheuk identified some crystals in seminal fluid corresponding to 
spermine (Spm) in 1678, more polyamines have been described, such as putrescine (Put) (in the 
late 1800s), spermidine (Spd) (at the beginning of twentieth century), cadaverine (Cad) and1,3-
diaminopropane (1,3-DAP). The first three are the most common ones, especially in mammals. 
Polyamines contain two amino groups in the case of primary diamines (Put, 1,4-diaminobutane; 
and Cad, 1,5-diaminopentane), while three and four amino groups are present in the structure of 
Spd (N-(3-aminopropyl)butane-1,4-diamine) and Spm (N,N′-bis(3-aminopropyl)butane-1,4-
diamine), respectively. Polyamine content varies among species. For instance, intracellular 
content of Spd (1-3 mM) is higher than Put content (0.1-0.2 mM) in most bacteria, whereas in 
Escherichia coli Put is the predominant polyamine (10-30 mM) (Shah and Swiatlo, 2008). In the 
same line, Cad is mainly present in bacteria and plants, with a reduced abundance in the 
remaining species (Kusano et al., 2008). 
 These positively charged aliphatic hydrocarbon molecules are relevantfor the 
maintenance of essential cellular processes. Indeed, due to their overall positive charge at 
physiological pH, they are known to bind macromolecules with acidic nature, such as nucleic 
acids, proteins and phospholipids (Pegg, 2009a) and cause effects on gene expression, cell 
proliferation and cellular stress (Miller-Fleming et al., 2015). Owing to their high interactive 
capacity, the free polyamine concentration is markedly lower than total polyamine content, which 
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also explains the fact that slight alterations in polyamine levels may have critical consequences 
on cell function (Pegg, 2009a). 
 
V.2 Polyamine functions 
V.2.1 Regulation of gene expression 
Polyamines are able to affect gene expression by different means (Fig. I10).These molecules are 
considered condensation agents that remodel chromatin structure by creating electrostatic bonds 
between desoxyribonucleic acid (DNA) and phosphate charges that stabilize the nucleic acid. In 
the same line, natural and synthetic polyamines precipitate DNA, depending on their 
concentration (Childs et al., 2003). Polyamines regulate the transcription rate of several genes, 
the oncogenic trancription factor c-MYC among them (Kumar et al., 2009). Interestingly, 
amplification of N-myc proto-oncogene protein (N-MYC), another transcription factor from the 
same family,has been reported to induce overexpression of ornithine decarboxylase 1 (ODC1), 
one of the rate-limiting enzymes of the polyamine synthesis pathway, in neuroblastoma (Hogarty 
et al., 2008). This fact emphasizes the presence of feedback loops in polyamine related 
regulation. 
 To try to understand the physiological role of polyamines, their distribution among acidic 
molecules in cells has been determined. Importantly, most polyamines form a ribonucleic acid 
(RNA)-bound complex, as assessed in bovine lymphocytes and rat liver, what suggests that these 
polycations could alter the structure of RNA (Igarashi and Kashiwagi, 2010) and regulate protein 
translation. Indeed, polyamines can induce the translation of a group of genes, named the 
“Polyamine modulon”, both in prokaryotes (Yoshida et al., 2004) and eukaryotes (Nishimura et al., 
2009a). Interestingly, polyamines regulate translation initiation and elongation (Yoshida et al., 
2002) as well as the phosphorylation of factors involved in translation (Landau et al., 2010). 
 
V.2.2 Control of cell proliferation 
Polyamines have been widely related to proliferation and growth (Fig. I10). Apparently, this 
regulation occurs through different mechanisms in prokaryotes and eukaryotes. In prokaryotes, as 
aforementioned, translation of growth-related transcription factors is induced in response to 
polyamines, according to the metabolic conditions. However, polyamines show a putative role in 
cell cycle progression in eukaryotes (Oredsson, 2003), although the exact mechanism underlying 
this activity remains to be elucidated (Miller-Fleming et al., 2015). 
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Another proliferation-related function of polyamines, especially of Spd, is to serve as substrate for 
the unique post-translational modification of eukaryotic translation initiation factor 5A (eIF5A), 
hypusination (Cooper et al., 1982). This exclusive modification is based on the formation of 
hypusine, a basic amino acid, by adding the 4-aminobutyl moiety of Spd to Lys50 in eIF5A (Park 
et al., 2009). The hypusination process consists of two enzymatic steps, deoxyhypusine 
intermediate formation by deoxyhypusine synthase (DHS), which transfers the 4-aminobutyl 
moiety from Spd to Lys50; and hydroxylation of deoxyhypusineby deoxyhypusine hydroxylase 
(DOHH) to form active eIF5A (Park et al., 2009). These two enzymes responsible for hypusination 
and eIF5A are highly conserved from archaea to eukaryotes, which suggests a vital role of this 
translation initiation factor in cell viability. Indeed, deletion of both eIF5A homologues in yeast 
(Hyp2 and Anb2) is lethal (Schnier et al., 1991), as well as eIF5A homozygous deletion in mice 
(Nishimura et al., 2012). Although eIF5A was initially described as a translation initiation factor, it 
was later demonstrated that it does not play an essential role in initiation, but binds to translating 
ribosomes and elongation factors, in an hypusine-dependent manner (Zanelli et al., 2006).  
 Finally, polyamines have been reported to affect signaling pathways by modulating 
phosphorylation of key regulatory proteins, such as kinases (AKT, GSK-3β, cyclin-dependent 
kinase 4, CDK-4), transcription factors (p53), E3 ubiquitin-protein ligases (murine doble minute 2, 
Mdm2) and signaling receptors (EGFR), among others (Pegg, 2009a). 
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Figure I10. Role of polyamines in cell physiology. Schematic representation of the main cellular 
processes and specific functions in which polyamines are involved at physiological level. 
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V.2.3 Implication in cellular stress 
Polyamines have been associated to the protection of cells against multiple types of cellular 
stresses, such as ROS, changes in pH, osmotic pressure and temperature (Miller-Fleming et al., 
2015) (Fig. I10). 
 Due to their polycationic nature, polyamines can function as ROS scavengers, by binding 
to alkyl, hydroxyl and peroxyl radicals and superoxide to protect DNA from oxidative stress 
(Fujisawa and Kadoma, 2005; Ha et al., 1998). Another reported function of polyamines is the 
induction of the defense mechanisms against stress. Evidence supporting this fact have been 
provided in E. coli, where Put and Spd upregulate the transcription of the stress-related 
transcription factors OxyR, SoxRS and RpoS (Tkachenko and Nesterova, 2003); in yeast, where 
overexpression of the polyamine exporter Tpo1 sensitizes cells to H2O2 (Krüger et al., 2013); and 
plants, where polyamines protect Arabidopsis from heat stress (Sagor et al., 2012). Polyamines 
also have the capacity to bind to proteins. This ability allows them, for instance, to bind to porins 
(membrane proteins that form channels) and inhibit them to prevent acidic and osmotic stress(Iyer 
and Delcour, 1997). In response to osmotic stress, polyamines can further act as “osmolytes”, 
accumulating for protection (Groppa and Benavides, 2007) or being excreted to balance charge 
alterations (Schiller et al., 2000). 
 We will focus on naturally occurring polyamines in mammals to delve into their synthesis, 
catabolism and transport. These processes are very tightly controlled through the specialized and 
unconventional means of regulation of the enzymes in polyamine metabolism. 
 
V.3 Polyamine metabolism 
V.3.1 Polyamine synthesis 
Polyamines are synthesized fromtwo proteinogenic amino acids, the essential amino acid 
methionine (Met, M) and the non-essential amino acid arginine (Arg, R). Argis converted into 
ornithine, a non-proteinogenic amino acid that is the real substrate for the synthesis of the first 
polyamine synthesized in the pathway, Put (Lee and MacLean, 2011). There are two rate-limiting 
and equally relevant enzymes implicated in the synthesis of polyamines, ODC1 and S-
adenosylmethionine decarboxylase (AMD1) (Pegg, 2009a) (Fig. I11). Both branches of the 
pathway start with a decarboxylation reaction. Ornithine is decarboxylated by ODC1 to form Put 
(Nowotarski et al., 2013). The other branch of the pathway is fueled with methionine, which is 
converted into SAM, the substrate that is then decarboxylated by AMD1 to form decarboxylated 
S-adenosylmethionine (dcSAM) (Miller-Fleming et al., 2015). This metabolite is the aminopropyl 
donor for the synthesis of the other two polyamines present in mammals,Spd and Spm (Pegg, 
2013). 
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The aminopropyl group is transferred to Put and Spd in consecutive reactions catalyzed by two 
aminopropyltransferases, spermidine synthase (SpdS) and spermine synthase (SpmS), 
respectively (Rhee et al., 2007) (Fig. I11). 
 
 
V.3.2 Polyamine catabolism 
Polyamine concentrationis not only regulated through their synthesis, but also through tightly 
regulatedcatabolic reactions. Polyamine catabolism consists of two main reactions, acetylation 
and oxidation (Fig. I11).  
 Acetylation of Spd and Spm, is catalyzed by Spermidine/spermine N1-acetyltransferase 
(SSAT). This inducible enzyme transfers the acetyl group from acetyl-coenzyme A to the N1 
position of either Spd or Spm (Casero and Marton, 2007), forming N1-acetylspermidine or N1-
acetylspermine. Acetylation of polyamines reduces their positive charge, which decreases their 
ability to bind to macromolecules and makes them prone to be excreted (Pegg, 2013). 
Alternatively, they become substrates for acetylpolyamine oxidase (APAO). Oxidases can be 
classified according to the cofactor they require, flavin adenine dinucleotide (FAD) or copper 
(Cu2+). On the one hand, FAD-dependent oxidases include: APAO, which efficiently acts on N1-
acetylspermine andN1-acetylspermidine and converts them into Spd and Put, respectively; and 
spermine oxidase (SMO), which shows a very high selectivity for spermine. These two enzymes 
generate reactive aldehydes and H2O2 thereby causing oxidative stress (Pegg, 2009a). On the 
other hand, there are Cu2+-containing oxidases, including: diamine oxidase, which degrades 
putrescine into Δ1-pyrroline, ammonia and H2O2; and serum amine oxidase, which transforms 
Spd and Spm to produce amino aldehydes, ammonia and H2O2. Importantly, oxidation products of 
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Figure I11. Methionine cycle and polyamine pathway connection. Schematic representation of the 
metabolic reactions of methionine cycle and polyamine synthesis and catabolism pathways. 
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serum polyamine oxidase or SMO can undergo spontaneous β elimination producing acrolein, a 
metabolite that shows very high toxicity (Pegg, 2013) (Fig. I11). 
 
V.3.3 Polyamine transport 
Polyamine transport may play an important role in the regulation of total polyamine pools through 
their uptake (Casero and Marton, 2007) and excretion (Pegg, 2009a). Despite their central 
function, polyamine-specific transport systems in mammals are not very well understood yet, 
although several mechanisms implying endocytosis have been suggested (Miller-Fleming et al., 
2015) (Fig. I12).  
 
Adapted from Poulin R, Casero RA and Soulet D, Amino Acids 2012
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Soulet et al. proposed a mechanism by which polyamines may be transported into the cell 
through an unknown transporter powered by membrane potential (model 1). Immediately after 
internalization, polyamines would accumulate into polyamine-sequestering vesicles (PSVs) 
through V-ATPase activity-bearing transporters (Soulet et al., 2004). Other models claim the 
implication of glycosaminoglycans (model 2) (Belting et al., 2003) or caveolin-1 (model 3) 
(Uemura et al., 2010) in the internalization process of polyamines. Model 2 only provides an 
explanation for spermine transport and both model 2 and 3 do not solve the steps of polyamine 
release from vesicles (Poulin et al., 2011). In the last years, a number of membrane proteins from 
solute carrier (SLC) and ATP-binding cassette (ABC) protein superfamilies have been suggested 
as putative polyamine transporters, such as SLC22A1 and SLC22A2, SLC3A2, SLC12A8A, 
SLC22A16 and MDR1 (from ABC superfamily) (Abdulhussein and Wallace, 2013). 
 
V.4 Rate Limiting enzymes of the pathway 
The polyamine pathway is tightly regulated by two rate-limiting enzymes implicated in the 
synthesis of these molecules. On the one hand, synthesis of the first polyamine in the synthetic 
pathway from decarboxylation of the amino acid ornithine is catalyzed by ODC1. On the other 
hand, the pathway relies on another important checkpoint control at the production of the other 
main substrate required for polyamine synthesis, dcSAM. This reaction is driven by AMD1, which 
decarboxylates SAM to produce dcSAM. 
V.4.1 ODC1 
ODC1 is the first rate-limiting enzyme in thesynthesis of polyamines.This enzyme requires 
pyridoxal phosphate (PLP) as a cofactor (Pegg, 2009a). An active ODC1 homodimer is the 
responsible for the synthesis of the diamine Put by decarboxylating ornithine (Pegg, 2006). The 
expression of ODC1 is tightly regulated at multiple levels, from transcription to degradation 
(Shantz and Pegg, 1999) (Fig. I13). This enzyme is of key importance for life, as demonstrated by 
Odc1 deletion in vivo, which results in early lethality at E3.5 days post-fertilization (Pendeville et 
al., 2001). 
 At transcriptional level, ODC1 expression responds to multiple stimuli, such as growth 
factors, hormones and tumor promoter signals. At the translational level, ODC1 messenger RNA 
(mRNA) contains both elements that reduce translation efficiency (a 5´untranslated region (UTR) 
Figure I12. Putative mechanism models for polyamine uptake, accumulation and sequestration into 
vesicles in mammalian cells. A, Model adapted from(Soulet et al.2004) illustrating atwo-step mechanism.B, 
Modeladapted from (Belting et al.2003) proposing Spm internalization bound to glycosaminoglycansand 
released from glypican-1 via NO-mediated oxidation. C, Model based on (Uemura et al.2010) suggesting a 
caveolin-1-dependent internalization bound to a potential polyamine receptor. NO, nitric oxide; NOS2, nitric 
oxide synthase-2; PA, polyamines; PUT, putrescine; SPM, spermine. 
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with a strong secondary structure, a small upstream open reading frame, uORF, and a GC-rich 
sequence) (Shantz and Pegg, 1999) and elements that enhance translation (internal ribosome 
entry sites, IRES) (Pyronnet et al., 2000). However, the most unusual and complex regulatory 
step of ODC1 is its degradation. ODC1 shows a half-life of 10-30 minutes, which suggests a very 
tight regulation of protein stability. This decarboxylase is degraded through the proteasome, 
although this process is independent of ubiquitination. Instead, ODC1 depends on antizyme (AZ) 
binding, which has high affinity for ODC1 monomers, for recognition by the proteasome and 
degradation (Coffino, 2001). AZ is encoded by two adjacent ORFs and its synthesis is regulated 
by a +1 frameshift event that happens in high polyamine concentration conditions(Hayashi and 
Murakami, 1995; Nilsson et al., 1997). Importantly, AZ is also regulated by an antizyme inhibitor 
(AZi), which is highly homologous to ODC1 but lacks catalytic activity (Fujita et al., 1982). AZ has 
higher affinity for AZi than ODC1, thus allowing ODC1 dimerization and activation upon AZi 
expression.  
 
 
V.4.2 AMD1 
AMD1 is the second rate limiting enzyme in polyamine synthesis pathway and the responsible for 
dcSAM production. To ensure that AMD1 does not deplete the pool of SAM, which is essential to 
maintain the methylation capacity of the cell (Locasale, 2013), this enzyme is expressed at very 
low levels. dcSAM is an essential substrate for polyamine synthesis, because it donates the 
aminopropyl group for Spd and Spm synthesis. In turn, AMD1 levels are very strictly regulated at 
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Adapted from Miller-Fleming J, et al, J Mol Biol 2015
Figure I13. Ornithine decarboxylase 1 (ODC1) and antizyme (AZ) regulation. A, Schematic picture 
describing ODC1 and AZ regulation by polyamine levels. B,Schematic picture showing the mechanism of 
regulation of ODC1.C, Schematic picture showing the mechanism of regulation of AZ. 
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multiple levels, such as transcription, translation, processing and degradation. Put positively 
regulates AMD1 levels, whereas Spd and Spm negatively regulate the enzyme (Pegg, 2009b). 
The vital relevance of AMD1 is further supported by the fact that homozygous deletion of AMD1 is 
lethal between E3.5 and E6.5 days post-fertilization (Nishimura et al., 2002). 
V.4.2.1 AMD1 regulation 
V.4.2.1.1 AMD1 processing 
This decarboxylase has a pyruvoyl prosthetic group covalently bound. AMD1 is synthesized as an 
inactive proenzyme (proAMD1) of 38 KDa, which requires to undergo an autocatalytic serinolysis 
between glutamic acid 67 and Ser68 (Stanley et al., 1989) to generate the two different subunits 
(a and b) that will in turn dimerize and form the active heterotetramer (Pegg et al., 1998) (Fig. 
I14). This process is activated by Put in mammals (Stanley and Pegg, 1991). 
 
 
 
V.4.2.1.2 AMD1 transcription 
Regulation of AMD1 transcription has not been clarified yet. There is some evidence suggesting 
that AMD1 mRNA levels are upregulatedin response to growth factors and Spd depletion. Indeed, 
human AMD1 promoter has been reported to contain a spd-responsive element (or polyamine-
responsive element, PRE), although the experimental evidence are inconclusive (Pegg et al., 
1998) (Fig. I15). 
 
V.4.2.1.3 AMD1 translation 
E67-S68 Autocatalytic cleavage point
Proenzyme 38 KDa
Cleaved enzyme 30,7 KDa (a) 
Autocatalytic
cleavage
b b
a a
Mature
Enzyme
Cleaved pept.  (b)
7,3 KDa
Figure I14. AMD1 processing mechanism. Schematic representation of the autocatalytic serinolysisprocess 
that the inactive proenzyme form of AMD1 suffers in order to produce the subunits “a” and “b” that will in turn 
dimerize giving the active mature enzyme. 
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AMD1 translation is regulated by uORFs. AMD1 mRNA contains a small ORF 14 nucleotides 
downstream the 5´ CAP that encodes for the hexapeptide MAGDIS (Hill and Morris, 1992). 
 
During translation of this peptide, when ribosomes reach the translation of last Ser (S) ribosomal 
stalling occurs, blocking the entrance of the ribosome to the AMD1 start codon. Spd and Spm 
stabilize the complex formed by the peptidyl-tRNA associated to the ribosome, inhibiting 
translation of AMD1 (Law et al., 2001; Raney et al., 2002) (Fig. I15). 
 
V.4.2.1.4 AMD1 degradation 
AMD1 in its proenzyme form shows a very short half-life (less than 1 h), and in some species the 
turnover takes less than five minutes. Importantly, the turnover is accelerated when Spd and Spm 
concentrations are high and no further polyamine synthesis is required (Miller-Fleming et al., 
2015). AMD1 degradation occurs through polyubiquitinationvia the 26S proteasome (Yerlikaya 
and Stanley, 2004). In the reaction chain that takes place to produce dcSAM, the last step 
consists on protonation of Cα of the product for the correct release of dcSAM and regeneration of 
the pyruvate. However, under some circumstances, Cα of the prosthetic group is protonated 
leading to the formation of alanine instead of pyruvate and to the release of an aldehyde group. 
This substrate-mediated transamination process irreversibly inactivates AMD1 (Pegg, 2009b). 
Pegg AE, Essays Biochem. 2009
A
B
C
Figure I15. Different levels of AMD1 regulation. A-C, Mechanism of regulation of AMD1 transcription (A), 
translation (B) and degradation (C). 
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Furthermore, this transformation has been suggested to cause conformational changes in the 
enzyme that would make it more accessible to ubiquitination and prone to proteasome-dependent 
degradation (Yerlikaya and Stanley, 2004) (Fig. I15). 
 
V.5 Polyamines and disease 
As a consequence of their multiple and varied physiological roles, polyamines have been 
implicated in a considerable number of pathologies. Nevertheless, there is only one inherited 
human disease directly associated to a genetic alteration in polyamine synthesis pathway, the 
Snyder-Robinson syndrome (SRS). This syndrome is caused by a splice mutation in SpmS gene 
located in chromosome X and characteristic features of this disorder encompass mental 
retardation, osteoporosis, facial asymmetry, hypotonia and movement disorders (Lauren Cason et 
al., 2003). There is also evidence reporting duplication of SsatI gene (encoding for SSAT1) as the 
responsible for keratosis follicularis spinulosa decalvans (KFSD), although further patient studies 
are required to conclude a direct relationship (Pegg, 2009a). 
 Ageing has been shown to negatively correlate with polyamine levels. In line with this fact, 
some age-related neurodegenerative diseases, such as Parkinson´s disease (PD) or Alzheimer´s 
disease (AD) show increased polyamine levels, suggesting a deranged polyamine pathway. 
However, these observations in PD and AD were reported to be polyamine and cell-type specific 
and no causative demonstration has been achieved yet (Miller-Fleming et al., 2015; Minois et al., 
2011). At molecular level, polyamines have been shown to promote α-synuclein (Antony et al., 
2003; Krasnoslobodtsev et al., 2012) and β-amyloid (Luo et al., 2013) aggregation in PD and AD, 
respectively. These results were not unexpected, based on the interaction capacity of polyamines, 
and thus, in vivo experiments showing the extent and relevance of the effect of polyamines on the 
formation of these aggregates are warranted (Minois et al., 2011). In the same line, while some 
polyamines, such as Spm, have been related to ischemic neuronal injury in stroke (Duan et al., 
2011), others, as Put, have been shown neuroprotective effects against epilepsy (Bell et al., 
2011). Polyamines are also associated with inflammatory responses, leading to an overall 
increase in inflammatory conditions, such as pancreatitis (Minois et al., 2011) and the capacity to 
recruit macrophages. Whether polyamines play a pro- or anti-inflammatory role still remains 
elusive (Puntambekar et al., 2011). In the same line, polyamines ameliorate parasitic infection-
related symptoms, probably by improving the adaptive immune response and leading to a 
beneficial outcome of the disease (Nishimura et al., 2009b). 
 Of note, byproducts of polyamine metabolism have been involved in multiple diseases. 
The potential toxic role of acroleinwas already suggested a century ago. Ever since, this aldehyde 
has been associated with neurological damage due to stroke or dementia, neurological disease 
and renal failure (Minois et al., 2011). 
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V.5.1 Polyamines and cancer 
Polyamines have been widely associated to active proliferation and cancer (Gerner and 
Meyskens, 2004a; Soda, 2011). The association of polyamines with this disease was first 
reported by Russell and Snyder in 1968, who demonstrated a dramatic increase of ODC1 in 
STAT-I sarcoma (Russell and Snyder, 1968). Thenceforth, higher polyamine concentration upon 
neoplastic transformation has been reported in a variety of cancer types, such as colorectal, 
breast or prostate cancer (Kingsnorth et al., 1984; Cañizares et al., 1999; Schipper et al., 2000). 
 Expression and activity of polyamine biosynthetic and catabolic enzymes have been 
related to cancer status (Soda, 2011). In this sense, upregulation of ODC1 in the intestinal 
mucosa of familial adenomatous polyposis (FAP) patients is the best described example. In this 
inheritable form of colon cancer, the tumor suppressor adenomatous polyposis coli (APC) 
appears mutated or lost, which upregulates the expression of MYC oncogene, leading to aberrant 
growth and cancer (Gerner and Meyskens, 2004a). ODC1 is a direct transcriptional target of MYC 
(Bello-Fernandez et al., 1993; Peña et al., 1993), and its expression has been correlated with 
colon cancer risk. Moreover, a single-nucleotide polymorphism (SNP) (G315A) in intron 1 of 
ODC1, which lies between two consensus MYC binding sites (E boxes), was reported to affect 
ODC1 transcription, due to the selective binding of the transcriptional repressor and MYC 
antagonist MAD1. Based on this molecular mechanism, it was found that individuals homozygous 
for thisallele showed a reduction in colon polyp development and cancer risk. Of note, aspirin use 
was observed to further decrease colon cancer risk in an allele-independent manner, through the 
activation of SSAT (Martínez et al., 2003). In vivo, ODC1 overexpression alone was not sufficient 
to induce tumorigenesis (Alhonen et al., 1995; Smith et al., 1998), whereas targeted ODC1 
expression to the skin, under the control of K6 keratin promoter, caused increased susceptibility 
to skin tumor development upon different carcinogen induction (Chen et al., 2000; O’Brien et al., 
1997). Of note, the development of skin tumors is polyamine-dependent, as it is reduced upon 
ODC1 inhibition with difluoromethylornithine (DFMO) (Smith et al., 1998), targeted AZ 
overexpression in the skin (Feith et al., 2001) or ODC1 heterozygosity (Guo et al., 2005). 
Likewise, ODC1 has also been related to other oncogenes. This enzyme is necessary to induce 
active H-Ras GTPase-driven oncogenic transformation in vitro (Shantz and Pegg, 1998) and to 
cooperate with H-Ras in the promotion of epidermal tumors in vivo (Smith et al., 1998).  
 Catabolic enzymes such us SSAT1 or SMO have also been related to the disease. These 
enzymes are also under the regulation of mutant KRAS. KRAS inactivates peroxisome 
proliferator-activated receptor gamma (PPARγ), which in turn fails to bind the PPAR response 
element (PPRE) in SSAT1 promoter (Gerner and Meyskens, 2004a). Nonetheless, studies using 
transgenic SSAT1 overexpression exhibit conflicting results. Overexpression of Ssat1 in the skin 
(K6/SSAT) (Coleman et al., 2002) or whole Ssat1 overexpression in combination with 
ApcMin/+mutation (which develop colon cancer) (Tucker et al., 2005) showed increased incidence 
of skin and intestinal tumors, respectively. Conversely, transgenic expression of Sat1 (Pietilä et 
al., 2001) in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model (which 
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develops prostate cancer) (Kee et al., 2004) led to significant reduction in tumor incidence. 
However, germline Ssat1 overexpression is known to cause multiple pleiotropic phenotypes that 
difficult drawing carcinogenesis-related conclusions. Furthermore, contrary to the targeted 
K6/SSAT mice, the SSAT1 transgenic expression in TRAMP mice led to a profound depletion of 
polyamines, through the inhibition of a compensatory increase of polyamine synthesis that would 
support tumor growth (Casero and Pegg, 2009). 
 SMO has recently been linked to carcinogenesis. Increased expression of this polyamine 
catabolic enzyme has been observed in inflammatory-associated cancers. Specifically, infectious 
agents such as enterotoxigenic Bacteroides fragilis (ETBF) and Helicobacter pylori induce an 
inflammatory state that increases colorectal cancer risk (bowel disease and colitis) and colon 
cancer (Ulger Toprak et al., 2006), and gastric cancer (Chaturvedi et al., 2011), respectively. In 
both cases the bacterial infection was demonstrated to increase SMO expression, resulting in 
DNA damage and apoptosis (Xu et al., 2004). This data was validated with the inhibitor of SMO 
MDL72527 and SMO knockdown. In this line, SMO expression was reported to be increased as 
an early event in PCa development, although further studies are warranted in order to assess the 
role of SMO-induced ROS in prostate carcinogenesis (Goodwin et al., 2008). 
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Despite decades of investigation on prostate cancer (PCa), it remains the fifth cause of death 
among men worldwide. This fact underscores the necessity to develop more selective and 
efficient therapies that would ensure disease eradication. Deregulation of energetic metabolism 
has recently been postulated as one of the hallmarks of cancer (Hanahan and Weinberg, 2011). 
This thesis work stems from the interest in deciphering the metabolic cues implicated in PCa 
initiation and progression, and is based in the following hypothesis: Oncogenic events trigger 
the deregulation of metabolism in prostate cancer, thus revealing potential therapeutic 
strategies. 
We based our work on the premise that there is strong conservation in the metabolic 
signals that regulate murine and human PCa pathogenesis. Therefore, we propose to perform a 
discovery study based on integrative metabolomics, starting from a conditional tissue specific 
Pten knockout mouse model of PCa (Chen et al., 2005; Nardella et al., 2010b). We integrated, 
validated and deconstructed this data using PCa patient specimens and PCa cell lines.  
In order to test this hypothesis, we establish the following specific aims: 
 Aim1: To identify metabolic alterations underlying prostate cancer pathogenesis 
To characterize metabolic alterations at the core of PCa, we undertook an integrative 
metabolomics approach. Recent innovation in metabolomics instrumentation and 
development of bioinformatic tools (Patti et al., 2012) offers the opportunity to select the most 
suitable metabolomics approach: 
1.1 Time-of-flight Mass Spectrometry (ToF-MS) to establish the panoramic 
semiquantitative view of prostate cancer metabolism. 
1.2 Liquid Chromatography-Mass Spectrometry (LC/MS) to focus on most altered and 
relevant pathways and analyze them quantitatively. 
1.3 Metabolic Flux Analysis (MFA) to validate the data in a dynamic setting, which 
accurately represents metabolic nature. 
 
 Aim2: To elucidate the molecular mechanism underlying the metabolic regulation 
observed in PCa 
PTEN is a tumor suppressor that regulates the oncogenic PI3K pathway, which has been 
reported to be altered in a large fraction of human cancers (Carracedo and Pandolfi, 2008; 
Engelman et al., 2006). Importantly, alterations in Pten have been observed in up to seventy 
percent of prostate cancers (Song et al., 2012). Hence, our mouse model, driven by the loss 
of Pten, will allow us to study the interconnection between the metabolic alterations observed 
and the hyper-activation of this oncogenic cascade. To ascertain the molecular mechanism 
triggering the metabolic alterations we will rely on two main strategies: 
2.1 Evaluation of transcriptional changes as drivers of the polyamine metabolic switch. 
2.2 Evaluation of post-transcriptional changes as drivers of the polyamine metabolic 
switch. 
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 Aim3: To ascertain the therapeutic potential of targeting the altered metabolic pathway 
and evaluation of prospective therapies 
Based on the need of new selective and efficient therapies that would drive us towards 
precision medicine, we will approach this aim in two ways: 
3.1 Genetic and pharmacological modulation of potential targets in vitro and in vivo to test 
their therapeutic potential. 
3.2 Evaluation of in vivo therapeutic strategies based on the target with highest potential. 
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I IN VIVO AND EX VIVO ASSAYS 
I.1 Analysis of tissue samples 
I.1.1 Analysis of murine samples 
All mouse experiments were carried out following the ethical guidelines established by the 
Biosafety and Animal Welfare Committee at CIC bioGUNE. The procedures employed were 
carried out following the recommendations from AAALAC. Mice were housed under controlled 
environmental conditions, such astime controlled lighting on standard 12:12 light:dark cycles, 
controlled temperature at 22 ± 2ºC and  30-50% relative humidity. Mice were fed regular Chow 
diet ad libitum, unless otherwise specified based on experimental designs. Mice were fasted for 
6h prior to tissue harvest (9 am-3 pm) in order to prevent metabolic alterations due to immediate 
food intake. At experimental end-point, all mice were sacrificed by CO2 inhalation followed by 
cervical dislocation. 
I.1.1.1 Genetically engineered mouse models (GEMM) 
In this thesis work we have studied three genetic alterations in mice: Cre recombinase-dependent 
Pten conditional deletion (Chen et al., 2005), whole body Gnmt mutation (Luka et al., 2006) and 
Cre recombinase expression under the control of androgen-dependent ARR2B Probasin promoter 
(Pb-Cre4). The Pb-Cre4 transgene allowed us to delete Pten in the prostate epithelium at puberty. 
The conditional tissue specific Pten knockout (C57BL6/129sv;Pb-Cre4; Pten lox/lox) model was 
kindly provided by Dr. Pandolfi (Chen et al., 2005). The whole body Gnmt knockout (C57BL6) was 
kindly provided by Dr. Martinez-Chantar (Luka et al., 2006). We generated a mouse line which we 
named PGN by breeding Pten prostate-specific knockout mice (Pb-Cre4Pten lox/lox) and Gnmt 
knockout mice. We intercrossed these two lines for at least three generations to obtain a founder 
colony with mixed homogeneous background. Probasin Cre was always retained in male mice, 
since in females Pb-Cre4 expression in utero can lead to recombination in embryos during 
pregnancy. Prostate Pten-deleted male mice were termed Pten pc+/- (heterozygous) or Pten pc-/-
(homozygous knockout). We generated a mouse colony of Pten pc-/- for metabolomic 
characterization and preclinical studies. Gnmt -/- and wildtype counterparts were generated to 
evaluate the relevance of this gene in prostate cancer (PCa) pathogenesis and metabolism. For 
the PGN line, Pten pc+/- Gnmt +/+ and Pten pc+/- Gnmt -/- mice were generated for pathological and 
metabolomics studies. The time of analysis was based on the experimental design, and it is 
indicated in the results section.  
 
I.1.1.2 Xenograft models in nude mice 
DU145 cells in suspension were injected subcutaneously into immunocompromised 8-10-week-
old male nude mice (Harlan). Measurement of tumor size was performed every two-three days 
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and tumor volume was estimated using the following formula: volume = length x width2 x 0.526. 
Final tumor weight was measured upon tissue harvest at the experimental end point. 
I.1.1.2.1 AMD1 OE in vivo 
DU145 cells transduced with either empty vector (Mock) or AMD1 expressing construct 
(DU145MYC-AMD1-HA WT) (4x 106 cells per condition) in PBS (supplemented with 5µM glucose) 
suspension were mixed at 1:1 ratio with Matrigel (Corning Cat# 354230) in a final volume of 
100µL and injected subcutaneously in two flanks per mouse (6 mice, n=12 per condition). 
I.1.1.2.2 AMD1 Silencing in vivo 
A suspension of DU145 cells (in PBS supplemented with 5µM glucose) transduced with a 
lentiviral inducible vector (TET-pLKO; Addgene Plasmid #21915) containing shRNA for AMD1 
(SIGMATRCN0000078462) (7,5 x 106 cells per condition) was mixed at 2:1 ratio with Matrigel 
(Corning Cat# 354230) in a final volume of 150 µL and injected subcutaneously in two flanks per 
mouse. Injected nude mice were fed regular Chow diet until tumors reached an average volume 
of 150mm3. Then mice (according to cage distribution) were fed doxycycline-containing diet 
(specifications are reflected in the datasheet in Anex) to induce AMD1 silencing or were 
maintained in chow food as control (7 mice, n=14 per condition). 
 
I.1.1.3 Preclinical trials 
I.1.1.3.1 RAD001 treatment in vivo 
The RAD001 preclinical trial was performed following the experimental design in Fig. M1. Two 
month-old Pten pc-/- mice were administered either vehicle (polyethylene glycol, PEG) or RAD001 
(10mg/Kg) six days a week during four weeks by oral gavage. At the experimental end-point, mice 
were euthanized as specified in I.1.1. and tissues of experimental interest were harvested. 
PEG 6days/week
by oral gavage
(n=5)
2Mo 3Mo
2Mo 3Mo
RAD001 
(10mg/Kg) 
6days/week by oral 
gavage (n=5)
Pten pc-/-
AMD1 
levels??
Figure M1. Schematic showing the experimental design of the RAD001 preclinical trial. 
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I.1.1.3.2 SAM486A treatment in vivo 
The SAM486A preclinical trial was performed following the experimental design in Fig. M2. Two 
month-old Pten pc-/- mice were administered either vehicle (0,9% NaCl) or SAM486A (2mg/Kg or 
5mg/Kg) five days a week during four weeks by intraperitoneal injection. At the experimental end-
point, mice were sacrificed as specified in I.1.1. and tissues of experimental interest were 
harvested. 
 
I.1.1.3.3 Methionine restriction in vivo 
Methionine restriction preclinical trials were performed following the experimental design detailed 
in Fig. M3 and Fig. M4 for one month- and four month-long experiments, respectively. Mice were 
weighed weekly to control diet safety. See Annex for diet specifications. At the experimental end-
point, mice were sacrificed as specified in I.1.1. and tissues of experimental interest were 
harvested. 
 
 
Chow Diet
4 weeks
(n=4/3)
2Mo 3Mo
2Mo 3Mo
PIN
???
MetDef Diet
4 weeks
(n=6/5)
Pten pc-/-
Pten pc+/+
Intraperitoneal
0,9% NaCl
5days/week (n=3)
2Mo 3Mo
2Mo 3Mo
PIN
???
Intraperitoneal
SAM486A 
(2mg/Kg) 
5days/week (n=6)
Pten pc-/-
2Mo 3Mo ???
IntraperitonealSAM
486A (5mg/Kg) 
5days/week (n=7)
Figure M2. Schematic showing the experimental design of the SAM486A preclinical trial. 
Figure M3. Schematic showing the experimental design of the methionine restriction preclinical trial 
for four weeks. 
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I.1.2 Analysis of human specimens 
All prostate specimens were obtained upon informed consent and with evaluation and approval 
from the corresponding ethics committee (CEIC code OHEUN11-12 and OHEUN14-14). Sample 
and pathological information from PCa and benign prostatic hyperplasia (BPH) patients used for 
LC/MS was obtained from the Basque biobank for research (BIOEF), andis specified in Table M1. 
The clinical-pathological information about the biopsies from the clinical trial with Everolimus is 
described in Table M2.  
 
Table M1: Detailed data of patient specimens from The Bioef Foundation biobank, describing salple type, 
specific characteristics of the sample and aggressiveness parameters of prostate cancer samples (Gleason 
Score and TNM Classification) 
Patient Sample type Characteristics Gleason  TNM 
Patient 1 BPH Hiperplasia. Squamousmetaplasia foci   
Patient 2 BPH Glandular hiperplasia mixed with estroma   
Patient 3 BPH Glandular hiperplasia   
Patient 4 BPH Glandular hiperplasia   
Patient 5 BPH 60% glandular, 40% estromal hiperplasia   
Patient 6 BPH 40% glandular, 60% estromal hiperplasia   
Patient 7 PCa Prostate adenocarcinoma 7 T2 
Patient 8 PCa Prostate adenocarcinoma with mucinous component 7 T1c 
Patient 9 PCa Prostate adenocarcinoma 7 T2a 
Patient 10 PCa Prostate adenocarcinoma 6 T1c 
Patient 11 PCa Prostate adenocarcinoma 7 T2c 
Patient 12 PCa Prostate adenocarcinoma 6 T2b 
 
 
 
Chow Diet
4 Mo
(n=6/6)
2Mo 6Mo
2Mo 6Mo
PCa
???
MetDef Diet
4 Mo
(n=6/13)
Pten pc-/-
Pten pc+/+
Figure M4. Schematic showing the experimental design of the methionine restriction preclinical 
trial for four months. 
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Table M2: Detailed data of patient biopsies from the clinical trial with Everolimus. 
Patie
nt 
Biopsies Primary 
Tumor 
Localization 
Dose 
(mg) 
Administra-
tion 
Response 
Day Localization 
P1 
Pre-tr. liver Mx 
colon liver Mx 20 weekly PD 
On-tr. liver Mx 
P2 
Pre-tr. breast 
breast liver M 5 daily PD 
On-tr. liver Mx 
P3 
Pre-tr. breast 
breast skin 5 daily PD 
On-tr. breast 
P4 
Pre-tr. breast 
breast skin 20 weekly PD 
On-tr. breast 
P5 
Pre-tr. liver Mx 
colon liver Mx 50 weekly PD 
On-tr. liver Mx 
P6 
Pre-tr. liver Mx 
pancreas liver Mx 50 weekly PD 
On-tr. liver Mx 
P7 
Pre-tr. breast 
breast skin 50 weekly PD 
On-tr. breast 
P8 
Pre-tr. melanoma axila 
melanoma 
axilar lymph 
node 
10 daily PD 
On-tr. melanoma axila 
P9 
Pre-tr. liver Mx 
liver Mx liver Mx 5 daily SD 
On-tr. liver Mx 
P10 
Pre-tr. breast 
breast skin 50 weekly PD 
On-tr. breast 
P11 
Pre-tr. breast 
breast skin 5 daily PD 
On-tr. breast 
P12 
Pre-tr. liver Mx 
liver Mx liver Mx 10 daily PD 
On-tr. liver Mx 
P13 
Pre-tr. maxilar 
H&N maxillar 10 daily NA 
On-tr. maxilar 
P14 
Pre-tr. breast 
breast skin 20 weekly NA 
On-tr. breast 
 
 
I.2 Methods 
I.2.1 Genotyping 
Breeding and tag and tailing was carried out by anmial house personnel. Genotyping was 
performed by technicians in the Carracedo lab, Sonia Fernández and Pilar Sanchez-Mosquera 
(CIC bioGUNE). 
I.2.1.1 Genomic DNA purification from mouse tail 
 Mouse tail samples (0,2-1cm) were lysed in 195uL of lysis buffer [100mM NaCl, 50mM 
Tris-HCl (pH 8.0), 25mM EDTA, 0.5% SDS or 100mM NaCl, 50mM Tris-HCl (pH 8.0), 5mM 
EDTA, 1% SDS] with 5uL of Proteinase K (stock 10mg/ml; Fluka) for 3-6h at 55ºC. 
Once soft tissue was solubilized, 200µl of phenol/chloroform/isoamyl (25:24:1) were added to 
separate DNA (in upper aqueous phase) from denaturalized proteins (in interphase) and RNA and 
lipids (in lower organic phase) by mixing well by inversion and centrifugation for 15 min at 
14,000rpm at room temperature. DNA containing aqueous phase was transferred to new tubes 
and washed/precipitated by adding 15uL sodium acetate (3M) and 400uL of 100% ethanol and 
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incubated at -20ºC overnight to enhance precipitation. Samples were centrifuged 10min at 
14000rpm at 4ºC and supernatant was discarded to dry DNA pellets. Dry pellets were 
resuspended in 50-100uL H2O (up to 500uL for tail fragments of 1cm). 
I.2.1.2 Polymerase Chain Reaction (PCR) for genotyping 
For genotyping, extracted mouse tail DNAs (1μL) were subjected to Polymerase Chain Reactions 
(PCR), optimized with specific primers (specified in Table M3) and PCR programs (See Fig. M5) 
for each gene of interest. All PCR assays were performed with DNA Polymerase Mix 
AccuStart™II PCR SuperMix (Quanta Biosciences).  
 
Table M3: Specific primer sequences used for genotyping mouse colonies. 
 
 
Figure M5. PCR programs followed for mouse tail DNA amplification and genotyping. 
Gene Forward 5´-3´ Reverse 5´-3´ Band size 
Pten TGTTTTTGACCAATTAAAGTAGGCTGTG AAAAGTTCCCCTGCTGATGATTTGT 
Pten pc+:350bp 
Pten pc lox: 480bp 
Cre GGTGCAAGTTGAATAACCGGA CGGTATTGAAACTCCAGCGC 850bp 
Gnmt + GTACCGCAGAGTACAAGGCG CAATCGCAGGAGGAACAGCGC 330bp 
Gnmt - CAATCGCAGGAGGAACAGCGC CTGAATGAACTGCAGGACGAG 1151bp 
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I.2.2 Pathological analysis of prostate tissues 
At the experimental end-point of all in vivogenetic mouse model experiments, one of each 
prostate lobes (AP, DLP and VP) was fixed in 10% neutral buffered formalin and stored at 4ºC for 
24 hours to allow tissue fixation for pathological analysis. All the tissue processing and staining 
steps were performed by Sonia Fernández (CIC bioGUNE). 
I.2.2.1 Tissue processing, paraffin embedding and sectioning 
After 24 hour fixation tissues were dehydrated and infiltrated with paraffin following the steps in 
Table M4. Infiltrated tissues were then embedded in paraffin blocks. 
Table M4: Steps followed to process mice tissues. 
Ice-cold paraffin blocks were sectioned to obtain 3 µm sections, which were then adhered to 
slides for tissue staining and analysis. 
 
I.2.2.2 Slide processing for immunohistochemistry 
Tissue slides were de-paraffined and hydrated, following steps in Table M5, to allow 
immunohistochemical analysis. 
Table M5: Steps followed to process tissue slides for immuhistochemistry. 
 
After the desired staining in each case, slides were dehydrated with 95% and 100% alcohol and 
cleared in xylene for final coverslip mounting with DPX. 
Tray Time Reagent Fuction 
T1 10 min 50% alcohol Dehydration 
T2 1 h 30 min 70% alcohol Dehydration 
T3 1 h 30 min 80% alcohol Dehydration 
T4 1 h 30 min 96% alcohol Dehydration 
T5 1 h 30 min 100% alcohol Dehydration 
T6 1 h 30 min 100% alcohol Dehydration 
T7 1 h 30 min 100% alcohol Dehydration 
T8 45min 
Citrosol or Xylene 
substitute 
Rinse, replace the alcohol with citrosol 
T9 2h Paraffin Replace the citrosol with paraffin 
T10 2h Paraffin Replace the citrosol with paraffin 
Time Repeats Reagent Fuction 
10-15 min Twice Citrosol or Xylene substitute Hydration 
3 min Twice 100% alcohol Hydration 
3 min Twice 95% alcohol Hydration 
3 min Twice dH2O Hydration 
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I.2.2.2.1 Haematoxylin and Eosin (H&E) staining 
Slides were incubated in haematoxylin for 5 min and rinsed in water for 1 min. After haematoxylin 
staining, they were incubated in acid alcohol (70% alcohol, 3% HCl) for 2 seconds for controlled 
leaching of non-specific background coloration and rinsed again in water (1 min). Finally, slides 
were incubated in eosin for 2 min and mounted.  
I.2.2.2.2 Ki67 and RpS6S235-236 staining 
Antigen retrieval was performed with citrate buffer (pH 6) in steamer (30 min). H2O2 was used to 
block the endogenous peroxidase, followed by blocking with goat serum and primary antibody 
[Ki67, Thermo MA5-14520 (1:100); RpS6S235-236, CST #4858 (1:500)] incubation overnight at 4 ºC. 
Goat anti-rabbit IgG antibody [Vector Laboratories, Cat# BA-1000 (1:1000)] was incubated at 
room temperature for 30 min. IHC detection was performed with the VECTASTAIN Elite ABC Kit 
(Cat# PK-6100) from Vector Laboratories and developed with DAB. A schematic of the procedure 
is shown in Fig. M6. 
I.2.2.2.3 AMD1 staining and scoring 
Immunohistochemical analysis of AMD1 [Proteintech, 11052-1-AP (1:100)] was performed using 
DAKO EnVisionTM Flex High pH (Tris/EDTA pH 9) (DAKO) (Technical details are shown in Fig. 
M6) The scoring system was based on the quantification of the percentage of cells negative (0), 
low (1+), medium (2+) or high (3+) immunoreactivity. Subsequently, h-score was calculated as 
follows: H = [percentage of cells 1+] + [2 x (percentage of cells 2+)] + [3 x (percentage of cells 
3+)]. 
 
Figure M6. Schematic of immunohistochemistry procedures. A, Avidin/Biotin Complex (ABC) method. 
B, DAKO EnVision Flex method. 
 
A B
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I.2.3 Molecular analysis of prostate tissues 
At the experimental end-point of all the in vivo experiments, one of the prostate lobes (AP,DLP 
and VP) was snap frozen in liquid nitrogen immediately after extraction for molecular or 
metabolomic analysis. 
For molecular analysis, prostate tissues were homogenized with Precellys techonology in the 
presence of ceramic beads, using two cycles of 30 seconds at 5000rpm. 
I.2.3.1 Gene expression analysis of murine prostate tissues 
For RNA extraction from prostatic tissue, samples were incubated overnight in the presence of 
RNAlater ICE® (Thermo) at -20ºC.  Prostate tissues were homogenized in the presence of 
TRIzol® reagent (Thermo) and RNA extraction was performed by TRIzol method and subsequent 
Macherey Nagel RNA extraction kit (Ref# 740955.250) (Ugalde-Olano et al., 2015). 
Retrotranscription and gene expression analysis by Real Time-Quantitative-Polymerase Chain 
Reaction (RT-QPCR) were then performed as explained in II.2.4.1.1. and II.2.4.1.2. 
I.2.3.2 Protein expression analysis of murine prostate tissues 
For protein extraction from prostatic tissue, the homogenization was performed in the presence of 
400uL of RIPA lysis buffer containing 2mM phosphatase inhibitors (sodium fluoride, sodium 
orthovanadate and β-glycerophosphate) and two tablets of protease inhibitor cocktail (Roche). 
Protein extraction and western blotting were then performed as explained in II.2.4.2.1. and 
II.2.4.2.2.  
 
I.2.4 Metabolomic analysis of murine prostate tissues 
Prostate tissues for metabolomic analysis were directly shipped frozen in dry ice for metabolite 
extraction by Agios Pharmaceuticals. 
I.2.4.1 Time of Flight-Mass Spectometry (ToF-MS) 
Following normalization to cell number or tissue weight, metabolites were extracted with cold 
80/20 (v/v) methanol/water. Samples were then dried and stored at -80°C until MS analysis. High-
throughput Time-Of-Flight analysis was conducted using flow injection analysis as previously 
described (Fuhrer et al., 2011.).  In short, samples were re-suspended and injected on an Agilent 
1100 coupled with an Agilent 6520 QToF mass spectrometer with an electrospray ionization 
source.  Mobile phase consisted of 60/40 methanol/water with 0.1% formic acid and was used to 
deliver 2µL of each sample to the MS, flowing at 150µL/min.  Data was collected in positive mode 
with 4 GHz HiRes resolving power with internal lock masses.  Data processing was conducted 
with Matlab R2010b.   
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I.2.4.2 Liquid Cromatography-Mass Spectometry (LC/MS) 
Quantitative liquid chromatography/mass spectrometry (LCMS) was conducted as previously 
described (Jha at al., 2015).  A Thermo Accela 1250 pump delivered a gradient of 0.025% 
heptafluorobutyric acid, 0.1% formic acid in water and acetonitrile at 400µL/min.  Stationary phase 
was an Atlantis T3, 3µm, 2.1x150mm column.  A QExactive Mass Spectrometer was used at 
70,000 resolving power to acquire data in full-scan mode.  Data analysis was conducted in 
MAVEN (Melamud et al., 2010) and Spotfire.   
I.2.4.3 Targeted metabolomics by UPLC-MS 
Levels of dcSAM in cell cultures and tissues were analyzed by ultra-high performance liquid-
chromatography coupled to mass spectrometry (UPLC-MS). Briefly, extraction and 
homogenization was done in methanol/acetic acid (80/20 %v/v) Speed-vacuum-dried metabolites 
were solubilized in 100 µL of a mixture of water/acetonitrile (40/60 %v/v) and injected onto the 
UPLC/MS system (Acquity and SYNAPT G2, Waters, Manchester). The extracted ion traces were 
obtained for dcSAM (RT = 3.0’, m/z 355.16) and putrescine (RT = 2.67’, m/z 89.1079). Corrected 
signals were normalized to relative cell number.  
I.2.4.4 Metabolic Flux Analysis (MFA) 
U-13C5-L-methionine was purchased from Cambridge Isotope laboratories and administered 
intravenously (by tail vein injection, performed by Dr. Beraza). A pilot experiment was performed 
to establish final concentrations and time-points. For the pilot experiment, final concentrations of 
100mg/Kg or 400mg/Kg for 3, 6, 10 and 24 hour pulses were tested. From the pilot experiment, 
100mg/Kg dose and two time-points (1hour to detect methionine cycle related metabolites; 
10hours to detect polyamine pathway related metabolites) were set. After 1hour and 10 hour 
pulses with U-13C5-L-methionine mice were sacrificed as specified in I.1.1. and tissues of 
experimental interest were harvested. 
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II IN VITRO ASSAYS 
II.1 Materials 
II.1.1 Cell lines and culture conditions 
Human prostate carcinoma cell lines (PC3, LNCaP, DU145) were purchased from Leibniz-Institut 
DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH), who provided 
authentication certificate, or American Type Culture Collection (ATCC) in the case of RWPE1, 
PWRE1and 22RV1 cell-lines. Virus packaging cell lines 293FT and Phoenix Ampho and C4.2 
were generously provided by the laboratory of Dr. Rosa Barrio and Pier Paolo Pandolfi, 
respectively.PC3, DU145, Phoenix Ampho and 293FT cell lines were cultured in Dulbecco's 
Modified Eagle Medium (DMEM; Gibco Cat# 41966-029), while LNCaP, C4.2 and 22RV1 were 
cultured in RPMI 1640 Medium (Gibco Cat# 61870-010; with GlutaMAX supplement). Both culture 
medias were complemented with 10% inactivated Fetal Bovine Serum (FBS) (Gibco), from same 
lot and previously analyzed to ensure experimental reproducibility, and 1% Penicillin/Streptomycin 
(Gibco) (complete media). RWPE1 and PWR1E benign prostate primary cell lines were cultured 
in Keratinocyte-Serum Free Medium (K-SFM; Gibco Cat# 17005-034), supplemented with human 
recombinant Epidermal Growth Factor 1-53 (EGF 1-53) and Bovine Pituitary Extract (BPE). See 
Table M6 for cell line specifications. 
Table M6: Detailed list of the characteristics of the different PCa cell-lines employed in the work. 
Cell-line Cell type Morphology Derivation 
Pten 
status 
Cultur 
media 
RWPE1 
CRL-
11609TM 
Prostate 
epithelial 
Epithelial 
From the peripheral zone of a 
histologically normal adult human 
prostate transfected with HPV-18 
Positive K-SFM 
PWR1E 
CRL-
11611TM 
Prostate 
epithelial 
Epithelial 
From a normal prostate with mild 
hyperplasia, immortalized with 
Ad12-SV40 
Positive K-SFM 
PC3 
(ACC 465) 
Prostate 
adenocarcin
oma 
Epithelial-
like 
Bone marrow metastasis of grade 
IV prostate cancer after androgen 
suppression therapy 
Negative DMEM 
DU145 
(ACC 261) 
Prostate 
carcinoma 
Epithelial-
like 
From metastatic central nervous 
system lesion 
Positive DMEM 
LNCaP 
(ACC 256) 
Prostate 
carcinoma 
Fibroblastoid 
From supraclavicular lymph node 
metastasis 
Negative RPMI 
C4-2 
Prostate 
carcinoma 
Fibroblastoid LNCaP derived androgen-resistant  Negative RPMI 
22RV1 
CRL-
2505TM 
Prostate 
carcinoma 
Epithelial 
From CWR22 xenograft propagation 
after castration-induced regression 
and relapse 
Positive RPMI 
HEK293FT 
Human 
Embryonic 
Kidney Cells 
Fibroblastoid 
From human primary embryonal 
kidney transformed by adenovirus 
type 5 
Negative DMEM 
HEK293 
Ampho 
Human 
Embryonic 
Kidney Cells 
Fibroblastoid 
From human primary embryonal 
kidney transformed by adenovirus 
type 5 
Negative DMEM 
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 All cell lines were grown at 37ºC in a humidified atmosphere of 5% CO2. Cells were 
regularly cultured in 100mm dishes and split every 2-3 days, maintaining them below 80-90% 
density, up to 30 passages maximum. To split the cells they were incubated in a trypsin-EDTA 
solution (Gibco) at 0.05% for 3-5 minutes at 37ºC and resuspended in fresh complete media. All 
cell-lines were periodically analyzed by PCR for mycoplasma presence and replaced or treated in 
case of positive result.For cell counting, after trypsinization, cells were diluted 1:2 in Trypan Blue 
Dye (Amresco) and 10μL were loaded in a Neubauer chamber to count viable cells by optical 
microscopy (Olympus CKX31). The Trypan Blue dye allows to determine cell viability based in the 
fact that damaged or dead cells show disrupted plasma membrane and allow the internalization of 
the dye staining their cytoplasm in blue, while alive cells remain non-stained. In general 
experiments were performed with technical duplicates or triplicates and a minimum of three 
biological replicates (n=3 minimum). 
Table M7: Approximate cell-number seeded according to each experimental technique. 
 
II.1.2 Drugs 
Information regarding the different inhibitors and drugs used for this thesis work are depicted 
inTable M8. 
Table M8: Commercial information and experimental specifications for the different drugs used throughout 
the thesis work. 
Drug Supplier Dose Function 
Rapamycin 
LC Laboratories 
(Cat.# R-5000) 
20nM Specific mTOR inhibitor 
RAD001 
(Everolimus) 
Provided by Dr. 
Alimonti and Dr. Serra 
10mg/Kg Rapamycin derivative, mTOR inhibitor 
Torin-1 
Tocris Bioscience 
(Cat.#4247) 
125-250nM 
Potent and selective ATP-competitive 
mTORC1 and mTORC2 inhibitor 
MK2206 
Shelleckchem 
(Cat.# S1078) 
500nM Highly selective allosteric pan-AKT inhibitor  
SAM486A Novartis 0.5-1µM Competitive AMD1 inhibitor 
Cicloheximide Sigma 5µg/mL Protein synthesis inhibitor in eukaryotes 
MG132 
Provided by Dr. 
Rodriguez 
5µM 
Potent, membrane-permeable proteasome 
inhibitor 
Assay Cellular density per well Plate type 
 PC3 LNCaP DU145 22RV1  
Protein/RNA extraction 100000 300000 120000  6-well plate 
Growth Curves 5000 30000 7500  12-well plate 
Soft Agar 2500 5000 3000  6-well plate 
Foci Formation   500   
Cell-Cycle  250000   6-well plate 
BrDU Incorportion  40000   12-well plate 
Metabolo
mics 
GNTM OE 350000 1000000 425000 2000000 100mm 
AMD1 acute Silencing 
100000-
110000 
 
120000-
200000 
 
6-well plate 
AMD1 Inducible Silencing   
50000-
100000 
 
6-well plate 
AMD1 OE   200000  6-well plate 
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II.2 Methods 
II.2.1 Cloning 
Different cloning strategies were followed to obtain the lentiviral and retroviral vectors required for 
GNMToverexpression, PTEN (Wild-Type, WT; and C124S) re-expression, and AMD1 
overexpression and silencing. The different strategies are briefly detailed below (See Table M9 
for primer specifications): 
HA-GNMT-TRIPZ: 
PCEP4-GNMT vector was amplified using high-fidelity PCR with the primers specified in Table 
M9 (GNMT01 and GNMT02) to generate a HA-GNMT cassettecontaining the restriction sites for 
AgeI-MluI. GNMT01 and GNMT02 provide Kozak, ATG, and stop sequences, The resulting 
amplicon was subcloned with TOPO Cloning technology. Then, TOPO was digested with AgeI-
MluI and the GNMT bearing fragment was introduced in an inducible TRIPZ vector. 
TRIPZ-YFP-PTEN (WT and C124S, catalytic-dead mutant):  
TRIPZ-FF3shRNA was digested with AgeI-MluI, which releases the tRFP, shRNAmir, and 
barcode from the plasmid backbone.  Vector was gel-purified.  Using PTEN expression clones 
(WT or C124S; from Dr. Pandolfi´s lab), a YFP-GSG-PTEN cassette was created by overlap-
extension PCR using high-fidelity PCR (KAPA Biosystems). Outer primers PTEN03 and PTEN02 
provide Kozak, ATG, and stop sequences.  Inner bridging primers (PTEN04 and PTEN05) join the 
YFP and PTEN portions with a flexible Gly-Ser linker. The final resulting amplicon (~1.9kb) was 
cleaned up, digested with AgeI-MluI, gel-purified and cloned into TRIPZ-FF3shRNA AgeI-MluI.  
Colonies were screened by restriction digest and positives confirmed by Sanger sequencing. 
sh3 AMD1 pLKO Tet ON: 
Lentiviral inducible pLKO Tet ON vector was opened using AgeI-EcoRI (Fermentas/Takara-
Clontech). Specific shRNA sequences for AMD1 were obtained from SIGMA (MISSION® shRNA) 
(see Table M9). Complementary primers were designed, in which an EcoRI site was added in the 
5´end, coinciding with complementary AgeI site in the template sequence. For the annealing, 
11.25 µL of each primerwere added to a 25 µL reaction with 2.5µL 10X annealing buffer (100mM 
NaCl, 50 mM HEPES, pH=7.4). The reaction was added to a preheated thermoblock (95°C), 
allowed to incubate for 5 min, and then the thermoblock was switched off, allowing slow cooling to 
room temperature.2.5 µl of annealed oligos were ligated to 4µl of linearized vector, in a reaction of 
10 µl, with 2 µl of 5x Invitrogen ligase buffer and 1.5 µl of NBE ligase (Invitrogen). After 1hr of 
incubation at room temperature (RT), ligation was transformed into competent XL-10 Gold E. coli 
and selected on Amp plates. Positive colonies were confirmed by restriction digest and Sanger 
sequencing. 
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Table M9: Information about the specific primers utilized for the different cloning approaches. 
 
LNCX-neo (HCX): 
Retroviral expression vector LNCX-neo was opened using HindIII-ClaI (Fermentas/Thermo).  A 
multiple cloning site was created by inserting a double-stranded synthetic oligo pair into the 
HindIII-ClaI site, to create LNCX-neo (HCX). For the annealing, 5µl of each oligo (100 µM stock) 
(Metabion) were added to a 50µl reaction, including 200 mM NaCl, 10 mM Tris-HCl pH 7.9, 20mM 
MgCl2 (2X NEB Buffer 3). The reaction was added to a preheated thermoblock (95 °C), allowed to 
Number Name Purpose Sequence 
GNMT01 
AgeI-HA-
GNMT F 
To produce a PCR product with AgeI 
restriction site in 5´end 
ACCGGTGCCACCatggcttatccttacgacg
tgcctgactacgccATGGTGGACAGCGT
GTACCGGACCCGC 
GNMT02 
HA-GNMT-MluI 
R 
To produce a PCR product with AgeI 
restriction site 
ACGCGTTCAGTCTGTCCTCTTGAG
CACGTGGATG 
PTEN02 MluI.PTEN.rev 
2-step PCR cloning of PTEN WT and 
mutants with YFP tag; for cloning as 
AgeI-MluI into TRIPZ 
gatatcacgcgtTCAGACTTTTGTAATTT
GTGTATGCTGATC 
PTEN03 
AgeI.KozGFP.f
or 
2-step PCR cloning of PTEN WT and 
mutants with YFP tag; for cloning as 
AgeI-MluI into TRIPZ 
agatcaccggtgccaccATGGTGAGCAAG
GGCGAGGAGC 
 
PTEN04 
GFP.GSG.PT
EN.for 
 
2-step PCR cloning of PTEN WT and 
mutants with YFP tag; for cloning as 
AgeI-MluI into TRIPZ 
GGCATGGACGAGCTGTACAAGggca
gcggtATGACAGCCATCATCAAAGAG 
 
PTEN05 
GFP.GSG.PT
EN.rev 
 
2-step PCR cloning of PTEN WT and 
mutants with YFP tag; for cloning as 
AgeI-MluI into TRIPZ 
CTCTTTGATGATGGCTGTCATaccgct
gccCTTGTACAGCTCGTCCATGCC 
 
sh3AMD
T01 
sh3 AMD top 
To introduce the shRNA in the pLKO 
Tet ON vector 
CCGGGTCTCCAAGAGACGTTTCAT
TCTCGAGAATGAAACGTCTCTTGGA
GACTTTTTG 
sh3AMD
B01 
sh3 AMD 
bottom 
To introduce the shRNA in the pLKO 
Tet ON vector 
AATTCAAAAAGTCTCCAAGAGACGT
TTCATTCTCGAGAATGAAACGTCTC
TTGGAGACCCGG 
AC.AMD
01 
HABMSXNC. 
for 
Linker for LNCX; HIII-Age1-Bgl2-
Mlu1-Sal1-Xho1-Not1-Cla1 
AGCTTACCGGTAGATCTACGCGTG
TCGACCTCGAGGCGGCCGCAT 
AC.AMD
02 
HABMSXNC. 
rev 
Llinker for LNCX; HIII-Age1-Bgl2-
Mlu1-Sal1-Xho1-Not1-Cla1 
CGATGCGGCCGCCTCGAGGTCGA
CACGCGTAGATCTACCGGTA 
AC.AMD
07 
BamHI.NheI.M
YC.AMD1.for 
to amplify AMD1/mutants with a N-
terminal MYC tag 
GATCGGATCCGCTAGCGCCACCAT
GGAGCAGAAGCTGATCTCCGAGGA
GGACCTGGGCTCCATGGAAGCTGC
ACATTTTTTCGAA 
AC.AMD
10 
BamHI.SalI.H
A. rev 
 
to amplify AMD1/mutants with C-
terminal HA 
GATCGGATCCGATCGTCGACTCAA
GCGTAATCTGGAACATCGTATGGG
TA 
3336 
AMD1.S298A.
qc. for 
 
to mutate S298 in AMD1 
aaatgtcgcacagtgcttgctGCCccccagaag
attgaaggttttaagc 
3337 
AMD1.S298A.
qc. rev 
 
to mutate S298 in AMD1 gcttaaaaccttcaatcttctggggGGCagc
aagcactgtgcgacattt 
3338 
AMD1.S298D.
qc. for 
 
to mutate S298 in AMD1 
aaatgtcgcacagtgcttgctGACccccagaaga
ttgaaggttttaagc 
3339 
AMD1.S298D.
qc. rev 
to mutate S298 in AMD1 
gcttaaaaccttcaatcttctggggGTCagcaagc
actgtgcgacattt 
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incubate for 5 min, and then the thermoblock was switched off, allowing slow cooling to room 
temperature. Finally, ~100 ng of linearized vector was ligated to 1µl of annealed oligos, in a 
reaction of 10 µl, with 2 µl of 5x T4 DNA ligase buffer and 1µl of T4 DNA ligase (Invitrogen). After 
1h of incubation at RT, ligation was transformed into competent XL-10 Gold E. coli and selected 
on Amp plates. Positive colonies were screened by PCR, confirmed by restriction digest and 
Sanger sequencing. 
LNCX-MYC-AMD1(WT)-HA: 
A retroviral expression construct for N-terminal MYC- and C-terminal HA-tagged AMD1 was 
created.  Primer AC.AMD07 and AC.AMD08 were used to amplify the AMD1 ORF using high-
fidelity PCR (KAPA Biosystems).  The resulting amplicon (~1kb) was digested with BamH1-Sal1, 
and cloned into LNCX-neo (HCX) Bgl2-Sal1. 
LNCX-MYC-AMD1(S298A)-HA (phospho-dead mutant): 
These mutants were created by 2-step overlap extension PCR.  Briefly, oligos AC.AMD07 and 
mutagenic oligos 3337 (or 3339) were used to create a 5’ amplicon, while mutagenic oligos 3336 
(or 3338) and AC.AMD10 were used to create a 3’ amplicon, using AMD1(WT) ORF as a 
template. Amplicons were gel-purified, mixed, elongated using 10 cycles of 
melting/annealing/extension, without amplification.  Outer primers AC.AMD07 and AC.AMD10 
were added and PCR with amplification was carried out for 25 cycles.  The resulting composite 
amplicons were cleaned up, digested with BamH1-Sal1, gel-purified, and then cloned into LNCX-
neo (HCX) Bgl2-Sal1. Colonies were screened by restriction digest and positives confirmed by 
Sanger sequencing. 
 
II.2.2 Virus production and target cell line infection 
Virus production was performed by employing a packaging cellline and the target cellline in which 
the transgene was aimed to be introduced. 
The general protocol was similar for both lentivirus and retrovirus production (Fig. M7): 
 Day1: 
 Morning: Packaging cells were seeded at high density (4x106 cells/100mm plate)  
 Afternoon: Packaging cells were transfected 
 
 Day2: Packaging cells´ media was changed to fresh culture-media and target cell line 
was seeded. 
 
 Day3: Target cells were first infected with virus containing supernatant (SN) from 
packaging cells and fresh media was added to these cells for further virus production 
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 Day4: Second infection of target cells was performed with virus containing SN and 
packaging cells were discarded.  
For infection, SN from packaging cells was filtered with 0.45µm filters and 4mL of fresh 
media were added to a total of 13mL. Protamine sulfate (Stock 8mg/ml) was added to the 
mixture (1:1000 dilution) to increase infection efficiency. 
 
 Day5: Target cells were submitted to selection with the corresponding antibioticin each 
case. 
Figure M7.Schematic showing the experimental design followed for virus production. 
 
II.2.2.1 Transient transfection in HEK293 cells 
Virus production was performed by transient transfection of Human Embryonic Kidney 293 cells 
(HEK293). In transient transfection, the exogenous DNA is not inserted into the genome, and 
hence, it is diluted in subsequent cellular divisions. 
Cells were transfected with packaging vectors and the vector of interest (transfer vector), 
by calcium phosphate method, to produce viral particles. DNA was first diluted in miliQ-water and 
then CaCl2 was added to a final concentration of 125 mM. This DNA solution was then mixed with 
same volume of a 2x HEPES-Buffered Solution (HBS) [50mM HEPES, 280mM NaCl, 10mM KCl, 
1.5mM Na2HPO4. 2H2O, 12mM dextrose, pH=7.05] in the presence of oxygen to facilitate the 
formation of calcium phosphate crystals. These crystals form pores in the cytoplasmic membrane 
allowing exogenous DNA entrance. 
4x106 HEK293 cells were seeded for each transfection and culture media was changed to fresh 
media 16h post-transfection to induce viral particle production. Then, the viral particles produced 
were used to infect target cell lines for genetic modification. 
 
Packaging
cell seeding
Packaging
cell
transfection
Media 
change
Target cell
seeding
D1 D2 D3 D4 D5
1st Infection 2nd Infection Selection
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II.2.2.2 Lentivirus production and target cell-line infection 
Lentivirus production was performed in HEK293FT cells transfected with packaging vectors and 
the vector carrying the transgene (Fig M8). We used lentiviral infection to over-express GNMT 
and to silence AMD1 in PCa cell lines. Depending on the back-bone vector containing our gene or 
shRNA of interest, second generation or third generation packaging vectors were employed. 
Figure M8.Representative image showing packaging system and lentivirus production in HEK293 cells. 
 
II.2.2.2.1 Second Generation Lentivirus production 
GNMT and PTEN (WT and C124S mutant) were introduced in a doxycycline inducible TRIPZ 
vector. TRIPZ vectors are not compatible with third generation packaging systems. Thus, a 
second generation strategy was followed to produce the virus. Second generation lentiviral 
vectors consist of three plasmids normally: the transfer vector, containing all the cis-acting 
sequences required and the transgene to be delivered, and two packaging vectors psPAX2 and 
pVSV-G, which provide the trans-acting factors (Fig. M9). The separation of cis-acting and trans-
acting sequences reduces the probability of recombination producing replication-competent viral 
particles. In this particular case, due to the TRIPZ backbone of the GNMT and PTEN bearing 
vector, as aforementioned, a pTAT vector was needed to help in transcription (See Table M10). 
Figure M9.Informative image showing the fragmentation of the lentiviral genome into a second generation 
packaging system. 
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Second generation lentivirus production was performed following standard protocol 
mentioned in II.2.1. Target cell-lines (PC3, DU145, LNCaP and 22RV1) were submitted to 
puromycin (2ug/mL) selection for 48-72h. 
Table M10: Information regarding the specific vectors employed for second generation lentivirus production. 
 
II.2.2.2.2 Third Generation Lentivirus production 
Third generation virus (Fig. M10) were generated for constitutive and inducible silencing of AMD1 
in DU145 and PC3 cells. A set of five short-hairpin RNA (shRNA) sequences against AMD1 in a 
pLKO backbone were purchased from SIGMA (MISSION® shRNA Bacterial Glycerol Stock). 
Figure M10.Informative image showing the fragmentation of the lentiviral genome into a third generation 
packaging system. 
 The set of shRNAs was validated and two efficient shRNAs were selected for further 
experiments. One of those two selected sequences was then cloned into a doxycycline inducible 
pLKO backbone in collaboration with Dr. Sutherland. pLKO vectors are compatible with third 
generation lentivirus production. Third generation lentivirus require three packaging vectors 
(pRRE, pREV, pVSV-G; which decreases recombination probability and makes them more secure 
to handle than second generation ones) and transfer vector (See Figure M10,11 and Table M11). 
Vector Name Role 
Encoding 
sequences 
Function Origin 
Amount 
transfected 
psPAX2 
Packaging 
vector 
Gag-Pol 
integrase, reverse 
transcriptase, and structural 
proteins 
Dr. James D. 
Sutherland 
1.66µg RRE Rev-responsive element 
Rev 
Enhancer of unspliced viral 
genomic RNA nuclear export 
pVSV-G 
Packaging 
vector 
VSV-G Envelope protein 
Dr. James D. 
Sutherland 
1.66µg 
pTAT 
Helper 
vector 
TAT 
Enhances trancription 
efficiency 
Dr. James D. 
Sutherland 
1.66µg 
HA-GNMT-
TRIPZ 
Transfer 
vector 
GNMT Gene to over-express 
Dr. James D. 
Sutherland 
5µg 
TRIPZ-YFP-
PTEN-WT 
Transfer 
vector 
PTEN-WT Gene to over-express 
Dr. James D. 
Sutherland 
5µg 
TRIPZ-YFP-
PTEN-C124S 
Transfer 
vector 
PTEN-C124S Mutant to over-express 
Dr. James D. 
Sutherland 
5µg 
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Figure M11. Illustrative image explaining the third generation lentiviral production in HEK283 cells and 
posterior infection of target cells. 
   
Table M11: Information regarding the specific vectors employed for third generation lentivirus production 
Vector Name Role 
Encoding 
sequence
s 
Function/Sequence Origin Amount  
pRRE 
Packaging 
vector 
Gag-Pol 
Integrase, reverse 
transcriptase, and structural 
proteins 
Dr. James D. 
Sutherland 
1.66µg 
RRE Rev-responsive element 
pREV 
Packaging 
vector 
Rev 
Enhancer of unspliced viral 
genomic RNA nuclear export 
Dr. James D. 
Sutherland 
1.66µg 
pVSV-G 
Packaging 
vector 
VSV-G Envelope protein 
Dr. James D. 
Sutherland 
1.66µg 
sh3 AMD1-
pLKO 
Transfer 
vector 
shRNA 
against 
AMD1 
CCGGGTCTCCAAGAGACGT
TTCATTCTCGAGAATGAAAC
GTCTCTTGGAGACTTTTTG 
SIGMA 
TRCN0000078
462 
5µg 
sh4 AMD1-
pLKO 
Transfer 
vector 
shRNA 
against 
AMD1 
CCGGCCCATTAAGTAGTGT
TCTATACTCGAGTATAGAAC
ACTACTTAATGGGTTTTTG 
SIGMA 
TRCN0000078
458 
5µg 
sh3 AMD1 
pLKO TeT ON 
Transfer 
vector 
shRNA 
against 
AMD1 
CCGGGTCTCCAAGAGACGT
TTCATTCTCGAGAATGAAAC
GTCTCTTGGAGACTTTTTG 
Dr. James D. 
Sutherland 
5µg 
. 
pVSV-G
pRRE
pREV
pLKO
Adapted from http://www.invivogen.com/review-lentiviral-vectors
HEK293
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II.2.2.2.3 Constitutive Silencing of AMD1 
First attempts to silence AMD1 were performed with SN infection as explained in II.2.1.2. 
However, due to the high silencing efficiency and the aggressive phenotype (high percentage of 
dead) observed upon AMD1 silencing, freshly infected cells were required per experiment, 
because stable growth of AMD1 silenced cells was not viable. 
To optimize the timing per infection, virus was submitted to concentration procedures. 
Concentrated virus aliquots were generated following the time-schedule mentioned in Fig. M7. 
until day 3, in which the SN was collected, filtered and fresh media was added to HEK293FT 
cells. 3 volumes of clarified supernatant were combined with 1 volume of Lenti-X Concentrator 
and, after gently mixing it by inversion, it was incubated at 4ºC until next day SN collection. On 
day 4, same procedure was repeated and SN was incubated at 4ºC for 1-3 hours. SN from both 
days were mixed and centrifuged at 1500G for 45 minutes at 4ºC. After centrifugation, SN was 
discarded and the pellet was resuspended in 400µl of PBS and aliquoted in 20uL aliquots, based 
on previous experience. Once the virus was concentrated, target cells were seeded on day 1 in 
the morning, infected with an aliquot in the afternoon, infected for the second time on day 2 and 
submitted to puromycin (2ug/mL) selection on day 3 for three days. In this ways infection protocol 
was shortened from 5 days to 3 days. 
II.2.2.2.4 Inducible AMD1silencing 
Inducible silencing of AMD1 was performed by SN infection with a third generation system 
following the timing aformentioned in II.2.1. Target cells were submitted to selection pressure with 
puromycin (2ug/mL). Packaging and transfer vector information is mentioned in II.2.1.2.2. (See 
Table M10). 
 
II.2.2.3 Retrovirus production and target cell-line infection 
Retrovirus production was performed transfecting HEK293 Ampho cells. These cells derive from 
HEK 293 cells, but were generated to stably express the viral gag-pol and env genes (Fig. M12), 
allowing rapid production of high-titer replication-incompetent amphotropic retrovirus. Thus, for 
retrovirus generation these packaging cells were transfected with the transfer vector only (Fig. 
M13, right), following the time-line specified in II.2.1. Target DU145 cells were submitted to G418 
(Geneticin) selection (starting from 200ug/mL and scaling the dose to 1mg/mL to reach total 
selection) during 3-4 weeks, because puromycin was used to maintain stable expression of the 
viral genes in HEK293 Ampho cell generation. Retrovirus mediated transduction was performed 
to over-express wild-type and phospho-mutant (S298A) AMD1 in DU145 cells (Table M12). 
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Figure M12.Informative image showing the fragmentation of the retroviral genome into the packaging 
system. 
 
Table M12: Information regarding the specific vectors employed for retrovirus production. 
Vector Name Role 
Encoding 
sequences 
Function Origin 
Amount 
transfected 
LNCX Neo (HCX)  
HABMSXNC linker 
Transfer 
vector 
Empty vector Control cells 
Dr. James D. 
Sutherland 
5µg 
LNCX-MYC-AMD1-
HA 
Transfer 
vector 
AMD1-WT 
Gene to over-
express 
Dr. James D. 
Sutherland 
5µg 
LNCX-MYC-
AMD1S298A-HA 
Transfer 
vector 
AMD1-S298A 
Mutant to over-
express 
Dr. James D. 
Sutherland 
5µg 
 
Figure M13.Informative image showing different retroviral packaging methods. 
Adapted from https://www.addgene.org/viral-vectors/retrovirus/retro-guide/
Adapted from https://www.addgene.org/viral-vectors/retrovirus/retro-guide/
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II.2.3 Cellular analysis 
II.2.3.1 Cell-growth analysis by crystal violet staining 
Cells were seeded in 12 well-plates (5000-8000 cells/well) for days 0, 2, 4 and 6 or 0, 1, 2 and 3 
(depending on the experiment). Each plate was washed with 10% PBS, fixed with 10% formalin 
and stored at 4ºC for further processing of all plates at the same time. Once fixed (> 15 minutes 
with formalin), cells were stained with crystal violet (0,1% crystal violet, 20%) for 40 minutes. After 
washing (4xdH2O) and air drying the plates, precipitates were dissolved with 10% acetic acid for 
30 minutes and absorbance was measured in 96well-plates by spectrophotometer at 595nm. 
 
II.2.3.2 Anchorage-independent growth (Soft agar) 
Anchorage independent growth is considered an aggressiveness parameter, utilized to 
characterize cellular phenotypes in vitro. For cell plating in anchorage independent conditions, 6 
well-plates were previously coated with a lower layer of 0,6% agar (SeaKem LE agarose, 
Lonza)/medium mixture (3mL/well) and stored at 4ºC for at least 30 minutes to let the agar 
solidify. Previous to the upper layer seeding, cells (3000-5000 cells/well) were suspended in a 
0.3% low melting agar/medium mixture and 1,5mL/well were plated. Low melting agar allows to 
maintain the agar/cell mixtureliquified at lower temperature, to avoid harming cells. Plates were 
stored at 4ºC (around 20 mins) to allow the solidificationof upper layer and then incubated at 37ºC 
in a humidified atmosphere of 5% CO2 for 3-4 weeks, until colony detection. 
 
II.2.3.3 Foci formation assay 
Foci formation assay measures the clonogenic capacity of transformed cells (Alvarez et al., 
2014), by means of number of foci formed at very low seeding cellular density. To perform these 
experiments, 500 cells/well were seeded in 6well/plates in adherence and incubated at 37ºC in a 
humidified atmosphere of 5% CO2 for 10 days. Plates were then fixed with 10% formalin solution 
at 4ºC for at least 15 minutes, washed with PBS and stained with crystal violet (0.1% crystal 
violet, 20% methanol) for 40 minutes. After washing (4 x dH2O) and air drying, plates were 
scanned to obtain digitalized images for foci counting. After scanning the plates, crystal violet 
precipitates were dissolvedin 10% acetic acid for 30 minutes and absorbance was measured in 
96 well-plates by spectrophotometer at 595 nm, for cell number quantification. 
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II.2.3.4 DNA synthesis rate analysis by bromo deoxyurdine (BrdU) 
One of the most commonly used techniques to analyze cell proliferation is the incorporation of the 
thymidine pirimidine analogue BrdU (5-bromodeoxyurdine) into newly replicated DNA, based on 
the direct correlation between DNA replication and cell division. 
II.2.3.4.1 BrdU Incorporation 
This analogue when added in culture media gets incorporated into DNA, during DNA replication 
process (Darzynkiewicz and Juan, 2001). Since monoclonal antibodies were developed to target 
incorporated BrdU into DNA (Gratzner, 1982), BrdU has been extensively used to estimate cell 
proliferation by immunofluorescence. In this thesis work BrdU was used in asynchronic cultures. 
Cells were seeded onto coverslips and once adhered BrdU was added to culture media to a final 
concentration of 0,2µg/mL and incubated for 3-4h at 37ºC. After incubation cells were washed 
with PBS and fixed with 4% paraformaldehide (PFA) solution in PBS for 15 minutes. Cells were 
washed twice to eliminate remaining PFA and ¡coverslips were stored in PBS at 4ºC until 
processing. 
II.2.3.4.2 BrdU exposure and detection by immunofluorescence (IF) 
BrdU needs to be exposed to detect it with monoclonal antibodies. To this end, coverslips were 
incubated with HCl 2Nfor 5 minutes and quickly washed twice with PBS to further neutralize the 
acid with Borax (Sodium tetraborate 0.1M, pH8.5) for two minutes. Cells were permeabilized with 
Triton X100 0.1% for 5 minutes and 10% goat serum was employed as blocking reagent for 30 
minutes at RT. Primary antibody against BrdU (BD Pharmingen™, Cat# 555627) was incubated 
at 1:100 dilution overnight at 4ºC. The next day, secondary anti-mouse antibody (labelled with 
Alexa Fluor® 594 dye) was incubated at 1:1000 dilution in 10% goat serum for 1h in the dark. 
Finally, cells were stained with DAPI (1:1000 dilution in PBS) for nuclear staining and coverslips 
were mounted onto slides with home-made Mowiol. The slides were stored at 4ºC in the dark until 
analysis with the upright fluorescent microscope Axio Imager D1 (Carl Zeiss). 
 
II.2.3.5 Cell cycle analysis 
Propidium Iodide (PI) is an intercalating fluorescent agent extensively used for cellcycle analysis 
(Krishan, 1975). Harvested cells were suspended in 1mL of PBS and fixed drop by drop with 2.5 
mL of absolute ethanol (70% final ethanol concentration). Samples were incubated overnight at -
20ºC for fixation. Next, cells were centrifuged and suspended in 200-500µL of PI staining solution 
[RNase 25ug/ml (stock 1mg/ml), Triton X-100 0,05%, PI: 1 µg/ml (stock 1mg/ml)]. Samples were 
incubated for 20-40 minutes at 37ºC and analyzed by flowcytometry. 
Amaia Arruabarrena-Aristorena Doctoral Thesis  
 
 
 
100 
 
M
A
T
E
R
IA
L
S
 &
 
M
E
T
H
O
D
S
 
II.2.4 Molecular Assays 
Cells were seeded for a final density of around 70-80% in 6 well plates. Plates were washed with 
PBS and processed or snap-frozen in liquid-nitrogen for later protein or RNA extraction, unless 
otherwise specified. 
II.2.4.1 Gene expression analysis 
II.2.4.1.1 RNA extraction and retrotranscription 
RNA was extracted using NucleoSpin® RNA isolation kit from Macherey-Nagel (ref: 
740955.240C) according to manufacturer´s protocol and concentration was determined by 
Nanodrop ND-1000 Spectrophotometer. 
1μg of the obtained RNA was used for complementary DNA (cDNA) synthesis using qScript 
cDNA Supermix from Quanta (ref. 95048). Resulting cDNA was diluted 1/6-1/30 in fresh mQ 
water (depending on the expression levels of each gene) and 1µL was used for RT-QPCR 
reaction. 
 
II.2.4.1.2 Real time quantitative PCR (RT-Q-PCR) 
RT-QPCR was performed using Viia7 system from Life Technologies´. The RT-QPCRs were 
performed according to the following program: 2min at 50ºC and 10min at 95ºC (Hold Stage) 
followed by 40 cycles of 15sec at 95ºC (denaturalization) and 1min for 60ºC (annealing and 
elongation). Polyamine pathway related enzyme gene expression was analyzed with primers and 
probes from Universal Probe Library from Roche. The Universal Probe Library Assay Design 
Center is available on-line in:http://lifescience.roche.com/shop/en/mx/overviews/brand/universal-
probe-library. This tool allows the design of primers and assigns the respective probe needed for 
each reaction in order to build a TaqMan assay. Methionine cycle-related enzyme gene 
expression was analyzed by SYBRGreen Technology and primers were kindly provided by Dr. 
Woodhoo (CIC bioGUNE). For the analysis of reference house-keeping genes (Gapdh, GAPDH 
and β-ACTIN) Taqman Probes were used. Two different master mixes were used to catalyze the 
reaction: FastStart Universal Probe Master (Roche ref. 04914058001) and TaqMan® Universal 
Master Mix II (Life Technologies ref. 4440046). For quantification of changes in gene 
expression,Comparative Ct method was selected. See Table M13 for specific primer sequences 
and references. 
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Table M13: Table detailing the specific primer sequences and probe numbers from Universal Probe Library 
from Roche, specific primers for SYBR technology and references of Taqman technology probes used for 
RT-QPCRs. 
 
II.2.4.2 Protein expression analysis 
II.2.4.2.1 Protein extraction 
Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer (See Table M14 for recipe) 
for protein extraction, based on predicted protein molecular weights smaller than 200KDa.Lysates 
were rocked at 4ºC for 20 minutes, centrifuged at 13500 rpm for 10 minutes and the supernatant 
was recovered. Protein concentration was quantified with PierceTM BCA Protein Assay Kit 
(Thermo Fisher Scientific Cat# 23225), and lowest protein concentration in the sample set was 
used as reference for normalization. Samples were prepared in Laemmli sample buffer.  
Gene Species Technology Forward 5´-3´ Reverse 5´-3´ Probe 
SpmS Mouse UPL Roche CAGCACGCTCGACTTCAA CCAGGTGTGCACTGACTCTG #68 
SpdS Mouse UPL Roche TCCAGTGCGAGATTGATGAG CCCACGTGGAGAGTCAGC #78 
Amd1 Mouse 
UPL Roche 
Taqman 
GACGCATGAATTCTGACTGC 
Mm04207265 
TGGGTCAAGCTCACTCATCA 
 
#47 
 
 Odc1 Mouse UPL Roche GCTAAGTCGACCTTGTGAGGA AGCTGCTCATGGTTCTCGAT #80 
 Sat1 Mouse UPL Roche TCTTGAAGACTTCTTCGTGATGAG CATACTGCTGCAGCGACACT #110 
Paox Mouse UPL Roche ACCGTTCGGGGAGTATACAGT TCGGTAAGTCCTTGGTAGCC #26 
Slc3a2 Mouse UPL Roche CAAAGTGCCAAGAAAAAGAGC CTGAGCAGGGAGGAACCAC #81 
Cbs Mouse SYBR CTTCAGGGACATCCCAGTGT AGCTGCCAGGTACATCTGCT 
 
Cth Mouse SYBR TGTTAAGGCCTTCCTCAAAA GTCCTTCTCAGGCACAGAGG 
 
Mthfr Mouse SYBR CAGGTCATCCTCGAAGCTCT AGACCTGGTGAAGCACATCC 
 
Ms Mouse SYBR CATCCAAGAGTGTGGTGGTG ATAAACGTGGGCTTCACTGG 
 
Sahh Mouse SYBR CCTGGCATCTCATTCTCAGC CGCCAGCATGTCTGATAAAC 
 
Bhmt Mouse SYBR GAACTCCCGATGAAGCTGAC CTTTGCACTGGAAAAGAGGG 
 
Pemt Mouse SYBR AGTTCTCTGCTCCCATCTCG AGTTCTCTGCTCCCATCTCG 
 
Mat2a Mouse SYBR CTTCCTTCAGAGAGCAGTGCTTT CTTACGCCATACCCCAGAATACA 
 
Mat2b Mouse SYBR CCAGTGGCACCAGTAATGAG AGCTCTCCATCCACTTCGTC 
 
Gnmt Mouse 
SYBR 
Taqman 
AAGCCCTCTTCCACCAGC 
Mm 4689 m1 
AGTACAAGGCGTGGTTGCTT 
  
Gnmt 338 Mouse SYBR AAAGGATGGCTCTTTCCTCC GTGCTGACGTAGCCTGTG 
 
Sardh Mouse 
SYBR 
Taqman 
GACAAAGGACAGCCTGATGG 
M 4657 m 
GCAGGATGTGCTTGATGCT 
  
Gapdh Mouse Taqman Mm99999915_g1   
AMD1 Human 
UPL Roche 
Taqman 
CAGACCTCCTATGATGACCTGA 
Hs00750876s1 
TCAGGTCACGAATTCCACTCT 
 
#72 
 
ODC1 Human UPL Roche 
AAAACATGGGCGCTTACACT 
TGGAATTGCTGCATGAGTTG #3 
GAPDH Human Taqman Hs02758991_g1   
β-ACTIN Human Taqman Hs99999903_m1   
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Table M14: Reagent concentrations used to prepare RIPA buffer for protein extraction 
RIPA Buffer Stock concentration Final concentration 
TrisHCl (pH 7.5) 2 M 50 mM 
NaCl 5 M 150 mM 
EDTA 0.5 M 1 mM 
SDS 10 % 0.10 % 
Sodium Deoxycholate 10 % 1 % 
NP-40 10 % 1 % 
Complete Protease inhibitors  1 pill/50mL 
NaF, NaOv,β-GP 100 mM 1 mM 
 
II.2.4.2.2 Western Blotting (WB) 
Protein lysates were boiled at 95ºC for 5 minutes for denaturalization, resolved in NuPAGE® 
Novex® 4-12% Bis-Tris Midi Protein gels (ref: WG1403BOX) at 180V for 1h 20mins in MES Buffer 
1X or MOPS Buffer 1X and transferred to nitrocellulose membranes at 100V for 1h 45mins. 
The membranes were blocked with 5% non-fat milk prepared in Tris-buffered saline solution 
containing 0,01% Tween-20 (TBS-T) and primary antibodies were incubated at 4ºC over-night 
(o/n). See table M15 for references of antibodies used for Western Blotting. 
Table M15: References and conditions of primary and secondary antibodies employed for western blotting 
and immunoprecipitation. 
Antibody (Clone) Reference Species Dilution 
AMD1 Proteintech 11052-1-AP Rabbit 1:1000 
AKTS473 (D9E) Cell Signaling Technology #4060 Rabbit 1:1000 
AKT Cell Signaling Technology #9272 Rabbit 1:1000 
 RpS6S240/244 Cell Signaling Technology #2215 Rabbit 1:1000 
 RpS6(54D2) Cell Signaling Technology #2317 Mouse 1:1000 
PTEN(6H2.1) CASCADEABM-2052 Mouse 1:1000 
c-MYC (D3N8F) Cell Signaling Technology #13987 Rabbit 1:1000 
HA-tag (16B12) COVANCE Mouse 1:1000 
β-ACTIN SIGMA A5316 Mouse 1:1000 
HSP90 Cell Signaling Technology #4874 Rabbit 1:1000 
α-TUBULIN ? - 1:1000 
Secondary Rabbit ab Jackson ImmunoResearch Rabbit 1:4000 
Secondary Mouse ab Jackson ImmunoResearch Mouse 1:4000 
 
II.2.4.2.3 Protein Immunoprecipitation (IP) Assay 
 Protein immunoprecipitation was performed to analyze AMD1 synthesis rate and for the 
phosphoproteomics study of AMD1 phosphorylation sites. Cell plates were washed with ice cold 
PBS (3 ml/p60; 5mL/p100; 10mL/p150) directly after removing medium and placed on a bed of 
ice. Cells were scrapped with RIPA lysis buffer and protein extraction and quantification was 
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performed as explained in II.2.3.2.1. 1mg of protein incubated diluted in a total volume of 800µL 
using pre-cold IP buffer (See table M16 for recipe) for immunoprecipitation with the primary 
antibody. For endogenous AMD1 precipitation, anti-AMD1 antibody (11052-1-AP, Proteintech) 
and Protein A/G agarose beads (PierceTM Thermo, Cat# 20421) were utilized, while exogenous 
AMD1 was immunoprecipitated with agarose HA-beads (A2095 SIGMA). Beads were centrifuged 
(30 seconds at 10000rpm at 4ºC) and washed with IP buffer (800µL) five times. After last washing 
step beads were dryed with capillary tips and suspended in 2x Laemmli sample buffer for elution 
by boiling them at 95ºC for 5 minutes. Bead supernatants were loaded in a bis-acrylamide gel for 
migration.  
Table M16: Reagent concentrations used to prepare immunoprecipitation buffer. 
 Stock [  ] For 50 mL Final [  ] 
Tris pH 7,6 2 M 1 mL 40 mM 
EDTA pH 8 0.5 M 0.1 mL 1 mM 
MgCl2 1 M 50 uL 1 mM 
NaCl 5 M 1.5 mL 150 mM 
Triton-100 10 % 500 uL 0.1 % 
NaF,Na Orthovanadate, β-GP 100 mM 500 uL/each 1 mM 
Protease Inhibitor Cocktail  1 pill  
 
II.2.4.2.4 AMD1 translation rate by 35S-Met labelling 
For AMD1 synthesis with radio-labelling assay, PC3 and DU145 cells were treated with either 
vehicle (dimethylsulfoxide (DMSO)) or Rapamycin (20 nM) for 20h in 60mm (PC3) and 100 mm 
(DU145) dishes. To asses AMD1 synthesis, cells were starved for 40 min from methionine and 
cystine and radio-labelled for 30 min with a 35S-Met/Cys mix (Cat# NEG772002MC EasyTag™ 
EXPRESS35S Protein Labeling Mix, [35S]-, 2 mCi (74 MBq), Stabilized Aqueous Solution) before 
lysis. Protein lysates were incubated with protein A/G agarose beads (30 uL) for 1h to pre-clear 
non-specific binding to the beads. Precleared lysates were then incubated with anti-AMD1 
polyclonal antibody (11052-1-AP, Proteintech) overnight at 4ºC in 400 µL of RIPA buffer. Next, 
samples were incubated with protein A/G agarose beads for 1h and following immunoprecipitation 
bead washing steps were performed as explained in II.2.3.2.3. Lysate migration was performed in 
a NuPAGE™ (Novex™ 4-12% Bis-Tris Protein Gels, 1.0 mm, 12-well, Life Technologies) precast 
gel, in parallel with Input samples as a control of total AMD1 levels and rapamycin effect. After 
migration, the gel was submitted to fixation in a trichloroacetic acid (TCA) solution [10 % TCA, 10 
% acetic acid, and 30 % ethanol] for 30 minutes and to signal amplification in sodium salicylate (1 
M) for 1h. The gel was then dried (Model 583 gel dryer, BIORAD) and exposed to a film at -80ºC 
for at least 96h (Fig. M12). 
II.2.4.2.5 Polysome Profiling 
Distribution of mRNAs across sucrose gradients was performed as described earlier (Fumagalli et 
al., 2012), except for minor modifications. 
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II.2.4.2.5.1 Sample extraction 
Briefly, 3,5x106 DU145 cells were plated in 150mm plates to ensure a final density no higher than 
50-60%. After 24h, cells were treated with either vehicle (DMSO) or rapamycin (20 nM) for 8 
hours. After treatment, cycloheximide (CHX) was added to the medium at 37ºC for 5 min at a 
concentration of 100 µg/mL. Cells were washed twice with cold PBS supplemented with CHX 
(100 µg/mL), scraped on ice and pelleted by centrifugation at 3000 rpm for 3’. Cell pellets were 
suspended in 250 μl of fresh hypotonic lysis buffer [1.5 mM KCl, 2.5 mM MgCl2, 5mM Tris HCl 
pH7.4, 1 mM dithiothreitol (DTT), 1% sodium deoxycholate, 1 % Triton X-100, 100 μg/ml CHX] 
supplemented with protease inhibitors Cocktail (Roche) and RNAse inhibitor (New England 
Biolabs) at a concentration of 100 U/ml and left on ice for 5 minutes. Cell lysates were cleared of 
debris and nuclei by centrifugation for 5 minutes at 13000 rpm and 4ºC, and the polysomal lysate 
in supernatant was transferred to new tubes. Protein concentrations were determined by BCA 
assay and aliquots of 900 µg-1,5 mg protein in 200 µL (same protein amount and volume among 
conditions per experiment) were prepared. Aliquots were snap frozen in liquid nitrogen, stored at -
80ºC and shipped to Dr. Thomas laboratory in IDIBELL for polysome profiling by Dr. Antonio 
Gentilella. 
 
35S-Met Pulse
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Rapamycin
30´
1h
Met depletion
1 x PBS
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NP-40
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31 KDa
38 KDa
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AMD1 
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Figure M12. Schematic of the protocol followed to analyze AMD1 protein synthesis rate. 
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II.2.4.2.5.2 Sample processing 
500 μg of lysate were loaded on 10-50% sucrose linear gradients containing 80 mM NaCl, 
5 mM MgCl2, 20 mM Tris HCl pH7.4, 1 mM DTT, 10 U/ml RNase inhibitor with a BIOCOMP 
gradient master. Gradients were centrifuged on a SW40 rotor for 3 hours at 35000 rpm. Gradients 
were analyzed on a BIOCOMP gradient station and collected in 12 fractions ranging from light to 
heavy sucrose. Fractions were supplemented with SDS at a final concentration of 1% and placed 
for 10 min at 65ºC. To each fraction was added 1ng of firefly luciferase mRNA, followed by 
phenol-chloroform extraction and precipitation with isopropanol. Purified RNAs from each fraction 
were reverse-transcribed and subjected to RT-QPCR. mRNA quantification was normalized to 
firefly mRNA.  
II.2.4.2.6 Phosphoproteomics 
DU145 cells stably expressing Myc-AMD1-HA were plated in 2-3 150mm plates per 
condition to ensure a final density no higher than 50-60% and sufficient protein amount to 
immunoprecipitate ectopic AMD1 and detect the corresponding band by Sypro-Ruby (Invitrogen, 
S12000) gel staining . Cells were treated for 8 hours with rapamycin (20nM) and Torin-1 (250nM) 
prior to immunoprecipitation, 
II.2.4.2.6.1 Sample Preparation 
Cells were washed with PBS on a bed of ice and lysed in 300µL RIPA lysis buffer per plate. 
Plates were scrapped and protein extraction was performed as explained in II.2.3.2.1. Ectopic 
AMD1 was immunoprecipitated as detailed in II.2.3.2.3. Specifically, the IP was performed in a 
total volume of 1mL with 40µL of HA-beads (A2095 SIGMA) for 1hour rolling at 4ºC. Beads were 
washed 5 times with IP Buffer and immunoprecipitate was prepared in 80 µL 2xLaemmli by 
boiling the samples at 95ºC for 5 min. After migrating samples in a 10% Sodium Dodecyl Sulfate 
Polyacrylamide MiniGel, the gel was fixed in fixing solution [10% acetic acid and 30% ethanol, 
fresh prepared] for 30 min and stained overnight with Sypro-Ruby (Invitrogen, S12000) under 
agitation in the dark. Next, the gel was rinsed in unstaining solution and water several times prior 
to image acquisition in theTyphoon Trio scanner (Variable Mode imager) (GE Healthcare life 
sciences). 
 The bands were unstained with several washes of 40% acetonitrile (ACN) in 50 mM 
ammonium bicarbonate. Then the proteins were reduced with 15 mM tris(2-
carboxyethyl)phosphine (TCEP) in 50 mM ammonium bicarbonate for 30 min at room 
temperature and alkylated with 55mM for 30 min in the dark. Proteins were digested overnight at 
37ºC with trypsin. The resulting peptides were desalted and concentrated using homemade 
reversed phase micro-columns filled with Poros Oligo R3 beads (Life Technologies). The samples 
were dried using the Speed-Vac and dissolved in 22 µL of loading buffer (0.1% formic acid).  
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II.2.4.2.6.2 LC-MS/MS analysis 
LC-MS/MS was performed by Pilar Ximenez and Javier Muñoz at CNIO. Peptides were separated 
by reversed-phase chromatography using a nanoLC Ultra system (Eksigent), directly coupled with 
a LTQ-Orbitrap Velos instrument (Thermo Fisher Scientific) via nanoelectrospray source 
(ProxeonBiosystem). Peptides were loaded onto the column (Dr. Maisch, ReproSil-Pur C18-AQ 
GmbH 2.4 µm, 500x0.075 mm), with a previous trapping column step (NS-MP-10 BioSphere C18 
5 µm 120 Å 360/100 µm, L=20 mm, Nanoseparations), during 10 min with a flow rate of 2.5 µl/min 
of loading buffer (0.1% formaldehyde, FA). Elution from the column was made with a 60 min 
linear gradient (buffer A: 4 % ACN, 0.1 % FA; buffer B: 100 % ACN, 0.1 % FA) at 250 nL/min. The 
peptides were directly electrosprayed into the mass spectrometer using a PicoTip emitter (360/20 
OD/ID µm tip ID 10 µm, New Objective), a 1.4 kV spray voltage with a heated capillary 
temperature of 325°C and S-Lens of 60 %. Mass spectra were acquired in a data-dependent 
manner, with an automatic switch between MS and MS/MS scans using a top 5 method with a 
threshold signal of 800 counts. MS spectra were acquired with a resolution of 60000 (FWHM) at 
400 m/z in the Orbitrap, scanning a mass range between 350 and 1500 m/z. Peptide 
fragmentation was performed using collision induced dissociation (CID/CAD) and fragment ions 
were detected in the linear ion trap. The normalized collision energy was set to 35%, the Q value 
to 0.25 and the activation time to 10 ms. The maximum ion injection times for the survey scan and 
the MS/MS scans were 500 ms and 100 ms respectively and the ion target values were set to 
1E6 and 5000, respectively for each scan mode.  
II.2.4.2.6.3 Data analysis 
Data analysis was performed by Pilar Ximenez and Javier Muñoz at CNIO. Raw files were 
analyzed either by Proteome Discoverer (version 1.4.1.2) or by MaxQuant (Cox and Mann, 2008) 
(version 1.5.3.30) against a forward-reverse concatenated human database (UniProtKB/Swiss-
Prot 20,187 sequences), including common contaminants. Carbamidomethylation of cysteines 
was considered as fixed modification whereas oxidation of methionines and phosphorylation on 
serine, threonine and tyrosine residues were set as variable modifications in both Sequest HT and 
Andromeda search engine (v2.2). Sequest HT, in conjunction with Percolator provided the list of 
proteins for Proteome Discoverer. Minimal peptide length was set to 6 amino acids and a 
maximum of two missed-cleavages were allowed. Peptides were filtered at 1% FDR (False 
Discovery Rate). For protein assessment in MaxQuant, at least one peptide provided by 
Andromeda search engine(Cox et al., 2011) with a FDR = 1% was required. Other parameters 
were set as default. Results at peptide label were exported to excel for further analysis. Extracted 
ion Chromatograms (XIC) of the identified phosphopeptides were manually obtained from 
Xcalibur (version 2.2). In order to normalize the XICs to the total protein amount, absolute 
intensities from MaxQuant were considered. 
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II.2.4.3 In-House targeted metabolomic approaches 
All samples were seeded in 6-well plates, unless otherwise specified, to a final density of no more 
than 80% of confluence, adjusting seeding cell numbers per condition to reach similar final 
density. At the experimental end-point, cells were washed three times with ammonium carbonate 
pH=7.4 (adjusted with acetic acid and sodium hydroxide), prepared in High-Performance Liquid 
Chromatography (HPLC) water, snap frozen in liquid nitrogen and stored at -80ºC until 
processing. 
II.2.4.3.1 One carbon Metabolism and Polyamine Pathway analysis by LC/MS in 
vitro 
Cell samples were shipped in frozen plates to Agios Pharmaceuticals, where metabolites were 
extracted and processed by LC/MS as specified in I.2.5.2.  
II.2.4.3.2 dcSAM and polyamine quantification in vitro 
Frozen plates were processed by the metabolomics platform in CIC bioGUNE to extract the 
metabolites and analyze them by UPLC-MS as specified in I.2.5.3. 
II.2.4.3.3 MFA in vitro 
Seeded cells were treated with either vehicle (DMSO) or rapamycin (20nM) in fresh medium for 
30 hours. After the treatment, cells were washed with methionine free (Gibco, Cat. # 21013-024) 
medium (with dialyzed FBS or no serum) and incubated with U-13C5-L-methionine (30 µg/mL) 
resuspended in same methionine-free medium (with dialyzed FBS or no serum) for 15 min to 
detect metabolites related to methionine cycle and 2 hours to detect metabolites related to 
polyamine synthesis pathway. 
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III STATISTICAL ANALYSIS 
All experiments were performed a minimum of three times (biological replicates), except for the 
exploratory experiments, such as metabolomics by ToF-MS, LC/MS, UPLC-MS or preclinical trials 
with mice, that were done once, but with independent biological replicates (n≥3). 
 Values in histograms represent average value, while values in plot graphs show individual 
values, with a line representing the mean in parametric analyses or the median in non-parametric 
analyses . The error bars represent the standard error (Std Er) in the parametric analyses, while 
they depict the interquartile range in non-parametric analyses . The confidence interval (CI) 
established for the statistical analysis was 95% (α=0.05). 
When comparing datasets from cell culture origin, a normal distribution was assumed and the 
statistic used for the analysis was paired or unpaired Student T-test, depending on the existence 
of dependency among samples. However, when analyzing differences among datasets from 
murine or human origin, a Gaussian distribution could not be assumed and thus, non--parametric 
Mann Whitney U-test was chosen for the analysis. Two-tailed analysis were the choice for 
experiments with non-predicted result, while one-tailed analysis was performed for hypothesis 
driven validations. 
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I Integrative metabolic study to uncover metabolic alterations 
underlying prostate cancer (PCa) 
The first aim of this thesis work was to uncover the metabolic alterations underlying the 
pathogenesis of PCa in order to understand the metabolic requirements of cancer cells. 
  
 In the last fifteen years, multiple studies have attempted to tackle this question by 
developing and applying metabolomics technologies to cancer models. These efforts have 
allowed to establish that the metabolome (the compendium of low-molecular weight intermediates 
produced by cellular biochemical reactions) (Oliver et al., 1998) is intrinsically different in normal 
and cancer cells, as well as among different cancer types (Liesenfeld et al., 2013). After the 
genomic and proteomic eras, metabolomics is considered the closest approach to understand 
cellular phenotypes (Liesenfeld et al., 2013). 
 Several metabolomics studies have been performed on cancer patient specimens, to 
elucidate key molecular alterations underlying tumorigenesis that would in turn help to find early 
diagnostic biomarkers (Ren et al., 2015). However, there is intrinsic noise in these analyses, 
coming from the complexity of human samples and inter-individual variability. This highlights the 
challenge of defining consistent and relevant altered pathways. In turn, metabolic studies 
identifying novel metabolic biomarkers remain controversial, such as sarcosine for prostate 
cancer diagnosis (Sreekumar et al., 2009). To avoid such heterogeneity, in this project we 
decided to take advantage of our Pten prostate-specific knockout genetic engineered mouse 
model (GEMM) (Pten pc-/-), that faithfully recapitulates the pathogenesis of the human disease, for 
a profound metabolic study.In order to better understand the development of the disease, we 
analyzed tissue from three different prostate lobes (the ventral, VP; the anterior, AP, and the 
dorsolateral, DLP) and two different ages, three and six month-old mice, as representative of 
early (prostate intraepithelial neoplasia - PIN - lesions) and late (prostate invasive carcinoma -
PCa) disease, respectively (Fig. R1). 
With these representative samples we performed an integrative metabolomics study by 
combining the power of untargeted metabolomics, the resolution of targeted metabolomics and 
the dynamism of isotope-labeled metabolite tracing. 
 
HYPOTHESIS 
Prostate cancer harbors metabolic alterations relevant to the pathogenesis of the 
disease 
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Figure R1. General experimental design of in vivo experiments. Pten pc-/- mice were compared to Pten 
pc+/+ mice at three (when mice develop PIN lesions) and six (when mice develop PCa) months of age. The 
three different lobes (VP, AP and DLP) of mouse prostate were extracted and snap-frozen in liquid N2 for 
metabolomics analysis. 
 
A. High-throughput Flow Injection-Time-of-Flight Mass Spectrometry (FI-ToF-MS) 
We first decided to perform an untargeted metabolic study by Time-of-Flight Mass Spectrometry 
(ToF-MS) to have an overall idea of the metabolic alterations that the loss of Pten could trigger 
during prostate tumorigenesis. We therefore measured hundreds of ionized peptides in an 
unbiased way (Hypothesis-generating approach) (Fig. R2A). 
 In this technique, the flow injection, omitting the usual chromatography, allows to analyze 
more than 1400 samples a day, making possible the analysis of all the samples of the study in a 
day to avoid the variability derived from measurements performed in different days. Furthermore, 
ToF-MS enables the detection and identification of metabolites, based on their mass to charge 
ratio (m/z). However, this technique only provides a semi-quantitative measurement of the altered 
metabolites (Fuhrer et al., 2011). 
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Figure R2. Experimental design of the integrative metabolomic study. The first study was approached 
by untargeted ToF-MS analysis (A). The second study was performed by targeted quantitative LC/MS 
analysis (B). Finally, results were corroborated by a dynamic U-13C5-labeled methionine tracing experiment. 
 
B. Liquid Chromatography / Mass Spectrometry (LC/MS) 
Based on the data obtained by FI-ToF-MS, we then decided to perform a hypothesis driven 
targeted metabolic experiment by LC/MS (Fig. R2B).With this strategy, we aimed at confirming 
the previous observations and obtaining a more accurate quantification. Thus, in this approach we 
only included the altered pathways and related routes detected by ToF-MS, hence decreasing the 
number of metabolites analyzed, and in accordance with the separation limit of the 
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chromatography (Fuhrer et al., 2011). Nevertheless, LC/MS shows very high specificity and 
quantitative reproducibility (Patti et al., 2012), what has promoted its use as a main option of 
choice for numerous metabolic studies (Liesenfeld et al., 2013).This second approach provided 
us with important accurate information and quantification of altered metabolites in PCa. However, 
these data were limited by its static nature. Due to the dynamic nature of metabolism, we 
perceived that these results were insufficient to understand the biochemical cues that drive those 
alterations (Zamboni et al., 2015). In order to overcome this limitation, we sought to apply 
metabolite tracing (Fig. R2C), a technique that allows the interpretation of dynamic metabolic data 
(Feng et al., 2012). 
C. In vivo 13C labeling Metabolic Flux Analysis (MFA) by LC/MS 
The purpose of labeling a metabolite of interest with 13C is to trace the fate of carbons derived 
from that metabolite in the metabolic pathway of choice. In this work we designed an in vivo non-
stationary MFA experiment, which focuses on the kinetics of the labeled isotope propagation 
before reaching isotopic equilibrium (Zamboni et al., 2015) (Fig. R2C). In this way, we have not 
only the measurement of the concentration of each metabolite by LC/MS, but also information 
about the flux from a particular metabolite into the related pathways. The fluxes provide 
directionality to the metabolic analysis, and the combination of 13C vs. 12C abundance for a 
carbon in a metabolite, informs about the reaction that originates the molecule. These knowledge 
is crucial in order to understand the mechanisms for metabolic regulation and in disease vs. 
healthy settings provides very valuable information in order to ascertain potential therapeutic 
targets (Zamboni et al., 2015).  
 
I.1.1 ToF-MS metabolomics. 
As mentioned in the description of the general experimental design followed for the integrative 
metabolomics study (Fig. R2), the first analysis was performed using FI-ToF-MS. In this first 
untargeted metabolomics experiment we analyzed prostate tissues from VP, AP and DLP lobes of 
Pten pc+/+ and Pten pc-/- mice at the age of three and six months in order to have representative 
time points of early (PIN) and advanced (PCa) disease. 
 At first glance, data represented in volcano plots showed multiple increased (Fold Change 
(FC)>1.5; p-value<0.05) and decreased (FC<1.5; p-value<0.05) ions, corresponding to altered 
metabolites (Fig. R3A). Furthermore, the number of altered metabolites increased as the disease 
progressed. However, that increase was variable among the prostate lobes: VP showed a 13.1% 
(61 significantly altered ions/3Mo; 69 significantly altered ions/6Mo) increase in altered 
metabolites in the Pten pc-/- mice compared to Pten pc+/+ (Table S1), while we could observe a 25% 
(80 significantly altered ions /3Mo; 100 significantly altered ions/6Mo) (Fig. R3B) increase in the 
DLP and a further increase of a 110% (60significantly altered ions/3Mo; 126 significantly altered 
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ions/6Mo) (Fig. R3C) in the AP. These results suggest different metabolic impact of Pten deletion 
and prostate tumorigenesis in the different lobes. 
 We identified 156 total metabolites (Fig. R3), based on their mass-to-charge ratio. From 
those, 130 were significantly altered in Pten pc-/- mice compared to Pten pc+/+ , in at least one of the 
lobes and time points. Such a numerous amount of alterations made it complicated to identify at a 
glance the metabolic pathways relevant to the disease. Thus, to further understand the implication 
of the deregulated metabolites observed, we analyzed the data by an enrichment analysis. This 
computational method identified several altered metabolic pathways in the different lobes of Pten 
pc-/- mice. Thus, data was represented as percentage of altered metabolites (Fig. R4). 
 In coherence with our previous observations, VP seemed to follow different disease 
evolution compared to AP and DLP, by means of altered pathway number. Indeed, no significant 
hits arose at three months of age in this lobe and only three metabolic pathways stood out as 
significantly altered at six months (Fig. R4A). These results could be explained by the different 
histological features of the three mouse prostate lobes and the higher similarity between DLP and 
AP. VP is composed of a flat monolayer of luminal cells, DLP shows a slightly stratified simple 
epithelium and AP is the lobe with the most marked papillary structure (Shappell et al., 2004). 
Based on the previous observations and the differential histological structure, we decided to focus 
in AP and DLP lobes for consistency for further analysis. Among the top hits, we observed 
consistent alterations in pathways related to amino acids (aa) (threonine, Thr/T; cysteine, Cys/C; 
glutamate, Glu/E; glutamine, Gln/Q; branched chain aa and Urea cycle), sugar (amino sugars) 
and mitochondrial metabolism (TCA, electron transport chain, ETC; oxidative phosphorylation, 
OXPHOS; and reactive oxygen species, ROS) (Fig. R3A,B). We then decided to consider 
pathways robustly altered in at least three of the four experimental settings: 
 
I.1.1.1 Tricarboxylic Acid Cycle (TCA) 
The Warburg effect establishes that cancer cells exhibit a preference for glycolysis as source of 
energy and metabolic intermediates, alternatively to the TCA, even in the presence of oxygen 
(Vander Heiden et al., 2009; Warburg, 1956b). In this respect, despite the fact that mutations in 
TCA enzymes have been associated to tumorigenesis, it has been found that these metabolic 
alterations stem primarily from the deregulation of oncogenes or tumor suppressors (Desideri et 
al., 2015). The enrichment analysis of the ToF-MS data (Fig. R4, in orange) revealed alterations 
in TCA related metabolites, such as a decrease in succinyl-CoA levels, which correlated with a 
less oxidative phenotype (Cardaci et al., 2012; Torrano et al., 2016). However, many other 
alterations where related to less TCA-specific metabolites, such us nicotinamide adenine 
dinucleotide (NAD) or quinone.  
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Figure R3. ToF-MS study unraveled increasing number of metabolic alterations through PCa 
development. Volcano plots representing each decreased (blue dots) or increased (red dots) ion detected 
by ToF-MS (FC>1.5 and FC<1.5; p-value<0.05) in VP (A), AP (B) and DLP (C) lobes at three months of age 
(left column) and six months of age (right column). Y axis represents negative Log10 of the adjusted p-
values. X axis represents Log2 Pten pc-/- to Pten pc+/+ fold change percentage of altered metabolites. 
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The Warburg effect was originally attributed to mitochondrial dysfunction and ROS production, 
although a causal effect remains unclear (Senyilmaz and Teleman, 2015). Other lines of research 
in the lab are focused in the regulation of this metabolic pathway (Torrano et al., 2016).  
I.1.1.2 Amino Sugar Synthesis Pathway 
Another top hit of the ToF-MS enrichment analysis was the amino sugar synthesis pathway or 
hexosamine biosynthetic pathway (HBP) (Fig. R4, in purple). N-acetylglucosamine (GlcNAc) was 
among the top altered metabolites in this group. GlcNAc is covalently bound to the hydroxyl group 
of serine (Ser, S) or Thr residues inproteins by the O-GlcNAc tranferase (OGT), a post-
translational modification process called O-Glc-N-acylation. Cancer cells have higher glucose 
uptake (Vander Heiden et al., 2009; DeBerardinis et al., 2008; Warburg, 1956b) which favors the 
synthesis of GlcNAc and consequent O-Glc-N-acylation. Indeed, the latter has been suggested as 
a nutrient sensor and metabolic regulator (Hanover et al., 2010; Jóźwiak et al., 2014). Hyper-O-
Glc-N-acylation and/or increased OGT expression have been related to different cancer type 
pathogenesis in multiple publications in the last five years (Ma and Vosseller, 2013), which is in 
line with our data. This pathway was first reported to increase breast cancer aggressiveness (Gu 
et al., 2010), but was later demonstrated to participate in various other cancer types, including 
PCa (Lynch et al., 2012) and pancreatic cancer (Guillaumond et al., 2013). 
I.1.1.3 Branched Chain Amino Acid (BCAA) Metabolism 
BCAA (Fig. R4, in light grey) are leucine (Leu, L), isoleucine (Ile, I) and valine (Val, V), and they 
compose around the 35% of essential amino acids in muscle proteins (O’Connell, 2013). BCAAs 
are first transaminated by the enzyme branched chain aminotransferase to produce branched 
chain ketoacids (BCKA) (O’Connell, 2013). This first reaction requires α-KG for the 
transamination, producing Glu in the reaction, which links BCAA metabolism to the previously 
mentioned TCA, also altered in our data. 
 mTORC1, a master nutrient sensor, depends on amino acid signals to become fully active 
(Bar-Peled and Sabatini, 2014). Furthermore, it has been reported that Sestrin-2, a protein that 
interacts with GATOR-2 complex to inhibit mTORC1, is a Leu sensor, what makes this aminoacid 
(one of the three BCAAs) necessary for mTORC1 activation (Wolfson et al., 2015). These data 
reveal a close relationship between BCAAs and mTORC1 signaling pathway, which confers 
coherence to our data.However, Val was the only altered specific signal among BCAA in the ToF-
MS data and the changes were very mild and inconsistent to make any conclusion. 
I.1.1.4 Serine, Glycine (Gly) and one-carbon (1C) Metabolism 
Ser and Gly (G) metabolism was the most altered pathway in our analysis (Fig. R4, in wine-red). 
Importantly, it remained altered in both lobes and the alteration was conserved along the two 
stages of the disease. 
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Figure R4. ToF-MS enrichment analysis uncovered alterations in amino sugar synthesis pathway, 
BCAA metabolism, TCA and Ser and Gly metabolism in PCa pathogenesis. Enrichment analysis of the 
ToF-MS data at three and six months of age in VP (A), AP (B) and DLP (C). The data is represented as 
percentage of altered metabolites. 
 
 Ser and Gly fuel 1C metabolism, composed of two cyclic pathways, namely folate and 
Met cycle. The two routes are coupled through the production of methyl-tetrahydrofolate (m-THF), 
which donates one carbon to homocysteine (HCys) to generate methionine (Met, M). The name of 
this pathway refers to the fact that these two cycles are fueled with a carbon residue from Ser and 
Gly that afterwards can be followed from one metabolite to another, reaction by reaction. Those 
carbon donors can be incorporated from the extracellular environment, can be synthesized de 
novo (from glucose) in the case of Ser or from other metabolites in the case of Gly (such as 
choline, betaine, dimethylglycine and sarcosine). The metabolic pathways involving Ser, Gly and 
1C metabolism have been related to tumorigenesis in multiple studies (Locasale, 2013). However, 
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carbons incorporated into 1C metabolism can be further followed through many other related 
pathways as the trans-sulphuration pathway, which is linked to Met cycle through HCys; or the 
synthesis of polyamines through the decarboxylation of S-adenosylmethionine (SAM). For 
polyamine synthesis, another carbon source coming from the urea cycle is needed, ornithine 
(Pegg, 2009a). 
 From the 130 differentially altered metabolites upon Pten loss, 107 appeared to be 
significantly increased or decreased in two of the experimental settings, meaning that were 
altered in AP and DLP at three or six months of age, or were altered at both stages of the disease 
in AP or DLP. From those 107 metabolites, 80 showed alterations in three of the four 
experimental settings, meaning that were altered in both lobes, but either AP or DLP did not show 
the alteration at one of the timepoints. Finally, 49 of the significantly altered metabolites showed 
consistent changes in location (both prostate lobes) and time points of the disease, as shown by 
the Venn diagram in Fig. R5A. 
 In order to identify a pathway of relevance through the pathogenesis of the disease, we 
decided to focus on those consistently altered 49 metabolites for further analysis (highlighted in 
Fig. R5B Waterfall). Among those 49 metabolites, the highest decrease was observed in 3-
Hexenedioic acid. This metabolite is an unsaturated dicarboxylic acid inversely correlated with 
fatty acid oxidation (FAO) (Jin and Tserng, 1989), which is coherent with the relevance of FAO in 
various cancerous settings (Wu et al., 2014; Carracedo et al., 2013; Liu, 2006). 
 On the other hand, three metabolites related to polyamine synthesis pathway were the 
top increased metabolites: decarboxylated SAM (dcSAM), N1-Acetylspermine and N1-
Acetylspermidine. dcSAM comes from decarboxylation of SAM, the master methyl donor in the 
cell belonging to Met cycle. dcSAM provides carbons for polyamine synthesis (Locasale, 2013). 
N1-Acetylspermine and N1-Acetylspermidine are acetylated forms of polyamines, a product of 
their catabolism by the enzyme spermidine/spermine N1-acetyltransferase 1 (SSAT1), a key 
regulator of polyamine levels (Pegg, 2008). 
In conclusion, these data suggest an increase in polyamine-related metabolites, from one 
of the essential substrates for their synthesis (dcSAM) to their catabolized form, the acetylated-
polyamines.Polyamines have been widely associated to proliferation, although the mechanism 
underlying their role in cancer remains to be elucidated (Gerner and Meyskens, 2004b). Thus, 
with this data, we focused our efforts on studying alterations in 1C-metabolism and polyamine 
pathway in prostate cancer pathogenesis.To further confirm these data with a more accurate 
quantification of these metabolites we addressed in a second step of our integrative metabolic 
design by LC/MS, as explained in Fig. R2. 
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Figure R5. The inclusion criteria established narrowed the number of consistently altered 
metabolites. A-B, VENN diagram (anterior prostate (AP) and dorsolateral prostate (DLP), A) and Waterfall 
pathway enrichment (AP and DLP, B) from the analysis of altered metabolites in TOF-MS metabolomic 
analysis carried out in Ptenpc-/- vs. Ptenpc+/+ mouse prostate samples at the indicated age (n=4-5). Values in 
(B) represent the average of the Log (Fold change) of the two lobes and two time points (3 and 6 months of 
age) per metabolite. 
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SECTION SUMMARY 
 The untargeted metabolomic study by FI-ToF-MS revealed alterations in 
TCA, amino sugar synthesis pathway, BCAA metabolism and Ser, Gly 
and 1C Metabolism in Pten pc-/-mice compared to Pten pc+/+at both stages 
of the disease. 
 From the integration of alterations in both AP and DLP prostate lobes 
and time-points we could identify 49 consistently altered metabolites, 
among which polyamine pathway related metabolites were 
predominantly increased. 
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I.1.2 LC/MS metabolomic study to quantify metabolic alterations in PCa 
I.1.2.1 LC/MS metabolomics in murine samples 
For the LC/MS study, we included polyamines and related pathways in the set of analysis. As 
previously mentioned, we analyzed AP and DLP tissues of Pten pc+/+ and Pten pc-/- mice at three 
and six months of age. 
I.1.2.1.1 Branched chain amino-acid metabolism 
The ToF-MS analysis showed an enrichment in BCAA metabolism in three of the four conditions 
(six months AP, three months DLP and six months DLP) of the experimental design (Fig. R4B,C). 
Interestingly, valine (BCAA) levels measured by LC/MS were slightly but significantly decreased, 
while leucine and isoleucine (also BCAAs) showed the same trend although without reaching 
statistical significance, in Pten pc-/-mice AP at three months of age. No significant alteration was 
observed in the rest of conditions (Fig. R6A,B). There are different potential explanations for this 
lack of coherence. Firstly, some of the metabolites that arose in the BCAA enrichment could had 
been misidentified. Secondly, other metabolites implicated in BCAA metabolism could be the 
responsible of the enrichment rather than the three BCAA themselves. Lastly, although the 
altered metabolites in Pten pc-/- mice seemed to be enriched in BCAA metabolism, those 
alterations could be quantitatively not significant and relevant enough to appear in the LC/MS 
analysis. 
I.1.2.1.2 Urea cycle 
Although excluded for consideration in our ToF-MS analysis, Urea cycle and arginine (Arg, R) 
metabolism showed significant alterations by LC/MS. Ornithine levels were consistently 
increased, whereas Arg levels were significantly decreased at three months of age in both lobes 
and showed the same tendency at six months of age (Fig. R6A, B). These data suggest a 
decrease in Arg in favor of ornithine production, the substrate for ornithine decarboxylase 1 
(ODC1), to further produce the polyamine putrescine (Put). 
I.1.2.1.3 Methionine cycle 
Met cycle metabolites also showed clear alterations in the LC/MS analysis, confirming the data 
obtained by ToF-MS. Met levels were only slightly decreased in Pten pc-/- mice AP at three months 
of age (Fig. R6A), while they remained unaltered in the rest of conditions.  Notwithstanding, SAM 
levels were consistently increased in both lobes and time-points, whereas we could observe a 
less consistent (due to variability among samples) but clear decrease of SAH levels (Fig. R6A, 
B). SAH levels did not correlate with the increased sarcosine levels. However, this increase could 
be explained by the increase in Gly, one of the substrates of the reaction, catalyzed by GNMT, to 
produce sarcosine. The increase in Gly, together with the increase in betaine observed in Ptenpc-/- 
mice prostates at six months of age compared  to Pten pc+/+, could also be the reflect of higher 
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metabolites in mice treated with either dose of SAM486A compared to vehicle-treated mice (Fig. 
R53). Put levels were dramatically increased in both treatment regimens. The increase in Put 
correlated with the alterations observed in ornithine and Arg, both metabolites of the urea cycle 
implicated in the synthesis of Put. These results indicate that SAM486A induces a robust increase 
in putrescine synthesis, presumably acting on ODC1 activity. The fact that the changes in Put 
occur in the absence of a consistent reduction in dcSAM strongly suggests that this event is not 
due to the intricate compensatory mechanisms of polyamine synthesis, but rather to some direct 
effect of the compound on Put synthesis. Our data was in line with previous in vitro studies 
(Regenass et al., 1994; Svensson et al., 1997), preclinical trials (Dorhout et al., 1995a, 1995b) 
and with some of the mentioned phase I and phase II clinical trials (Millward et al., 2005; Siu et 
al., 2002), in which SAM486A treatment caused an increase in Put. The authors in these studies 
argued that the increase in putrescine was due to a compensatory mechanism rising from the 
decrease in dcSAM. However, although SAM486A treatment was able to decrease Spd and Spm 
levels in the in vitro studies and in the preclinical leukemia trials, none of them had any data about 
dcSAM levels. According to the clinical trials, PA levels showed in most cases very high inter-
patient variability and inconsistency. It should be noted that the analysis of PA pools in those 
cases was done in peripheral blood leucocytes, and not in the target tissue (Eskens et al., 2000). 
Only in one phase I trial were able to confirm a decrease from pre-treatment to post-treatment 
analysis of dcSAM levels in a biopsy of a melanoma patient with apparently very high initial levels 
of dcSAM (Siu et al., 2002). In that particular patient, they were also able to detect decreased 
Put/Spd ratio and a reduction in Spm levels. Interestingly in the phase II melanoma trial 
reductions in Spd levels were also achieved (Millward et al., 2005), suggesting tumor type-specific 
efficacy of the treatment. 
 In our preclinical trial, SAM486A 2mg/Kg dose was not able to alter the levels of PA pools 
or dcSAM (Fig. R53 left). However, the higher dose caused an increase in the putrescine/Spd 
ratio and a mild but significant decrease in Spm levels. In the same line, dcSAM levels showed a 
tendency to decrease (Fig. R53 right). 
 Polyamine synthesis is tightly regulated through multiple feedback mechanisms. We 
speculate that SAM486A might retain structural similarities with SAM and dcSAM to interfere with 
ODC1 regulation, leading to an activation of putrescine synthesis. Our results suggest that local 
dose reached in the tumor tissue is sufficient to activate ODC1, but it does not inhibit AMD1 
efficiently, as shown in the metabolomics analysis. Further research is needed in order to define 
whether such an off-target effect could hamper the therapeutic efficacy of SAM486A and explain 
the poor therapeutic efficacy observed in the preclinical and clinical trials with the compound.  
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III.2.3 Analysis of AMD1 levels in a clinical trial of RAD001 
Our data demonstrated that regulation of AMD1 by mTORC1 is preservedin vivo in mice and that 
AMD1 levels can be modulated upon mTORC1 inhibition with Everolimus (RAD001). To further 
study the extent of our findings, we sought to validate our data in human specimens from a 
clinical trial with RAD001. Thanks to the collaboration with Dr. Baselga and Dr.Tabernero´s 
laboratory at Vall D´Hebron Hospital, we had access to pre- and post-treatment biopsy samples 
from cancer patients with advanced solid tumors treated with either daily (5 or 10 mg) or weekly 
(20 or 50 mg) administration (Fig. R54A) of RAD001 (Tabernero et al., 2008). 
Paired pre- and post-treatment biopsies were processed by IHC to assess AMD1 
immunoreactivity and analyze changes upon RAD001 treatment. To quantify AMD1 protein 
expression,an H-Scoring was performed. Strikingly, 62% of the patient biopsies analyzed 
exhibited a decrease in AMD1 levels upon RAD001 treatment in the tumor (Fig. R54B), as 
appreciable in the decreased immunoreactivity of AMD1 in the post-treatment staining of biopsies 
(Fig. R54C, lower panels) compared to pre-treatment samples (Fig. R54C, upper panels). 
To further analyze whether AMD1 levels were differently altered in the RAD001 treatment 
regimens, we evaluated differential AMD1 immunoreactivity for each regime. Interestingly, AMD1 
levels were significantly decreased only in patients treated with low doses of Everolimus (a 
maximum cumulative dose of 35mg/week; 5mg/day or 20mg/week), but not in response to high 
dose regimens (a minimum cumulative dose of 50mg/week; 10mg/day or 50mg/week) (Fig. 
R55A). Strikingly, the Everolimus regime resulting in AMD1 reduction was the only capable of 
impacting tumor cell proliferation, assessed by Ki67 staining (Fig, R55B). 
Analysis of the phosphorylation level of molecular markers of mTOR pathway showed 
that phosphorylation of all markers downstream mTOR (S6S235/236, S6S240/244, 4EBPT70 and 
eukaryotic initiation factor 4G, eIF4GS1106) was significantly inhibited at the time-points analyzed 
irrespective of the Everolimus regime (Fig.  R55C). This data suggests that AMD1 is a more 
sensitive biomarker of therapeutic efficacy for mTORC1 than other targets evaluated. AKT 
SECTION SUMMARY   
 Methionine deficient diet resulted insufficient to revert the metabolic 
alterations observed in Ptenpc-/- mice and did not show therapeutic 
advantage, compared to regular Chow diet fed mice. 
 Pharmacological AMD1 inhibition with SAM486A in vivo showed no 
efficacy in decreasing dcSAM levels, and lacked therapeutic potential. 
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phosphorylation, which stands upstream mTOR, showed trend to upregulation upon high dose 
administration (Tabernero et al., 2008). This upregulation is caused by a negative feedback loop 
inducing upstream insulin-like growth factor 1 receptor (IGF-1R) signaling, which in term would 
result in AKT activation (O’Reilly et al., 2006; Tabernero et al., 2008). This feedback loop would 
also explain higher polyamine content upon re-phosphorylation of AKT (Rajeeve et al., 2013) and 
the rationale for the attenuation of the clinical activity of this agent . 
 
 
Figure R54. Impact of pharmacological mTORC1 inhibition with RAD001 on AMD1 levels in a clinical 
trial. A, Schematic of the different dose regimens administered in the clinical trial (5-10 mg/day or 20-50 
mg/week) B,Quantification of AMD1 immunoreactivity difference (H-score change) between pre- and post-
treatment biopsies. C, Representative images of AMD1 staining by IHQ in pre- and post-treatment biopsies 
and H-score quantification of each case. ΔH: H-score difference. 
 
 In conclusion,our data led us to hypothesize that the effect on AMD1 upon mTORC1 
inhibitionisresponsible of the reduced cancer cell proliferation and thus, unveil AMD1 as an 
important marker to monitor in mTOR-targeting therapies. 
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Figure R55. Impact of pharmacological mTORC1 inhibition with RAD001 on AMD1 levels in a clinical 
trial. A, Differential AMD1 immunoreactivity (quantified as H-score post-treatment – H-score pre-treatment) 
in each dose regime (5-10 mg/day or 20-50 mg/week). B,Differential AMD1 (left panel) or Ki67 (right 
panel)immunoreactivity (quantified as differential H-score) according to combined low dose regimens (5 
mg/day or 20 mg/week) or combined high dose regimens (10 mg/day or 50 mg/week). C, Differential H-
scores of molecular biomarkers (phospho-AKT, phospho-RpS6, phospho-4EBP1 and phospho-eIF4G) for 
mTOR pathway inhibition according to combined dose regimens mentioned in B. 
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SECTION SUMMARY   
 Regulation of AMD1 levels upon mTORC1 inhibition (Rapamycin, 
RAD001 or Everolimusin vivo) is preserved in human specimens and 
associated to its anti-proliferative activity, enforcing the relevance of this 
enzyme for therapeutic purposes.  
Results and Discussion:  Aim III 
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CONCLUSION III 
 Genetic and pharmacological modulation of AMD1 underscored the 
therapeutic potential of targeting this enzyme 
 Methionine restriction alone and pharmacological AMD1 inhibition with 
SAM486A in vivo did not show any therapeutic benefit against PCa 
development, arguably due to reduced pathway inhibitory effects 
 AMD1 downstream mTORC1 might be a critical component of the 
cytostatic effect of mTORC1inhibitors 
EXPERIMENTAL IMPROVEMENTS AND FUTURE PERSPECTIVES 
 The polyamine rescue experiment could be validated by overexpressing 
AMD1 ectopically and then performing AMD1 silencing with an shRNA 
that targets endogenous, but not exogenous AMD1, mimicking in that 
way endogenous polyamine depletion and further polyamine addition. 
 Methionine restriction beyond 0.15% would be more appropriate to 
evaluate the impact of nutritional manipulation in PCa 
 Combination of SAM486A treatment with DFMO (ODC1 inhibitor) 
couldprevent the increase of putrescine and increase the therapeutic 
benefit in pre-clinical trials 
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I THE REVOLUTION OF OMICS: MILESTONESAND REMAINING 
CHALLENGESIN CANCER RESEARCH 
Omics development and cancer research 
Large-scale profiling methods have been innovatively employed to elucidate metabolic pathways 
implicated in tumor initiation, progression and metastasis (Benjamin et al., 2012). The last of the 
“omics”, metabolomics, has transformed cancer research (Klupczyńska et al., 2015). Previously 
developed “omics”, such as genomics, transcriptomics or proteomics, offered valuable information 
about the expression levels of oncogenes or tumor-suppressors, which led to the discovery of 
altered signaling pathways that play relevant roles in cancer pathogenesis (Stratton et al., 2009; 
Hanash and Taguchi, 2010). However, the information provided by these large-scale profiling 
methods was limited to the quantification of gene alterations and transcript or protein levels, which 
do not necessarily correlate with the enzymatic activities, reaction rates and, in general, metabolic 
dynamics (Holmes et al., 2008). Metabolomics conferred the capacity ofmeasuringmetabolite 
pools, which provide faithful information about substrate, intermediate and product amounts of the 
biochemical reactions that sustain cellular metabolism (Patti et al., 2012). Furthermore, this data 
can provide a speculative idea of the regulation status of involved metabolic enzymes. 
Consequently, metabolomics is considered the OMIC that most closely relates to the phenotype 
(Klupczyńska et al., 2015). 
 The technological blooming of instrumentation offered a broad variety of metabolomic 
techniques, from untargeted screenings to targeted MFA. Steady-state metabolomics provide 
valuable information regarding deregulated metabolic pathways. However, this type of 
metabolomics offers a static view, a snapshot of the metabolome, providing cues about the 
altered biochemical reactions in a particular moment (Zhao and Yang, 2015). The challenge of 
capturing the dynamic essence of metabolism was achieved by the development of metabolic flux 
techniques (Zamboni et al., 2015). Non-stationary metabolic flux analysis provides reaction rate 
information and directionality based on the 13C/12C labeling ratio, and recapitulates more closely 
the dynamism of metabolism (Wiechert and Nöh, 2013).  
 In this work we combined untargeted (ToF/MS), targeted (LC-MS) and MFA 
metabolomics in an integrative metabolomics study to faithfully uncover, narrow down and 
validate the most relevant metabolic alterations underlying PCa pathogenesis in murine and 
human specimens. This approach allowed us to characterize a metabolic wiring showing 
increased flux from methionine cycle towards polyamine metabolic pathway in PCa. Importantly, 
the metabolic routes identified by ToF/MS in the murine prostates, were then validated by LC/MS 
and MFA employing murine, human and cell line samples to elucidate the extent and relevance of 
this metabolic switch in PCa. 
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Challenges and future prospects of metabolomics in eukaryotes  
Despite the informative potential of metabolomics and the valuable information obtained by this 
approach, the technology exhibits limitations and faces challenges in the analysis of samples of 
eukaryotic origin. Contrary to prokaryotic cells, eukaryotic cells arecompartmentalized into 
specialized organelles, with compartment-specific and shared metabolic activities (Wahrheit et al., 
2011). Furthermore, cells have achieved sophisticated mechanisms to separate zones inside 
each compartment, as liquid-liquid phase separation, leading to membraneless 
compartmentalization (Aguzzi and Altmeyer, 2016). Compartmented subcellular structure results 
in numerous cellular metabolic microenvironments (Wahrheit et al., 2011), which allow the 
isolation and regulation of the numerous reactions that take place within a cell. However, 
compartmentalization has a price: the development of communication mechanisms to transmit 
signals and exchange material among the different organelles (Prinz, 2014). In turn, subcellular 
compartmentalization remarkably complicates the interpretation of metabolic networks from whole 
cell lysates (Niklas et al., 2010). Most current techniques obviate this variable and measure 
average labeling and metabolite levels of all mixed compartments in a cell (Buescher et al., 2015).  
 These facts are in support of our results. Indeed, although increased entrance (dcSAM) 
and exit (ac-polyamines) metabolites were detected, polyamine pools did not show consistent 
alterations, but rather remained fairly constant throughout the different experimental approaches 
addressed. In a metaphoric comparison, we could imagine polyamine reservoir as a water tank 
with continuous enter/exit flux, where an increased influx will be immediately compensated with a 
proportional efflux. In a biological context where the influx is increased (in our case Pten loss), the 
metabolomics data would reveal as increased influx and efflux metabolites, without major 
changes in the total pool of the central metabolites. Our hypothesis was reinforced by the 
metabolic flux experiments. The dynamic essence of this technique provided us the opportunity to 
demonstrate the increased production of dcSAM with carbons being incorporated into polyamines 
and subsequently into their acetylated derivatives (Fig. D2). Thus, our results highlight the 
relevance changes in polyamine influx and efflux, rather than total polyamine pools. 
Compartmentalization is particularly relevant when studying polyamine dynamics. Polyamines 
have been suggested to exhibit vesicle sequestration upon cell internalization through yet 
undefined mechanisms (Poulin et al., 2011). Importantly, quick polyamine through yet undefined 
mechanisms (Poulin et al., 2011). Importantly, quick polyamine  import/export capacity from these 
putative vesicles could explain the rapid regulation of polyamine levels in response to exogenous 
alterations. Moreover, most polyamines are found in RNA-bound complexes (Igarashi and 
Kashiwagi, 2010). These two factors combined imply that the free polyamine pool is minor relative 
to total polyamine amounts. In turn, changes in free polyamines that are negligible when 
measuring total polyamine pool size, could exert profoundeffects in cell biology.  
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Figure D1. Schematic representation of polyamine pools according to the observed in Pten pc-/- mice 
and upon AMD1 inhibition with SAM486A. 
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Figure D2. Schematic representation of the hypothesis postulating increased flux through 
polyamine pathway in prostate cancer. The representation reflects the importance of altered enter and 
exit fluxes despite unaltered total polyamine pools. 
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 The considerations postulated herein might be of vital importance for therapies targeting 
polyamine metabolism. Indeed, despite the promising results in vitro and in in vivo models, drugs 
targeting polyamine synthesis enzymes, such as DFMO (ODC1) or SAM486A (AMD1) failed to 
show clear antitumoral benefit in clinical trials (Millward et al., 2005; Vlastos et al., 2005; Pless et 
al., 2004; Siu et al., 2002; Paridaens et al., 2000; Eskens et al., 2000; Loprinzi and Messing, 
1992; Horn et al., 1987). The lack of therapeutic efficacy of these and other polyamine pathway 
modulators could be explained in part by the aforementioned data. By targeting de novo 
polyamine synthesis, these drugs should alter free polyamine levels. However, it is plausible that 
these pools are rapidly equilibrated by polyamine export from sequestrating vesicles. Following 
this rationale, polyamine pathway-targeting therapies might need to be rethinked. Probably, 
specific therapies targeting polyamine vesicle sequestration upon internalization would show 
higher benefit.  
 The possibility of measuring metabolites in a compartment-dependent manner could 
profoundly change our understanding of polyamine pathway regulation. In this work we have 
demonstrated that AMD1 is regulated by mTORC1. This serine-threonine kinase complex is 
reported to localize to the lysosome (Sancak et al., 2010). Based on these data, it is tempting to 
speculate that AMD1 could temporarily localize to the lysosome to be subject to mTORC1-
dependent regulation. 
 
II THE INTERPLAY OF mTORC1 SIGNALING AND POLYAMINE 
METABOLISM IN CANCER AND BEYOND 
The crosstalk between signaling and metabolism in cancer 
Most oncogenes and tumor suppressor genes discovered during the genomics era encode 
proteins implicated in signal transduction (Ward and Thompson, 2012). In the last decade of the 
twentieth century, cancer research focused on characterizingthe oncogenic or tumor suppressive 
nature of genes based on gain or loss of function analysis with genetic tools. Traditionally, these 
genes have been attributed the capacity to support the acquisition of cancer hallmarks (Hanahan 
and Weinberg, 2000). However, increasing evidence reveal and alternative scenario, where 
oncogenes and tumor suppressors are essential mediators of the metabolic reprogramming, 
leading to the possibility of metabolic regulation as the ancient function of many of these genes 
(Ward and Thompson, 2012). In the same line, downstream aberrantly activated oncogenic 
signals, cell metabolism is reprogrammed to comply with anabolic needs. Nevertheless, 
metabolism also remodels the signaling network through the control of the epigenetic landscape 
(Pavlova and Thompson, 2016). This renewed understanding of cancer hallmarks implies an 
exquisite crosstalk between signaling and metabolism. In this sense, we provide a direct link 
between one of the master sensors that integrates and interprets growth signals, mTORC1, and a 
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metabolic route essential for cell proliferation and survival, the polyamine pathway. In support of 
our data, other metabolic enzymes related to polyamine synthesis and catabolism have previously 
been reported to be under the regulation of oncogenes and tumor suppressor genes. Indeed, the 
other rate limiting enzyme in polyamine synthesis, ODC1, is and established direct target of the 
oncogene c-MYC (Bello-Fernandez et al., 1993; Peña et al., 1993). Moreover, this decarboxylase 
cooperates with the oncogene H-RAS in fibroblast transformation in vitro (Shantz and Pegg, 
1998) and in skin carcinogenesis in vivo (Smith et al., 1998). Likewise, the catabolic enzyme 
SSAT1 has been shown to lie under the control of the oncogene K-RAS (Ignatenko et al., 2004). 
 mTORC1 promotes growth and proliferation depending on the nutrient and energy status 
of the cell (Howell and Manning, 2011). This complex induces anabolic metabolism by 
orchestrating several biosynthetic pathways. Under energy and nutrient-availability conditions, 
mTORC1blocks autophagy by inhibiting a protein complex containing the kinases ULK1/2, which 
is essential for the autophagic process (Yecies and Manning, 2011; Neufeld, 2010). However, 
mTORC1 is also capable of directly regulating the synthesis of macromolecules, such as proteins, 
lipids and nucleic acids (Dibble and Manning, 2013a). The implication of mTORC1 in protein 
synthesis regulation is the best characterized of its functions. Indeed, this master regulator 
controls not only cap-dependent translation through phosphorylation of its targets 4EBP1 and 
S6K, but also protein degradation to ensure protein homeostasis (Zhang et al., 2014; Ma and 
Blenis, 2009). mTORC1 is also implicated in the regulation of lipid homeostasis. In fact, this 
protein complex induces lipid synthesis and storage, while inhibiting processes that imply lipid 
consumption (Ricoult and Manning, 2013). In the same line, mTORC1 induces purine synthesis, 
through the regulation of folate cycle (Ben-Sahra et al., 2016), as well as, de novo pyrimidine 
production by direct phosphorylation of carbamoyl-phosphate synthetase 2 (CAD) by its 
Nucleic
acids
proteins
Autophagy mRNA
translation
Aerobic 
glycolisis
PPPDe novo
lipogenesis
De novo
nucleotide
synthesis
AMD1 
mTORC1
mTOR mLST8
Raptor
Membranes PAs
Figure D3. Scheme depicting the anabolic processes regulated downstream mTORC1, including 
AMD1 regulation and polyamine production. 
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downstream target S6K (Ben-Sahra et al., 2013). In this work we have described a previously 
unidentified branch under the control of mTORC1 (Fig. D3). Based on our preliminary data, this 
regulatory pathway would stem from direct phosphorylation of AMD1, although ongoing validation 
experiments are warranted to validate thisassumption. If our hypothesis is confirmed, AMD1 
would be a direct target immediately downstream mTORC1, together with 4EBP1 and S6K. The 
regulation of AMD1 by mTORC1 is of vital importance since connects a signaling cascade and a 
metabolic pathway, both relevantly implicated in such an essential cellular process as proliferation 
(Dibble and Cantley, 2015; Miller-Fleming et al., 2015). Importantly, this connection also 
intergrates polyamines and the synthesis of macromolecules. Polyamines induce adipogenesis 
(Hyvönen et al., 2013; Ishii et al., 2011) and bind to DNA and RNA affecting their structure and 
stability (Iacomino et al., 2012; Igarashi and Kashiwagi, 2010). Furthermore, Spd is essential for 
eIF5A hypusination, a post-translational modification required for its activation and subsequent 
correct mRNA translation elongation (Park et al., 2009; Cooper et al., 1982). In conclusion, we 
have identified a mTORC1-AMD1-PAs axis, which enriches the metabolic landscape downstream 
mTORC1. 
 
Signaling-metabolism crosstalk beyond cancer 
The fact that polyamine pathway enzymes are so tightly regulated under the control of oncogenes 
and tumor suppressors underscores the relevance of these molecules in cancer and, potentially, 
in physiology. We show that mTORC1 regulates polyamine synthesis to support proliferation. 
Indeed, both mTORC1 signaling and polyamines are involved in relevant processes throughout 
our lifespan. This perspective well correlates with new perspectives on aging, which define this 
vital process as "any change in an organism over time", thus aging being synonymous of change 
rate (Bowen and Atwood, 2004).In view of this, the developmental processes occurring in 
mammals sequentially through lifespan could reasonably be separated into a "positive phase", 
from conception to adulthood; followed by a "negative phase", senescence, from adulthood to 
death (Scalabrino and Ferioli, 1984). 
 Embryonic development and tissue growth are processes that imply high proliferation and 
change rates ("positive phase"). In this context, mTORC1 is of vital importance. In fact, germline 
deletion of mTOR components showed that both mTORC1 and mTORC2 are essential during 
embryogenesis, although mTORC1 is primordial at early stages of the development, whereas 
mTORC2 plays its decisive role at midgestation (Guertin et al., 2009). In fact, mTOR is criticalfor 
gastrulation and tissue growth during organogenesis (Land et al., 2014). Interestingly, polyamines 
are essential during embryonic development. Knockout of both polyamine biosynthetic enzymes 
(AMD1 and ODC1) lead to embryonic lethality at early stages of development (Nishimura et al., 
2002; Pendeville et al., 2001). In the same line, polyamines play a relevant role during pregnancy, 
especially during first half of development (Sooranna et al., 1998). These data support a role for 
mTORC1-AMD1-PAs in early life stages.  
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 The connection of this axis might result less certain in later stages of life, when 
proliferation requirements are reduced. Experimental evidence suggest that mTOR controls aging 
through the regulation of several downstream processes (Blagosklonny and Hall, 2009). 
Researchers in the gerontology field support the notion of non-programmed aging, which 
hypothesizes that aging is the consequence of the incorrect inactivation of the growth program 
(Blagosklonny, 2013). Aging impacts on the entire organism, through the accumulation of damage 
in molecules, cells and tissues over time. Tissue dysfunction in aging has been correlated with a 
switch in cellular status,from reversible G0 quiescence to irreversible G0 senescence, a 
proliferation block driven by mTOR (Demidenko and Blagosklonny, 2008) and named 
"geroconversion". This process leads to hypertrophic cells, due to active mTOR signaling despite  
cell-cycle inhibition (Blagosklonny, 2014). Importantly, both mTORC1 specific and dual mTORC1 
and mTORC2 inhibitors have been demonstrated to efficiently prevent geroconversion, preserving 
proliferative potential (Leontieva et al., 2015; Sousa-Victor et al., 2015; Demidenko et al., 
2009).However, polyamine levels show a sustained inverse correlation with ageing, although 
there is certain tissue specificity. (Nishimura et al., 2006; Scalabrino and Ferioli, 1984). For 
instance, spermidine and spermine levels decreasewith age in mice (Nishimura et al., 2006) and 
humans (Pucciarelli et al., 2012). Strikingly, in this study nona/centenarian people showed an 
enrichment in Spd and Spm concentrations relative to total polyamines, suggesting that 
maintaining these polyamines in aging contribute to longevity (Pucciarelli et al., 2012). This 
evidence supports the notion that polyamines are required for the extension of lifespan. 
Embryonic
development
Senescence Aging
Polyamines
PI3K-mTORC1 signaling
A
B
Polyamines
Embryonic
development
Cancer
PI3K-mTORC1 signaling
Other proliferative
processes
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processes
Figure D4. Interplay between PI3K-mTORC1 signaling and polyamine levels. A-B, Crosstalk throughout 
proliferation-related processes in lifespan (A) and cancer (B). 
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  In the search for anti-aging strategies,genetic or pharmacological inhibition of mTOR was 
found to extend lifespan in yeast, nematodes, flies and mice (Harrison et al., 2009; Powers et al., 
2006; Kaeberlein et al., 2005; Kapahi et al., 2004; Jia et al., 2004; Vellai et al., 2003). In turn, 
rapamycin and its derivatives (Rapalogs) have become the best-supported candidates as anti-
aging therapeutics. Likewise, exogenous Spd supplementation was demonstrated to increase the 
lifespan of yeast, flies, worms, human immune cells and to decrease oxidative stress in aging 
mice. In this study Eisenberg and coworkers showed that Spd addition caused general 
hypoacetylation of histone H3 and induced autophagy by promoting acetylation of autophagy-
related autophagy related 7 (ATG7) gene promoter (Eisenberg et al., 2009). Thus, polyamines, 
and especially Spd, have aroused as anti-aging molecules, which can be supplemented in food or 
water to increase their levels in the organism (Minois, 2014). Rapamycin also shares with Spd 
multiple potential mechanisms by which it exerts its anti-aging effect, such as regulation of cell 
growth, autophagy induction and anti-inflammatory mechanisms. Nonetheless, despite its 
encouraging effects rapamycin, it seems unlikely that this drug will be approved for preventive 
use, due to its side effects (Lamming et al., 2013). 
 Our data demonstrate a direct regulation of AMD1 downstream mTORC1, which led us to 
speculate that this axis also operates throughout development and aging. This might be true until 
the axis is disconnected from proliferation. Nevertheless, in conditions where proliferation is 
sustained, such as cancer, the axis might be preserved, as we observed in PCa. In conclusion, 
the analogous activities of PI3K signaling and polyamines, are observed in several facets of life. 
Elucidating this complex relationship would help us better understand physiological processes at 
the cellular and systemic level, and could reveal novel therapeutic avenues for pathological 
alterations related to cell growth and senescence. 
III AMD1 AS A PREDICTIVE BIOMARKER AND TARGET IN 
PROSTATE CANCER 
The combination of established clinical-pathological acquaintance with state-of-the-art molecular 
profiling to achieve diagnostic, prognostic and therapeutic strategies is termed precision medicine 
(Mirnezami et al., 2012). In this regard, genomic technologies have inspired this stratification 
approach, whereas other high throughput technologies that provide better information about the 
phenotype of the tumor remain underdeveloped in this area of research (Friedman et al., 2015). In 
the particular case of PCa, precision medicine is yet far from becoming a reality. Indeed, 
stratification of PCa patients depends on very general parameters, such as PSA, Gleason Score 
and TNM classification, and targeted therapy is limited to the inhibition of androgen signaling. 
Therefore, novel stratification markers and targeted therapies are needed to treat the disease 
once first line therapy (surgery or radiotherapy) fails. This fact underscores the need for reliable 
and reproducible prognostic biomarkers to discriminate patients that would benefit from early 
adjuvant treatment from those requiring more aggressive therapy (Sedelaar and Schalken, 2015). 
Patient derived tumor xenograft (PDTX) models, which maintain the molecular, genetic and 
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histological heterogeneity of the tumor of origin, might represent excellent platforms to predict 
clinical efficacy based on potential biomarkers (Cho et al., 2016; Tentler et al., 2012). 
 In this project we have shown that the rapamycin-derivative Everolimus is capable of 
decreasing AMD1 levels in vivo.Interestingly, a decrease in AMD1 immunoreactivity exhibits 
better association to a decrease in tumor cell proliferation than the rest of mTORC1 activity 
readout proteins (Tabernero et al., 2008), that remained inhibited regardless of Everolimus regime 
and therapeutic effects. Thus, we hypothesize that AMD1 might be a key contributing factor to the 
cytostatic effect triggered by Everolimus. This fact would be of relevance to predict therapeutic 
efficacy, and underscore the relevance of AMD1 as a potential predictive biomarker for response 
to mTORC1inhibition-based therapies. 
 Genetic and pharmacological inhibition of AMD1 in vitro and in xenograft models 
demonstrated the therapeutic potential of targeting this metabolic enzyme for PCa treatment. 
However, in contrast to previous studies showing and antitumoral effect of SAM486A in xenograft 
models (Dorhout et al., 1995a, 1995b), pharmacological inhibition of AMD1 in vivo failed to 
support an antitumoral effect in our PCa model. This drug reached the prostate, but was unable to 
efficiently decrease neither dcSAM, nor polyamine levels. For yet unclear reasons, SAM486A led 
to a dramatic induction of putrescine levels (Fig. R53). One plausible explanation for this effect is 
that SAM486A would not reach prostate cancer cells at sufficient concentration to exert its 
pharmacological activity. In this regard, the emerging field of drug nanoencapsulation might 
provide advantageous alternatives. Nanoparticles (NP) possess unique properties, such as 
nanoscopic size, large surface-to-volume ratio, the capacity to encapsulate large payloads and a 
modifiable external surface. These characteristics provide them with advantages over bulk drugs: 
the possibility of adding targeting-ligands on their surface, efficient navigation through the often 
hostile microenvironments in the body, the capability of co-transporting multiple drugs, controlled 
release of the drug and increased cellular uptake (Davis et al., 2008). Furthermore, NPs offer the 
possibility of targeting them to specific organelles to achieve maximal therapeutic benefit, with 
minimal side-effects (Biswas and Torchilin, 2014). Thus, encapsulation of SAM486A into 
nanoparticles would allow directly targeting the drug to the prostate and would facilitate its 
incorporation, thereby enhancing the probabilities of achieving an effective therapeutic 
concentration. This approach could potentiate the efficacy of this drug. 
 Our data reflects another alternative for targeting AMD1, mTORC1 inhibition. We have 
shown that mTORC1 inhibition with rapamycin and Torin-1 effectively decreases AMD1 protein 
levels and dcSAM production in vitro and in vivo. We propose that Everolimus could show 
therapeutic benefit in patients with high AMD1 levels. Importantly, Everolimus-based 
combinatorial therapy might increase treatment efficacy, decrease the emergence of resistance 
and avoid therapy-induced metastasis (Nastiuk and Krolewski, 2016). Despite the discouraging 
results in the latest attempts to test rapamycin for combination therapies in prostate cancer 
clinical trials (Vaishampayan et al., 2015; Nakabayashi et al., 2012), the elucidation of AMD1 as 
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the plausible downstream effector of mTORC1 raises the alternative of combining Everolimus with 
another polyamine pathway inhibitor, such as the ODC1 inhibitor, difluoromethylornithine (DFMO). 
Previous studies in which DFMO in combination with SAM486A showed beneficial effect against 
leukemic xenografts support this hypothesis. In summary, we believe AMD1 shows predictive 
capacity for mTORC1 inhibition-based therapies and represents a potential target for combination 
therapies in PCa. 
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 The results obtained throughout this thesis work confirm our initial hypothesis and 
demonstrate that oncogenic events trigger the deregulation of metabolism in prostate cancer. The 
results are summarized as follows: 
 Pten loss induces a metabolic switch from methionine cycle towards polyamine synthesis 
pathway in murine and human prostate cancer.  
 Gnmt loss as a single or compound genetic event is not relevant for disease initiation. 
 AMD1 increase upon Pten loss induces the metabolic switch observed in prostate cancer. 
 AMD1 is under the control of mTORC1. 
 We propose the direct phosphorylation of proAMD1 by mTORC1 as the mechanism of 
regulation, leading to stabilization of the proenzyme and subsequent processing. 
 Genetic and pharmacological inhibition of AMD1 exhibits therapeutic potential. 
 
 
GENERAL CONCLUSION 
The results obtained in this thesis work demontrate that the oncogenic loss of 
Pten induces the metabolic deregulation in prostate cancer, through the 
increase of AMD1. Furthermore, we propose a mechanism of AMD1 
regulation downstream mTORC1, which opens new alternatives to target this 
enzyme. 
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m3121 355.1572 S-Adenosylmethioninamine // HMDB00988:.H(+) // 355.1572 // 40 4.0000 3.8596 0.4530 1.0000 3.5599 0.0000 1.0000 3.3865 0.0000 1.0000 4.2056 0.0000 1.0000 4.2866 0.0000
m1902 245.2357 N1-Acetylspermine // HMDB01186:.H(+) // 245.2357 // 49 4.0000 2.5583 0.4530 1.0000 2.2243 0.0000 1.0000 2.2557 0.0000 1.0000 2.5526 0.0000 1.0000 3.2005 0.0000
m1253 188.1765
N1-Acetylspermidine // HMDB01276:.H(+) // 
188.1765 // 100 /// N8-Acetylspermidine // 
HMDB02189:.H(+) // 188.1765 // 100
4.0000 2.2403 1.3709 1.0000 1.3295 0.0002 1.0000 1.5478 0.0001 1.0000 1.8083 0.0000 1.0000 4.2756 0.0000
m574 135.0410
(S)-Ureidoglycolic acid // HMDB01005:.H(+) // 
135.0410 // 100 /// trans-1,2-Dihydrobenzene-
1,2-diol // HMDB01164:.Na(+) // 135.0410 // 30 
/// trans-1,2-Dihydrobenzene-1,2-diol // 
HMDB01164:.H/Na.H(+) // 135.0410 // 30
4.0000 1.1221 0.4189 1.0000 0.8319 0.0004 1.0000 0.7250 0.0036 1.0000 1.3103 0.0000 1.0000 1.6211 0.0000
m85 85.0641
Methyl propenyl ketone // HMDB01184:.H(+) // 
85.0641 // 100 /// 3-Methyl-2-butenal // 
HMDB12157:.H(+) // 85.0641 // 100
4.0000 -0.7481 0.0722 1.0000 -0.7522 0.0000 1.0000 -0.6463 0.0000 1.0000 -0.7813 0.0000 1.0000 -0.8125 0.0000
m4116 459.2372
3-Sulfodeoxycholic acid // HMDB02504:.H(+) // 
459.2372 // 100 /// MG(P-18:0e/0:0/0:0) // 
HMDB11153:.(NaCl)2.H(+) // 459.2372 // 43 /// 
Retinoyl b-glucuronide // HMDB03141:-
H2O.H(+) // 459.2372 // 13 /// DHAP(18:0) // 
HMDB11133:.H/Na.H(+) // 459.2372 // 10
4.0000 -0.7579 0.0941 1.0000 -0.8818 0.0000 1.0000 -0.6769 0.0023 1.0000 -0.7798 0.0002 1.0000 -0.6933 0.0015
m3014 345.0746
Thiamine monophosphate // HMDB02666:.H(+) 
// 345.0746 // 100 /// L-isoleucyl-L-proline // 
HMDB11174:.(NaCl)2.H(+) // 345.0746 // 12 /// 
L-leucyl-L-proline // HMDB11175:.(NaCl)2.H(+) 
// 345.0746 // 12 /// Salicin // 
HMDB03546:.NaCl.H(+) // 345.0746 // 12
4.0000 -0.7836 0.1381 1.0000 -0.5996 0.0041 1.0000 -0.8991 0.0001 1.0000 -0.8798 0.0000 1.0000 -0.7557 0.0007
m3054 349.1120
Riboflavin reduced // HMDB01557:.H(+) // 
349.1120 // 98 /// 6,7-Dimethyl-8-(1-D-
ribityl)lumazine // HMDB03826:.H/Na.H(+) // 
349.1120 // 44 /// 2-O-a-L-Fucopyranosyl-
galactose // HMDB06590:.H/Na.H(+) // 
349.1120 // 29 /// 3-O-a-L-Fucopyranosyl-D-
glucose // HMDB06701:.H/Na.H(+) // 349.1120 
// 29
4.0000 -0.8354 0.2292 1.0000 -1.1297 0.0000 1.0000 -0.6061 0.0081 1.0000 -0.8932 0.0000 1.0000 -0.7127 0.0016
m3411 384.1205
Succinyladenosine // HMDB00912:.H(+) // 
384.1205 // 59 /// Dityrosine // 
HMDB06045:[+1].Na(+) // 384.1205 // 9
4.0000 -0.9400 0.1410 1.0000 -1.1190 0.0000 1.0000 -0.7793 0.0001 1.0000 -0.9593 0.0000 1.0000 -0.9026 0.0000
m3421 385.1211
S-Adenosylhomocysteine // HMDB00939:.H(+) 
// 385.1211 // 53 /// Succinyladenosine // 
HMDB00912:[+1].H(+) // 385.1211 // 33
4.0000 -0.9441 0.2320 1.0000 -1.0422 0.0000 1.0000 -0.6040 0.0028 1.0000 -1.1239 0.0000 1.0000 -1.0062 0.0000
m1131 177.0405
Ascorbic acid // HMDB00044:.H(+) // 177.0405 
// 88 /// D-Glucurono-6,3-lactone // 
HMDB06355:.H(+) // 177.0405 // 88 /// 2,4-
Diaminobutyric acid // HMDB02362:.NaCl.H(+) 
// 177.0405 // 10 /// L-2,4-diaminobutyric acid 
// HMDB06284:.NaCl.H(+) // 177.0405 // 10
4.0000 -0.9702 0.1324 1.0000 -0.9446 0.0000 1.0000 -0.9898 0.0000 1.0000 -0.8127 0.0000 1.0000 -1.1336 0.0000
m2958 339.0723
AICAR // HMDB01517:.H(+) // 339.0723 // 100 
/// L-Aspartyl-L-phenylalanine // 
HMDB00706:.NaCl.H(+) // 339.0723 // 23 /// L-
beta-aspartyl-L-phenylalanine // 
HMDB11167:.NaCl.H(+) // 339.0723 // 23
4.0000 -1.0534 0.2248 1.0000 -1.0784 0.0001 1.0000 -0.7296 0.0097 1.0000 -1.1763 0.0000 1.0000 -1.2294 0.0000
m759 147.1139
L-Lysine // HMDB00182:.H(+) // 147.1139 // 94 
/// D-Lysine // HMDB03405:.H(+) // 147.1139 // 
94 /// (3S,5S)-3,5-Diaminohexanoate // 
HMDB12115:.H(+) // 147.1139 // 94 /// (3S)-3,6-
Diaminohexanoate // HMDB12114:.H(+) // 
147.1139 // 94 /// Pipecolic acid // 
HMDB00070:.NH4(+) // 147.1139 // 10 /// L-
Pipecolic acid // HMDB00716:.NH4(+) // 
147.1139 // 10 /// N4-Acetylaminobutanal // 
HMDB04226:.NH4(+) // 147.1139 // 10 /// D-
Pipecolic acid // HMDB05960:.NH4(+) // 
147.1139 // 10
4.0000 -1.0879 0.4549 1.0000 -0.8222 0.0000 1.0000 -1.1900 0.0000 1.0000 -0.6566 0.0001 1.0000 -1.6827 0.0000
m1617 219.1481
5-Methoxydimethyltryptamine // 
HMDB02004:.H(+) // 219.1481 // 100 /// 
Gamma-glutamyl-L-putrescine // 
HMDB12230:[+1].H(+) // 219.1481 // 5
4.0000 -1.1083 0.0721 1.0000 -1.0134 0.0000 1.0000 -1.0916 0.0000 1.0000 -1.1595 0.0000 1.0000 -1.1689 0.0000
m144 98.9860
Phosphoric acid // HMDB02142:.H(+) // 98.9860 
// 73 /// Acetic acid // HMDB00042:.H/K.H(+) // 
98.9860 // 8 /// Glycolaldehyde // 
HMDB03344:.H/K.H(+) // 98.9860 // 8
4.0000 -1.1257 0.3138 1.0000 -0.9543 0.0004 1.0000 -0.8140 0.0047 1.0000 -1.2055 0.0000 1.0000 -1.5289 0.0000
Supplementary table. Time of Flight analysis of murine prstate tissue from Pten wt or prostate deficient mice at 3 months (X3M) or 6 moths (X6M) in AP and DLP lobes.
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m510 130.0872
Pipecolic acid // HMDB00070:.H(+) // 130.0872 
// 100 /// L-Pipecolic acid // HMDB00716:.H(+) 
// 130.0872 // 100 /// N4-Acetylaminobutanal 
// HMDB04226:.H(+) // 130.0872 // 100 /// D-
Pipecolic acid // HMDB05960:.H(+) // 130.0872 
// 100 /// trans-1,2-Dihydrobenzene-1,2-diol // 
HMDB01164:.NH4(+) // 130.0872 // 10
4.0000 -1.1554 0.3959 1.0000 -1.0800 0.0001 1.0000 -1.1290 0.0001 1.0000 -0.7275 0.0056 1.0000 -1.6853 0.0000
m4407 491.1316
L-2-Aminoadipate adenylate // 
HMDB06941:.H(+) // 491.1316 // 100 /// 
11beta,20-Dihydroxy-3-oxopregn-4-en-21-oic 
acid // HMDB11651:.(NaCl)2.H(+) // 491.1316 // 
13
4.0000 -1.1949 0.4107 1.0000 -1.3480 0.0000 1.0000 -0.6970 0.0099 1.0000 -1.6632 0.0000 1.0000 -1.0714 0.0001
m965 162.0772
Aminoadipic acid // HMDB00510:.H(+) // 
162.0772 // 87 /// 3-Hexenedioic acid // 
HMDB00393:.NH4(+) // 162.0772 // 10 /// 3-
Methylglutaconic acid // HMDB00522:.NH4(+) // 
162.0772 // 10 /// (E)-2-Methylglutaconic acid 
// HMDB02266:.NH4(+) // 162.0772 // 10 /// 7-
Aminomethyl-7-carbaguanine // HMDB11690:-
H2O.H(+) // 162.0772 // 10 /// Glucosamine // 
HMDB01514:-H2O.H(+) // 162.0772 // 9 /// 
Fructosamine // HMDB02030:-H2O.H(+) // 
162.0772 // 9
4.0000 -1.2200 0.1892 1.0000 -1.1564 0.0000 1.0000 -0.9914 0.0000 1.0000 -1.3016 0.0000 1.0000 -1.4307 0.0000
m1566 214.9955
2-Oxo-3-hydroxy-4-phosphobutanoic acid // 
HMDB06801:.H(+) // 214.9955 // 100 /// 
Ascorbic acid // HMDB00044:.H/K.H(+) // 
214.9955 // 16 /// D-Glucurono-6,3-lactone // 
HMDB06355:.H/K.H(+) // 214.9955 // 16 /// 
Ascorbic acid // HMDB00044:.K(+) // 214.9955 
// 8 /// D-Glucurono-6,3-lactone // 
HMDB06355:.K(+) // 214.9955 // 8 /// 
Cyclohexanone // HMDB03315:.(NaCl)2.H(+) // 
214.9955 // 6
4.0000 -1.2285 0.2206 1.0000 -1.1241 0.0000 1.0000 -1.1637 0.0000 1.0000 -1.0715 0.0000 1.0000 -1.5546 0.0000
m663 142.0268
O-Phosphoethanolamine // HMDB00224:.H(+) 
// 142.0268 // 100 /// Dimethylglycine // 
HMDB00092:.H/K.H(+) // 142.0268 // 10 /// 
Gamma-Aminobutyric acid // 
HMDB00112:.H/K.H(+) // 142.0268 // 10 /// L-
Alpha-aminobutyric acid // 
HMDB00452:.H/K.H(+) // 142.0268 // 10 /// D-
Alpha-aminobutyric acid // 
HMDB00650:.H/K.H(+) // 142.0268 // 10 /// 2-
Aminoisobutyric acid // HMDB01906:.H/K.H(+) 
// 142.0268 // 10 /// (S)-b-aminoisobutyric acid 
// HMDB02166:.H/K.H(+) // 142.0268 // 10 /// 
(R)-b-aminoisobutyric acid // 
HMDB02299:.H/K.H(+) // 142.0268 // 10 /// 3-
Aminoisobutanoic acid // HMDB03911:.H/K.H(+) 
// 142.0268 // 10 /// Dimethylglycine // 
HMDB00092:.K(+) // 142.0268 // 5 /// Gamma-
Aminobutyric acid // HMDB00112:.K(+) // 
142.0268 // 5 /// L-Alpha-aminobutyric acid // 
HMDB00452:.K(+) // 142.0268 // 5 /// D-Alpha-
aminobutyric acid // HMDB00650:.K(+) // 
142.0268 // 5 /// 2-Aminoisobutyric acid // 
HMDB01906:.K(+) // 142.0268 // 5 /// (S)-b-
aminoisobutyric acid // HMDB02166:.K(+) // 
142.0268 // 5 /// (R)-b-aminoisobutyric acid // 
HMDB02299:.K(+) // 142.0268 // 5 /// 3-
Aminoisobutanoic acid // HMDB03911:.K(+) // 
142.0268 // 5
4.0000 -1.2293 0.4047 1.0000 -0.8021 0.0005 1.0000 -1.4331 0.0000 1.0000 -0.9928 0.0000 1.0000 -1.6891 0.0000
m982 163.0750 Safrole // HMDB02333:.H(+) // 163.0750 // 100 4.0000 -1.2307 0.0436 1.0000 -1.2461 0.0000 1.0000 -1.1713 0.0000 1.0000 -1.2748 0.0000 1.0000 -1.2304 0.0000
m3458 389.2524 5,6-Dihydroxyprostaglandin F1a // HMDB12109:.H(+) // 389.2524 // 100 4.0000 -1.2369 0.3401 1.0000 -1.6806 0.0000 1.0000 -1.2490 0.0000 1.0000 -1.1608 0.0000 1.0000 -0.8571 0.0004
m264 109.0287
Quinone // HMDB03364:.H(+) // 109.0287 // 
100 /// 1,2-Benzoquinone // HMDB12133:.H(+) 
// 109.0287 // 100 /// Gamma-Butyrolactone // 
HMDB00549:.H/Na.H(+) // 109.0287 // 8 /// 
Oxolan-3-one // HMDB02523:.H/Na.H(+) // 
109.0287 // 8 /// Diacetyl // 
HMDB03407:.H/Na.H(+) // 109.0287 // 8 /// But-
2-enoic acid // HMDB10720:.H/Na.H(+) // 
109.0287 // 8
4.0000 -1.3449 0.1220 1.0000 -1.3798 0.0000 1.0000 -1.3312 0.0000 1.0000 -1.4810 0.0000 1.0000 -1.1875 0.0000
m1276 189.1612
N6,N6,N6-Trimethyl-L-lysine // 
HMDB01325:.H(+) // 189.1612 // 69 /// 
Gabapentin // HMDB05015:.NH4(+) // 189.1612 
// 10
4.0000 -1.3504 0.2480 1.0000 -1.2960 0.0000 1.0000 -1.0984 0.0011 1.0000 -1.3151 0.0000 1.0000 -1.6922 0.0000
m2 55.0189
2-Propyn-1-al // HMDB06803:.H(+) // 55.0189 // 
96 /// Pyruvaldehyde // HMDB01167:-H2O.H(+) 
// 55.0189 // 10 /// Malondialdehyde // 
HMDB06112:-H2O.H(+) // 55.0189 // 10
4.0000 -1.3712 0.1631 1.0000 -1.4370 0.0000 1.0000 -1.1481 0.0000 1.0000 -1.3684 0.0000 1.0000 -1.5314 0.0000
m5505 608.0843
Uridine diphosphate-N-acetylglucosamine // 
HMDB00290:.H(+) // 608.0843 // 98 /// Uridine 
diphosphate-N-acetylgalactosamine // 
HMDB00304:.H(+) // 608.0843 // 98
4.0000 -1.3955 0.5839 1.0000 -1.3068 0.0000 1.0000 -0.6927 0.0080 1.0000 -1.4690 0.0000 1.0000 -2.1137 0.0000
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m1641 221.1175 N-Acetyl-b-glucosaminylamine // HMDB01104:.H(+) // 221.1175 // 63 4.0000 -1.4692 0.0633 1.0000 -1.4014 0.0000 1.0000 -1.5496 0.0000 1.0000 -1.4417 0.0000 1.0000 -1.4838 0.0000
m1874 243.0247 Inositol cyclic phosphate // HMDB01125:.H(+) // 243.0247 // 100 4.0000 -1.4757 0.3377 1.0000 -1.4158 0.0000 1.0000 -1.0751 0.0000 1.0000 -1.5160 0.0000 1.0000 -1.8958 0.0000
m2402 290.0858
N-Succinyl-2-amino-6-ketopimelate // 
HMDB12266:.H(+) // 290.0858 // 100 /// 
Adenosine // HMDB00050:.H/Na.H(+) // 
290.0858 // 38 /// Deoxyguanosine // 
HMDB00085:.H/Na.H(+) // 290.0858 // 38 /// 
Neuraminic acid // HMDB00830:.H/Na.H(+) // 
290.0858 // 33 /// Adenosine // 
HMDB00050:.Na(+) // 290.0858 // 14 /// 
Deoxyguanosine // HMDB00085:.Na(+) // 
290.0858 // 14 /// Neuraminic acid // 
HMDB00830:.Na(+) // 290.0858 // 12
4.0000 -1.4777 0.3933 1.0000 -0.9745 0.0068 1.0000 -1.6864 0.0000 1.0000 -1.8739 0.0000 1.0000 -1.3760 0.0004
m5570 615.1504 Cytidine monophosphate N-acetylneuraminic acid // HMDB01176:.H(+) // 615.1504 // 75 4.0000 -1.5080 0.1152 1.0000 -1.5394 0.0000 1.0000 -1.3397 0.0000 1.0000 -1.5527 0.0000 1.0000 -1.6003 0.0000
m4421 492.9931 2 -Deoxyinosine triphosphate // HMDB03537:.H(+) // 492.9931 // 100 4.0000 -1.5238 0.4706 1.0000 -1.3615 0.0000 1.0000 -1.0142 0.0000 1.0000 -1.5834 0.0000 1.0000 -2.1360 0.0000
m2504 298.0977 5 -Methylthioadenosine // HMDB01173:.H(+) // 298.0977 // 100 4.0000 -1.5445 0.3976 1.0000 -1.5381 0.0000 1.0000 -1.0222 0.0022 1.0000 -1.6333 0.0000 1.0000 -1.9844 0.0000
m2313 282.0985 4-Hydroxyphenylacetylglutamine // HMDB06061:.H(+) // 282.0985 // 100 4.0000 -1.5930 0.4208 1.0000 -1.9625 0.0000 1.0000 -0.9941 0.0000 1.0000 -1.7774 0.0000 1.0000 -1.6380 0.0000
m38 73.0288
Pyruvaldehyde // HMDB01167:.H(+) // 73.0288 
// 100 /// Malondialdehyde // 
HMDB06112:.H(+) // 73.0288 // 100
4.0000 -1.7501 0.2295 1.0000 -1.6041 0.0000 1.0000 -1.5329 0.0000 1.0000 -1.8233 0.0000 1.0000 -2.0402 0.0000
m1003 165.0765
L-Fucose // HMDB00174:.H(+) // 165.0765 // 
100 /// Rhamnose // HMDB00849:.H(+) // 
165.0765 // 100 /// 1,5-Anhydrosorbitol // 
HMDB02712:.H(+) // 165.0765 // 100 /// Beta-D-
Fucose // HMDB03081:.H(+) // 165.0765 // 100 
/// L-Rhamnulose // HMDB10207:.H(+) // 
165.0765 // 100 /// 2-Deoxygalactopyranose // 
HMDB12327:.H(+) // 165.0765 // 100 /// S-(2-
carboxypropyl)-Cysteamine // 
HMDB02169:[+1].H(+) // 165.0765 // 12 /// 
Galactitol // HMDB00107:-H2O.H(+) // 165.0765 
// 7 /// Sorbitol // HMDB00247:-H2O.H(+) // 
165.0765 // 7 /// Mannitol // HMDB00765:-
H2O.H(+) // 165.0765 // 7 /// L-Iditol // 
HMDB11632:-H2O.H(+) // 165.0765 // 7
4.0000 -1.7919 0.1879 1.0000 -1.8893 0.0000 1.0000 -1.7940 0.0000 1.0000 -1.5283 0.0000 1.0000 -1.9560 0.0000
m1185 183.0504
3-Methyluric acid // HMDB01970:.H(+) // 
183.0504 // 100 /// 9-Methyluric acid // 
HMDB01973:.H(+) // 183.0504 // 100 /// 1-
Methyluric acid // HMDB03099:.H(+) // 
183.0504 // 100 /// 7-Methyluric acid // 
HMDB11107:.H(+) // 183.0504 // 100
4.0000 -1.8532 0.3210 1.0000 -1.5959 0.0000 1.0000 -1.5560 0.0000 1.0000 -2.1519 0.0000 1.0000 -2.1090 0.0000
m7245 876.2956
Lacto-N-fucopentaose III // 
HMDB06576:.H/Na.H(+) // 876.2956 // 63 /// 
Lacto-N-fucopentaose-2 // 
HMDB06577:.H/Na.H(+) // 876.2956 // 63 /// 
Lex-lactose // HMDB06696:.H/Na.H(+) // 
876.2956 // 63 /// Lacto-n-fucopentaose I // 
HMDB06705:.H/Na.H(+) // 876.2956 // 63 /// 
Lacto-N-fucopentaose V // 
HMDB06706:.H/Na.H(+) // 876.2956 // 63
4.0000 -1.8635 1.1104 1.0000 -1.0908 0.0001 1.0000 -1.7322 0.0000 1.0000 -1.1589 0.0000 1.0000 -3.4723 0.0000
m17 62.0606
Ethanolamine // HMDB00149:.H(+) // 62.0606 
// 100 /// L-Serine // HMDB00187:-CO2.H(+) // 
62.0606 // 10 /// D-Serine // HMDB03406:-
CO2.H(+) // 62.0606 // 10 /// O-
Phosphoethanolamine // HMDB00224:-
HPO3.H(+) // 62.0606 // 8
4.0000 -1.8965 0.5065 1.0000 -2.1527 0.0000 1.0000 -1.1403 0.0000 1.0000 -2.2060 0.0000 1.0000 -2.0872 0.0000
m7199 868.1383
Succinyl-CoA // HMDB01022:.H(+) // 868.1383 
// 100 /// Methylmalonyl-CoA // 
HMDB01269:.H(+) // 868.1383 // 100 /// R-
Methylmalonyl-CoA // HMDB02255:.H(+) // 
868.1383 // 100 /// S-Methylmalonyl-CoA // 
HMDB02310:.H(+) // 868.1383 // 100
4.0000 -1.9301 0.2726 1.0000 -1.9944 0.0001 1.0000 -1.7047 0.0017 1.0000 -1.7323 0.0006 1.0000 -2.2890 0.0000
m4582 511.1162
3-Methyl-1-hydroxybutyl-ThPP // 
HMDB06865:.H(+) // 511.1162 // 100 /// 2-
Methyl-1-hydroxybutyl-ThPP // 
HMDB12310:.H(+) // 511.1162 // 100 /// 8-iso-
PGA1 // HMDB02236:.(NaCl)3.H(+) // 511.1162 
// 8 /// Prostaglandin A1 // 
HMDB02656:.(NaCl)3.H(+) // 511.1162 // 8 /// 
Prostaglandin B1 // HMDB02982:.(NaCl)3.H(+) // 
511.1162 // 8
4.0000 -1.9542 0.6627 1.0000 -2.0776 0.0000 1.0000 -1.0114 0.0014 1.0000 -2.1673 0.0000 1.0000 -2.5606 0.0000
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m717 145.0499
3-Hexenedioic acid // HMDB00393:.H(+) // 
145.0499 // 100 /// 3-Methylglutaconic acid // 
HMDB00522:.H(+) // 145.0499 // 100 /// (E)-2-
Methylglutaconic acid // HMDB02266:.H(+) // 
145.0499 // 100 /// 2-Hydroxyadipic acid // 
HMDB00321:-H2O.H(+) // 145.0499 // 10 /// 3-
Hydroxyadipic acid // HMDB00345:-H2O.H(+) // 
145.0499 // 10 /// 3-Hydroxymethylglutaric acid 
// HMDB00355:-H2O.H(+) // 145.0499 // 10 /// 
2(R)-Hydroxyadipic acid // HMDB00368:-
H2O.H(+) // 145.0499 // 10 /// Glucosan // 
HMDB00640:-H2O.H(+) // 145.0499 // 10 /// 
Inositol cyclic phosphate // HMDB01125:-
H3PO4.H(+) // 145.0499 // 8 /// Erythritol // 
HMDB02994:.H/Na.H(+) // 145.0499 // 7 /// D-
Threitol // HMDB04136:.H/Na.H(+) // 145.0499 
// 7
4.0000 -1.9775 0.2866 1.0000 -1.8237 0.0000 1.0000 -1.6594 0.0000 1.0000 -2.1413 0.0000 1.0000 -2.2855 0.0000
m2968 340.1038
6-Hydroxy-5-methoxyindole glucuronide // 
HMDB10362:.H(+) // 340.1038 // 92 /// 5-
Hydroxy-6-methoxyindole glucuronide // 
HMDB10363:.H(+) // 340.1038 // 92 /// 
Topiramate // HMDB05034:.H(+) // 340.1038 // 
44
4.0000 -2.0220 0.5242 1.0000 -1.9965 0.0000 1.0000 -1.3318 0.0000 1.0000 -2.1662 0.0000 1.0000 -2.5935 0.0000
m1584 216.0641
Glycerylphosphorylethanolamine // 
HMDB00114:.H(+) // 216.0641 // 100 /// 
Phenylacetylglycine // HMDB00821:.Na(+) // 
216.0641 // 20 /// Methylhippuric acid // 
HMDB00859:.Na(+) // 216.0641 // 20 /// 2-
Methylhippuric acid // HMDB11723:.Na(+) // 
216.0641 // 20 /// Phenylacetylglycine // 
HMDB00821:.H/Na.H(+) // 216.0641 // 20 /// 
Methylhippuric acid // HMDB00859:.H/Na.H(+) 
// 216.0641 // 20 /// 2-Methylhippuric acid // 
HMDB11723:.H/Na.H(+) // 216.0641 // 20 /// 
Glucosamine-1P // HMDB01109:-CO2.H(+) // 
216.0641 // 6 /// Glucosamine 6-phosphate // 
HMDB01254:-CO2.H(+) // 216.0641 // 6
4.0000 -2.0593 0.5319 1.0000 -2.2906 0.0000 1.0000 -1.2649 0.0000 1.0000 -2.3939 0.0000 1.0000 -2.2876 0.0000
m2129 265.1125 Thiamine // HMDB00235:.H(+) // 265.1125 // 100 4.0000 -2.1733 0.5043 1.0000 -2.0592 0.0000 1.0000 -1.6429 0.0006 1.0000 -2.1345 0.0000 1.0000 -2.8567 0.0000
m4337 483.0610 Gestrinone // HMDB02720:.(NaCl)3.H(+) // 483.0610 // 59 4.0000 -2.3934 0.7886 1.0000 -2.4408 0.0000 1.0000 -1.3339 0.0009 1.0000 -2.5615 0.0000 1.0000 -3.2375 0.0000
m1640 221.0784
L-beta-aspartyl-L-serine // HMDB11168:.H(+) // 
221.0784 // 100 /// Guaifenesin // 
HMDB04998:.H/Na.H(+) // 221.0784 // 60 /// 
Guaifenesin // HMDB04998:.Na(+) // 221.0784 
// 13 /// L(-)-Nicotine pestanal // 
HMDB01934:.NaCl.H(+) // 221.0784 // 10 /// 
Anabasine // HMDB04350:.NaCl.H(+) // 
221.0784 // 10 /// 3,4,5-Trimethoxycinnamic 
acid // HMDB02511:-H2O.H(+) // 221.0784 // 5 
/// Trans-2, 3, 4-Trimethoxycinnamate // 
HMDB11721:-H2O.H(+) // 221.0784 // 5
4.0000 -2.5567 0.2958 1.0000 -2.3355 0.0000 1.0000 -2.3063 0.0000 1.0000 -2.6518 0.0000 1.0000 -2.9333 0.0000
m981 163.0612
2-Hydroxyadipic acid // HMDB00321:.H(+) // 
163.0612 // 94 /// 3-Hydroxyadipic acid // 
HMDB00345:.H(+) // 163.0612 // 94 /// 3-
Hydroxymethylglutaric acid // HMDB00355:.H(+) 
// 163.0612 // 94 /// 2(R)-Hydroxyadipic acid // 
HMDB00368:.H(+) // 163.0612 // 94 /// 
Glucosan // HMDB00640:.H(+) // 163.0612 // 94 
/// Fructose 6-phosphate // HMDB00124:-
H3PO4.H(+) // 163.0612 // 7 /// Myo-inositol 1-
phosphate // HMDB00213:-H3PO4.H(+) // 
163.0612 // 7 /// Galactose 1-phosphate // 
HMDB00645:-H3PO4.H(+) // 163.0612 // 7 /// 
Dolichyl phosphate D-mannose // HMDB00994:-
H3PO4.H(+) // 163.0612 // 7 /// Fructose 1-
phosphate // HMDB01076:-H3PO4.H(+) // 
163.0612 // 7 /// Mannose 6-phosphate // 
HMDB01078:-H3PO4.H(+) // 163.0612 // 7 /// D-
Myo-inositol 4-phosphate // HMDB01313:-
H3PO4.H(+) // 163.0612 // 7 /// Glucose 6-
phosphate // HMDB01401:-H3PO4.H(+) // 
163.0612 // 7 /// Glucose 1-phosphate // 
HMDB01586:-H3PO4.H(+) // 163.0612 // 7 /// 
Inositol phosphate // HMDB02985:-H3PO4.H(+) 
// 163.0612 // 7 /// Beta-D-Glucose 6-
phosphate // HMDB03498:-H3PO4.H(+) // 
163.0612 // 7 /// Beta-D-Fructose 6-phosphate 
// HMDB03971:-H3PO4.H(+) // 163.0612 // 7 /// 
D-Tagatose 1-phosphate // HMDB06328:-
H3PO4.H(+) // 163.0612 // 7 /// D-Mannose 1-
4.0000 -3.0721 0.3097 1.0000 -2.8657 0.0000 1.0000 -2.7577 0.0000 1.0000 -3.2591 0.0000 1.0000 -3.4057 0.0000
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m1155 180.0879
7-Aminomethyl-7-carbaguanine // 
HMDB11690:.H(+) // 180.0879 // 100 /// 
Glucosamine // HMDB01514:.H(+) // 180.0879 
// 79 /// Fructosamine // HMDB02030:.H(+) // 
180.0879 // 79 /// 2-Hydroxyadipic acid // 
HMDB00321:.NH4(+) // 180.0879 // 10 /// 3-
Hydroxyadipic acid // HMDB00345:.NH4(+) // 
180.0879 // 10 /// 3-Hydroxymethylglutaric acid 
// HMDB00355:.NH4(+) // 180.0879 // 10 /// 
2(R)-Hydroxyadipic acid // HMDB00368:.NH4(+) 
// 180.0879 // 10 /// Glucosan // 
HMDB00640:.NH4(+) // 180.0879 // 10
4.0000 -3.1365 0.3375 1.0000 -2.9768 0.0000 1.0000 -2.7526 0.0000 1.0000 -3.3053 0.0000 1.0000 -3.5112 0.0000
m727 146.0534
3-Hexenedioic acid // HMDB00393:[+1].H(+) // 
146.0534 // 60 /// 3-Methylglutaconic acid // 
HMDB00522:[+1].H(+) // 146.0534 // 60 /// (E)-
2-Methylglutaconic acid // 
HMDB02266:[+1].H(+) // 146.0534 // 60
4.0000 -8.0329 1.6120 1.0000 -7.3597 0.0001 1.0000 -6.1108 0.0029 1.0000 -9.7047 0.0000 1.0000 -8.9564 0.0000
m3132 356.1582 S-Adenosylmethioninamine // HMDB00988:[+1].H(+) // 356.1582 // 28 3.0000 2.2382 0.5438 1.0000 2.1516 0.0004 0.0000 1.5467 0.0169 1.0000 2.8496 0.0000 1.0000 2.4047 0.0002
m6109 682.3244
(3a,5b)-24-oxo-24-[(2-sulfoethyl)amino]cholan-
3-yl-b-D-Glucopyranosiduronic acid // 
HMDB02429:.H/Na.H(+) // 682.3244 // 100
3.0000 1.8443 0.7981 1.0000 1.7312 0.0019 0.0000 1.1363 0.0631 1.0000 1.5269 0.0060 1.0000 2.9828 0.0000
m639 140.0691
Trigonelline // HMDB00875:.H(+) // 140.0691 // 
66 /// 3,4-Dihydroxybenzylamine // 
HMDB12153:.H(+) // 140.0691 // 66 /// Betaine 
// HMDB00043:.Na(+) // 140.0691 // 20 /// L-
Valine // HMDB00883:.Na(+) // 140.0691 // 20 
/// Vaporole // HMDB01382:.Na(+) // 140.0691 
// 20 /// N-Methyl-a-aminoisobutyric acid // 
HMDB02141:.Na(+) // 140.0691 // 20 /// 5-
Aminopentanoic acid // HMDB03355:.Na(+) // 
140.0691 // 20 /// Betaine // 
HMDB00043:.H/Na.H(+) // 140.0691 // 20 /// L-
Valine // HMDB00883:.H/Na.H(+) // 140.0691 // 
20 /// Vaporole // HMDB01382:.H/Na.H(+) // 
140.0691 // 20 /// N-Methyl-a-aminoisobutyric 
acid // HMDB02141:.H/Na.H(+) // 140.0691 // 
20 /// 5-Aminopentanoic acid // 
HMDB03355:.H/Na.H(+) // 140.0691 // 20
3.0000 1.6322 0.7956 0.0000 0.8322 0.0779 1.0000 1.3658 0.0072 1.0000 1.6087 0.0007 1.0000 2.7220 0.0000
m1277 189.1799
N1-Acetylspermidine // HMDB01276:[+1].H(+) // 
189.1799 // 60 /// N8-Acetylspermidine // 
HMDB02189:[+1].H(+) // 189.1799 // 60
3.0000 1.5120 1.1827 0.0000 0.6981 0.0398 1.0000 0.9494 0.0096 1.0000 1.1350 0.0009 1.0000 3.2657 0.0000
m3289 372.3133 Tetradecanoylcarnitine // HMDB05066:.H(+) // 372.3133 // 65 3.0000 1.3306 0.7064 0.0000 0.6101 0.0218 1.0000 1.3211 0.0000 1.0000 1.0992 0.0001 1.0000 2.2920 0.0000
m1766 232.1551
Isobutyryl-L-carnitine // HMDB00736:.H(+) // 
232.1551 // 100 /// Butyrylcarnitine // 
HMDB02013:.H(+) // 232.1551 // 100
3.0000 1.1760 0.3065 1.0000 1.0555 0.0055 1.0000 1.6064 0.0001 0.0000 0.8906 0.0186 1.0000 1.1516 0.0043
m5934 660.8692 Myo-inositol hexakisphosphate // HMDB03502:.H(+) // 660.8692 // 100 3.0000 1.1639 0.3730 1.0000 1.5010 0.0000 0.0000 0.6398 0.0278 1.0000 1.3334 0.0000 1.0000 1.1816 0.0000
m2336 284.1279
N-Phenylacetylphenylalanine // 
HMDB02372:.H(+) // 284.1279 // 100 /// 
Morphinone // HMDB03563:.H(+) // 284.1279 // 
100 /// 2-Methylbutyroylcarnitine // 
HMDB00378:.H/K.H(+) // 284.1279 // 8 /// 
Isovalerylcarnitine // HMDB00688:.H/K.H(+) // 
284.1279 // 8
3.0000 1.0616 0.2792 1.0000 1.0132 0.0015 0.0000 0.7391 0.0327 1.0000 1.0758 0.0008 1.0000 1.4184 0.0000
m3546 398.3281 trans-Hexadec-2-enoyl carnitine // HMDB06317:.H(+) // 398.3281 // 100 3.0000 1.0032 0.3887 0.0000 0.4641 0.0530 1.0000 1.1047 0.0000 1.0000 1.0539 0.0000 1.0000 1.3901 0.0000
m6244 701.2895 Pentacarboxyl porphyrinogen III // HMDB01957:.H(+) // 701.2895 // 66 3.0000 0.8541 0.4913 1.0000 1.0451 0.0000 0.0000 0.1413 0.6398 1.0000 0.9679 0.0001 1.0000 1.2622 0.0000
m1024 167.0322
Phthalic acid // HMDB02107:.H(+) // 167.0322 // 
59 /// Benzoquinoneacetic acid // 
HMDB02334:.H(+) // 167.0322 // 59 /// 
Terephthalic acid // HMDB02428:.H(+) // 
167.0322 // 59 /// 3-Hexenedioic acid // 
HMDB00393:.Na(+) // 167.0322 // 20 /// 3-
Methylglutaconic acid // HMDB00522:.Na(+) // 
167.0322 // 20 /// (E)-2-Methylglutaconic acid 
// HMDB02266:.Na(+) // 167.0322 // 20 /// 3-
Hexenedioic acid // HMDB00393:.H/Na.H(+) // 
167.0322 // 20 /// 3-Methylglutaconic acid // 
HMDB00522:.H/Na.H(+) // 167.0322 // 20 /// (E)-
2-Methylglutaconic acid // 
HMDB02266:.H/Na.H(+) // 167.0322 // 20
3.0000 0.8229 0.1766 1.0000 0.6706 0.0075 0.0000 0.6714 0.0136 1.0000 1.0002 0.0001 1.0000 0.9492 0.0004
m3009 344.2812 Dodecanoylcarnitine // HMDB02250:.H(+) // 344.2812 // 94 3.0000 0.7399 0.3188 0.0000 0.3525 0.0298 1.0000 0.8102 0.0000 1.0000 0.6754 0.0001 1.0000 1.1217 0.0000
m3837 429.0170
IDP // HMDB03335:.H(+) // 429.0170 // 69 /// 1-
Phosphatidyl-D-myo-inositol // 
HMDB06953:.H/K.H(+) // 429.0170 // 10 /// 
Homoanserine // HMDB05767:.(NaCl)3.H(+) // 
429.0170 // 5
3.0000 -0.5269 0.6281 1.0000 -0.6840 0.0022 0.0000 0.3839 0.1182 1.0000 -1.0542 0.0000 1.0000 -0.7534 0.0015
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m2422 292.0444
Parathion // HMDB01355:.H(+) // 292.0444 // 
72 /// L-Threoneopterin // 
HMDB00727:.H/K.H(+) // 292.0444 // 29 /// 
Neopterin // HMDB00845:.H/K.H(+) // 292.0444 
// 29 /// Umanopterin // HMDB00877:.H/K.H(+) 
// 292.0444 // 29 /// Hydroxysepiapterin // 
HMDB02109:.H/K.H(+) // 292.0444 // 29
3.0000 -0.6161 0.2475 1.0000 -0.6167 0.0011 0.0000 -0.2706 0.1972 1.0000 -0.8384 0.0000 1.0000 -0.7385 0.0003
m719 145.1052 Proline betaine // HMDB04827:[+1].H(+) // 145.1052 // 60 3.0000 -0.6973 0.0857 1.0000 -0.6808 0.0001 0.0000 -0.5846 0.0013 1.0000 -0.7433 0.0000 1.0000 -0.7807 0.0000
m5119 565.0325
3-carboxy-1-hydroxypropylthiamine 
diphosphate // HMDB06744:.H/K.H(+) // 
565.0325 // 77
3.0000 -0.7523 0.4224 1.0000 -0.8329 0.0000 0.0000 -0.1619 0.4140 1.0000 -0.8484 0.0000 1.0000 -1.1659 0.0000
m2822 326.0468
Uridine 5 -monophosphate // 
HMDB00288:[+1].H(+) // 326.0468 // 61 /// 
Pseudouridine 5 -phosphate // 
HMDB01271:[+1].H(+) // 326.0468 // 61 /// 
Uridine 2 -phosphate // HMDB11641:[+1].H(+) 
// 326.0468 // 61
3.0000 -0.7582 0.2700 1.0000 -0.8387 0.0000 0.0000 -0.3879 0.0345 1.0000 -1.0320 0.0000 1.0000 -0.7742 0.0000
m6801 791.5228 Solanesyl-PP // HMDB02367:.H(+) // 791.5228 // 82 3.0000 -0.7654 0.4952 1.0000 -0.9746 0.0001 0.0000 -0.0291 0.9261 1.0000 -0.9552 0.0001 1.0000 -1.1026 0.0000
m3412 384.1488
N-Acetyllactosamine // HMDB01542:.H(+) // 
384.1488 // 100 /// Beta-1,4-mannose-N-
acetylglucosamine // HMDB06535:.H(+) // 
384.1488 // 100 /// Lacto-N-biose I // 
HMDB06575:.H(+) // 384.1488 // 100 /// Poly-N-
acetyllactosamine // HMDB06583:.H(+) // 
384.1488 // 100
3.0000 -0.8025 0.1917 1.0000 -0.8474 0.0000 0.0000 -0.5206 0.0027 1.0000 -0.9028 0.0000 1.0000 -0.9394 0.0000
m3679 413.0477
dADP // HMDB01508:[+1].H(+) // 413.0477 // 94 
/// 1-Phosphatidyl-D-myo-inositol // 
HMDB06953:.H/Na.H(+) // 413.0477 // 37
3.0000 -0.8057 0.6067 1.0000 -0.8729 0.0004 0.0000 0.0714 0.8166 1.0000 -1.1758 0.0000 1.0000 -1.2456 0.0000
m245 106.0497
L-Serine // HMDB00187:.H(+) // 106.0497 // 100 
/// D-Serine // HMDB03406:.H(+) // 106.0497 // 
100
3.0000 -0.8063 0.2701 1.0000 -0.7598 0.0000 0.0000 -0.4763 0.0025 1.0000 -0.8584 0.0000 1.0000 -1.1305 0.0000
m1652 222.0962
N-Acetylgalactosamine // HMDB00212:.H(+) // 
222.0962 // 100 /// N-Acetyl-D-glucosamine // 
HMDB00215:.H(+) // 222.0962 // 100 /// Beta-N-
Acetylglucosamine // HMDB00803:.H(+) // 
222.0962 // 100 /// N-Acetyl-b-D-galactosamine 
// HMDB00853:.H(+) // 222.0962 // 100 /// N-
Acetylmannosamine // HMDB01129:.H(+) // 
222.0962 // 100 /// N-Acetyl-D-mannosamine // 
HMDB11744:.H(+) // 222.0962 // 100 /// 2 -
Deoxysepiapterin // HMDB00389:.H(+) // 
222.0962 // 43
3.0000 -0.8491 0.7314 1.0000 -0.9022 0.0008 0.0000 0.1824 0.5677 1.0000 -1.5104 0.0000 1.0000 -1.1663 0.0001
m2239 276.1574
Epsilon-(gamma-Glutamyl)-lysine // 
HMDB03869:.H(+) // 276.1574 // 75 /// L-a-
glutamyl-L-Lysine // HMDB04207:.H(+) // 
276.1574 // 75
3.0000 -0.8687 0.2529 1.0000 -1.0913 0.0000 0.0000 -0.5061 0.0017 1.0000 -0.9614 0.0000 1.0000 -0.9162 0.0000
m4388 489.1123 Citicoline // HMDB01413:.H(+) // 489.1123 // 100 3.0000 -0.9818 0.4606 1.0000 -0.8649 0.0000 0.0000 -0.3992 0.0647 1.0000 -1.1921 0.0000 1.0000 -1.4710 0.0000
m2314 282.1202
1-Methyladenosine // HMDB03331:.H(+) // 
282.1202 // 100 /// N6-Methyladenosine // 
HMDB04044:.H(+) // 282.1202 // 100 /// 2 -O-
Methyladenosine // HMDB04326:.H(+) // 
282.1202 // 100 /// 3 -O-Methyladenosine // 
HMDB06023:.H(+) // 282.1202 // 100
3.0000 -1.0661 0.3876 1.0000 -1.2781 0.0004 0.0000 -0.5039 0.2065 1.0000 -1.3605 0.0002 1.0000 -1.1217 0.0033
m7048 838.0606 Diadenosine tetraphosphate // HMDB01211:[+1].H(+) // 838.0606 // 60 3.0000 -1.2019 0.6040 1.0000 -1.3157 0.0003 0.0000 -0.4314 0.2786 1.0000 -1.1610 0.0011 1.0000 -1.8993 0.0000
m6788 789.0787
Diguanosine triphosphate // HMDB01379:.H(+) 
// 789.0787 // 100 /// Diguanosine 
tetraphosphate // HMDB01340:-HPO3.H(+) // 
789.0787 // 24
3.0000 -1.2433 0.5731 1.0000 -1.5053 0.0001 0.0000 -0.5055 0.2085 1.0000 -1.1213 0.0020 1.0000 -1.8412 0.0000
m6397 725.0656 Molybdopterin-AMP // HMDB12262:.H(+) // 725.0656 // 61 3.0000 -1.3239 0.6416 1.0000 -1.7413 0.0000 0.0000 -0.3695 0.2149 1.0000 -1.6446 0.0000 1.0000 -1.5401 0.0000
m7043 837.0612 Diadenosine tetraphosphate // HMDB01211:.H(+) // 837.0612 // 100 3.0000 -1.3286 0.4464 1.0000 -1.3268 0.0003 0.0000 -0.7095 0.0786 1.0000 -1.7431 0.0000 1.0000 -1.5349 0.0001
m1193 184.0748
Phosphorylcholine // HMDB01565:.H(+) // 
184.0748 // 67 /// Tryptophanol // 
HMDB03447:.H/Na.H(+) // 184.0748 // 13 /// 3-
Dehydroxycarnitine // HMDB06831:.H/K.H(+) // 
184.0748 // 7 /// Acetylcholine // 
HMDB00895:.H/K.H(+) // 184.0748 // 7
3.0000 -1.3954 1.3083 1.0000 -1.7767 0.0001 0.0000 0.4940 0.3082 1.0000 -2.5256 0.0000 1.0000 -1.7733 0.0001
m5960 664.1161 NAD // HMDB00902:.H(+) // 664.1161 // 100 3.0000 -1.4594 1.1332 1.0000 -1.0161 0.0021 0.0000 -0.1594 0.6934 1.0000 -1.8585 0.0000 1.0000 -2.8035 0.0000
m3563 400.3444 L-Palmitoylcarnitine // HMDB00222:.H(+) // 400.3444 // 100 2.0000 1.0739 0.4195 0.0000 0.7930 0.0108 0.0000 0.7656 0.0240 1.0000 1.0680 0.0007 1.0000 1.6688 0.0000
m2210 273.1097
5C-aglycone // HMDB04810:.H(+) // 273.1097 // 
99 /// Ubiquinone // HMDB02012:.H/Na.H(+) // 
273.1097 // 48 /// N-Succinyl-L,L-2,6-
diaminopimelate // HMDB12267:-H2O.H(+) // 
273.1097 // 7
2.0000 0.9872 0.3964 0.0000 0.7471 0.0306 1.0000 1.0222 0.0062 0.0000 0.6474 0.0609 1.0000 1.5322 0.0000
Page 6 of 11
m5354 591.2973
Dimethylprotoporphyrin IX dimethyl ester // 
HMDB00810:.H(+) // 591.2973 // 100 /// 
Protoporphyrinogen IX // 
HMDB01097:.H/Na.H(+) // 591.2973 // 54 /// 
Protoporphyrinogen IX // HMDB01097:.Na(+) // 
591.2973 // 54 /// D-Urobilinogen // 
HMDB04158:.H(+) // 591.2973 // 41 /// I-
Urobilin // HMDB04160:.H(+) // 591.2973 // 41 
/// Lithocholate 3-O-glucuronide // 
HMDB02513:.H/K.H(+) // 591.2973 // 20 /// 
(3a,5b,7a)-23-Carboxy-7-hydroxy-24-norcholan-
3-yl-b-D-Glucopyranosiduronic acid // 
HMDB02430:.Na(+) // 591.2973 // 10 /// 
Deoxycholic acid 3-glucuronide // 
HMDB02596:.Na(+) // 591.2973 // 10 /// 
(3a,5b,7a)-23-Carboxy-7-hydroxy-24-norcholan-
3-yl-b-D-Glucopyranosiduronic acid // 
HMDB02430:.H/Na.H(+) // 591.2973 // 10 /// 
Deoxycholic acid 3-glucuronide // 
HMDB02596:.H/Na.H(+) // 591.2973 // 10 /// 
Stigmastanol // HMDB00494:.(NaCl)3.H(+) // 
591.2973 // 5
2.0000 0.8909 0.5290 0.0000 0.7271 0.0149 0.0000 0.2319 0.5094 1.0000 1.1604 0.0001 1.0000 1.4440 0.0000
m1831 239.0912
3,4,5-Trimethoxycinnamic acid // 
HMDB02511:.H(+) // 239.0912 // 100 /// Trans-
2, 3, 4-Trimethoxycinnamate // 
HMDB11721:.H(+) // 239.0912 // 100
2.0000 0.8765 0.4974 0.0000 0.5354 0.0604 0.0000 0.3860 0.2224 1.0000 1.1522 0.0001 1.0000 1.4325 0.0000
m4123 460.1959
5-Methyltetrahydrofolic acid // 
HMDB01396:.H(+) // 460.1959 // 100 /// 
Dodecanoylcarnitine // 
HMDB02250:.(NaCl)2.H(+) // 460.1959 // 18
2.0000 0.8071 0.4191 0.0000 0.3091 0.1976 0.0000 0.6175 0.0157 1.0000 1.0944 0.0000 1.0000 1.2076 0.0000
m773 148.0382 Indole-5,6-quinone // HMDB06779:.H(+) // 148.0382 // 87 2.0000 0.7777 0.4078 0.0000 0.3952 0.0433 0.0000 0.5259 0.0129 1.0000 0.8852 0.0000 1.0000 1.3046 0.0000
m1843 240.0945
3,4,5-Trimethoxycinnamic acid // 
HMDB02511:[+1].H(+) // 240.0945 // 60 /// 
Trans-2, 3, 4-Trimethoxycinnamate // 
HMDB11721:[+1].H(+) // 240.0945 // 60 /// N-a-
Acetylcitrulline // HMDB00856:.Na(+) // 
240.0945 // 20 /// N-a-Acetylcitrulline // 
HMDB00856:.H/Na.H(+) // 240.0945 // 20
2.0000 0.7325 0.4390 0.0000 0.4047 0.0937 0.0000 0.3278 0.2197 1.0000 0.9594 0.0001 1.0000 1.2380 0.0000
m3809 426.3551 Elaidic carnitine // HMDB06464:.H(+) // 426.3551 // 100 2.0000 0.6550 0.4549 0.0000 0.3901 0.1411 0.0000 0.2162 0.4788 1.0000 0.7714 0.0033 1.0000 1.2421 0.0000
m798 150.0274 2-Oxo-4-methylthiobutanoic acid // HMDB01553:[+1].H(+) // 150.0274 // 46 2.0000 0.6517 0.3267 0.0000 0.4310 0.0075 0.0000 0.3408 0.0541 1.0000 0.7880 0.0000 1.0000 1.0470 0.0000
m1097 174.0888
2-Oxoarginine // HMDB04225:.H(+) // 174.0888 
// 69 /// N-Methylphenylethanolamine // 
HMDB01387:.Na(+) // 174.0888 // 20 /// 
Phenylpropanolamine // HMDB01942:.Na(+) // 
174.0888 // 20 /// N-Methyltyramine // 
HMDB03633:.Na(+) // 174.0888 // 20 /// N-
Methylphenylethanolamine // 
HMDB01387:.H/Na.H(+) // 174.0888 // 20 /// 
Phenylpropanolamine // 
HMDB01942:.H/Na.H(+) // 174.0888 // 20 /// N-
Methyltyramine // HMDB03633:.H/Na.H(+) // 
174.0888 // 20
2.0000 0.6421 0.2748 0.0000 0.4407 0.0121 0.0000 0.3811 0.0479 1.0000 0.7991 0.0000 1.0000 0.9475 0.0000
m1844 240.1199
Propionylcarnitine // HMDB00824:.H/Na.H(+) // 
240.1199 // 45 /// Propionylcarnitine // 
HMDB00824:.Na(+) // 240.1199 // 26 /// 
Bupropion // HMDB01510:.H(+) // 240.1199 // 
11
2.0000 0.5778 0.3087 0.0000 0.3111 0.0845 0.0000 0.3289 0.0972 1.0000 0.7353 0.0001 1.0000 0.9357 0.0000
m1119 176.0677
Guanidinosuccinic acid // HMDB03157:.H(+) // 
176.0677 // 94 /// Indoleacetic acid // 
HMDB00197:.H(+) // 176.0677 // 34 /// 5-
Hydroxyindoleacetaldehyde // 
HMDB04073:.H(+) // 176.0677 // 34 /// 
Dopamine // HMDB00073:.H/Na.H(+) // 
176.0677 // 20 /// p-Octopamine // 
HMDB04825:.H/Na.H(+) // 176.0677 // 20 /// 
Vanillylamine // HMDB12309:.H/Na.H(+) // 
176.0677 // 20 /// Dopamine // 
HMDB00073:.Na(+) // 176.0677 // 20 /// p-
Octopamine // HMDB04825:.Na(+) // 176.0677 
// 20 /// Vanillylamine // HMDB12309:.Na(+) // 
176.0677 // 20
2.0000 0.5539 0.3066 0.0000 0.3565 0.0137 0.0000 0.2282 0.1551 1.0000 0.8037 0.0000 1.0000 0.8271 0.0000
m2714 316.2498 Decanoylcarnitine // HMDB00651:.H(+) // 316.2498 // 86 2.0000 0.5290 0.2199 0.0000 0.2131 0.3166 1.0000 0.6676 0.0029 0.0000 0.5457 0.0083 1.0000 0.6897 0.0018
m1508 209.0803
4-Hydroxybenzyl alcohol // HMDB11724:.H(+) // 
209.0803 // 100 /// (R)-2-Benzylsuccinate // 
HMDB12127:.H(+) // 209.0803 // 100
2.0000 0.4966 0.2195 0.0000 0.3447 0.0012 0.0000 0.2900 0.0117 1.0000 0.5907 0.0000 1.0000 0.7611 0.0000
m395 123.0558 Niacinamide // HMDB01406:.H(+) // 123.0558 // 100 2.0000 0.1739 0.5493 0.0000 0.2399 0.2390 1.0000 -0.5963 0.0058 0.0000 0.3535 0.0775 1.0000 0.6986 0.0011
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m3159 359.1101
Pantetheine 4 -phosphate // HMDB01416:.H(+) 
// 359.1101 // 59 /// N1-(5-Phospho-a-D-
ribosyl)-5,6-dimethylbenzimidazole // 
HMDB03882:.H(+) // 359.1101 // 39 /// Valproic 
acid glucuronide // HMDB00901:.H/K.H(+) // 
359.1101 // 38 /// Octanoylglucuronide // 
HMDB10347:.H/K.H(+) // 359.1101 // 38 /// 3-
Oxotetradecanoic acid // 
HMDB10730:.(NaCl)2.H(+) // 359.1101 // 12
2.0000 -0.3685 0.4129 1.0000 -0.6870 0.0056 0.0000 0.1998 0.4906 1.0000 -0.6606 0.0076 0.0000 -0.3261 0.2310
m3216 365.0447
Xanthylic acid // HMDB01554:.H(+) // 365.0447 
// 100 /// 6-Hydroxymelatonin // 
HMDB04081:.(NaCl)2.H(+) // 365.0447 // 9 /// 
Histidylproline diketopiperazine // 
HMDB02053:.(NaCl)2.H(+) // 365.0447 // 5
2.0000 -0.4705 0.4109 0.0000 -0.4361 0.0063 0.0000 0.0936 0.6281 1.0000 -0.7069 0.0000 1.0000 -0.8327 0.0000
m1703 227.0531
Chorismate // HMDB12199:.H(+) // 227.0531 // 
100 /// Prephenate // HMDB12283:.H(+) // 
227.0531 // 100 /// Pyridoxamine // 
HMDB01431:.NaCl.H(+) // 227.0531 // 7
2.0000 -0.5085 0.2040 0.0000 -0.5655 0.0027 0.0000 -0.2061 0.3332 1.0000 -0.6286 0.0009 1.0000 -0.6337 0.0016
m3398 383.1527 Loratadine // HMDB05000:.H(+) // 383.1527 // 92 2.0000 -0.5227 0.2443 1.0000 -0.7799 0.0000 0.0000 -0.5067 0.0017 1.0000 -0.6064 0.0001 0.0000 -0.1977 0.2265
m3236 367.0660
Phosphoribosyl formamidocarboxamide // 
HMDB01439:.H(+) // 367.0660 // 100 /// 7-
Hydroxy-6-methyl-8-ribityl lumazine // 
HMDB04256:.H/K.H(+) // 367.0660 // 55 /// 
Thiamine monophosphate // 
HMDB02666:.H/Na.H(+) // 367.0660 // 18 /// 
Malvidin // HMDB03201:.H(+) // 367.0660 // 17 
/// Warfarin // HMDB01935:.NaCl.H(+) // 
367.0660 // 12 /// Bisdemethoxycurcumin // 
HMDB02114:.NaCl.H(+) // 367.0660 // 12
2.0000 -0.5452 0.2243 0.0000 -0.5165 0.0144 0.0000 -0.2469 0.3004 1.0000 -0.7709 0.0003 1.0000 -0.6466 0.0040
m46 75.0448
Propionic acid // HMDB00237:.H(+) // 75.0448 
// 100 /// Lactaldehyde // HMDB03052:.H(+) // 
75.0448 // 100 /// 3-Hydroxypropanal // 
HMDB03453:.H(+) // 75.0448 // 100 /// D-
Lactaldehyde // HMDB06458:.H(+) // 75.0448 // 
100 /// Hydroxyacetone // HMDB06961:.H(+) // 
75.0448 // 100
2.0000 -0.5488 0.1776 0.0000 -0.3859 0.0205 1.0000 -0.6118 0.0008 0.0000 -0.4268 0.0102 1.0000 -0.7708 0.0000
m1112 175.1203
L-Arginine // HMDB00517:.H(+) // 175.1203 // 
74 /// D-Arginine // HMDB03416:.H(+) // 
175.1203 // 74 /// N-Methyltryptamine // 
HMDB04370:.H(+) // 175.1203 // 37
2.0000 -0.5522 0.4749 0.0000 -0.3062 0.1121 1.0000 -0.9608 0.0000 0.0000 -0.0040 0.9849 1.0000 -0.9377 0.0000
m1663 223.0760
Flavone // HMDB03075:.H(+) // 223.0760 // 100 
/// L-Cystathionine // HMDB00099:.H(+) // 
223.0760 // 76 /// Allocystathionine // 
HMDB00455:.H(+) // 223.0760 // 76
2.0000 -0.5767 0.3265 0.0000 -0.3722 0.0386 0.0000 -0.2444 0.2215 1.0000 -0.7368 0.0001 1.0000 -0.9534 0.0000
m2537 300.0977
8-Hydroxyguanosine // HMDB02044:.H(+) // 
300.0977 // 70 /// Gamma glutamyl ornithine // 
HMDB02248:.H/K.H(+) // 300.0977 // 13 /// 
Aspartylysine // HMDB04985:.H/K.H(+) // 
300.0977 // 13 /// Alpha-Aspartyl-lysine // 
HMDB04987:.H/K.H(+) // 300.0977 // 13
2.0000 -0.6109 0.1387 1.0000 -0.6262 0.0037 0.0000 -0.4976 0.0342 0.0000 -0.5188 0.0158 1.0000 -0.8010 0.0005
m3606 405.0116 Uridine 5 -diphosphate // HMDB00295:.H(+) // 405.0116 // 100 2.0000 -0.6647 0.4331 0.0000 -0.2869 0.1403 0.0000 -0.4293 0.0409 1.0000 -0.6740 0.0005 1.0000 -1.2685 0.0000
m3672 412.0435 dADP // HMDB01508:.H(+) // 412.0435 // 100 2.0000 -0.6745 0.2940 0.0000 -0.5700 0.0005 0.0000 -0.3777 0.0334 1.0000 -0.6756 0.0001 1.0000 -1.0749 0.0000
m3828 428.0385
Adenosine 3 ,5 -diphosphate // 
HMDB00061:.H(+) // 428.0385 // 100 /// dGDP 
// HMDB00960:.H(+) // 428.0385 // 100 /// ADP 
// HMDB01341:.H(+) // 428.0385 // 100 /// 
Acetyl adenylate // HMDB06880:.H/K.H(+) // 
428.0385 // 15 /// N-Acetylneuraminic acid 9-
phosphate // HMDB04381:.H/K.H(+) // 
428.0385 // 8 /// N-Acetylneuraminate 9-
phosphate // HMDB06268:.H/K.H(+) // 
428.0385 // 8
2.0000 -0.8815 0.8469 0.0000 -0.4874 0.0231 0.0000 0.0474 0.8640 1.0000 -1.1835 0.0000 1.0000 -1.9026 0.0000
m7051 838.2349 3 -Sialyl-3-fucosyllactose // HMDB06606:.NaCl.H(+) // 838.2349 // 72 1.0000 3.2499 1.4786 0.0000 4.7631 0.0000 0.0000 1.4486 0.1753 0.0000 2.6929 0.0052 1.0000 4.0950 0.0001
m966 162.1136
4-Trimethylammoniobutanoic acid // 
HMDB01161:.H(+) // 162.1136 // 92 /// L-
Carnitine // HMDB00062:.H(+) // 162.1136 // 92
1.0000 0.6324 0.2945 0.0000 0.2981 0.3793 0.0000 0.5187 0.1531 0.0000 0.7236 0.0269 1.0000 0.9890 0.0045
m347 118.0869
Betaine // HMDB00043:.H(+) // 118.0869 // 100 
/// L-Valine // HMDB00883:.H(+) // 118.0869 // 
100 /// Vaporole // HMDB01382:.H(+) // 
118.0869 // 100 /// N-Methyl-a-aminoisobutyric 
acid // HMDB02141:.H(+) // 118.0869 // 100 /// 
5-Aminopentanoic acid // HMDB03355:.H(+) // 
118.0869 // 100 /// Senecioic acid // 
HMDB00509:.NH4(+) // 118.0869 // 10 /// Tiglic 
acid // HMDB01470:.NH4(+) // 118.0869 // 10 
/// 2-Ethylacrylic acid // HMDB01862:.NH4(+) // 
118.0869 // 10 /// 3-Methylbutyrolactone // 
HMDB02167:.NH4(+) // 118.0869 // 10 /// 
Aminoadipic acid // HMDB00510:-CO2.H(+) // 
118.0869 // 10 /// 
Glycerylphosphorylethanolamine // 
HMDB00114:-H3PO4.H(+) // 118.0869 // 5
1.0000 0.5917 0.4486 0.0000 0.1205 0.7554 0.0000 0.5510 0.1564 0.0000 0.4948 0.1651 1.0000 1.2004 0.0013
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m983 163.1167
4-Trimethylammoniobutanoic acid // 
HMDB01161:[+1].H(+) // 163.1167 // 60 /// L-
Carnitine // HMDB00062:[+1].H(+) // 163.1167 
// 60 /// 4-Hydroxycyclohexylcarboxylic acid // 
HMDB01988:[+1].NH4(+) // 163.1167 // 6
1.0000 0.5344 0.2489 0.0000 0.2610 0.3734 0.0000 0.4262 0.1753 0.0000 0.6101 0.0310 1.0000 0.8405 0.0053
m2194 271.1394
2-(3-Carboxy-3-(methylammonio)propyl)-L-
histidine // HMDB11654:.H(+) // 271.1394 // 
100
1.0000 0.5287 0.5895 0.0000 -0.1193 0.7340 0.0000 0.4100 0.2531 0.0000 0.5155 0.1096 1.0000 1.3087 0.0002
m1966 252.1045
Muramic acid // HMDB03254:.H(+) // 252.1045 
// 100 /// Deoxyadenosine // HMDB00101:.H(+) 
// 252.1045 // 95 /// 5 -Deoxyadenosine // 
HMDB01983:.H(+) // 252.1045 // 95 /// 
Prolylhydroxyproline // HMDB06695:[+1].Na(+) 
// 252.1045 // 53 /// Deoxyadenosine 
monophosphate // HMDB00905:-HPO3.H(+) // 
252.1045 // 5
1.0000 0.5094 0.1593 0.0000 0.3641 0.0483 0.0000 0.5818 0.0035 0.0000 0.3924 0.0325 1.0000 0.6994 0.0004
m340 117.1033
5-Aminopentanamide // HMDB12176:.H(+) // 
117.1033 // 91 /// 2-Piperidinone // 
HMDB11749:.NH4(+) // 117.1033 // 10
1.0000 0.4978 0.7146 0.0000 -0.0002 0.9994 0.0000 0.1812 0.4887 0.0000 0.2524 0.2728 1.0000 1.5578 0.0000
m1148 179.1051
5-Phenylvaleric acid // HMDB02043:.H(+) // 
179.1051 // 63 /// 4-Hydroxynonenal // 
HMDB04362:.H/Na.H(+) // 179.1051 // 20 /// 
Monoisobutyl phthalic acid // HMDB02056:-
CO2.H(+) // 179.1051 // 6 /// Aminoadipic acid 
// HMDB00510:.NH4(+) // 179.1051 // 5
1.0000 0.4017 0.2877 0.0000 0.2162 0.0816 0.0000 0.1299 0.3554 0.0000 0.4974 0.0001 1.0000 0.7635 0.0000
m2275 279.2305
Alpha-Linolenic acid // HMDB01388:.H(+) // 
279.2305 // 100 /// Gamma-Linolenic acid // 
HMDB03073:.H(+) // 279.2305 // 100 /// 
Palmitic acid // HMDB00220:.H/Na.H(+) // 
279.2305 // 27 /// Trimethyltridecanoic acid // 
HMDB02396:.H/Na.H(+) // 279.2305 // 27
1.0000 0.3686 0.2359 0.0000 0.1503 0.3213 0.0000 0.2494 0.1263 0.0000 0.3825 0.0093 1.0000 0.6924 0.0000
m288 112.0522 Cytosine // HMDB00630:.H(+) // 112.0522 // 61 1.0000 0.3477 0.3367 0.0000 0.2787 0.1714 0.0000 0.4386 0.0458 0.0000 -0.0675 0.7592 1.0000 0.7411 0.0006
m2946 338.0519
Famotidine // HMDB01919:.H(+) // 338.0519 // 
100 /// Dihydrozeatin // 
HMDB12215:.(NaCl)2.H(+) // 338.0519 // 8
1.0000 -0.1275 0.4154 1.0000 -0.6856 0.0023 0.0000 -0.0430 0.8812 0.0000 -0.0992 0.6840 0.0000 0.3177 0.1944
m3599 404.0202
CDP // HMDB01546:.H(+) // 404.0202 // 76 /// 
Molybdopterin precursor Z // 
HMDB11683:.NaCl.H(+) // 404.0202 // 6 /// 
Cyclic GMP // HMDB01314:.NaCl.H(+) // 
404.0202 // 6 /// Guanosine 2 ,3 -cyclic 
phosphate // HMDB11629:.NaCl.H(+) // 
404.0202 // 6
1.0000 -0.2193 0.4499 0.0000 0.0577 0.7833 0.0000 0.2277 0.2857 0.0000 -0.3957 0.0365 1.0000 -0.7667 0.0002
m6727 777.9710 Phosphoribosyl-ATP // HMDB03665:.NaCl.H(+) // 777.9710 // 98 1.0000 -0.2217 0.3005 0.0000 -0.0556 0.7277 0.0000 0.0435 0.8135 0.0000 -0.2372 0.1055 1.0000 -0.6373 0.0001
m2641 309.0955
Glutathione // HMDB00125:[+1].H(+) // 
309.0955 // 86 /// Salicin // 
HMDB03546:.H/Na.H(+) // 309.0955 // 30 /// 
Salicin // HMDB03546:.Na(+) // 309.0955 // 30 
/// 2-(3-Carboxy-3-(methylammonio)propyl)-L-
histidine // HMDB11654:.H/K.H(+) // 309.0955 
// 16 /// 2-(3-Carboxy-3-
(methylammonio)propyl)-L-histidine // 
HMDB11654:.K(+) // 309.0955 // 8
1.0000 -0.2512 0.3532 0.0000 0.0554 0.7333 0.0000 -0.0155 0.9366 0.0000 -0.3255 0.0279 1.0000 -0.7193 0.0000
m1146 179.0489 Cysteinylglycine // HMDB00078:.H(+) // 179.0489 // 100 1.0000 -0.3310 0.3865 0.0000 -0.1361 0.4911 0.0000 0.0512 0.8315 0.0000 -0.3989 0.0337 1.0000 -0.8403 0.0000
m2629 308.0926 Glutathione // HMDB00125:.H(+) // 308.0926 // 65 1.0000 -0.3717 0.5962 0.0000 0.1154 0.6118 0.0000 0.0661 0.8046 0.0000 -0.5103 0.0158 1.0000 -1.1579 0.0000
m338 117.0536
Alpha-ketoisovaleric acid // HMDB00019:.H(+) // 
117.0536 // 100 /// Methylacetoacetic acid // 
HMDB00310:.H(+) // 117.0536 // 100 /// 
Levulinic acid // HMDB00720:.H(+) // 117.0536 
// 100 /// 2-Oxovaleric acid // HMDB01865:.H(+) 
// 117.0536 // 100 /// 2-Methylacetoacetic acid 
// HMDB03771:.H(+) // 117.0536 // 100 /// 
Glutarate semialdehyde // HMDB12233:.H(+) // 
117.0536 // 100
1.0000 -0.3911 0.1665 0.0000 -0.2850 0.0199 0.0000 -0.2850 0.0329 0.0000 -0.3594 0.0034 1.0000 -0.6353 0.0000
m7631 971.9021 Dolichol-14 // HMDB05181:.H(+) // 971.9021 // 100 1.0000 -0.4851 0.7255 0.0000 -0.0553 0.8836 0.0000 0.1351 0.7501 0.0000 -0.5315 0.1194 1.0000 -1.4889 0.0001
m48 76.0399 Glycine // HMDB00123:.H(+) // 76.0399 // 100 1.0000 -0.5103 0.2109 0.0000 -0.4254 0.0320 0.0000 -0.2738 0.2145 0.0000 -0.5747 0.0038 1.0000 -0.7674 0.0003
m990 164.0683
4-(3-Pyridyl)-3-butenoic acid // 
HMDB01424:.H(+) // 164.0683 // 84 /// 3-
Methyldioxyindole // HMDB04186:.H(+) // 
164.0683 // 84 /// S-(2-carboxypropyl)-
Cysteamine // HMDB02169:.H(+) // 164.0683 // 
34 /// 2-Hydroxyadipic acid // 
HMDB00321:[+1].H(+) // 164.0683 // 6 /// 3-
Hydroxyadipic acid // HMDB00345:[+1].H(+) // 
164.0683 // 6 /// 3-Hydroxymethylglutaric acid 
// HMDB00355:[+1].H(+) // 164.0683 // 6 /// 
2(R)-Hydroxyadipic acid // 
HMDB00368:[+1].H(+) // 164.0683 // 6 /// 
Glucosan // HMDB00640:[+1].H(+) // 164.0683 
// 6
1.0000 -0.5262 0.0680 0.0000 -0.4609 0.0043 0.0000 -0.5200 0.0029 0.0000 -0.5026 0.0019 1.0000 -0.6212 0.0003
m1441 204.2270 Spermine // HMDB01256:[+1].H(+) // 204.2270 // 60 1.0000 -1.0216 0.7944 0.0000 -0.6055 0.2158 0.0000 -0.4102 0.4639 0.0000 -0.8957 0.0625 1.0000 -2.1750 0.0000Page 9 of 11
m1413 203.2242 Spermine // HMDB01256:.H(+) // 203.2242 // 85 1.0000 -1.1929 0.8880 0.0000 -0.6931 0.1882 0.0000 -0.5782 0.3239 0.0000 -1.0027 0.0527 1.0000 -2.4974 0.0000
m4772 530.2008
O-6-deoxy-a-L-galactopyranosyl-(1->2)-O-b-D-
galactopyranosyl-(1->3)-2-(acetylamino)-2-
deoxy-D-Galactose // HMDB02060:.H(+) // 
530.2008 // 63 /// Lewis X trisaccharide // 
HMDB06568:.H(+) // 530.2008 // 63 /// Lewis a 
trisaccharide // HMDB06582:.H(+) // 530.2008 
// 63
1.0000 -3.2375 0.7342 1.0000 -3.9912 0.0004 0.0000 -2.8848 0.0159 0.0000 -3.6867 0.0009 0.0000 -2.3872 0.0424
m105 89.1076 Putrescine // HMDB01414:.H(+) // 89.1076 // 100 0.0000 0.9402 0.4181 0.0000 1.1322 0.0703 0.0000 0.8636 0.2127 0.0000 0.3952 0.5532 0.0000 1.3699 0.0392
m651 140.9953
Acetylphosphate // HMDB01494:.H(+) // 
140.9953 // 100 /// Phosphonoacetate // 
HMDB04110:.H(+) // 140.9953 // 100 /// 2-
Ketobutyric acid // HMDB00005:.H/K.H(+) // 
140.9953 // 10 /// Acetoacetic acid // 
HMDB00060:.H/K.H(+) // 140.9953 // 10 /// 2-
Methyl-3-oxopropanoic acid // 
HMDB01172:.H/K.H(+) // 140.9953 // 10 /// 
Succinic acid semialdehyde // 
HMDB01259:.H/K.H(+) // 140.9953 // 10 /// (S)-
Methylmalonic acid semialdehyde // 
HMDB02217:.H/K.H(+) // 140.9953 // 10 /// 4-
Hydroxycrotonic acid // HMDB03381:.H/K.H(+) 
// 140.9953 // 10 /// 2-Ketobutyric acid // 
HMDB00005:.K(+) // 140.9953 // 5 /// 
Acetoacetic acid // HMDB00060:.K(+) // 
140.9953 // 5 /// 2-Methyl-3-oxopropanoic acid 
// HMDB01172:.K(+) // 140.9953 // 5 /// 
Succinic acid semialdehyde // HMDB01259:.K(+) 
// 140.9953 // 5 /// (S)-Methylmalonic acid 
semialdehyde // HMDB02217:.K(+) // 140.9953 
// 5 /// 4-Hydroxycrotonic acid // 
HMDB03381:.K(+) // 140.9953 // 5
0.0000 0.7655 0.0719 0.0000 0.7468 0.0231 0.0000 0.6719 0.0634 0.0000 0.8146 0.0130 0.0000 0.8286 0.0178
m4911 543.4860
7,7 ,8,8 ,11,11 ,12,12 -Hexahydro-y,y-Carotene 
// HMDB02272:.H(+) // 543.4860 // 100 /// 
Phytofluene // HMDB02871:.H(+) // 543.4860 // 
100 /// cis-7,7 ,8,8 ,11,12-Hexahydro-Carotene 
// HMDB02936:.H(+) // 543.4860 // 100
0.0000 0.4255 0.1331 0.0000 0.3364 0.1804 0.0000 0.2938 0.2902 0.0000 0.4943 0.0451 0.0000 0.5775 0.0279
m473 127.0243 Taurine // HMDB00251:[+1].H(+) // 127.0243 // 59 0.0000 0.4195 0.1145 0.0000 0.3039 0.0366 0.0000 0.3392 0.0322 0.0000 0.5310 0.0003 0.0000 0.5037 0.0012
m3550 399.1471 S-Adenosylmethionine // HMDB01185:.H(+) // 399.1471 // 39 0.0000 0.3893 0.2899 0.0000 0.5820 0.0087 0.0000 0.5520 0.0222 0.0000 0.4621 0.0367 0.0000 -0.0388 0.8892
m4567 509.3381 Reduced Vitamin K (phylloquinone) // HMDB04198:.H/K.H(+) // 509.3381 // 71 0.0000 0.2803 0.2954 0.0000 0.4231 0.0419 0.0000 -0.1292 0.6054 0.0000 0.2759 0.1921 0.0000 0.5516 0.0124
m5550 613.1583 Oxidized glutathione // HMDB03337:.H(+) // 613.1583 // 100 0.0000 0.2746 0.4037 0.0000 -0.1440 0.7639 0.0000 0.8146 0.0899 0.0000 0.1279 0.7884 0.0000 0.3000 0.5534
m758 147.0765
L-Glutamine // HMDB00641:.H(+) // 147.0765 // 
100 /// Ureidoisobutyric acid // 
HMDB02031:.H(+) // 147.0765 // 100 /// D-
Glutamine // HMDB03423:.H(+) // 147.0765 // 
100 /// Alanylglycine // HMDB06899:.H(+) // 
147.0765 // 100 /// Pyroglutamic acid // 
HMDB00267:.NH4(+) // 147.0765 // 5 /// 
Pyrrolidonecarboxylic acid // 
HMDB00805:.NH4(+) // 147.0765 // 5 /// 
Pyrroline hydroxycarboxylic acid // 
HMDB01369:.NH4(+) // 147.0765 // 5 /// N-
Acryloylglycine // HMDB01843:.NH4(+) // 
147.0765 // 5 /// 1-Pyrroline-4-hydroxy-2-
carboxylate // HMDB02234:.NH4(+) // 147.0765 
// 5
0.0000 0.1792 0.2155 0.0000 0.3585 0.0110 0.0000 0.2934 0.0583 0.0000 0.1924 0.1804 0.0000 -0.1274 0.4267
m2741 318.2966 Phytosphingosine // HMDB04610:.H(+) // 318.2966 // 100 0.0000 0.1701 0.1084 0.0000 0.3143 0.0835 0.0000 0.1258 0.5599 0.0000 0.1813 0.3331 0.0000 0.0590 0.7913
m2752 319.2575
Allopregnanolone // HMDB01449:.H(+) // 
319.2575 // 60 /// Alloepipregnanolone // 
HMDB01455:.H(+) // 319.2575 // 60 /// 
Epipregnanolone // HMDB01471:.H(+) // 
319.2575 // 60 /// Epimetendiol // 
HMDB06012:.H(+) // 319.2575 // 60 /// 3a-
Hydroxy-5b-pregnane-20-one // 
HMDB06759:.H(+) // 319.2575 // 60 /// 2,6 
dimethylheptanoyl carnitine // 
HMDB06320:.NH4(+) // 319.2575 // 16
0.0000 0.1639 0.1541 0.0000 0.2466 0.1552 0.0000 -0.0670 0.7553 0.0000 0.2456 0.1572 0.0000 0.2303 0.2202
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m3799 425.2859
1b-Hydroxycholic acid // HMDB00307:.H(+) // 
425.2859 // 94 /// 3b,4b,7a,12a-Tetrahydroxy-
5b-cholanoic acid // HMDB00311:.H(+) // 
425.2859 // 94 /// 2b,3a,7a,12a-Tetrahydroxy-
5b-cholanoic acid // HMDB00316:.H(+) // 
425.2859 // 94 /// 3a,7a,12a,19-Tetrahydroxy-
5b-cholanoic acid // HMDB00340:.H(+) // 
425.2859 // 94 /// 3a,6b,7b,12a-Tetrahydroxy-
5b-cholanoic acid // HMDB00367:.H(+) // 
425.2859 // 94 /// 3a,6b,7b,12b-Tetrahydroxy-
5b-cholanoic acid // HMDB00377:.H(+) // 
425.2859 // 94 /// 3a,6b,7a,12a-Tetrahydroxy-
5b-cholanoic acid // HMDB00399:.H(+) // 
425.2859 // 94 /// 1,3,7,12-Tetrahydroxycholan-
24-oic acid // HMDB00433:.H(+) // 425.2859 // 
94 /// 3a,4b,7a,12a-Tetrahydroxy-5b-cholanoic 
acid // HMDB00437:.H(+) // 425.2859 // 94
0.0000 0.1523 0.2659 0.0000 0.2161 0.3004 0.0000 0.2749 0.2253 0.0000 -0.2373 0.2555 0.0000 0.3555 0.1050
m3559 400.1495 S-Adenosylmethionine // HMDB01185:[+1].H(+) // 400.1495 // 37 0.0000 0.1274 0.2576 0.0000 0.3584 0.1368 0.0000 0.1476 0.6071 0.0000 0.2404 0.3298 0.0000 -0.2368 0.3771
m1329 195.0091
p-Cresol sulfate // HMDB11635:.H/Na.H(+) // 
195.0091 // 66 /// p-Cresol sulfate // 
HMDB11635:.Na(+) // 195.0091 // 19 /// 
Glycerol 3-phosphate // HMDB00126:.H/Na.H(+) 
// 195.0091 // 11 /// Beta-Glycerophosphoric 
acid // HMDB02520:.H/Na.H(+) // 195.0091 // 
11 /// Hypoxanthine // HMDB00157:.NaCl.H(+) 
// 195.0091 // 7 /// Erythronic acid // 
HMDB00613:.NaCl.H(+) // 195.0091 // 5 /// 
Threonic acid // HMDB00943:.NaCl.H(+) // 
195.0091 // 5
0.0000 0.1093 0.1457 0.0000 -0.0981 0.5921 0.0000 0.2056 0.2861 0.0000 0.1138 0.5346 0.0000 0.2160 0.2530
m3057 349.2395
3b,15b,17a-Trihydroxy-pregnenone // 
HMDB00353:.H(+) // 349.2395 // 100 /// 
3b,17a,21-Trihydroxypregnenone // 
HMDB00382:.H(+) // 349.2395 // 100 /// 3a,21-
Dihydroxy-5b-pregnane-11,20-dione // 
HMDB06755:.H(+) // 349.2395 // 100 /// 11b,21-
Dihydroxy-5b-pregnane-3,20-dione // 
HMDB06757:.H(+) // 349.2395 // 100 /// 17a,21-
Dihydroxypreg-nenolone // HMDB06762:.H(+) // 
349.2395 // 100
0.0000 0.1087 0.2307 0.0000 -0.0469 0.7410 0.0000 -0.1166 0.4355 0.0000 0.2211 0.0876 0.0000 0.3771 0.0059
m524 131.1183 N-Acetylputrescine // HMDB02064:.H(+) // 131.1183 // 100 0.0000 0.0205 0.0459 0.0000 0.0599 0.5508 0.0000 -0.0458 0.6942 0.0000 0.0324 0.7558 0.0000 0.0356 0.7597
m329 116.0708
L-Proline // HMDB00162:.H(+) // 116.0708 // 
100 /// D-Proline // HMDB03411:.H(+) // 
116.0708 // 100
0.0000 -0.0494 0.1101 0.0000 -0.0141 0.9333 0.0000 -0.0508 0.7857 0.0000 0.0650 0.6862 0.0000 -0.1978 0.2225
m760 147.1694 Spermidine // HMDB01257:[+1].H(+) // 147.1694 // 60 0.0000 -0.0666 0.2396 0.0000 0.1153 0.6977 0.0000 0.1492 0.6548 0.0000 -0.1835 0.5304 0.0000 -0.3476 0.2483
m731 146.1660 Spermidine // HMDB01257:.H(+) // 146.1660 // 100 0.0000 -0.0679 0.2470 0.0000 0.1106 0.7334 0.0000 0.1702 0.6358 0.0000 -0.2134 0.4988 0.0000 -0.3387 0.3029
m109 90.1106 Putrescine // HMDB01414:[+1].H(+) // 90.1106 // 60 0.0000 -0.1182 0.1365 0.0000 -0.1343 0.8058 0.0000 -0.1640 0.7932 0.0000 -0.2480 0.6447 0.0000 0.0733 0.9070
m4640 517.3012
Taurocholic acid // HMDB00036:[+1].H(+) // 
517.3012 // 100 /// Tauroursocholic acid // 
HMDB00889:[+1].H(+) // 517.3012 // 100 /// 
Taurallocholic acid // HMDB00922:[+1].H(+) // 
517.3012 // 100 /// Tauro-b-muricholic acid // 
HMDB00932:[+1].H(+) // 517.3012 // 100 /// 
Taurohyocholate // HMDB11637:[+1].H(+) // 
517.3012 // 100 /// Campesterol // 
HMDB02869:.(NaCl)2.H(+) // 517.3012 // 8 /// 4-
alpha-Methyl-5-alpha-cholest-7-en-3-beta-ol // 
HMDB11605:.(NaCl)2.H(+) // 517.3012 // 8 /// 
(5Alpha)-campestan-3-one // 
HMDB12116:.(NaCl)2.H(+) // 517.3012 // 8
0.0000 -0.1690 0.2887 0.0000 -0.1336 0.5510 0.0000 -0.5839 0.0108 0.0000 0.0690 0.7665 0.0000 -0.0273 0.9189
m868 156.0762 L-Histidine // HMDB00177:.H(+) // 156.0762 // 100 0.0000 -0.1915 0.2785 0.0000 0.0283 0.9073 0.0000 -0.3185 0.1817 0.0000 0.0483 0.8369 0.0000 -0.5243 0.0217
m123 94.9982 Dimethyldisulfide // HMDB05879:.H(+) // 94.9982 // 100 0.0000 -0.2167 0.0451 0.0000 -0.2246 0.2218 0.0000 -0.1547 0.4619 0.0000 -0.2244 0.2239 0.0000 -0.2631 0.1813
m1568 215.0535
Quinic acid // HMDB03072:.H/Na.H(+) // 
215.0535 // 63 /// Canavanine // 
HMDB02706:.H/K.H(+) // 215.0535 // 31 /// 
Serotonin // HMDB00259:.H/K.H(+) // 215.0535 
// 7 /// Cotinine // HMDB01046:.H/K.H(+) // 
215.0535 // 7 /// Phosphoguanidinoacetate // 
HMDB03705:.NH4(+) // 215.0535 // 6
0.0000 -0.2375 0.1567 0.0000 -0.2287 0.1955 0.0000 -0.1453 0.4725 0.0000 -0.1148 0.5361 0.0000 -0.4611 0.0125
m799 150.0581 L-Methionine // HMDB00696:.H(+) // 150.0581 // 100 0.0000 -0.3051 0.2633 0.0000 -0.0742 0.6504 0.0000 -0.5454 0.0010 0.0000 -0.0803 0.6255 0.0000 -0.5204 0.0013
m2237 276.0848 N-Acetylvanilalanine // HMDB11716:.H/Na.H(+) // 276.0848 // 77 0.0000 -0.3694 0.1454 0.0000 -0.4848 0.0025 0.0000 -0.1576 0.3890 0.0000 -0.4345 0.0064 0.0000 -0.4006 0.0183
m4162 464.0653 Chondroitin sulfate // HMDB00580:.H(+) // 464.0653 // 65 0.0000 -0.6532 0.2521 0.0000 -0.8510 0.0151 0.0000 -0.3061 0.4526 0.0000 -0.6282 0.0738 0.0000 -0.8275 0.0265
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Standard Product Form: Pellet
Macronutrients Vitamins
Crude Protein % 14.3 Vitamin A e, f IU/g 6.0
Fat (ether extract) a % 4.0 Vitamin D3 
e, g IU/g 0.6
Carbohydrate (available) b % 48.0 Vitamin E IU/kg 120
Crude Fiber % 4.1 Vitamin K3 (menadione) mg/kg 20
Neutral Detergent Fiber c % 18.0 Vitamin B1 (thiamin) mg/kg 12
Ash % 4.7 Vitamin B2 (riboflavin) mg/kg 6
Energy Density d kcal/g (kJ/g) 2.9 (12.1) Niacin (nicotinic acid) mg/kg 54
Calories from Protein % 20 Vitamin B6 (pyridoxine) mg/kg 10
Calories from Fat % 13 Pantothenic Acid mg/kg 17
Calories from Carbohydrate % 67 Vitamin B12 (cyanocobalamin) mg/kg 0.03
Minerals Biotin mg/kg 0.26
Calcium % 0.7 Folate mg/kg 2
Phosphorus % 0.6 Choline mg/kg 1030
     Non-Phytate Phosphorus % 0.3 Fatty Acids
Sodium % 0.1 C16:0 Palmitic % 0.5
Potassium % 0.6 C18:0 Stearic % 0.1
Chloride % 0.3 C18:1ω9 Oleic % 0.7
Magnesium % 0.2 C18:2ω6 Linoleic % 2.0
Zinc mg/kg 70 C18:3ω3 Linolenic % 0.1
Manganese mg/kg 100 Total Saturated % 0.6
Copper mg/kg 15 Total Monounsaturated % 0.7
Iodine mg/kg 6 Total Polyunsaturated % 2.1
Iron mg/kg 175 Other
Selenium mg/kg 0.23 Cholesterol mg/kg -- 
Amino Acids
Aspartic Acid % 0.9
Glutamic Acid % 2.9
Alanine % 0.9
Glycine % 0.7
Threonine % 0.5
Proline % 1.2
Serine % 0.7
Leucine % 1.4
Isoleucine % 0.6
Valine % 0.7
Phenylalanine % 0.7
Tyrosine % 0.4
Methionine % 0.3
Cystine % 0.3
Lysine % 0.7 f 1 IU vitamin A = 0.3 µg retinol
Histidine % 0.4 g 1 IU vitamin D = 25 ng cholecalciferol
Arginine % 0.8 For nutrients not listed, insufficient data is available to quantify.
Tryptophan % 0.2
0915© 2015 Envigo
Teklad Diets + Madison WI + envigo.com + tekladinfo@envigo.com + (800) 483-5523
b Carbohydrate (available) is calculated by subtracting neutral detergent fiber
  from total carbohydrates.
c Neutral detergent fiber is an estimate of insoluble fiber, including cellulose, 
  hemicellulose, and lignin. Crude fiber methodology underestimates total fiber.
Product Description-  2014 is a fixed formula, non-autoclavable diet 
manufactured with high quality ingredients and designed to promote 
longevity and normal body weight in rodents. 2014 does not contain alfalfa 
or soybean meal, thus minimizing the occurrence of natural 
phytoestrogens. Typical isoflavone concentrations (daidzein + genistein 
aglycone equivalents) range from non-detectable to 20 mg/kg. Exclusion of 
alfalfa reduces chlorophyll, improving optical imaging clarity. Absence of 
animal protein and fish meal minimizes the presence of nitrosamines.  
Also available certified (2014C) and irradiated (2914). For autoclavable 
diet, refer to 2014S (Sterilizable). 
Ingredients (in descending order of inclusion)- Wheat middlings, ground 
wheat, ground corn, corn gluten meal, calcium carbonate, soybean oil, 
dicalcium phosphate, iodized salt, L-lysine, vitamin E acetate, DL-methionine, 
magnesium oxide, choline chloride, manganous oxide, ferrous sulfate, 
menadione sodium bisulfite complex (source of vitamin K activity), zinc oxide, 
copper sulfate, niacin, calcium pantothenate, calcium iodate, pyridoxine 
hydrochloride, riboflavin, thiamin mononitrate, vitamin A acetate, vitamin B12 
supplement, folic acid, cobalt carbonate, biotin, vitamin D3 supplement.
Teklad Global 14% Protein Rodent Maintenance Diet
Teklad Diets are designed and manufactured 
for research purposes only.
Nutrient data represent the best information available, calculated from 
published values and direct analytical testing of raw materials and finished 
product. Nutrient values may vary due to the natural variations in the 
ingredients, analysis, and effects of processing.
d Energy density is a calculated estimate of metabolizable energy  based on the 
  Atwater factors assigning 4 kcal/g to protein, 9 kcal/g to fat, and 4 kcal/g to 
  available carbohydrate. 
e Indicates added amount but does not account for contribution from other 
  ingredients.
a Ether extract is used to measure fat in pelleted diets, while an acid hydrolysis 
  method is required to recover fat in extruded diets. Compared to ether 
  extract, the fat value for acid hydrolysis will be approximately 1% point higher.
2014 
Arginine, % 0.93
Biotin, ppm 0.2
Calcium, % 0.52
Chloride, % 0.73
Choline Chloride, ppm 1,000
Cobalt, ppm 0.0
Copper, ppm 6.0
Fat, % 8.1
Fiber (max), % 5.0
Folic Acid, ppm 2.0
Histidine, % 0.27
Iodine, ppm 0.21
Iron, ppm 37
Isoleucine, % 0.82
Leucine, % 1.11
Lysine, % 1.13
Magnesium, % 0.05
Manganese, ppm 59
Methionine, % 0.15
Pantothenic Acid, ppm 15
Phenylalanine, % 1.16
Phosphorus, % 0.40
Potassium, % 0.36
Protein, % 12.3
Pyridoxine, ppm 5.8
Riboflavin, ppm 6.0
Selenium, ppm 0.11
Sodium, % 0.13
Thiamin Hydrochloride, ppm 6.0
Threonine, % 0.82
Tryptophan, % 0.18
Tyrosine, % 0.00
Valine, % 0.82
Vitamin A, IU/g 4.0
Vitamin B-12, mcg/kg 10
Vitamin D-3 (added), IU/g 1.0
Vitamin E, IU/kg 50.0
Vitamin K (as menadione), ppm 0.50
Zinc, ppm 29
Niacin, ppm 30
Ascorbic Acid, ppm 0.0
Cystine, % 0.00
Minerals
Vitamins
4/8/2011
Fluorine, ppm 0.0
Chromium, ppm 2.0
N U T R I T I O N A L   P R O F I L E 1
1.  Formulation based on calculated values from the latest ingredient analysis information.  Since nutrient composition of natural ingredients varies and some nutrient loss will occur due to manufacturing processes, analysis will differ accordingly.  Nutrients expressed as percent of ration on an As-Fed basis except where otherwise indicated.  2.  Energy (kcal/gm) - Sum of decimal fractions of protein, fat and carbohydrate x 4,9,4 kcal/gm respectively.
D E S C R I P T I O N
AIN-76A Semi-Purified Diet with 0.15% L-Methionine
Storage conditions are particularly critical to TestDiet® products, due to the absence of antioxidants or preservative agents.  To provide maximum protection against possible changes during storage, store in a dry, cool location.  Storage under refrigeratation (2 ° C) is recommended.  
F E E D I N G   D I R E C T I O N S
Feed ad libitum.  Plenty of fresh, clean water should be available at all times.
I N G R E D I E N T S (%)
Carbohydrates, % 69.9
Energy (kcal/g) 4.01
Molybdenum, ppm 0.00
2
CAUTION: Perishable - store properly upon receipt.For laboratory animal use only; NOT for human consumption.
w w w . t e s t d i e t .  c o m 
AIN-76A w/0.15% L-Methionine
Cholesterol, ppm 0
58MK
Product Forms Available* Catalog #
*Other Forms Available On Request
Protein 12.3
Fat (ether extract) 18.1
Carbohydrates 69.6
%kcalFrom:
0.493
0.728
2.794
Linoleic Acid, % 4.57
Linolenic Acid, % 0.07
Arachidonic Acid, % 0.00
Omega-3 Fatty Acids, % 0.07
Total Saturated Fatty A 1.02
Total Monounsaturated Fatty Acids, % 1.94
Glycine, % 2.31
Serine, % 0.00
Aspartic Acid, % 0.00
Glutamic Acid, % 3.56
Alanine, % 0.00
Proline, % 0.00
Taurine, % 0.00
Polyunsaturated Fatty Acids, % 4.65
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Prostate cancer is among themost frequent cancers inmen, and despite its high rate of cure, the high num-
ber of cases results in an elevated mortality worldwide. Importantly, prostate cancer incidence is dra-
matically increasing in western societies in the past decades, suggesting that this type of tumor is
exquisitely sensitive to lifestyle changes. Prostate cancer frequently exhibits alterations in the PTEN gene
(inactivating mutations or gene deletions) or at the protein level (reduced protein expression or altered
sub-cellular compartmentalization). The relevance of PTEN in this type of cancer is further supported
by the fact that the sole deletion of PTEN in the murine prostate epithelium recapitulates many of the fea-
tures of the human disease. In order to study themolecular alterations in prostate cancer, we need to over-
come the methodological challenges that this tissue imposes. In this review we present protocols and
methods, using PTEN as proof of concept, to study different molecular characteristics of prostate cancer.
 2015 Published by Elsevier Inc.1. Introduction
Prostate cancer (PCa) is among the deadliest forms of cancer
(WHO), and represents the third cause of death by cancer in
men (www.globocan.iarc.fr). The tumor suppressor PTEN is
among the most mutated and lost tumor suppressors in PCa
[1]. Up to 70% of PC as harbor loss of PTEN at presentation. This
26 A. Ugalde-Olano et al. /Methods 77–78 (2015) 25–30tumor suppressor is located at the top of a highly oncogenic sig-
naling pathway, the PI-3 Kinase (PI-3K) cascade, which contains
many other oncogenes and tumor suppressors [2]. In addition,
regulatory feedback loops stem from the PTEN/PI-3K pathway
to ensure cell homeostasis, which decrease the efﬁcacy of single
agent therapies [2,3].
PTEN down-regulation is not restricted to genetic events, and
regulation of its transcription, translation and stability can play
an important role. PTEN is frequently lost in heterozygosity,
whereas mostly advanced cancers exhibit complete loss of the
tumor suppressor. Interestingly, the prostate epithelium is
exquisitely sensitive to the reduction in PTEN levels. This
concept has been formally proven in mice through the use of
genetic interference, which allows a partial reduction of the
expression of the interfered allele [4,5]. While PTEN heterozy-
gous mice present PIN lesions in the prostate with long latency
[6], PTEN hypomorphic mice show progression of the prostate
lesions to invasive cancer at higher penetrance [5]. Importantly,
while a gradual decrease of PTEN promotes prostate cancer
progression, acute and complete PTEN-loss elicits the activation
of a fail-safe senescence response, which is driven by the
up-regulation of the tumor suppressor p53 [7]. This novel type
of senescence is genuinely distinct from the classic oncogene-
induced senescence [8]. Importantly, genetic or environmental
events regulating this process may be key players in the progres-
sion of prostate cancer and therefore attractive targets for anti-
cancer therapy [9,10].
All these evidence point to the need of studying PTEN-depen-
dent pathways in prostate cancer. However, the technical chal-
lenges related to the study of this type of tumor require special
attention, and hence, in this review we aim at describing a series
of methodologies to study prostate cancer biology, with a reference
to the pathway aforementioned.2. Methods and results
2.1. Preparation of well-diagnosed prostate cancer specimens for
molecular studies
Cancerous lesions in the prostate, unlike in other tissues, are
difﬁcult to identify macroscopically. This poses a challenge when
the aim is to obtain well-diagnosed frozen tissue. To overcome this
limitation, we have set up together with the Basque Biobank
and Basurto University Hospital (OSI-Basurto, Bilbao, Spain), inD
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Fig. 1. Preparation of well-diagnosed fresh frozen biopsies. (A–D) Preparation of the pu
surgical piece with eosin (C) and longitudinal separation of the punch with scalpel (D). (E
whole section hematoxylin/eosin staining is shown together with a zoom to show the hcollaboration with the Dept. of Pathology at Mount Sinai, a proce-
dure to obtain this type of specimen.
2.2. Key materials
– A biopsy punch (Miltex Ref. 33–34).
Due to the characteristics of prostate cancer, we established a
procedure by which fresh tissue obtained from radical prostatecto-
my is sliced into left and right lobe (after delimiting the margins of
the surgical piece with ink and ﬁxing the ink with acetic acid). All
prostate specimens were obtained upon informed consent and
with evaluation and approval from the corresponding ethics com-
mittee (CEIC code OHEUN11-12 and OHEUN14-14). From each
lobe, the dermatologic punch is employed to harvest 8 tissue cylin-
ders of 4 mm diameter. The site of the punches is selected blindly
due to the lack of macroscopic alterations associated to cancerous
lesions. However, we did notice that the expertise of the patholo-
gist does inﬂuence the rate of success in harvesting cylinders with
cancer. Of note, this approach prevents from damaging the capsule
and a drop of eosin on the site of tissue harvest can help monitor-
ing the histological alterations surrounding the area for diagnostic
purposes. Tissue cylinders are then divided longitudinally with a
scalpel and dedicated to snap-freeze (in liquid nitrogen or isopen-
tane at 80 C) and to parafﬁn embedding for diagnostic purposes
(procedure in Fig. 1A–D). Due to the width of the cylinder (4 mm
diameter), the diagnosed tissue fraction will closely represent the
histological properties of the frozen adjacent tissue. In Fig. 1E,
hematoxylin/eosin staining of whole tissue sections from cylinders
with different tumor abundance are shown, together with a zoom
that shows the correct preservation of the histological properties of
the sections. Importantly, this protocol allows us to closely esti-
mate the tumor abundance that we have in the frozen tissue piece,
hence solving an otherwise challenge in the acquisition of frozen
material. The material obtained from this approach is sufﬁcient
to carry out different molecular biology studies, including RNA
preparation (described below), protein extraction and metabolite
proﬁling (data not shown).
2.3. Molecular biology analysis from frozen tissue: tips for good quality
RNA preparation
Preparation of RNA of high quality from prostate cancer speci-
mens remains a challenge, primarily due to the abundance of
RNAses and proteases in the prostate and prostatic ﬂuid. A varietyTumor % 0 60 100
W
ho
le
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ct
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n
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om
E
nch biopsy (A) and excision with scalpel (B), identiﬁcation of the harvest point in
) Histological features of punch biopsies with different abundance of tumoral tissue,
istological features of the piece.
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from biopsies of different origin [11–14] (see also protocols from
Prostate Cancer Biorepository Network; SOP N:006 http://www.
prostatebiorepository.org). While real time PCR is a low-demand-
ing approach in terms of RNA integrity, the latest OMIC technolo-
gies, including RNA sequencing, require material in optimal
conditions.
To deﬁne the technical needs of an appropriate RNA extraction
strategy, we have tested one main technical implementation (the
use of phenolic extraction agents) and one variable (the presence
of ink and acetic acid in the preparation).
2.4. Key materials
– Trizol (Life Technologies/Invitrogen Ref. 15596-018).
– Total RNA extraction kit (NucleoSpin miRNA Ref. 740971.10/
50/250).
The protocol is the following, where the alternative procedure
with and without Trizol is underlined (the Trizol-based implemen-
tation is described in the user manual of the NucleoSpin miRNA
kit):
1. RNAse inhibition and tissue thawing (a minimal amount of tis-
sue of 10 mg is sufﬁcient for the procedure). RNA later ICE (Life
Technologies Ref. AM7030) is used to ensure the maximal inhi-
bition of RNAses and the optimization of tissue homogenization
afterwards. The protocol is based on transferring frozen tissue
(stored dry at 80 C) to RNA later ICE (also at 80 C) and
thawing the tissue at 20 C overnight.
2. Regular lysis buffer. Tissue is transferred to the recommended
volume of NucleoSpin miRNA lysis buffer.6.4 9.6 5.7 3.6 8.4 7.6 RIN
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Fig. 2. Evaluation of the impact on phenol-based lysis and ink/acetic acid contaminant
absence (A) or presence (B) of Trizol lysis (average RIN values for the samples analyzed
lysis of samples with increasing amount of ink (the intensity of the dark color reﬂects the
three groups as indicated) (D), and RIN values obtained from the RNA preparation (E). (F)
Ct ampliﬁcation values in all samples (left panel) and the lack of correlation between CtTrizol-based lysis. Tissue is transferred to 400 lL volume of
Trizol. Additional 400 lL are added after homogenization.
3. Homogenization. 5–6 beads/tube (Ceramic Bead Tubes 2.8 mm,
Cat.: 13114-50; MO BIO Laboratories). Homogenization is car-
ried out in Precellys in two cycles of 6000 rpm and 30 s.
4. RNA extraction. Following the manufacturer´s instructions.
RNA extraction. Following homogenization, we add 160 lL of
Chloroform, mix by vortex, incubate 3 minand centrifuge
15 minat 12,000g in tabletop centrifuge. The supernatant
(350–400 lL) is transferred to a new tube and mixed with
1 mL of MX buffer. After vortex, the product is loaded in the
column and the same process indicated in point 4 is followed.
The results obtained from frozen tissues with a stabilizing agent
(RNA later ICE), a total RNA extraction kit, and with or without Tri-
zol implementation are shown in Fig. 2. RNA stabilizing agents and
the standard non-phenol based lysis buffer is not sufﬁcient to pre-
vent the RNA from degrading (Fig. 2A), while Trizol implementa-
tion results in total RNA of optimal quality for transcriptomic
studies (Fig. 2B, RNA Integrity Number – RIN – values in Fig. 2C).
Of note, although small RNAs have not been monitored in this pro-
cedure, the kit presented herein would allow for their isolation.
On the other hand, we have evaluated with an independent
phenol-based RNA extraction kit (Absolutely RNA miRNA KIT.
Cat. 400814, Agilent) whether the presence of ink and acetic acid
from the margins of the non-tumoral prostate tissue could inﬂu-
ence RNA quality. To this end, we selected biopsies containing
increasing amounts of these contaminants (Fig. 2D). The presence
of these agents did not impact the quality of RNA, as quantiﬁed
by Agilent Bioanalyzer (Fig. 2E). We further studied if despite
yielding good quality RNA, ink and acetic acid could interfere withD
 Trizol Trizol
RIN
** A B C D E F
Ink 1 2 3
APDH
s in RNA quality. (A–C) Bioanalyzer analysis of RNA preparations performed in the
are presented in C; ⁄⁄, signiﬁcance p < 0.01). (D and E) Representative images of the
increasing concentration of ink in the sample of origin, which has been separated in
Real time quantitative PCR of PTEN (two Taqman probes) and GAPDH shows average
values and the increase in ink (right panel).
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predicted that if the ink/acetic acid interferes with the retrotran-
scription or real time PCR, we would observe an increase in the
Ct values of the genes studied in the high ink conditions. However,
evaluation of PTEN expression with two independent Taqman
probes (PTEN 48: Universal Probe library [Roche] #48; primer F:
ggggaagtaaggaccagagac Primer R: tccagatgattctttaacaggtagc; PTEN
60: Universal Probe library [Roche] #60; primer F: gcacaagaggccc-
tagatttc Primer R: cgcctctgactgggaatagt) and GAPDH (REF. Life
Technologies Hs02758991_g1) as housekeeping gene clearly
showed a lack of correlation between the amount of ink and any
alteration in gene expression (Fig. 2F). In summary, phenol-based
RNA extraction coupled to column-based puriﬁcation signiﬁcantly
improves RNA quality and the presence of ink/acetic acid in the tis-
sue sample does not inﬂuence RNA preparation, retrotranscription,
or real time PCR ampliﬁcation.
2.5. Monitoring PTEN expression in prostate cancer: an
immunohistochemical (IHC) procedure
Immunodetection of PTEN could become critical in the coming
years to stratify patients and deﬁne the best therapeutic strategies
[15,16]. Therefore, good standardized IHC procedures need to be
established. Lotan et al. recently established an immunohisto-
chemical protocol for PTEN [17]. We have employed a different
clone from Cell Signaling Technology PTEN (138G6) and we have
established a sensitive and speciﬁc IHC protocol for research
purposes.
2.6. Key material
– Rabbit monoclonal PTEN antibody, clone 138G6 (Cell Signaling
Technology, Ref. 9559).
Antigen retrieval was performed with Tris–EDTA (pH 9) in
microwave (4 min). H2O2 was used to block the endogenous
peroxidase, followed by blocking with goat serum and primary
antibody (1:100) incubation overnight at 4 C. Goat anti-rabbit
IgG antibody (1:1000) was incubated at room temperature for
30 min. IHC detection was performed with the ABC Kit from VectorA
C
B
Fig. 3. An immunostaining protocol for PTEN in human prostate cancer specimens. (A
(DU145) and PTEN deﬁcient (PC3) human tumor xenografts. Asterisks indicate stromal c
tissue (BPH) and prostate cancer (PCa) biopsies with PTEN high and low immunoreactivLaboratories. This protocol with DAB-based development results in
speciﬁc detection of PTEN, which was setup in DU145 (PTEN posi-
tive) and PC3 (PTEN negative) xenograft-derived formalin ﬁxed,
parafﬁn embedded (FFPE) slides. Sections were counterstained
with hematoxylin.
With this protocol, tumors with known PTEN status (described
above) were correctly identiﬁed (Fig. 3A and B). We also stained
human biopsies consisting of benign hyperplasias and prostate
cancer. We could identify PTEN positive epithelia in the hyper-
plasia cases as well as prostate cancer biopsies with and without
detectable PTEN immunoreactivity (Fig. 3C). Of note, we observed
that often the stromal component exhibited greater PTEN expres-
sion that the adjacent epithelial tissue (see asterisks in Fig. 3). In
summary, we present here a protocol that is valuable for the detec-
tion of PTEN in human specimens for research purposes.2.7. Extracellular vesicle isolation from urine samples of prostate
cancer patients
Due to the close proximity of the prostate to the urinary track,
urine-mediated diagnosis of prostate cancer has remained an
attractive concept. Extracellular vesicles (EVs) have been described
to contain mRNA, protein and metabolites that could be selectively
loaded [18]. Importantly, EVs have been identiﬁed in urine and
cancerous alterations in the bladder have been shown to impact
on their composition, suggesting that they could serve as a source
for non-invasive biomarker identiﬁcation. Since current non-inva-
sive prostate cancer biomarkers have been proven to have limita-
tions [19–21], urine EVs might provide a future source of novel
biomarkers. Here, we describe the current protocol for urine EV
isolation we are employing (a setup carried out by the group of
Dr. Falcón-Pérez).2.8. Key material
– Ultracentrifuge.
Urine EVs can be isolated through this methodology starting
from 50 mL of urine. Urine is centrifuged in a tabletop centrifugeand B) Representative immunohistochemical images (200) of PTEN expressing
ells. (C) Representative micrographs (200) of PTEN staining in benign hyperplasia
ity, arrows indicate epithelial cells and asterisk depict stromal area.
A. Ugalde-Olano et al. /Methods 77–78 (2015) 25–30 29at 3000 rpm for 5 min and the supernatant is ﬁltered (0.22 micra)
at the moment of collection, and then frozen at 80 C. At the time
of processing, urine is subjected to a ﬁrst centrifugation of 11,500g
for 30 min, and the supernatant is subjected to a second centrifu-
gation of 118,000g for 90 min. The pellet (containing EVs) is then
collected, resuspended in 150 lL of cold PBS and frozen for later
processing. The EV pellet is subjected to RNA extraction, for which
purpose we employ the miRCURY RNA isolation kit (EXIQON, fol-
lowing manufacturer´s instructions, DNAse I – Qiagen – digestion)
and we carried out the retrotranscription with SuperScript III
(Invitrogen). 35 lL of total RNA is isolated, and despite the low
yield of RNA in the preparation (in the range of nanograms),
60–80 lL of cDNA can be prepared for qPCR analysis (Fig. 4A and
B). As proof of concept of the validity of this method, we have
carried out qPCR analysis in 10 benign hyperplasias and 13
prostate cancers (paired samples to the biopsies presented in the
histochemical analysis). We have used as positive control a gene
known to be present in EVs, GAPDH [22] (Fig. 4C).
PTEN has been recently reported to be secreted [23,24], and
PTEN protein abundance in blood exosomes has been suggested
to reﬂect status of the tumor suppressor in the prostate tumor
([25]. Hence we sought to ascertain to which extent the transcript
abundance of PTEN would be altered in urine EVs from prostate
cancer patients. The results revealed that both PTEN and GAPDH
were present in all EV preparations analyzed at a similar abun-
dance regardless of the benign of the tumoral status. This result
was in discordance with PTEN protein expression, since the urine
samples analyzed include cases that we identiﬁed as negative for
PTEN immunoreactivity (displayed in Fig. 3). This lack of differ-
ences could be due to two main factors: ﬁrst, the content of EVs
in urine might be strongly inﬂuenced by bladder cells, perhaps
more than by prostate cells. Second, PTEN is down-regulated at
multiple levels, through mutations, deletions, but also through
post-transcriptional regulation, which would not necessarily
impact on the transcript levels.
3. Discussion
In this methods manuscript, we present approaches that allow
us to study the biology of prostate cancer. While much workA
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Fig. 4. A method to harvest RNA from urine EVs. (A) Experimental procedure of the EV is
Microscopy (TEM) of the isolated EVs with this approach (scale represents 100 nm). (C) A
quantitative PCR.remains to be carried out in order to understand the molecular
changes in this disease, we believe that the technological improve-
ments that we present herein could serve as the basis to ensure the
acquisition of (i) fresh and well diagnosed prostate cancer tissue,
(ii) RNA of high quality for OMIC studies, (iii) immunostaining
methodology to ascertain the expression of PTEN in human tissues
and (iv) isolation of urine EVs for molecular studies.
The interaction between pathologists, uro-oncologists and basic
scientists is fundamental in order to reach clinically relevant con-
clusions in prostate cancer research. The fresh tissue preparation
procedure that we present has proven to be sustainable in a
hospital with biobanking support and, importantly, to preserve
the integrity of the surgical material for diagnostic purposes.
Unpublished evidence also suggest that the area/volume ratio of
the biopsy is directly proportional to the quality of the RNA
obtained, and it is therefore plausible that the dimensions of these
punch biopsies will allow molecular studies of the highest quality
requirements. It is worth noting that the surgical material in our
studies was obtained from robotic surgeries, where the warm
ischemia period (the time the surgical piece stays excised and
inside the patient) is of 60–80 min, while the cold ischemia (the
time elapsed from the extraction of the piece to the snap-freeze
of the punch biopsy) is at least of 30 min. These ischemic periods
do not alter the RNA quality of the biopsy (which we consider a
good readout of tissue integrity) and can be achieved in any
urology and pathology service.
Importantly, the molecular studies described herein can greatly
beneﬁt from the analysis of public databases. In the recent years,
bioinformatic platforms have been developed in order to aid in
the analysis of publicly available genomic, epigenomic, transcrip-
tomic and proteomic studies. These platforms now allow quickly
browsing through tens of studies (which imply thousands of sam-
ples) looking at a gene or pathway of interest. Two outstanding
examples of this effort are Oncomine (www.oncomine.org) [26]
and cbioportal (www.cbioportal.org) [27,28]. These sites allow
the researcher to get information about the status of a gene or
genes of interest in a given cancer, the mutational landscape
throughout different cancers, the epigenetic modiﬁcations regulat-
ing its expression and the clinical variables associated with its
expression. Therefore, these platforms can serve both as aCentrifuge
11500 x g
30 min
Centrifuge
118000 x g
90 min
Supernatant
Resuspend pellets in 
150µL of cold PBS and 
freeze
r
GAPDH
olation from urine samples. (B) Representative image by cryo-Transmission Electron
bundance of PTEN (with two probes) and GAPDH transcript in urine EVs by real time
30 A. Ugalde-Olano et al. /Methods 77–78 (2015) 25–30discovery starting point or a clinical validation end point. In sum-
mary, a good balance between experimental approaches with
human cancer specimens and data mining studies can maximize
the relevance of the conclusions met by the researcher.
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Pharmacological inhibition of fatty-acid oxidation
synergistically enhances the effect of L-asparaginase in
childhood ALL cells
I Hermanova1, A Arruabarrena-Aristorena2, K Valis3,4, H Nuskova5, M Alberich-Jorda6, K Fiser1, S Fernandez-Ruiz2, D Kavan3,4, A Pecinova5,
M Niso-Santano7,8, M Zaliova1, P Novak3,4, J Houstek5, T Mracek5, G Kroemer7,8,9,10, A Carracedo2,11,12, J Trka1,13 and J Starkova1
L-asparaginase (ASNase), a key component in the treatment of childhood acute lymphoblastic leukemia (ALL), hydrolyzes plasma
asparagine and glutamine and thereby disturbs metabolic homeostasis of leukemic cells. The efﬁcacy of such therapeutic strategy
will depend on the capacity of cancer cells to adapt to the metabolic challenge, which could relate to the activation of
compensatory metabolic routes. Therefore, we studied the impact of ASNase on the main metabolic pathways in leukemic cells.
Treating leukemic cells with ASNase increased fatty-acid oxidation (FAO) and cell respiration and inhibited glycolysis. FAO, together
with the decrease in protein translation and pyrimidine synthesis, was positively regulated through inhibition of the RagB-mTORC1
pathway, whereas the effect on glycolysis was RagB-mTORC1 independent. As FAO has been suggested to have a pro-survival
function in leukemic cells, we tested its contribution to cell survival following ASNase treatment. Pharmacological inhibition of FAO
signiﬁcantly increased the sensitivity of ALL cells to ASNase. Moreover, constitutive activation of the mammalian target of
rapamycin pathway increased apoptosis in leukemic cells treated with ASNase, but did not increase FAO. Our study uncovers a
novel therapeutic option based on the combination of ASNase and FAO inhibitors.
Leukemia (2016) 30, 209–218; doi:10.1038/leu.2015.213
INTRODUCTION
L-asparaginase (ASNase) is an essential component in the
treatment of childhood acute lymphoblastic leukemia (ALL).1
Intensiﬁed use of ASNase increases event-free survival in children
with ALL by 10–15%.2,3 ASNase has the potential to be used in
other types of cancers besides childhood ALL – at present, it is
already used in the treatment protocol of adult T-ALL and
lymphomas.4,5 There are also ongoing in vitro studies on its use in
solid tumors (brain, prostate and ovarian cancers).6–10 Although
ASNase has been in clinical use for the treatment of childhood ALL
for several decades, our knowledge of mechanisms behind its
therapeutic effect is still incomplete. ASNase catalyzes deamina-
tion of asparagine (Asn) and glutamine (Gln).11,12 Intracellular Asn
is typically produced by Asn synthetase (ASNS). The cytotoxic
effect of ASNase on leukemic cells was traditionally explained by
the lower activity of ASNS in leukemic cells compared with healthy
cells.13,14 However, recent studies reported that basal ASNS
expression does not predict resistance to ASNase among ALL
patients15–18 and has no biological or clinical consequences in ALL
patients.19 These ﬁndings indicate that the mechanism of action of
ASNase is more complex and cannot be explained by the
expression of a single gene.
Proliferating cancer cells are characterized by considerably
different metabolic requirements compared with normal differ-
entiated cells.20,21 Cancer cell metabolism is therefore studied with
a focus on potential therapeutic targets. As metabolic modulators
are widely used for pathologies beyond cancer, drug repurposing
has become a very appealing concept in the ﬁeld, as exempliﬁed
by metformin, an antidiabetic that has been newly investigated
for its inhibitory effect on cancer progression.22–24 By deaminating
Asn and Gln, ASNase obviously also perturbs metabolism, but
these metabolic consequences have not yet been described. The
main sensor of amino-acid deprivation is mammalian target of
rapamycin (mTOR), which has been associated with the activity of
ASNase.25 Moreover, it has been shown that Gln depletion can
efﬁciently inhibit downstream mTOR signaling in acute myeloid
leukemia and ovarian cancer cells.26,27 Under nutrient-rich
conditions, mTORC1 promotes cell growth by stimulating
biosynthetic pathways. Meanwhile, cellular catabolism, such as
autophagy, is inhibited. Signaling via mTOR also inﬂuences a wide
range of metabolic mechanisms28–31 and the impact of ASNase on
the downstream mTOR targets that are involved in metabolic
processes has not yet been studied thoroughly. This study for the
ﬁrst time describes the profound effect of ASNase on the
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metabolism of lymphoid leukemic cells that is driven by mTOR.
The characterization of these cellular processes reveals novel
potential targets for the treatment of ALL to enhance the effects of
chemotherapy and improve clinical outcome in patients.
MATERIALS AND METHODS
Cell culture
REH (human B-cell precursor leukemia, ets variant 6/runt-related transcrip-
tion factor 1 (ETV6/RUNX1, TEL/AML1) - positive); NALM-6 (human B-cell
precursor leukemia, TEL/platelet derived growth factor receptor beta 1
(PDGFRB1); (TEL/PDGFRB1) - positive) and RS4;11 (human B-cell precursor
leukemia, mixed-lineage leukemia/AF4/FMR2 family, member 1 (AF4); MLL/
AF4-positive) cell lines were purchased from German Collection of
Microorganisms and Cell Cultures (DSMZ-Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) and
cultivated according to the producer’s instructions. Cell lines were negative
for mycoplasma contamination.
Patient samples
Bone marrow samples from untreated children initially diagnosed with
B-cell precursor ALL were collected from the Czech Pediatric Hematology
Centers. Within 24 h after aspiration, mononuclear cells were isolated by
density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare,
Chalfont St Giles, UK). Ethical committee approved the study no. NT12429.
All samples were obtained with the informed consent of the children’s
parents or guardians. Isolated blasts were maintained in Roswell Park
Memorial Institute media with 10% fetal bovine serum (Life Technologies,
Carlsbad, CA, USA) and insulin-transferrin-sodium selenite supplement
(Sigma-Aldrich, St Louis, MO, USA).32 The characteristics of the patients
whose samples were used for western blot analysis (1–3), Annexin
V/4',6-diamidino-2-phenylindole (Annexin V/DAPI) staining (4–8) and
measurement of respiration (9–11) are listed in Supplementary Table 1.
Isolation of B lymphocytes
Human B-Cell Enrichment Cocktail (Stemcell Technologies, Vancouver, BC,
Canada) was used according to the manufacturer’s instructions to isolate B
cells from the buffy coat of healthy donors. B cells were incubated in
Roswell Park Memorial Institute media supplemented with 10% fetal
bovine serum, interleukin-21 (50 ng/ml) andinterleukin-2 (50 ng/ml)
(Sigma-Aldrich). B cells were isolated from three healthy donors.
Electrophoresis and western blotting
Protein lysates were prepared as previously described.19 Proteins
(10–40 µg per well) were resolved by NuPAGE Novex 4–12% Bis-Tris Gels
(Life Technologies) and transferred to a nitrocellulose membrane (Bio-Rad,
Hercules, CA, USA). The membrane was probed overnight with primary
antibodies listed in Supplementary Table 2. The bound antibodies were
detected with the appropriate secondary antibodies (Bio-Rad) conjugated
with horseradish peroxidase and visualized using enhanced chemilumi-
nescence reagent followed by exposure to X-ray ﬁlm (Kodak, Rochester,
NY, USA). Rapamycin (Sigma-Aldrich) served as a positive control of
mTORC1 inhibition. Densitometry was performed using Image J software.
The densitometry value was normalized against the value for β-actin.
RNA extraction, complementary DNA synthesis and quantitative
real-time PCR
Total cellular RNA was extracted using the RNeasy mini-kit (Qiagen GmbH,
Hilden, Germany) according to the manufacturer’s instructions and
converted to complementary DNA using an iScript complementary DNA
synthesis kit (Bio-Rad). The c-Myc transcript was detected using the Power
SYBR Green PCR Master Mix (Life Technologies). The primer sequences of
c-Myc are listed in Supplementary Table 3. β2 microglobulin served as a
house-keeping gene. PCR reactions were performed in a LightCycler 480
real-time PCR machine (Roche Diagnostics GmbH, Mannheim, Germany).
Assessment of cell death
Cells were treated with ASNase (Medac GmbH, Hamburg, Germany),
etomoxir (Sigma-Aldrich) or both and apoptosis was quantiﬁed by Annexin
V-FITC (Exbio Praha, a.s., Czech Republic) and DAPI (Life Technologies) or
propidium iodide (PI) (Miltenyi Biotec, Bergisch Gladbach, Germany)
staining using ﬂow cytometer. Measurements were performed in triplicate.
Combination index (CI) calculation
CI values were calculated using CompuSyn software (www.combosyn.
com). The calculation of dose-effect relationship for each drug we used
was done via serial dilution. CI was calculated from serial dilution of
ASNase and each dose of etomoxir. CI was used to express synergism
(CIo1), additive effect (CI = 1) or antagonism (CI41).33
Assessment of autophagic ﬂux
Cells were treated with ASNase and baﬁlomycin (Sigma-Aldrich) for 6, 12
and 24 h. Autophagic ﬂux was quantiﬁed by western blotting.
Detection of de novo intermediates of pyrimidine synthesis by
UPLC-ToF-MS
The cells were seeded to fresh media and incubated overnight. Next we
treated the cells with ASNase (4 IU/ml) for 24 h. Five million of cells were
harvest for each condition and washed in phosphate-buffered saline. Dried
cell pellets were resuspended in 500 μl of a methanol/water (50/50; v/v%)
mixture containing 10mM acetic acid. After precipitation of the protein
content, the supernatant was evaporated. The dried pellets were
resuspended in 150 μl of water/acetonitrile/formic acid (39.9/60/0.1v/v/v
%) and centrifuged. The resulting extracts were injected into the LC-MS
system using ACQUITY UPLC with Acquity UPLC amide column 1.7 μm
(2.1 × 100mm) and ToF MS, SYNAPT G2 (Waters Corporation, Milford, MA,
USA). Retention time for uridine monophosphate and uridine was 2.95 and
1.68min, respectively. The limit of detection of those compounds: uridine
monophosphate 0.5 μM, uridine 0.05 μM. The measurement was performed
in three independent experiments.
High performance liquid chromatography analysis
High performance liquid chromatography analysis of amino acids was
performed using Waters AccQ-Tag Chemistry Package (WAT052875) on
two pump Beckman Coulter Gold chromatograph with Merck-Hitachi
F-1080 ﬂuorescence detector (ex.250 nm, em. 395 nm). Data were collected
and evaluated with DataApex CSW32 chromatography software.
Glucose-uptake measurement
Cells were washed twice with Krebs-Ringer-4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid, pH 7.4, 136 mM NaCl, 4.7 mM KCl, 1.25mM MgSO4, 1.25mM
CaCl2), resuspended in 900 μl of Krebs-Ringer-4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid buffer and incubated for 15min at 37 °C. Next, we
added 100 μl of 10 × START solution (1 mM 2-deoxyglucose, 5 μCi/ml [3H]-
2-deoxyglucose, PerkinElmer Life Sciences, Waltham, MA, USA) and
incubated the cells for 10min at 37 °C. Cells were washed with
phosphate-buffered saline, collected by centrifugation, and the cell pellet
was solubilized in 1ml of 0.03% sodium dodecyl sulphate for 10min at 37 °C.
Radioactivity was measured using a 1900TR liquid scintillation analyzer
(Packard). The measurement was performed in four independent
experiments.
Extracellular lactate
Extracellular lactate was measured using the Lactate Kit (Trinity Biotech,
Bray, Ireland) according to the manufacturer’s directions. Changes in
lactate production were normalized to the protein content. The measure-
ment was performed in ﬁve independent experiments.
FAO measurement
Cells were incubated for 4 h in culture medium containing 100 μM palmitic
acid, 1 mM carnitine and 1.7 μCi [9,10(n)-3H]palmitic acid (GE Healthcare) in
the presence or absence of etomoxir (100 μM, Sigma-Aldrich), and the
medium was collected to analyze the amount of released 3H2O that was
formed during the cellular oxidation of [3H]-palmitate.34–36 Medium was
precipitated with 10% TCA, and supernatants were neutralized with 6 M
NaOH and loaded onto ion exchange columns packed with DOWEX
1× 2-400 resin (Sigma-Aldrich). 3H2O was eluted with water and
quantitated by liquid scintillation counting. The oxidation of [3H]-palmitate
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I Hermanova et al
210
Leukemia (2016) 209 – 218 © 2016 Macmillan Publishers Limited
was normalized to the protein content, as determined using a DC Protein
Assay (Bio-Rad). Non-mitochondrial FAO and background signal
(FAO measured in samples after incubation with etomoxir) was extracted,
and mitochondrial FAO (etomoxir counts extracted from total counts) was
presented in nCi/mg protein/h. The measurement was performed in four
independent experiments.
Respiration
The endogenous respiration of intact cells was measured in the culture
medium at 37 °C using Oxygraph-2k-respirometer (OROBOROS Instruments
Corporation, Innsbruck, Austria). Respiratory rates were determined in both
coupled and uncoupled states, the latter after titration of the uncoupler
carbonyl cyanide-4-(triﬂuoromethoxy)phenylhydrazone (Sigma-Aldrich).
Inhibition by ATP synthase inhibitor oligomycin (Sigma-Aldrich) was used
to verify dependence of coupled respiration on mitochondrial FoF1-ATP
synthase. The following concentrations of cells and respiratory inhibitors
were applied: 0.4 mg/ml cells, 1 μM oligomycin, 200–300 nM carbonyl
cyanide-4-(triﬂuoromethoxy)phenylhydrazone and 0.5 μM antimycin A
(respiratory chain inhibitor; Sigma-Aldrich). The measurement was
performed in four (REH, NALM-6) and three (healthy B lymphocytes,
BCP-ALL) independent experiments.
NAD+/NADH ratio
The ratio of oxidized and reduced form of nicotinamide adenine
dinucleotide (NAD+/NADH) was measured using the NAD+/NADH Glo
assay (Promega, Madison, WI, USA) according to the manufacturer’s
protocol. The ratio was measured in three independent experiments.
Lentiviral RagB cell models
We have used Flag pLJM1 RagB wild-type (RagB wt; Addgene plasmid
19313) and Flag pLJM1 RagB 99L (Addgene plasmid 19315) lentiviral
constructs (Addgene, Cambridge, MA, USA).37 Lentiviral particles were
produced as previously described38 and used for the transduction of
NALM-6 cells. Positive clones were selected by puromycin resistance and
further used for experiments.
Statistical analysis
Student’s t-tests were performed in GraphPad Prism software (GraphPad
Software, Inc., San Diego, CA, USA) for statistical analyses.
RESULTS
ASNase treatment extensively alters cellular metabolism
As ASNase disrupts nutrient homeostasis, we studied its effect on
key metabolic pathways in leukemic cells. Effect of applied ASNase
dosage (RS4;11: 0.5 IU/ml; REH, NALM-6: 4 IU/ml) chosen according
to the pharmacokinetics of ASNase39 was conﬁrmed as a change in
extracellular amino-acid levels by high-performance liquid chroma-
tography (Supplementary Figure S1). First, we focused on the
impact of ASNase on FAO. We incubated REH, NALM-6 and RS4;11
B-precursor leukemic cells with ASNase for 18 h and measured the
activity of FAO. ASNase treatment signiﬁcantly increased FAO in
these cell lines (Figure 1a). The effect of etomoxir on FAO in ALL
cells is shown in Supplementary Figure S2. Next, we determined the
effect of ASNase on glucose metabolism in REH and NALM-6 cells
and observed that ASNase treatment signiﬁcantly reduced glucose
uptake in both cell lines (Figure 1b). This was accompanied by
decreased lactate production in NALM-6 cells (Supplementary
Figure S3). Lactate production in RS4;11 was also signiﬁcantly
reduced after ASNase treatment. There were no observable
changes in REH cells; however, the basal lactate level was
substantially lower in REH cells compared with NALM-6 (data not
shown). Furthermore, we determined the levels of the glycolysis
regulator c-Myc and glucose transporter type 1 (GLUT1). As shown
in Supplementary Figure S4, ASNase signiﬁcantly decreased c-Myc
messenger RNA expression in ALL cell lines with a concomitant
decrease in the protein levels of c-Myc and GLUT1. Consistent with
these results observed in ALL cell lines, we detected decreased
c-Myc protein levels also in some primary ALL cells following
ASNase treatment (Supplementary Figure S4).
Both FAO and glucose oxidation yield NADH, which
is then oxidized by mitochondrial respiratory chain. In the
subsequent experiment we therefore investigated the impact
of ASNase on the mitochondrial respiration in ALL cells.
ASNase signiﬁcantly increased basal oxygen consumption (routine
respiration) of REH cells (P= 0.0276) (Figure 1c and Supplementary
Figure S5). In the uncoupled state, which serves as a measure of
the maximum capacity of the respiratory chain, we observed a
signiﬁcant increase in oxygen consumption in ALL cell lines
(Figure 1c and Supplementary Figure S5). More interestingly, we
observed signiﬁcant increase of the spare respiratory capacity
(uncoupled/coupled respiration) in REH and NALM-6 cell lines
treated with ASNase (Figure 1d). The increase of spare respiratory
capacity was borderline signiﬁcant (P= 0.062) in RS4;11 cell line.
We found a similar increase in the spare respiratory capacity also
in the primary ALL cells on ASNase treatment (Figure 1d). In
contrast, this was not the case for the control B lymphocytes
isolated from peripheral blood of healthy subjects (Figure 1d),
indicating that the effect of ASNase is speciﬁc to leukemic cells.
The increase in the respiratory capacity was not accompanied by a
change in the content of oxidative phosphorylation proteins
(Supplementary Figure S6), meaning that it likely represents a shift
in the balance of available substrates. Indeed, we detected a
signiﬁcant increase in the NAD+/NADH ratio in ALL cell lines
following ASNase treatment (Supplementary Figure S7).
ASNase modulates pyrimidine synthesis and autophagy via
mTORC1 inhibition
Our previous experiments have shown that ASNase treatment
affects key metabolic pathways in ALL cells. Based on the
sensitivity of mTORC1 to amino-acid levels and the evidence that
ASNase treatment inhibits mTORC1 signaling,25 we hypothesized
that the effect of ASNase on metabolism is driven through
mTORC1. First, we conﬁrmed the effect of ASNase on main
mTORC1 targets. We detected dephosphorylated p-P70S6K and
p-S6 in ALL cell lines and some primary ALL samples treated with
ASNase (Figure 2a and Supplementary Figure S8). Furthermore, we
detected dephosphorylated carbamoyl phosphate synthase II
(p-CAD), suggesting a decrease in the de novo synthesis of
pyrimidines (Figure 2a).40 Similar effect on p-CAD status was also
observed using speciﬁc mTOR inhibitor rapamycin (Figure 2a). We
also measured the intermediates of de novo pyrimidine synthesis
using UPLC-ToF-MS in REH and NALM-6 cells treated with ASNase.
In concordance with the dephosphorylation of p-CAD, we
observed signiﬁcantly decreased synthesis of uridine mono-
phosphate and uridine in REH and NALM-6 cells treated with
ASNase (Figure 2b). Another mechanism that may be activated on
mTORC1 inhibition is autophagy. To investigate whether ASNase
treatment augments autophagic ﬂux, we detected the conversion
of the marker of autophagosome, microtubule-associated protein
light chain 3 (LC3), LC3-I to LC3-II, by western blot. Treatment with
ASNase induced a time-dependent increase in the expression of
LC3-II in the NALM-6 cell line (Figure 2c), indicating that ASNase
activates autophagy. Consistent with increased autophagic ﬂux
following treatment with ASNase, there was a time-dependent
decrease in the level of p62 (selective substrate of autophagy).
LC3-II accumulation following ASNase treatment was intensiﬁed in
the NALM-6 cell line after treatment with baﬁlomycin A1
(Figure 2c). Baﬁlomycin A1 is an inhibitor of the vacuolar ATPase,
which blocks the fusion of autophagosomes with lysosomes,
leading to an accumulation of autophagosomes.41 This result
conﬁrms that the observed increase in LC3-II after ASNase
treatment was due to increased autophagic ﬂux and not because
of decreased degradation of lipidated LC3.
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ASNase acts through the RagB-mTORC1 pathway
Next, we investigated the mechanism whereby ASNase inhibits
the mTORC1 pathway. The activation of mTORC1 in the presence
of amino acids is mediated by the Rag GTPases (guanosine-
5'-triphosphatases) A, B, C and D. A key event in the amino-acid-
dependent activation of mTORC1 is the conversion of RagA or
RagB from a guanosine-5'-diphosphate (GDP) to guanosine-
5'-triphosphate (GTP)-bound state.31,37,42 To determine whether
ASNase inhibits mTORC1 by the same mechanism as general
amino-acid deprivation, we established RagB wt and RagB mutant
(RagB 99L) cells (Figure 3). The mutation of RagB causes
constitutive activation of mTORC1 by permanent conversion to
GTP and localization of mTOR in the vesicle compartments
regardless of amino-acid deprivation.37 We used a lentiviral
system to achieve permanent expression of RagB in the NALM-6
cell line. The resistance of the mTOR pathway inhibition to
amino-acid deprivation by ASNase treatment was conﬁrmed in
RagB 99L. There was no change in p-S6 level in the RagB 99L cells,
whereas ASNase treatment inhibited p-S6 protein in RagB wt cells.
Concordantly, p-CAD protein was inhibited more extensively in
RagB wt cells than in RagB 99L cells (Figure 3a). Importantly, the
ability to enhance FAO was impaired in RagB 99L cells exposed to
ASNase (Figure 3b). These results suggest that the effect of
ASNase on protein translation, de novo pyrimidine synthesis and
FAO is mediated through the RagB-mTORC1 pathway. By contrast,
c-Myc expression was decreased in both RagB wt and RagB 99L
cells (Figure 3a). Consistent with this result, there was a signiﬁcant
decrease in the level of extracellular lactate in RagB 99L cells
(Supplementary Figure S9), indicating that ASNase inhibits
glycolysis in a RagB-mTORC1-independent manner. To test
whether c-Myc inhibition following ASNase treatment is mTORC1
independent, we detected the c-Myc protein level in REH and
NALM-6 cells treated with the mTORC1 inhibitor rapamycin.
Figure 1. Effect of ASNase on the metabolism of leukemic cells. (a) ALL cell lines were cultured for 18 h with or without ASNase and the rate of
fatty-acid oxidation was assessed. The concentration of ASNase was 4 IU/ml (REH, NALM-6) and 0.5 IU/ml (RS4;11) The experiment was
performed in quadruplicate. (b) ALL cell lines were cultured overnight with or without ASNase (4 IU/ml). Changes in glucose uptake were
measured by the accumulation of [3H]-2-deoxyglucose in cells. (c) ALL cell lines (d) healthy B lymphocytes and BCP-ALL patient samples were
cultured with or without ASNase for 24 h. The dose of ASNase was 4 IU/ml for all samples except of RS4;11 (0.5 IU/ml). The endogenous
respiratory rates were determined in both coupled and uncoupled states (the latter after titration of the uncoupler FCCP) and also after the
addition of oligomycin. The spare respiratory capacity was calculated. The following concentrations of cells and respiratory inhibitors were
applied: 0.4 mg/ml cells, 1 μM oligomycin, 200–300 nM FCCP. Asterisks represent signiﬁcant changes. ***Po0.001; **Po0.01; *Po0.05.
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Contrary to the effects of ASNase, inhibition of mTORC1 by
rapamycin did not cause a substantial decrease in c-Myc
(Supplementary Figure S10).
These results suggest that ASNase inhibits protein translation and
DNA synthesis directly through RagB-mTORC1, and inhibition of the
mTORC1 pathway also causes enhancement of FAO. However,
glycolysis seems to be regulated through a different mechanism.
Inhibition of FAO increases the cytotoxic effect of ASNase in ALL
cells
The activation of FAO has been suggested to exert a pro-survival
function in leukemic cells under nutrient stress conditions. We
tested whether the increase of FAO upon ASNase treatment
allows leukemic cells to cope with metabolic stress. We treated
REH and NALM-6 cells with the FAO inhibitor etomoxir, ASNase, or
both drugs, and measured its effect on the viability of the cells.
The concentrations of etomoxir were 25, 50, 100, 200 and 400 μM.
The range of etomoxir was chosen according to previous
publications.43,44 Pharmacological inhibition of FAO in combination
with ASNase increased apoptosis in REH and NALM-6 cells. As
shown in Figure 4a, CI for etomoxir with ASNase were o1,
indicating synergistic mode of action in both cell lines.33 Complete
data on the effect of both drugs are shown in Supplementary
Figure S11. The most effective concentrations of etomoxir in the
combination with ASNase were 100 and 200 μM. Importantly, similar
results were obtained in primary diagnostic ALL patient samples co-
treated with ASNase and etomoxir. Etomoxir increased the
cytotoxic effect of ASNase in ex vivo conditions in four out of ﬁve
diagnostic BCP-ALL patient samples (Figure 4b). These results reveal
that increased FAO is crucial for the survival of ALL cells treated
with ASNase. Moreover, cells with the inability to induce FAO
(RagB 99L) were signiﬁcantly more sensitive to ASNase compared
with RagB wt cells, shown by the cleavage of PARP (Figure 3a) and
the assessment of apoptosis by Annexin V/DAPI staining (Figure 4c).
Figure 2. Effect of ASNase on mTORC1 targets. (a) ALL cell lines were cultured for 24 h with or without ASNase (4 IU/ml). Levels of phospho-
CAD and CAD proteins were measured by immunoblotting, with β-actin used as a loading control. Rapamycin (Rapa; 10 nM) served as a
positive control of mTORC1 inhibition. Phospho-S6 and phospho-CAD proteins were measured in ASNase-treated cells (4 IU/ml; 24 h) from
three different patients by immunoblotting, using β-actin as a loading control. (b) ALL cell lines were cultured for 24 h with or without ASNase
(4 IU/ml). Uridine monophosphate (UMP) and uridine levels were measured using UPLC-ToF-MS. (c) NALM-6 cells were cultured with or
without ASNase (4 IU/ml) in the presence or absence of baﬁlomycin A1 (BafA1, 100 nM) for 6, 12 and 24 h to analyze autophagic ﬂux. LC3 I/II
and p62 protein levels were measured by immunoblotting, with β-actin used as a loading control. Asterisks represent signiﬁcant changes.
**Po0.01; *Po0.05.
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Altogether, our results revealed enhanced cytotoxic effect of
ASNase owing to FAO inhibition.
Distinct effect of Asn and Gln on mTOR downstream targets and
FAO activity
At last, we examined the individual roles of Gln and Asn on cellular
processes. We cultured ALL cell lines under four different
conditions: complete media, media without Asn, media without
Gln and complete media treated with ASNase. In REH and NALM-6,
p-S6 and c-Myc protein levels were decreased after cultivation in
media without Asn or Gln but the effect of Gln depletion was
more pronounced in NALM-6 cells. On the other hand, in RS4;11
we detected a substantial reduction of p-S6 and c-Myc in the cells
cultured in media without Asn. Apoptosis detected by cleaved
PARP was not increased by depletion of any amino acid in
NALM-6, whereas in REH and RS4;11 apoptosis was triggered by
Asn depletion. Depletion of either Asn or Gln had similar impact
on p-CAD levels in all studied cell lines (Figure 5a). RS4;11 cells are
dependent on Asn presence as also documented by a signiﬁcant
increase of FAO in this cell line after cultivation in media without
Asn. FAO was signiﬁcantly increased after cultivation in
Gln-depleted media in NALM-6 cells (Figure 5b). Cell respiration
did not follow the FAO activation upon individual amino-acid
depletion (Supplementary Figure S12). In general, Gln depletion
causes suppression of NADH production which, in our
experiments, was reﬂected as the inhibition of maximum capacity
of cell respiration. Moreover, we studied the rescue effect of Asn
and Gln after ASNase treatment. We pre-treated NALM-6 and REH
cell line with ASNase for 8 h and then changed the media to
complete media, media without Asn or without Gln, respectively.
Media without Asn represent addition of Gln and vice versa, media
without Gln represent addition of Asn. After overnight cultivation
we detected mTOR targets (p-S6, S6) and PARP cleavage. Rescue
effect of Asn after ASNase treatment is more evident in REH cells.
There is an increase in p-S6 as well as a decrease of cleaved PARP
compared with addition of Gln in the media. In the NALM-6 cell
line though, p-S6 was increased by addition of either Asn or Gln
after ASNase treatment. Apoptosis was decreased after addition of
both amino acids (Supplementary Figure S13).
DISCUSSION
ASNase was incorporated into the treatment protocol for child-
hood ALL in 1970. Despite the successful use of this drug for
decades, the mechanism underlying its cytotoxic effect remains
surprisingly obscure. ASNase depletes two extracellular amino
acids, Asn and Gln. The depletion of amino acids changes nutrient
availability and consequently inﬂuences metabolic signaling.
Metabolic pathways in malignant cells can be rewired depending
on the cellular availability of the nutrients45 and thus participate in
the mechanisms of drug resistance. This study, for the ﬁrst time,
presents evidence that ASNase triggers extensive metabolic
reprogramming in leukemic cells and reveals the adaptive
activation of pro-survival metabolic pathways following ASNase
treatment. Our data show increased levels of FAO, inhibition of
glycolysis and elevated respiratory activities after ASNase treat-
ment. FAO serves as a source of NADH, FADH2 and acetyl-CoA
Figure 3. Effect of ASNase on RagB wild-type and RagB mutant cells. (a) RagB wild-type (RagB wt) and mutant (RagB 99L) NALM-6 cells were
cultured with or without ASNase (4 IU/ml) for 24 h. Expression levels of phospho-S6, S6, phospho-CAD, CAD, c-Myc, cleaved PARP and RagB
proteins were measured by immunoblotting, with β-actin used as a loading control and quantiﬁed by densitometry (lower graph). The
measurement was performed in three independent experiments. (b) RagB wt and RagB 99L cells were cultured overnight with or without
ASNase (4 IU/ml) and the rate of fatty-acid oxidation was measured. The experiment was performed in quadruplicate. Asterisks represent
signiﬁcant changes. *Po0.05.
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feeding the Krebs cycle and mitochondrial oxidative phosphoryla-
tion. Utilization of FAO for energy provision is thus important for
the growth and survival of cancer cells under both normal
and metabolic stress conditions.36,46–50 The metabolic rescue
role of FAO has been described in different tumors such
as diffuse large B-cell lymphoma, multiple myeloma and
glioblastoma.50–52 Moreover, FAO can contribute to chemo-
resistance.51,52 Pharmacological inhibition of FAO showed a
therapeutic beneﬁt in combination with chemotherapy in mouse
models of human myeloid leukemia, suggesting that the shift
Figure 4. Effect of FAO inhibition on ASNase-mediated cytotoxicity. (a) REH and NALM-6 cells were treated with ASNase (1, 2, 4, 8 and 16 IU/ml) in
combination with etomoxir (Eto1, 100 μM; Eto2, 200 μM) for 24 h. The percentage of cell death was determined by Annexin V/PI staining followed
by FACS analysis. Combination indexes (CI) were obtained by entering the resulting speciﬁc death values into the CompuSyn program. Fraction
affected (FA; Percentage of Annexin V/PI positive cells)-CI plots indicate that the combinations of ASNase with etomoxir are synergistic (CIo1).
(b) Leukemic blasts isolated from the bone marrow of patients with ALL were cultivated with or without ASNase (4 IU/ml) in the presence or
absence of the FAO inhibitor etomoxir (Eto1, 100 μM; Eto2, 200 μM) for 24 h. (c) RagB wt and RagB 99L NALM-6 cells were cultivated with or
without ASNase (4 IU/ml) for 24 h. The percentage of cell death was determined by Annexin V/DAPI staining followed by FACS analysis. Values
represent the mean of triplicate measurements. Asterisks represent signiﬁcant changes. ***Po0.001; **Po0.01; *Po0.05.
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toward FAO could be a target for the treatment of hematological
malignancies.43,53 In this study, we combined ASNase and the FAO
inhibitor etomoxir in the treatment of childhood ALL samples for
the ﬁrst time. Our experiments showed an increase in FAO after
ASNase treatment, providing a rationale for the combination
treatment. Etomoxir-sensitized leukemic cells to ASNase in two
leukemic cell lines in vitro as well as under ex vivo conditions when
treating BCP-ALL patient samples. These data support the
pro-survival effect of FAO in the treatment of ALL cells with
ASNase and demonstrate the potential of this combination
treatment. Previous studies have described a negative association
between mTOR and FAO and a positive relation of mTOR
upregulation with fatty-acid synthesis.54–56 Our results show that
ASNase inhibited mTORC1 through RagB (Ras-related GTPase),
which is a mediator of amino-acid signaling.37 Importantly, in the
presence of ASNase, RagB mutant cells with the constitutively
activated mTOR pathway exhibited a reduction of FAO compared
with the signiﬁcant FAO elevation observed in RagB wt cells.
Accordingly, RagB mutant cells were signiﬁcantly more sensitive
to ASNase than RagB wt cells. These results demonstrate that
RagB-mTOR inhibition senses metabolic stress, which induces
FAO. We hypothesize that the limited elevation of FAO after
ASNase treatment in RagB mutant cells was not sufﬁcient to
protect these cells from amino-acid deprivation.
As ASNase treatment inhibited mTORC1, we focused on the
downstream targets of mTORC1 that are involved in cellular
metabolism. ASNase treatment inhibited protein translation and
pyrimidine synthesis in ALL cells as part of the apoptotic process.
Concurrently, leukemic cells treated with ASNase increased
autophagy as has been already shown in other cancer type.10,26
Autophagy may serve to maintain intracellular metabolic home-
ostasis through the degradation of unfolded or aggregated
proteins and organelles.57 Thus, autophagy may serve as another
rescue mechanism by producing amino acids or even fatty acids58
that restore the nutrient balance disrupted by ASNase. Glycolysis
was yet another metabolic pathway affected by ASNase. ASNase
inhibited c-Myc, but it is not clear if this was a direct effect or a
feedback loop resulting from the inhibition of glycolysis. Of
particular note is our ﬁnding that treatment with ASNase increases
spare respiration exclusively in leukemic cells. Increase in
respiration may reﬂect increased ﬂux of nutrients that can be
oxidized by mitochondria. Although this could be both
FAO-dependent and FAO-independent, the observed increase in
FAO (involving the whole pathway from uptake of palmitate from
culture media to its ﬁnal oxidation to water) argues that at least
substantial part of these fatty acids originated from extracellular
environment and was oxidized by mitochondria. The increased
ratio of NAD+/NADH measured after ASNase treatment further
supports the increased mitochondrial oxidation of reducing
equivalents.
The role of individual amino acids in these cellular processes is
cell line speciﬁc. The tested leukemic cell lines differ in their
sensitivity to ASNase and also in ASNS protein level. RS4;11 cells
are the most sensitive with undetectable ASNS protein, REH cells
are intermediate sensitive and have higher ASNS protein levels,
and NALM-6 cells are the most resistant of the studied cell lines
with higher ASNS protein level.19,59 Most importantly, we did not
see any differences in the effect of ASNase in ALL cell lines on
mTOR targets and metabolic processes. Next, we propose that the
higher the sensitivity, the deeper the cells' dependence on Asn.
Figure 5. Effect of Asn and Gln depletion on ALL cells. (a) ALL cell lines were incubated in complete RPMI media (Ctrl), RPMI media without
Asn (–ASN), RPMI media without Gln (−GLN) or complete RPMI media with ASNase for 24 h. The concentration of ASNase was 4 IU/ml
(REH, NALM-6) and 0.5 IU/ml (RS4;11). Levels of phospho-S6, S6, phospho-CAD, CAD, c-Myc, cleaved PARP (cl.PARP), ASNS proteins were
measured by immunoblotting, with β-actin used as a loading control. (b) ALL cell lines were incubated in complete RPMI media (Ctrl), RPMI
media without Asn (−ASN), RPMI media without Gln (−GLN) or complete RPMI media with ASNase for 18 h and the rate of fatty-acid
oxidation was assessed. Asterisks represent signiﬁcant changes. ****Po0.0001; *Po0.05.
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In other words, the cells’ dependence on Asn is inversely
proportional to the ASNS protein expression. Accordingly, the
rescue effect of Asn was pronounced in sensitive cells (REH) after
ASNase treatment, whereas in NALM-6 cells both amino acids
displayed rescue properties. Our data support previous ﬁnding
presenting that glutaminase activity of ASNase is not essential in
anticancer effect of ASNS-negative cancer cells.59
In conclusion, our results demonstrate that ASNase has a strong
effect on the bioenergetics and biosynthesis in leukemic cells. Our
data further show that increased FAO has a pro-survival effect on
leukemic cells. Moreover, our results also suggest that pharmaco-
logical blocking of FAO sensitizes leukemic cells to ASNase
treatment. Metabolic changes similar to those described here in
acute leukemia cells are rather frequent among other cancer
subtypes; therefore, using ASNase in combination with etomoxir
may represent a treatment option not only for ALL but also for
other types of cancers.
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PTEN mediates Notch-dependent stalk cell
arrest in angiogenesis
Helena Serra1,*, In˜igo Chivite1,*, Ana Angulo-Urarte1, Adriana Soler1, James D. Sutherland2,
Amaia Arruabarrena-Aristorena2, Anan Ragab3, Radiance Lim4, Marcos Malumbres5, Marcus Fruttiger6,
Michael Potente4, Manuel Serrano5, A`ngels Fabra7, Francesc Vin˜als8,9, Oriol Casanovas8, Pier Paolo Pandolﬁ10,
Anna Bigas11, Arkaitz Carracedo2,12,13, Holger Gerhardt3,14 & Mariona Graupera1
Coordinated activity of VEGF and Notch signals guides the endothelial cell (EC) speciﬁcation
into tip and stalk cells during angiogenesis. Notch activation in stalk cells leads to proliferation
arrest via an unknown mechanism. By using gain- and loss-of-function gene-targeting
approaches, here we show that PTEN is crucial for blocking stalk cell proliferation down-
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V
essel sprouting is a central mechanism of blood vessel
growth1,2 and it relies on the induction of specialized
endothelial cell (EC) populations, each accounting for
distinct functions. At the very front of the sprouts, tip cells
provide guidance and migrate towards gradients of vascular
endothelial growth factor (VEGF)-A, but rarely proliferate2–4.
Instead, trailing stalk cells located at the base of the sprout
proliferate, establish adherent and tight junctions and form the
vascular lumen1,2,5.
The tip cell phenotype is usually associated with high levels of
Delta-like 4 (Dll4), which activate Notch in neighbouring stalk
cells, preventing them from becoming a new tip cell. Notch
signalling is initiated by receptor–ligand recognition between
adjacent cells. This interaction results in two sequential
proteolytic events that release the Notch intracellular domain
(NICD). Subsequently, NICD translocates to the nucleus, where it
forms a complex with the transcriptional factor Rbpj/Cbf1 and
the Mastermind-like proteins to drive target gene expression6,7.
Activation of Notch in ECs leads to cell cycle arrest both in vitro8
and in vivo9–11. However, it is still unclear how Notch exerts its
negative effects on EC proliferation, and the transcriptional
programme that triggers stalk cell function is not
understood2,5,12. Furthermore, it is not clear how stalk cells are
ultimately released from this arrest to provide sufﬁcient cell
numbers for the sprout to elongate and stabilize.
PTEN (phosphate and tensin homologue deleted on
chromosome TEN) is a dual lipid/protein phosphatase, which
is often underexpressed in cancer13–15. The main activity of
PTEN is to dephosphorylate the lipid phosphatidylinositol
3,4,5-trisphosphate (PtdIns(3,4,5)P3) at the 3´-position, thereby
counterbalancing class I phosphoinositide 3-kinase (PI3K)
signalling that mediates growth, cell division, survival,
migration and metabolism13,16–18. Genetic studies in mouse
and zebraﬁsh point to a restrictive role of PTEN in angiogenesis.
Mice lacking PTEN speciﬁcally in ECs exhibit cardiac failure and
severe haemorrhages due to defects of the myocardial wall and
impaired mural cell coverage of blood vessels19. Mutant zebraﬁsh
embryos lacking functional PTEN show enhanced angiogenesis20;
whether this is due to a cell-autonomous effect of PTEN in ECs or
is simply a consequence of increased VEGF levels is unclear.
Importantly, the speciﬁc functions of PTEN in endothelial
behaviour and vascular patterning remain unknown.
In most cells and tissues, PTEN localizes to the cytoplasm and
the nucleus13,15. There is evidence to suggest that PTEN
has nuclear, non-lipid phosphatase-dependent functions21,22.
Interestingly, PTEN localization is cell cycle-dependent, with
higher levels of nuclear PTEN during the G0–G1 phase than
during the S phase23,24. This is in line with the observation that
nuclear PTEN negatively regulates cell cycle progression13,22.
Indeed, in late mitosis and G1, nuclear PTEN enhances the E3
ligase activity of APC/C by facilitating the association of APC/C
with its activator Fzr1/Cdh1 (encoded by the Fzr1 gene), with no
requirement of its phosphatase activity22. The APC/C-Fzr1/Cdh1
complex controls G1 progression by targeting several proteins for
degradation, including mitotic cyclins (Cyclin-A), mitotic kinases
(Aurora Kinase A (Aurora A) and Polo-like kinase 1 (Plk1)),
proteins involved in chromosome segregation and DNA
replication (Geminin; ref. 25). Despite the large body of
molecular evidence, the role and relevance of nuclear PTEN in
physiology is poorly understood.
Here we report that endothelial PTEN regulates stalk cell
proliferation during vessel development. Our data further identify
PTEN as a key mediator of the antiproliferative responses of
Notch. We show that Dll4/Notch signalling arrests stalk cell
proliferation by inducing expression of PTEN to balance stalk cell
numbers and coordinate patterning. On PTEN deletion, Notch
signalling fails to arrest early stalk cells and result in defective
sprout length and patterning. Our results strongly indicate that
both catalytic and non-catalytic activities of PTEN contribute to
this function, providing evidence for an important in vivo
physiological function for the PTEN-APC/C-Fzr1/Cdh1/axis.
Results
PTEN negatively regulates vascular density in angiogenesis.
To study the EC-autonomous role of PTEN in sprouting
angiogenesis, we crossed Ptenﬂox/ﬂox mice with PdgfbiCreERT2
transgenic mice that express a tamoxifen-activatable Cre
recombinase in ECs26 (further referred to as PTENiDEC/iDEC) and
assessed postnatal retinal angiogenesis. 4-hydroxytamoxifen
(4-OHT) was administrated in vivo at postnatal day 1 (P1) and
P2, followed by analysis of the retinal vasculature at different time
points. Comparing whole-mount-stained retinas of control
(Ptenﬂox/ﬂox) to PTENiDEC/iDEC mice at P5 revealed a mild
increase in vessel width (Supplementary Fig. 1a–g). By P7, loss of
PTEN resulted in excessive branching and substantially increased
vessel width (Fig. 1a–d), a phenotype that was further exacerbated
at P10 (Fig. 1h,i). PTENiDEC/iDEC P7 retinas showed efﬁcient
recombination of the Cre-reporter R26-R and depletion of PTEN
in the retinal endothelium (Supplementary Fig. 1h,i), with an
increase in staining for phosphoS6 (pS6), a marker of PI3K
pathway activation (Supplementary Fig. 1j). Isolated mouse lung
ECs (mECs) from PTENiDEC/iDEC mice conﬁrmed that effective
depletion of PTEN protein in mECs was achieved 96 h following
4-OHT administration (Supplementary Fig. 1k,l). To further
characterize the cell-autonomous role of PTEN in ECs, we
therefore focused on the P7 time point. No differences in radial
expansion (Fig. 1e) and in the number of sprouts per 100mm of
leading endothelial membrane were found in PTENiDEC/iDEC
when compared with control retinas (Fig. 1f). Instead, the length
of the sprouts was signiﬁcantly reduced in the PTENiDEC/iDEC
retinal vasculature compared with controls (Fig. 1g). The
hyperplastic phenotype observed on PTEN loss was validated in
an independent cellular system based on embryoid body (EB)
formation, in which clusters of embryonic stem cells respond to
VEGF by forming vascular tubes27. Compared with wild type
(WT), PTEN null EBs showed increased sprout width and length
(Supplementary Fig. 2a–d), with no differences in the number of
sprouts (Supplementary Fig. 2e).
Next, we sought to address whether regulated elevation in
PTEN expression in vivo would oppose the phenotype induced by
loss of PTEN. To this end, we used super-PTEN transgenic mice
(PTENTG)28, a mouse model that allows moderate organismal
elevation of PTEN levels (two-fold over WT littermates),
including in the vasculature (Supplementary Fig. 1m). PTENTG
retinas exhibited decreased vessel width and increased sprout
length (Fig. 1j,k,m,p), with no changes in the number of branches
(Fig. 1l) and sprouts (Fig. 1o). A slight reduction in radial
expansion was also observed on moderate PTEN overexpression
(Fig. 1n), similar to retinas from mice that are heterozygous for a
kinase-dead p110a PI3K allele29. Neither loss nor gain of PTEN
function resulted in changes in Dll4 or Notch target genes
(Supplementary Fig. 3a–c), further supporting that PTEN is not
required for tip/stalk selection. Analysis of EphB4, EphrinB2 and
Nr2f2 gene expression, key genes involved in arteriovenous
differentiation, did also not reveal any obvious difference between
control and loss and gain of PTEN function in ECs, suggesting
that PTEN signalling does not play a predominant role in this
process (Supplementary Fig. 3d,e).
Taken together, these data uncover a selective role for PTEN in
angiogenesis, regulating vascular density and consequently vessel
growth in vivo.
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PTEN regulates endothelial stalk cell number. Previous data
have shown that constitutive targeting of PTEN in ECs results in
altered mural cell coverage19. Instead, immunostaining with
desmin, a retinal pericyte marker30, did not reveal any obvious
defect in mural cell coverage in PTENiDEC/iDEC retinas compared
with control, consistent with the lack of sprouting defects on
PTEN loss (Supplementary Fig. 3f).
Analysis of PTENiDEC/iDEC retinas stained with a nuclear
endothelial marker (Erg) revealed increased EC numbers in the
angiogenic vasculature (Fig. 2a,b). Conversely, elevated PTEN
expression resulted in reduced EC numbers at the sprouting front
(Fig. 2c,d). We sought to validate whether these differences relate
to changes in EC proliferation. Surprisingly, no difference in the
number of proliferative ECs located in the subfront retinal area,
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behind the sprouting front, was found on either loss (Fig. 2e,f) or
gain of PTEN function (Fig. 2h,i). This is unexpected, given that
in the growing vasculature ECs with high turnover are located in
this subfront area (Supplementary Fig. 4a,b). To test whether
PTEN regulated proliferation of ECs in other retinal locations,
we focused on the ﬁrst line of cells located at the sprouting front
where proliferating cells are rarely observed (Supplementary
Fig. 4a,b). Interestingly, a 40% increase in proliferation in
PTENiDEC/iDEC retinas (Fig. 2g) or 60% reduction in PTENTG
retinas (Fig. 2j) compared with control retinas was observed in
ECs at the front. These data point towards a selective role of
PTEN in restricting EC proliferation in cells located at the
sprouting front.
PTEN executes Notch-dependent cell cycle arrest. Given
that the impact of PTEN loss or overexpression in vivo on
proliferation are restricted to the sprouting front that is highly
Notch-dependent9, we hypothesized that a functional connection
exists between these two signalling pathways. Activation of
Notch in mECs, both in vivo and in vitro, resulted in cell cycle
arrest, shown by reduced 5-bromo-2’-deoxyuridine (BrdU)
incorporation (Supplementary Fig. 4c,d and Fig. 3a) and
downregulation of cell cycle regulators including Cyclin D and
A, Plk1, Aurora A and Geminin (Fig. 3b). Interestingly, genetic
manipulation of PTEN levels in ECs altered the antiproliferative
response to Notch activation (Fig. 3c,e). PTENiDEC/iDEC mECs
failed to stop proliferation on Notch activation (Fig. 3c,d),
whereas PTENTG mECs showed a 50% increase in the cell cycle
arrest response (Fig. 3e,f). Consistent with a role of PTEN in
regulating the cell cycle arrest, higher PTEN levels in ECs in vivo
corresponded to nonproliferative cells (Supplementary Fig. 4e,f).
Our results suggest that PTEN is necessary for the growth-
suppressive activity of Notch signalling in ECs and imply that the
PTEN loss-of-function phenotype is the result of an impaired
response to Dll4 stimulation.
Because PTEN is required for the Notch-dependent regulation
of endothelial proliferation, we tested whether PTEN expression
is regulated by Notch. Bioinformatic analysis of the PTEN locus
identiﬁed the presence of three Rbpj motifs that are conserved in
both the human and mouse PTEN gene (Fig. 3g). We used
chromatin immunoprecipitation (ChiP) analysis on human ECs
to determine the recruitment of NICD protein to the PTEN
promoter after 2 h of incubation with Dll4. PTEN promoter
occupancy was determined using real-time quantitative PCR
(qPCR) probes that amplify seven regions spanning from  2,380
to  590 relative to the transcription initiation site. Our analysis
revealed NICD occupancy in the  1,492 region, which contains
one of the three predicted Rbpj-binding sites (Fig. 3g). We next
validated the functional signiﬁcance of Rbpj binding to the
promoter in luciferase reporter assays. Indeed, analysis of PTEN
promoter activity showed activation in response to Dll4 (Fig. 3h)
and on overexpression of the intracellular domain of the Notch
receptor (NICD; Fig. 3i). Importantly, enhanced PTEN promoter
responsiveness to Dll4 was abrogated by the g-secretase inhibitor
dibenzazepine (DBZ; Fig. 3i). Western blot experiments con-
ﬁrmed that Dll4 stimulation results in elevated protein levels of
PTEN in human ECs and mECs (Fig. 3j,k). Using lungs as highly
vascularized tissue, we validated that overactivation of Notch
signalling by inhibiting the Notch ligand, Jagged 1 (Jag1)11,
resulted in higher PTEN expression levels (Fig. 3l). Taken together,
these results demonstrate that PTEN is a target gene of Notch
signalling in ECs, which becomes induced by Dll4 stimulation.
PTEN is required for Notch function in vivo. We sought to
conﬁrm the Notch/PTEN functional interaction in vivo. We took
advantage of endothelial Jag1 inactivation, which results in
reduced EC proliferation and decreased vascular branching due to
overactivation of Notch signalling11. We hypothesized that,
if the regulation of the angiogenic process by Notch requires
the increase in PTEN function, loss of PTEN would prevent
the phenotype of Jag1 deletion. We tested this hypothesis in
inducible endothelial-cell-speciﬁc PTENiDEC/iDEC;Jag1iDEC/iDEC
double mutants. The vasculature of Jag1iDEC/iDEC retinas
showed reduced endothelial proliferation and reduced vessel
width, conﬁrming previous reports (Fig. 4a–g and Supplementary
Fig. 5a)11. However, concomitant PTEN deletion abrogated the
phenotype observed in Jag1iDEC/iDEC retinas (Fig. 4a–g), while the
phenotype of PTEN loss remained unaffected by Jag1 deletion
(the increase in endothelial proliferation at the spouting front).
Next, we validated our hypothesis in the PTENTG mice by
blocking Notch activation with the g-secretase inhibitor DAPT
(N-[N-(3,5-diﬂuorophenacetly)-L-alanyl]-S-phenylglycine t-butyl
ester) that strongly enhances angiogenesis partially due to
increased EC proliferation9. Remarkably, DAPT-induced
increase in vascular density at the angiogenic front was
abolished by increased levels of PTEN (Fig. 4h,j,m,n and
Supplementary Fig. 5b). However, elevated levels of PTEN did
not prevent the enhanced sprouting caused by DAPT (Fig. 4i,k,l),
further indicating that PTEN is not required for Notch-
dependent tip/stalk selection.
Dual function of PTEN in angiogenesis. To gain insight into the
biological mechanism underlying the role of PTEN in sprouting
angiogenesis, we investigated the contribution of phosphatase-
dependent and -independent activities of PTEN at the organismal
and cellular levels. We observed a compartmentalization of PTEN
in the nucleus and cytoplasm in cultured control cells (Fig. 5a),
whereas PTENiDEC/iDEC mECs showed no nuclear staining with
some residual positivity in the cytoplasm. PTEN depletion
in mECs resulted in increased Akt phosphorylation and in
accumulation of the E3 ubiquitin ligase APC/C-Fzr1/Cdh1
complex substrates Aurora A, Plk1 and Geminin (Fig. 5b).
Control mECs treated with 4-OHT did not show any of the
aforementioned changes (Fig. 5c). In contrast, mECs isolated
from PTENTG lungs showed reduced Akt phosphorylation and
reduced accumulation of E3 ubiquitin ligase APC/C-Fzr1/Cdh1
complex substrates compared with WT cells (Fig. 5d).
To investigate whether increased levels of the APC/C-Fzr1/
Cdh1 targets were only a consequence of increased PI3K activity,
we tested the impact of GDC-0941 (a pan-class I PI3K inhibitor
that blocks p110a, p110b, p110d and p110g; ref. 31). While
pretreatment with GDC-0941 abrogated Akt activation in
PTENiDEC/iDEC mECs (Fig. 5e), it did not modify the levels of
Aurora A and Geminin (Fig. 5e), further corroborating that the
function of PTEN promoting the APC/C-Fzr1/Cdh1 activity is
independent of its ability to inhibit PI3K signalling through its
lipid phosphatase activity22.
As our data indicate that the principal function of PTEN in
sprouting angiogenesis is to regulate EC proliferation, we tested
to what extent phosphatase-dependent and -independent
activities of PTEN participate in this regulation. In vitro
isolated PTENiDEC/iDEC and PTENTG mECs showed increased
and decreased BrdU incorporation, respectively (Fig. 5f and
Supplementary Fig. 6a,b). Inhibition of PI3K activity and Aurora
kinase, one of the main targets of APC/C-Fzr1/Cdh1 (ref. 22),
partially rescued normal proliferation rate in PTENiDEC/iDEC
mECs (Fig. 5f and Supplementary Fig. 6a). A synergistic effect
was observed on pretreatment with both GDC-0941 and VX680,
further implying a dual function of PTEN in this process.
Next, we complemented PTEN-depleted ECs with either WT
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(PTENWT), phosphatase-inactive (C124S; PTENC124S; refs 32,33)
or nuclear-excluded (K13,289E; PTENK13,289E) PTEN (ref. 22).
Expression of PTENWT, PTENC124S and PTENK13,289E abrogated
the increase in EC proliferation (Fig. 5g and Supplementary
Fig. 6c) of PTEN null ECs, albeit most prominently seen with
PTENWT. All together, these data indicate that phosphatase-
dependent and -independent activities of PTEN are important to
regulate EC proliferation.
Next, we tested the differential contribution of each of these
functions in vivo, by ﬁrst analysing the retinas of PTENiDEC/iDEC
on inhibition of class I PI3K activity with GDC-0941. The
hyperplasia induced by PTEN loss was rescued by inhibiting
PtdIns(3,4,5)P3 production (Fig. 6a–d and Supplementary
Fig. 7a), indicating, as expected, an important role of PTEN
lipid phosphatase activity in vascular growth. Next, we assessed
the contribution of phosphatase-independent activity of PTEN to
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sprouting angiogenesis by inhibiting Aurora kinase. Strikingly,
the phenotype of PTENiDEC/iDEC was abrogated by Aurora kinase
inhibition (Fig. 6e–h), which is consistent with the contribution
of the phosphatase-independent activity of PTEN to sprouting
angiogenesis in vivo. This was further corroborated by genetic
conditional and inducible deletion of Fzr1 in ECs. Complete
depletion of Fzr1/Cdh1 protein was achieved 48 h post incubation
with 4-OHT (Supplementary Fig. 7b,c). Therefore, pups were
treated with 4-OHT at P5 and P6, followed by analysis of the
retinal vasculature at P7. The retinas of Fzr1iDEC/iDEC showed
increased vascular density and reduced length of sprouts
(Fig. 6i–n) comparable to PTENiDEC/iDEC. All together, these
data suggest that, in ECs, there is a dual contribution of PTEN,
counterbalancing the PI3K signalling pathway through its lipid
phosphatase activity and facilitating the APC/C-Fzr1/Cdh1
complex activity, which has been reported to be independent of
its catalytic function22.
Discussion
Here we report that PTEN in ECs is required in a cell-
autonomous and dose-dependent manner for the control of
vascular density and vessel growth, but is dispensable for the
regulation of the sprouting activity of tip cells. We show that
endothelial PTEN restricts vascular growth by limiting stalk cell
proliferation during sprouting angiogenesis. An important
conclusion from this study is that PTEN is not required in all
ECs to regulate proliferation in vivo, as shown in cultured ECs
(our data and ref. 19). Instead, our results indicate that the
consequence of PTEN loss or overexpression in vivo is restricted
speciﬁcally to the zone of the vasculature that is highly
Notch-dependent.
Constitutive targeting of PTEN in ECs leads to embryonic
lethality due to aberrant angiogenesis19. Although these studies
have established that PTEN regulates EC proliferation, the
analysis of vasculature in Tie2Cre-PTENﬂox/ﬂox embryos did
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not allow unravelling precisely how PTEN regulates sprouting
angiogenesis. Furthermore, Hamada et al. were unclear of
whether the aberrant vasculature, which results on PTEN loss,
was a consequence of aberrant PTEN signalling in ECs or simply
a consequence of an altered pro-angiogenic cytokine proﬁle19.
Similarly, zebraﬁsh studies have shown that loss of PTEN leads to
increased VEGF levels and in turn vessel hyperplasia, highlighting
indeed that PTEN also regulates angiogenesis in a paracrine
manner20. Another difference between Hamada et al. and our
study is that constitutive loss of PTEN in ECs also results in
altered mural cell coverage, while induced loss of postnatal
endothelial PTEN does not. These discrepancies suggest that
PTEN may differently regulate angiogenesis in different
vascular beds.
Activation of Notch leads to cell cycle arrest8–11,34. In this
study, we identify PTEN as a critical mediator of Notch
antiproliferative response in stalk cells. If PTEN is not
expressed in ECs, stalk cells become insensitive to the
antiproliferative signals of Notch and exhibit unrestricted
expansion, hence perturbing sprout length and pattern and
eventually resulting in profound hyperplasia. Interestingly, our
results also reveal that stalk cells located further away from the
a
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front are insensitive to changes in PTEN expression. Given that
these stalk cells at the subfront area are highly proliferative, our
data support the existence of two biological states for stalk cells.
A ﬁrst state in which stalk cells must remain arrested to ensure
the correct patterning of the sprout, and a second state in which
cells enter the cell cycle to expand the plexus. These two states are
likely the consequence of dynamic changes in Notch signalling,
with high Notch activity in early nonproliferative stalk cells and
low Notch activity in the late proliferative stalk cells. Our data
predict a rise and fall in PTEN levels that will accompany
the early quiescent and late proliferative phases, respectively.
This is supported by the observation that, in WT cultured ECs,
higher PTEN levels are seen 8 h post stimulation with Dll4
compared with 24 h post stimulation. Furthermore, co-staining of
PTEN and 5-ethynyl-20-deoxyuridine (Edu) in the growing
vasculature showed that Edu-negative cells express higher levels
of PTEN than Edu-positive cells, supporting the notion that
PTEN protein levels rise to guarantee cell cycle arrest. Whether
high PTEN cells correspond to high Notch signalling still needs to
be determined. Moya et al. speculated that early and late stalk cell
behaviours might be orchestrated by oscillation in Notch activity.
The authors proposed that Id proteins, members of HLH
proteins, govern these two states by releasing the negative
autoregulatory loop of Hes1 (ref. 35). While our results are
consistent with the idea of two states, they identify PTEN
as the key mediator of early stalk cell function in response
to Notch.
Why and how Notch exerts a unique negative regulation in the
endothelium while driving proliferation in virtually every other
cell type and in cancer has been a mystery5,36. Our data show that
PTEN negatively regulates cell cycle progression in ECs through
conserved pathways. Critically, what our results illustrate is a
novel interaction between Notch and PTEN in ECs. We ﬁnd that
Notch stimulates PTEN transcription in the endothelium,
an effect that is required for Notch-mediated cell cycle
arrest. Interestingly, in cell types where Notch stimulates cell
cycle progression, PTEN is transcriptionally repressed by
Notch/Hes36–38. The PTEN gene locus contains both Rbpj- and
Hes-binding sites, suggesting that binding to one or another is
what determines the ﬁnal biological output.
In line with the observation that PTEN restricts stalk cell
proliferation, endothelial gain and loss of PTEN proliferation
phenotypes are reminiscent of gain and loss of Notch function in
stalk cells9–11. However, in response to Notch signalling PTEN
appears to only regulate EC proliferation while it is not required
for tip and stalk speciﬁcation. This is shown by the observation
that Notch mutants not only show aberrant proliferation
phenotypes in the nascent plexus but also sprouting defects9,11,
while PTEN mutants only show vascular density defects. In the
same line, increased levels of PTEN protect angiogenic ECs
treated with DAPT from uncontrolled proliferation but fail to
prevent excessive tip cell numbers. Conversely, a recent study has
shown that inhibitors of the VEGFR3 kinase activity rescue the
hypersprouting phenotype of Notch loss-of-function mutants,
without reducing EC proliferation39. Taken together, these data
suggest that Notch regulates tip cell numbers and stalk cell
proliferation independently through VEGFR3 and PTEN
pathways, respectively.
The predominant activity of PTEN is the dephosphorylation
of PtdIns(3,4,5)P3 and thus the counteraction of class I
PI3K-mediated functions13,15. However, PTEN also exhibits
PtdIns(3,4,5)P3-independent functions, including protein
phosphatase14 and non-catalytic activities13,15. In this context,
PTEN can be found in the nucleus where it regulates DNA
stability and cell cycle progression22,40. Several reports have
highlighted the relevance of nuclear PTEN in disease22,41–43. To
date, the physiological relevance of nuclear PTEN in vivo remains
elusive. Our results reveal that both lipid phosphatase-dependent
and non-catalytic activities of PTEN regulate stalk cell
proliferation during sprouting angiogenesis. Inhibition of class I
PI3K activity with GDC-0941 or Aurora kinase with VX680
signiﬁcantly abrogates the phenotype observed on PTEN loss.
However, the observation that pretreatment with either GDC-
0941 or VX680 is not able to completely rescue the hyperplasia
phenotype of PTENiDEC/iDEC retinas and cultured ECs indicates
that both types of activities of PTEN are required to drive the
PTEN response in angiogenesis. Furthermore, genetic deletion of
Fzr1 in ECs recapitulates the phenotype observed on endothelial
loss of PTEN, reinforcing the relevance of nuclear PTEN
facilitating the APC/C-Fzr1/Cdh1 function. Taken together, our
study provides in vivo evidence that nuclear PTEN is not only
involved in disease such as cancer or cerebral ischaemia22,41–43
but is also critical to regulate a fundamental physiological process
such as angiogenesis.
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We and others have previously shown that inhibition of class I
PI3K isoform in vivo does not lead to blockade of EC
proliferation29,44–46. Although contradictory, these observations
may reﬂect that PTEN principally regulates EC proliferation
independently of its lipid phosphatase activity22. In line with this,
our data also reveal that the regulation of APC/C-Fzr1/Cdh1 by
PTEN seems to play a major role in response to Notch signalling
in angiogenesis. This is shown by the altered APC/C-Fzr1/Cdh1
target expression under conditions of PTEN loss and Notch
activation. This observation, together with the fact that Notch
stimulation in ECs results in phosphorylation of Akt47,48, suggest
that Notch stimulates PTEN nuclear translocation. These ﬁndings
would be in agreement with the notion that higher nuclear PTEN
levels are found during G0–G1 phase than during the S
phase23,24. Further experiments are needed to elucidate how
PTEN accumulates in the nucleus on Notch activation.
The unique direction of the coupling of Notch and PTEN in
the endothelium (Fig. 7), and the highly selective effects on the
active vascular front raise the prospect that targeting this
interaction and stimulation of PTEN signalling may be used
therapeutically to render EC quiescence in aberrant tumour
angiogenesis and in turn promote a normalization effect.
Clinically, our results imply that stimulating both arms of PTEN
function in ECs could render a more quiescence phenotype of
highly proliferative tumour ECs2,49. However, inhibition of PI3K
in the tumour stroma not only results in reduced EC proliferation
but also in reduced vascular function47. It is thus tempting to
speculate that promoting nuclear PTEN may offer more
selectivity towards a tight control of EC proliferation.
Methods
Reagents. Sources and catalogue numbers of antibodies were as follows: Cell
Signaling Technology: PTEN (#9559), pS473-Akt (#4060) and pSer240/244-S6
(#2215); BD Pharmingen: p27 (#610242), cyclin-D1 (#556470), BrdU (#347580)
and Aurora A Kinase (#610939); NeoMarkers: Ki67 (#RM-9106-S); Abcam: NICD
(#ab27526), desmin (ab15200) and PTEN (ab32199); Santa Cruz Biotechnology:
VE-cadherin (sc-6458), Geminin (#sc-13015), cyclin-A (#sc-53230), Hes1
(#sc-25392) and Erg (sc-353); Millipore: Plk1 (#06-813) and Fzr1/Cdh1 (#CC43);
Sigma-Aldrich: b-actin (A5441) and a-tubulin (T6074). Isolectin GS-IB4 and
secondary antibodies conjugated to Alexa 488, Alexa 568 and Alexa 633, and
Click-iT EdU Alexa 488 and 647 Imaging Kit were from Molecular Probes. Human
(#1506-D4) and mouse Dll4 (#1389-D4) were from R&D Systems. The GDC-0941
compound was from Chem Express Haoyuan (China). The VX680 (MK-0457)
compound was from Selleckchem (USA). All chemicals, unless otherwise stated,
were from Sigma-Aldrich.
Inducible genetic protocols and pharmacological inhibition in mice. Mice were
kept in individually ventilated cages and cared for according to the guidelines
and legislation of the UK Home Ofﬁce and Catalan Departament d’ Agricultura,
Ramaderia i Pesca, with procedures accepted by the Ethics Committees of
CRUK-London Research Institute and IDIBELL-CEEA.
To delete PTEN in postnatal vessels, we crossed the PTENﬂox mice50 into the
transgenic mice expressing the tamoxifen-inducible recombinase CreERT2 under
the control of the endothelial Pdgfb promoter26. To generate PdgfbiCreERT2;
PTENﬂox/ﬂox and PTENﬂox/ﬂox littermates, PdgfbiCreERT2; PTENﬂox/ﬂox were
interbred with PTENﬂox/ﬂox. Cre activity and gene deletion were induced by
intraperitoneal injection of 25 mg 4-OHT (Sigma, H7904 10mgml 1) in all pups
of the litter at P1 and P2, and retinas were collected at different time points (P5, P7
and P10). Class I PI3K signalling or Aurora kinase was inhibited in half of the pups
by subcutaneous injection at 18:00 pm of P6 and 10:00 am of P7 with 37.5 mg g 1
GDC-0941 (ref. 31) or with 50 mg g 1 VX680, respectively, dissolved in
dimethylsulphoxide (DMSO). Retinas were harvested at 18:00 pm of P7.
Control mice were injected with DMSO only.
PTENTG (ref. 28) was maintained in C57/BL6 background and were fed with a
19% protein-extruded rodent diet (Harlan, 2019) in a 1:1 proportion with normal
diet. Notch signalling was inhibited in half of the pups by subcutaneous injection at
P5 and P6, with 100mg kg 1 DAPT (Calbiochem, #565770) and retinas being
harvested at P7.
PdgfbiCreERT2; Fzr1ﬂox/ﬂox were interbred with Fzr1ﬂox/ﬂox (ref. 51) to generate
PdgfbiCreERT2; Fzr1ﬂox/ﬂox and Fzr1ﬂox/ﬂox littermates. Pups were injected with
25mg 4-OHT (10mgml 1) at P5 and P6 and dissected at P7.
For combined endothelial-cell-speciﬁc loss-of-function of PTEN and Jag1, we
crossed PTENﬂox/ﬂox (ref. 50) with Jagged1ﬂox/ﬂox (ref. 52) and PdgfbiCreERT2
(ref. 26). To generate PdgfbiCreERT2; PTENﬂox/ﬂox; Jag1ﬂox/ﬂox (PTENiDEC/iDEC;
Jag1iDEC/iDEC), PdgfbiCreERT2; PTENﬂox/ﬂox (PTENiDEC/iDEC) and PdgfbiCreERT2;
Jag1ﬂox/ﬂox (Jag1iDEC/iDEC) littermates, two different types of breeding were set up;
PdgfbiCreERT2; PTENﬂox/ﬂox; Jag1ﬂox/ﬂox were interbred with PTENﬂox/ﬂox;
Jag1ﬂox/WT or with PTENﬂox/WT; Jag1ﬂox/ﬂox. Cre activity and gene deletion were
induced by intraperitoneal injection of 25 mg 4-OHT (10mgml 1) in all pups of
the litter, at P1 and P3 and retinas were collected at P7. To assess proliferating ECs,
the pups were injected intraperitoneally with 60 ml of Edu (0.5mg 1ml 1) 2 h
before being killed. Edu was dissolved in a 1:1 ratio DMSO:PBS.
Immunoﬂuorescence. Eyes were ﬁxed in 4% paraformaldehye (PFA) for 2 h at
4 C. For PTEN staining, mice were exsanguinated by transcardiac perfusion of
PBS, followed by perfusion with 4% PFA before dissecting and continuing ﬁxing
the retinas with methanol at  20 C. Samples were rehydrated for 30min at room
temperature (RT). After washing twice in PBS, retinas were permeabilized in PBS
containing 1% bovine serum albumin (BSA) and 0.3% Triton X-100 overnight
(ON) at 4 C, followed by incubation with primary antibodies (PTEN (Abcam;
1:75), pSer240/244-S6 (1:100), Erg (1:200), desmin (1:200), Hes1 (1:50) and Ki67
(1:50) in permeabilization buffer ON at 4 C. The following day, the eyes were
washed three times with PBS containing 0.1% Tween (PBT), one time in Pblec
buffer (1% Triton X-100, 1mM CaCl2, 1mM MgCl2 and 1mM MnCl2 in PBS,
pH 6.8) for 30min and then incubated for 2 h at RT or ON at 4 C in Pblec buffer
containing Alexa-conjugated secondary antibodies (1:200) and IB4 (1:300), washed
three times further with PBT and ﬂat-mounted on microscope glass slides with
Mowiol. For ﬁxed confocal laser scanning microscopy, we use a Leica SP5. Images
were analysed with Image J Software and Adobe Photoshop CS5.
Embryoid bodies. ES cells were cultured and EBs were generated, as previously
described27. Brieﬂy, ES cells were regularly cultured on a layer of irradiated
DR4 mouse embryonic ﬁbroblast in DMEM glutamax (Life Technologies,
#61965-026) in the presence of 20% fetal bovine serum, HEPES (30mM), sodium
pyruvate (1.5mM), monothioglycerol (1.5%) and leukaemia inhibitory factor
(Chemicon#ESG1107, 123 units ml 1). For vascular sprouting assays, cells were
cultured for two passages without feeders, depleted of leukaemia inhibitory factor
and left in suspension as hanging drops. Four days after, the formed EBs were
transferred to a polymerized collagen I gel with the addition of 60 ngml 1 VEGF
(Peprotech). The medium was changed on day 6 and every day thereafter. Overall,
70,000 WT ES cells and 10,000 PTEN / ES cells were plated to generate EB.
PTEN / ES cells were provided in ref. 53.
Isolation and stimulation of mECs. Mouse lungs were digested with Dispase
(Life Technologies, #17105-041; 4 unitsml 1) for 1 h at 37 C, followed by positive
selection with antimouse vascular endothelial-cadherin (Pharmingen, #555289)
antibody coated with magnetic beads (Dynal Biotech, #110-35). Cells were
seeded on a 12-well plate, and were coated with gelatin (0.5%) in DMEM/F12
supplemented with 20% fetal calf serum and EC growth factor (PromoCell,
#C30140). After the ﬁrst passage, the cells were re-puriﬁed with vascular
endothelial-cadherin antibody-coated magnetic beads. Cells were cultured until
passage 6. To induce gene deletion, 4-OHT (5 mM) or vehicle (ethanol) was added
to the cultured medium at P4 for 96 h and the medium was replaced every other
day. For Dll4 stimulation, mouse Dll4 (500 mgml 1) was immobilized by coating
culture dishes for 1 h at RT, followed by seeding mECs for 6, 8 or 24 h. Mouse and
human Dll4 were used accordingly.
In vitro measurement of mEC cell proliferation. Overall, 104 mECs were plated
in a 24-well plate for 48 h; 2 h before the termination of the experiment, BrdU
(10 mM) was added to the medium. For Ki67 staining, cells were plated for 24 h in
Dll4-coated dishes. Cells were ﬁxed in 4% PFA for 10min at RT, permeabilized for
10min with TBS-T (25mM Tris HCl pH 7.4, 150mM NaCl, 0.5% Triton X-100),
blocked with TBS-T containing 2% BSA and incubated with primary antibodies
BrdU (1:100) or Ki67 (1:50) at 4 C ON. The following day, cells were washed three
times with TBS-T and incubated with Alexa-conjugated secondary antibodies for
2 h at RT. DAPI was added in the ﬁnal wash. Specimens were mounted in Mowiol.
Cells were visualized in a Nikon-80I microscope. For pharmacological inhibition of
class I PI3K and Aurora kinase, GDC-0941 (1 mM) and VX680 (0.5 mM) were
added, respectively, on plating.
Plasmids and transfections. pRK5-Myc-PTEN, C124S pEGFP-PTEN-wt and
pEGFP-PTEN-K13,289E expressing human WT, lipid phosphatase-inactive and
nuclear-excluded PTEN mutants, respectively, were provided in ref. 22. All three
PTEN mutants were subcloned with an N-terminal yellow ﬂuorescent protein
into a modiﬁed lentiviral vector TRIPZ. Lentiviral particles were prepared by
transfecting HEK293FT cells with the TRIPZ vector of interest and the packaging
vectors psPAX, VSV-G and pTAT. Viral particles in the supernatant were
concentrated with Lenti-X-concentrator (Clontech). mECs of P2 or P3 from
PdgfbiCreERT2; PTENﬂox/ﬂox were infected with lentivirus expressing WT PTEN,
PTEN (C124S) or PTEN (K13,289E) in the presence of viralplus transduction
enhancer (Applied Biological Material #G698). For infection, mECs were plated at
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a density of 4 104 per well of 12-well plate and infected with virus from 293FT
cells 48 h after transfection. After 48 h post infection, mECs were re-plated and
treated with 4-OHT (5 mM) to induce gene deletion for 72 h. Next, 104 mECs were
plated in 24-well plate for 48 h in the presence of doxycycline (4 mM); 2 h before the
termination of the experiment, BrdU (10 mM) was added to the medium. Cells were
then ﬁxed in 4% PFA for 10min at RT, permeabilized for 10min with TBS-T
(25mM Tris HCl pH 7.4, 150mM NaCl, 0.5% Triton X-100), blocked with TBS-T
containing 2% BSA and incubated with primary antibodies BrdU (1:100) at 4 C
ON. The following day, cells were washed three times with TBS-T and incubated
with Alexa-conjugated secondary antibodies for 2 h at RT. DAPI was added in the
ﬁnal wash. Specimens were mounted in Mowiol. Cells were visualized in a Nikon-
80I microscope.
MTS viability assay. mECs were cultured in 96-well plate (2,000 cells per 100 ml
culture medium per well) in the presence of the test compounds (GDC-0941 (1 mM)
and VX680 (0.5 mM)) or the respective controls for 48 h, followed by MTS assay
(Promega, #G5421).
Protein extraction and immunoblotting. mECs, human umbilical vascular ECs
(HUVECs (Lonza #CC-2519)) and lungs were lysed in 50mM Tris HCl pH 7.4,
5mM EDTA, 150mM NaCl, 50mM NaF and 1% Triton X-100 supplemented with
2mgml 1 aprotinin, 1mM pepstatin, 1 ngml 1 leupeptin, 1mM phenylmethy-
sulfonylﬂuoride and 1mM sodium orthovanadate, followed by clearance of lysates
using microcentrifugation. Supernatants were resolved on a 10% SDS–PAGE gel,
transferred on nitrocellulose membranes and probed with the indicated antibodies.
Detection was performed by enhanced chemiluminescence. Uncropped immuno-
blots and larger blot areas are presented in Supplementary Fig. 8.
qPCR analysis. qPCR was performed using the following proprietary TaqMan
Gene Expression assay FAM/TAMRA primers (Applied Biosystems): Dll4
(Mm00446968_m1), Hes1 (Mm01342805_m1), Hey1 (Mm00468865_m), Nrarp
(Mm00482529_m1), Ephb4 (Mm00438750_m1), Efnb2 (Mm01215897_m1),
Nr2f2 (Mm00772789_m1) and Hprt (Mm00446968_m1). The levels of PTEN
mRNA were measured using SYBR Green I Master (Roche, #04.887.352.001) in the
LightCycler480 system. Primers used are as follow: forward (50-GTTTACCGGCA
GCATCAAAT-30) and reverse (50-CCCCCACTTTAGTGCAC-30).
Luciferase assays. Reporter assays in HUVECs were performed with the Dual
Luciferase Assay System (Promega, #E1910) and a LUMAT LB 9507 luminometer
(BERTHOLD Technologies). HUVECs were grown to 60–70% conﬂuence in
endothelial basal medium (EGM; Lonza #CC-3124) and co-transfected (Trans Pass
V Reagents (New England Biolabs, # M2558S)) with V5-NICD (ref. 54),
PTEN-luciferase reporter (pGL3 PTEN HindIII-NotI) construct37 and the
constitutive Renilla luciferase reporter pGL4.74hRluc/TK (Promega). Twenty-four
hours after, HUVECs were lysed and reporter assays performed according to the
manufacturers’ protocol. To induce Notch activity with Dll4, transfected HUVECs
were re-plated on Dll4-coated dishes 6 h after plasmid infection. Luciferase activity
was measured after an additional 24 h. To inhibit Notch signalling, cells were
pretreated for at least 1 h before stimulating with Dll4 with 0.08 mM DBZ
((S,S)-2-[2-(3,5-Diﬂuorophenly)acetylamino]-N-(5-methyl-6-oxo-6,7-dihydro-
5H-dibenzo[b,d]azepin-7-yl)propionamide).
ChiP assay. To analyse the binding sites for RBPJ located in the PTEN proximal
promoter, we used the Genomatix software. For analysis, the gene bank sequence
used was NG_007466.2, which contains the promoter sequence AF406618.1. Three
putative RBPJ-binding sites located at  1,914,  1,492 and  1,132 positions
relative to transcription initiation site37 were identiﬁed. ChiP assay was performed
as previously described55. Brieﬂy, chromatin was isolated from HUVECs
stimulated for 2 h with vehicle or Dll4 (500 ngml 1). Crosslinked chromatin was
sonicated for 10min, to medium-sized powder particles, at 0.5-min intervals, with
a Bioruptor (Diagenode) and precipitated with anti-NCID or control IgG. After
crosslinkage reversal, DNA was used as a template for PCR. qPCR was performed
with SYBR Green I Master (Roche, #04.887.352.001) in the LIghtCycler480 system.
Primers used are described in Supplementary Table 1.
References
1. Adams, R. H. & Alitalo, K. Molecular regulation of angiogenesis and
lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8, 464–478 (2007).
2. Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of
angiogenesis. Cell 146, 873–887 (2011).
3. Ruhrberg, C. et al. Spatially restricted patterning cues provided by heparin-
binding VEGF-A control blood vessel branching morphogenesis. Genes Dev.
16, 2684–2698 (2002).
4. Gerhardt, H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip
cell ﬁlopodia. J. Cell Biol. 161, 1163–1177 (2003).
5. Blanco, R. & Gerhardt, H. VEGF and Notch in tip and stalk cell selection. Cold
Spring Harb. Perspect. Med. 3, a006569 (2012).
6. Roca, C. & Adams, R. H. Regulation of vascular morphogenesis by Notch
signaling. Genes Dev. 21, 2511–2524 (2007).
7. Phng, L. K. & Gerhardt, H. Angiogenesis: a team effort coordinated by notch.
Dev. Cell 16, 196–208 (2009).
8. Noseda, M. et al. Notch activation induces endothelial cell cycle arrest and
participates in contact inhibition: role of p21Cip1 repression. Mol. Cell Biol. 24,
8813–8822 (2004).
9. Hellstrom, M. et al. Dll4 signalling through Notch1 regulates formation of tip
cells during angiogenesis. Nature 445, 776–780 (2007).
10. Phng, L. K. et al. Nrarp coordinates endothelial Notch and Wnt signaling to
control vessel density in angiogenesis. Dev. Cell 16, 70–82 (2009).
11. Benedito, R. et al. The notch ligands Dll4 and Jagged1 have opposing effects on
angiogenesis. Cell 137, 1124–1135 (2009).
12. Benedito, R. & Hellstrom, M. Notch as a hub for signaling in angiogenesis. Exp.
Cell Res. 319, 1281–1288 (2013).
13. Song, M. S., Salmena, L. & Pandolﬁ, P. P. The functions and regulation of the
PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283–296 (2013).
14. Leslie, N. R., Maccario, H., Spinelli, L. & Davidson, L. The signiﬁcance of
PTEN’s protein phosphatase activity. Adv. Enzyme Regul. 49, 190–196 (2009).
15. Hopkins, B. D., Hodakoski, C., Barrows, D., Mense, S. M. & Parsons, R. E. PTEN
function: the long and the short of it. Trends Biochem. Sci. 39, 183–190 (2014).
16. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655–1657
(2002).
17. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. & Bilanges, B. The
emerging mechanisms of isoform-speciﬁc PI3K signalling. Nat. Rev. Mol. Cell
Biol. 11, 329–341 (2010).
18. Hawkins, P. T., Anderson, K. E., Davidson, K. & Stephens, L. R. Signalling through
Class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34, 647–662 (2006).
19. Hamada, K. et al. The PTEN/PI3K pathway governs normal vascular
development and tumor angiogenesis. Genes Dev. 19, 2054–2065 (2005).
20. Choorapoikayil, S., Weijts, B., Kers, R., de Bruin, A. & den Hertog, J. Loss of
Pten promotes angiogenesis and enhanced vegfaa expression in zebraﬁsh. Dis.
Model Mech. 6, 1159–1166 (2013).
21. Lindsay, Y. et al. Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a
nuclear pool that is insensitive to PTEN expression. J. Cell Sci. 119, 5160–5168
(2006).
22. Song, M. S. et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive
complex in a phosphatase-independent manner. Cell 144, 187–199 (2011).
23. Whiteman, D. C. et al. Nuclear PTEN expression and clinicopathologic features
in a population-based series of primary cutaneous melanoma. Int. J. Cancer 99,
63–67 (2002).
24. Ginn-Pease, M. E. & Eng, C. Increased nuclear phosphatase and tensin
homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7
cells. Cancer Res. 63, 282–286 (2003).
25. Manchado, E., Eguren, M. & Malumbres, M. The anaphase-promoting
complex/cyclosome (APC/C): cell-cycle-dependent and -independent
functions. Biochem. Soc. Trans. 38, 65–71 (2010).
26. Claxton, S. et al. Efﬁcient, inducible Cre-recombinase activation in vascular
endothelium. Genesis 46, 74–80 (2008).
27. Jakobsson, L. et al. Heparan sulfate in trans potentiates VEGFR-mediated
angiogenesis. Dev. Cell 10, 625–634 (2006).
28. Ortega-Molina, A. et al. Pten positively regulates brown adipose function,
energy expenditure, and longevity. Cell Metab. 15, 382–394 (2012).
29. Graupera, M. et al. Angiogenesis selectively requires the p110alpha isoform of
PI3K to control endothelial cell migration. Nature 453, 662–666 (2008).
30. Armulik, A., Genove, G. & Betsholtz, C. Pericytes: developmental,
physiological, and pathological perspectives, problems, and promises. Dev. Cell
21, 193–215 (2010).
31. Edgar, K. A. et al. Isoform-speciﬁc phosphoinositide 3-kinase inhibitors exert
distinct effects in solid tumors. Cancer Res. 70, 1164–1172 (2010).
32. Nelen, M. R. et al. Germline mutations in the PTEN/MMAC1 gene in patients
with Cowden disease. Hum. Mol. Genet. 6, 1383–1387 (1997).
33. Wang, H. et al. Allele-speciﬁc tumor spectrum in pten knockin mice. Proc. Natl
Acad. Sci. USA 107, 5142–5147 (2010).
34. Siekmann, A. F. & Lawson, N. D. Notch signalling limits angiogenic cell
behaviour in developing zebraﬁsh arteries. Nature 445, 781–784 (2007).
35. Moya, I. M. et al. Stalk cell phenotype depends on integration of Notch and
Smad1/5 signaling cascades. Dev. Cell 22, 501–514 (2012).
36. Bertrand, F. E., McCubrey, J. A., Angus, C. W., Nutter, J. M. & Sigounas, G.
NOTCH and PTEN in prostate cancer. Adv. Biol. Regul. 56, 51–65 (2014).
37. Palomero, T. et al. Mutational loss of PTEN induces resistance to NOTCH1
inhibition in T-cell leukemia. Nat. Med. 13, 1203–1210 (2007).
38. Wong, G. W., Knowles, G. C., Mak, T. W., Ferrando, A. A. &
Zuniga-Pﬂucker, J. C. HES1 opposes a PTEN-dependent check on survival,
differentiation, and proliferation of TCRbeta-selected mouse thymocytes. Blood
120, 1439–1448 (2012).
39. Benedito, R. et al. Notch-dependent VEGFR3 upregulation allows angiogenesis
without VEGF-VEGFR2 signalling. Nature 484, 110–114 (2012).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8935
12 NATURE COMMUNICATIONS | 6:7935 |DOI: 10.1038/ncomms8935 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
40. Shen, W. H. et al. Essential role for nuclear PTEN in maintaining chromosomal
integrity. Cell 128, 157–170 (2007).
41. Trotman, L. C. et al. Ubiquitination regulates PTEN nuclear import and tumor
suppression. Cell 128, 141–156 (2007).
42. Howitt, J. et al. Ndﬁp1 regulates nuclear Pten import in vivo to promote
neuronal survival following cerebral ischemia. J. Cell Biol. 196, 29–36 (2012).
43. Freeman, D. J. et al. PTEN tumor suppressor regulates p53 protein levels and
activity through phosphatase-dependent and -independent mechanisms.
Cancer Cell 3, 117–130 (2003).
44. Herbert, S. P. et al. Arterial-venous segregation by selective cell sprouting: an
alternative mode of blood vessel formation. Science 326, 294–298 (2009).
45. Nicoli, S., Knyphausen, C. P., Zhu, L. J., Lakshmanan, A. & Lawson, N. D.
wmiR-221 is required for endothelial tip cell behaviors during vascular
development. Dev. Cell 22, 418–429 (2012).
46. Graupera, M. & Potente, M. Regulation of angiogenesis by PI3K signaling
networks. Exp. Cell Res. 319, 1348–1355 (2013).
47. Soler, A. et al. Inhibition of the p110alpha isoform of PI 3-kinase stimulates
nonfunctional tumor angiogenesis. J. Exp. Med. 210, 1937–1945 (2013).
48. Wustehube, J. et al. Cerebral cavernous malformation protein CCM1 inhibits
sprouting angiogenesis by activating DELTA-NOTCH signaling. Proc. Natl
Acad. Sci. USA 107, 12640–12645 (2010).
49. Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization
for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417–427
(2011).
50. Suzuki, A. et al. T cell-speciﬁc loss of Pten leads to defects in central and
peripheral tolerance. Immunity 14, 523–534 (2001).
51. Garcia-Higuera, I. et al. Genomic stability and tumour suppression by the
APC/C cofactor Cdh1. Nat. Cell Biol. 10, 802–811 (2008).
52. Brooker, R., Hozumi, K. & Lewis, J. Notch ligands with contrasting functions:
Jagged1 and Delta1 in the mouse inner ear. Development 133, 1277–1286 (2006).
53. Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolﬁ, P. P. Pten is essential
for embryonic development and tumour suppression. Nat. Genet. 19, 348–355
(1998).
54. Guarani, V. et al. Acetylation-dependent regulation of endothelial Notch
signalling by the SIRT1 deacetylase. Nature 473, 234–238 (2011).
55. Guiu, J. et al. Hes repressors are essential regulators of hematopoietic stem cell
development downstream of Notch signaling. J. Exp. Med. 210, 71–84 (2013).
Acknowledgements
We thank Ramon Parsons (The Mount Sinai Hospital, NY, US) for pGL3 PTEN
HindIII-NotI construct and Lluis Espinosa (IMIM, Barcelona), Alba Martinez (Research
Laboratory, Catalan Institute of Oncology, IDIBELL, Barcelona) and Magali Castells
(Vascular Signalling laboratory, IDIBELL) for support with experiments. This work was
supported by research grants SAF2010-15661 and SAF2013-46542-P from MICINN
(Spain), 2014-SGR-725 from the Catalan Government, from the People Programme
(Marie Curie Actions) of the European Union’s Seventh Framework Programme
FP7/2007-2013/ (REA grant agreement 317250) and Ajuts Joves Investigadors from
IDIBELL to M.G., and SAF2013-40922 and RD12/0036/0054 to A.B. Personal support
was from FPI of the Spanish Ministry of Education (A.S.), IDIBELL (H.S.) and Ramon y
Cajal fellow of the Spanish Ministry of Education (M.G. and O.C.). The work of A.C. is
supported by the Ramo´n y Cajal award, the Basque Department of Industry, Tourism
and Trade (Etortek), health (2012111086) and education (PI2012-03), Marie Curie
(277043), Movember, ISCIII (PI10/01484, PI13/00031) and ERC (336343). The work of
M.P. is supported by the Max Planck Society, the Deutsche Forschungsgemeinschaft
(SFB 834) and an ERC Starting Grant (ANGIOMET). H.G. is supported by Cancer
Research UK, the Lister Institute of Preventive Medicine, the Leducq Network Grant
ARTEMIS, BIRAX and an ERC starting grant Reshape 311719.
Author contributions
H.S., I.C., A.A.-U., J.D.S., A.S., A.A.-A., A.R., R.L. and A.F. performed experiments,
H.S., I.C., A.C., M.G. and H.G. designed research, analysed data and wrote the paper;
R.L., A.F., F.V., M.P., A.B. and O.C. analysed data, M.M., M.F., M.S., P.P.P. and
A.B. provided reagents.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Serra, H. et al. PTEN mediates Notch-dependent stalk cell arrest
in angiogenesis. Nat. Commun. 6:7935 doi: 10.1038/ncomms8935 (2015).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8935 ARTICLE
NATURE COMMUNICATIONS | 6:7935 | DOI: 10.1038/ncomms8935 | www.nature.com/naturecommunications 13
& 2015 Macmillan Publishers Limited. All rights reserved.
Oncotarget6835www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 6
Transcriptomic profiling of urine extracellular vesicles reveals 
alterations of CDH3 in prostate cancer
Felix Royo1,2,*, Patricia Zuñiga-Garcia1,*, Verónica Torrano1,*, Ana Loizaga3,*, 
Pilar Sanchez-Mosquera1, Aitziber Ugalde-Olano4, Esperanza González1, Ana R. 
Cortazar1, Laura Palomo1, Sonia Fernández-Ruiz1, Isabel Lacasa-Viscasillas3, Maria 
Berdasco5, James D. Sutherland1, Rosa Barrio1, Amaia Zabala-Letona1, Natalia 
Martín-Martín1, Amaia Arruabarrena-Aristorena1, Lorea Valcarcel-Jimenez1, 
Alfredo Caro-Maldonado1, Jorge Gonzalez-Tampan3, Guido Cachi-Fuentes3, Manel 
Esteller5, Ana M. Aransay1,2, Miguel Unda3, Juan M. Falcón-Pérez1,2,6,Ω, Arkaitz 
Carracedo1,6,7,Ω
1CIC bioGUNE, Bizkaia Technology Park, Biscay, Spain
2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Spain
3Department of Urology, Basurto University Hospital, Bilbao, Spain
4Department of Pathology, Basurto University Hospital, Bilbao, Spain
5Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
6Ikerbasque, Basque Foundation for Science, Bizkaia, Spain
7Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), Bizkaia, Spain
*These authors contributed equally to this work
ΩThese authors contributed equally to this work
Correspondence to:  Arkaitz Carracedo, e-mail: acarracedo@cicbiogune.es
 Juan M. Falcón-Pérez, e-mail: jfalcon@cicbiogune.es
Keywords: extracellular vesicles, exosomes, prostate cancer, urine biomakers
Received: August 18, 2015 Accepted: November 26, 2015 Published: January 12, 2016
ABSTRACT
Extracellular vesicles (EV) are emerging structures with promising properties for 
intercellular communication. In addition, the characterization of EV in biofluids is an 
attractive source of non-invasive diagnostic, prognostic and predictive biomarkers. 
Here we show that urinary EV (uEV) from prostate cancer (PCa) patients exhibit 
genuine and differential physical and biological properties compared to benign 
prostate hyperplasia (BPH). Importantly, transcriptomics characterization of uEVs led 
us to define the decreased abundance of Cadherin 3, type 1 (CDH3) transcript in uEV 
from PCa patients. Tissue and cell line analysis strongly suggested that the status of 
CDH3 in uEVs is a distal reflection of changes in the expression of this cadherin in the 
prostate tumor. CDH3 was negatively regulated at the genomic, transcriptional, and 
epigenetic level in PCa. Our results reveal that uEVs could represent a non-invasive 
tool to inform about the molecular alterations in PCa.
INTRODUCTION
In the recent years, the search of biomarkers in urine 
has focused on the characterization of urinary extracellular 
vesicles (uEVs), trying to overcome the complexity and 
variation of this biofluid [1, 2]. Under the denomination 
of uEVs, there is a complex mixture of vesicles, including 
exosomes, microvesicles and apoptotic bodies [3, 4]. 
Although there are no clear markers to distinguish them, 
exosomes are defined as small membrane vesicles with a 
diameter of 40–150 nm formed by inward budding of the 
membrane of late endosomes resulting in the formation 
of multivesicular bodies (MVB) fulfilled of intraluminal 
vesicles. Then, some of these (MVB) fuse to the plasma 
membrane releasing in this manner the exosomes to the 
extracellular milleu [5]. Microvesicles or ectosomes refer 
to plasma membrane shedding vesicles of 0.1–1 μm [6]. 
Apoptotic bodies are assumed to be of bigger size [7]. 
uEVs are released by several tissues along the urinary 
tract and their cargo varies depending on their origin [8]. 
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Evidence of the presence of uEVs belonging to prostate 
has been already reported [9, 10] and the cargo includes 
proteins of prostate origin such as prostate-specific 
membrane antigen (PSMA) [11]. Proteomic analysis of 
uEVs in PCa patients has been recently carried out with 
promising results as a source of biomarkers [12] and the 
use of microRNAs as markers for this disease have been 
also extensively reported and reviewed [13]. Most of 
the studies to date focus on the comparative analysis of 
healthy and PCa patients. This raises the question of the 
existence of biomarkers that can discriminate PCa from 
BPH [14], a pathology that has been shown to interfere 
with well established biomarkers such as prostate-specific 
antigen (PSA) [15]. In the present work, we aimed at 
identifying PCa biomarkers within uEVs through the 
analysis of the uEV transcriptome. We selected transcripts 
with a presence-absence pattern in BPH and PCa, and we 
extensively validated the candidate transcript encoded 
by the Cadherin 3, type 1 gene (CDH3). Importantly, 
we corroborated this observation in a miniaturized assay 
that could facilitate the translation of the results into the 
clinic. Finally, the analysis of mRNA in prostate tumor 
tissue from patients revealed alterations in this gene, 
coherent with genomic transcriptional and epigenetic 
changes, all pointing at the inhibition of CDH3 in PCa. 
Overall, our results support that analysis of uEVs could 
represent a non-invasive method to evaluate and monitor 
PCa alterations. 
RESULTS
Characterization of uEVs from BPH and PCa 
patients
As a first approach, we analyzed the physical 
characteristics of uEVs from patients with BPH and PCa by 
comparing more than 23–30 independent preparations from 
each group (Supplementry Table S1). In order to validate 
the ultracentrifugation procedure [16] for isolation of uEVs, 
the presence of double membrane vesicles by cryo-electron 
microscopy (Figure 1A) and EV markers by western blot [28] 
was confirmed (Supplementary Figure S1). We next analyzed 
uEV size and number in urine of BPH and PCa patients. 
Nanoparticle-tracking analysis (NTA) was performed 
in samples before and after urine ultracentrifugation. 
NTA-estimated particle number was comparable before 
(8.9e10 ± 1.47e10 particles/ml in BPH, and 9.3e10 ± 1.29e10 
particles/ml in PCa; mean ± s.e.m.; n = 5; p > 0.05) and was 
reduced in PCa after ultracentrifugation (2.49e8 ± 2.46e7 
particles/ml in BPH, and 1.56e8 ± 1.69e7 particles/ml in PCa; 
mean ± s.e.m.; p = 0.04) (Figure 1B). However, no significant 
changes were observed in particle size before (217 ± 13.2 nm 
in BPH, and 215.8 ± 6.9 nm in PCa; mean ± s.e.m.; n = 5; 
p > 0.05) or after ultracentrifugation (176.6 ± 6.7 nm in BPH, 
and 182.4 ± 6.9 nm in PCa; mean ± s.e.m.; n = 5; p > 0.05) 
(Figure 1C). It is worth noting that NTA analysis in 
samples before ultracentrifugation could detect non-uEV 
particles and contaminants as positive events (and hence 
explain the larger number and average size) while after 
filtration and ultracentrifugation the values obtained are 
more representative of an uEV-enriched preparation. 
Although no statistically significant differences were 
found, NTA analysis revealed a trend to a different 
size distribution of the uEVs, with a lower abundance 
of small vesicles (0–100 nm) and a greater abundance 
of large (150–200 nm) and very large (250–350 nm) 
vesicles in PCa when compared with BPH (Figure 1D). 
Of note, we observed a size discrepancy between TEM 
and NTA analysis of uEVs. Although it warrants further 
investigation, this fact is probably due to two main 
factors: the technology employed by NTA to determine 
particle size and the potential effect of the TEM sample 
preparation protocol on this parameter.
Further to this characterization, we analyzed the 
changes in cargo in BPH and PCa. RNA concentration per 
vesicle was comparable in BPH and PCa uEVs (0.017 ± 
0.006 ng RNA per million uEVs in BPH and 0.0046 ± 
0.0005 ng RNA per million uEVs in PCa; mean ± s.e.m.; 
n = 9–10; Mann Whitney U p = 0.13). Similarly, we did 
not observe significant differences in protein concentration 
(0.041 ± 0.01 µg protein per million uEVs in BPH and 
0.019 ± 0.003 µg protein per million uEVs in PCa; mean ± 
s.e.m.; n = 9–10; Mann Whitney U p = 0.18). 
Transcriptomic analysis of PCa and BPH uEVs
We next aimed at identifying molecular alterations 
in uEV cargo from PCa patients. It has been recently 
reported that these particles present a genuinely differential 
proteome in patients harboring PCa [12]. However, little 
is known about the transcript content of uEVs and the 
potential of these molecules to inform about the biological 
characteristics of PCa, especially when comparing to 
patients with BPH. To address this question, we extracted 
RNA of uEVs from BPH and PCa patient samples. First, 
we observed lack of overt changes in overall RNA size 
distribution (Figure 2A). Next, we labeled and hybridized 
BPH and PCa uEV-derived RNA into whole genome 
Illumina gene expression microarrays. The results showed 
the detection (detection p-value < 0.01) of 1336 unique 
transcripts in the two groups analyzed (presence in 50% 
of the cases in either group was defined as positive, 
Supplementry Table S3), 1010 in BPH and 956 in PCa 
(Figure 2B). Venn analysis revealed an overlap of 47.1% 
from total unique transcripts in BPH and PCa (Figure 2B). 
We performed a further step in candidate transcript 
selection by identifying genes that were selectively 
detected in one of the two biological settings (BPH or 
PCa, in at least 75% of the cases). Illumina platform 
provides information about the probability of a probe to 
present a signal that is different to background noise, for 
which purpose we established a confidence interval of 
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99% (p < 0.01). The list of differentially detected probes is 
shown in Figure 2C. In addition, we took advantage of the 
microarray analysis in order to define housekeeping genes 
that would have similar abundance in uEVs from BPH 
and PCa patients. To this end, starting from normalized 
signal values, we defined genes with no differential 
abundance (p-value > 0.95 and fold change no greater 
than ± 5%; Supplementry Table S4). From this analysis, 
we selected two transcripts, Eukaryotic Elongation Factor 
1A1 (EEF1A1) and Ribosomal Protein L6 (RPL6), that 
we monitored in subsequent studies. In addition, we also 
included Glyceraldehyde Phosphate Dehydrogenase 
(GAPDH) as a housekeeping gene supported by prior 
studies of our group [16].
Validation of uEV biomarkers of PCa
To ascertain the potential of candidate uEV transcripts, 
we performed qRTPCR from an independent set of 
ultracentrifuge-purified uEV retrotranscribed RNA (using an 
average of 1.5e7 uEVs per reaction). Firstly, the abundance 
of housekeeping transcripts (RPL6, EEF1A1, GAPDH) was 
strongly correlated (Supplementry Figure S2A), reinforcing 
the notion of their value as housekeeping transcripts. The 
use of these controls allowed us to identify 4 cases with 
lack of amplification in all three transcripts, which was 
considered an exclusion criterion for the analysis. Secondly, 
the evaluation of 10 transcripts of interest (From Figure 2C) 
revealed that two candidates, Cadherin 3, type 1 (CDH3) 
and CKLF-Like MARVEL Transmembrane Domain 
Figure 1: Physical characterization of uEVs from PCa and BPH samples. (A) Representatives cryo-TEM micrographs of uEVs 
isolated from BPH and PCa urine samples. Bar, 100 nm. n = 3. (B and C) Box-plots showing number (B) or size (C) of particles isolated 
from each group, indicating the mean and s.e.m. (n = 23 fo BPH and 30 for PCa). (D) Size distribution of the particles isolated from each 
preparation (Mean ± s.e.m. is depicted, n = 23 fo BPH and 30 for PCa). Statistic test: Student t test.
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Containing 3 (CMTM3), exhibited the predicted behavior 
in the validation dataset (Figure 2D). These two transcripts 
were predominantly detected in BPH uEVs, whereas the 
detection rate was below 30% in PCa uEVs. Of note, 
we confirmed that these transcripts were contained in 
uEVs, since they exhibited resistance to RNase treatment 
(Supplementary Figure S2B).
Our results demonstrate that we can identify 
transcripts with differential abundance in PCa uEVs, 
employing 50 mL of urine and using an ultracentrifugation-
based method for uEV isolation [16]. However, biomarker 
identification requires miniaturization of the assay with 
the consequent scaling down of the starting material. To 
refine our detection method, we employed a commercial 
exosomal RNA purification procedure (Norgen Biotek) in 
an independent set of samples that allowed us to reduce 
urine volume to 10 mL. We then performed qRTPCR from 
Norgen-purified retrotranscribed RNA. We evaluated the 
expression level of the two best candidates, CMTM3 and 
CDH3. As shown before, the two housekeeping transcripts 
employed (GAPDH and RPL6) exhibited a strong and 
significant correlation (Supplementry Figure S2C). 
Interestingly, this purification method precluded detection 
of CMTM3, while recapitulated the reduction in CDH3 
with higher sensitivity using normalization against RPL6 
(0.69 ± 0.1; mean ± s.e.m.; p = 0.055) and GAPDH (0.65 
± 0.08; mean ± s.e.m.; p = 0.01) (Figure 2E). 
Taken together, our transcriptomic analysis reveals 
that CDH3 abundance is reduced in PCa uEVs and sets the 
basis for PCa biomarker search based on uEV transcript 
analysis. 
uEVs are indicators of PCa alterations
Our results convincingly show that CDH3 
abundance is reduced in uEVs from PCa patients. On the 
basis of these results, we hypothesized that the alteration 
observed in uEVs might be a reflection of transcriptomic 
changes in the prostate tumor.
In order to confirm our hypothesis, we studied the 
expression of CDH3, in a set of BPH and PCa tissue 
specimens. The results of CDH3 expression analysis 
demonstrated that it was significantly decreased in tissue 
from patients with PCa compared to BPH (0.52 ± 0.12; 
mean ± s.e.m.; p = 0.018), in full coherence with our 
observation in uEVs (Figure 3A). Of note, these results 
could lead to the notion that the association between 
transcriptomic tumor cell landscape and exosome RNA 
cargo correlate at high frequency. However, prior studies 
from our lab showed that known cancer genes, such as 
PTEN, do not exhibit a direct correlation between uEVs 
mRNA abundance and PTEN tumor alterations [16], 
suggesting a selective process in cargo loading into uEVs. 
Next, we ascertained the potential extrapolation 
of this observation to other biological contexts, such 
as a panel of benign prostate cells and metastatic 
prostate cancer cell lines and large human PCa datasets. 
Interestingly, the expression of CDH3 in prostate cell lines 
revealed a down-regulation of the transcript in metastatic 
cancer cell lines (black), compared to benign-immortalized 
cells (grey) (0.17 ± 0.07; mean ± s.e.m.) (Figure 3B). 
Importantly, this observation was confirmed in two datasets 
where the expression of PCa specimens was compared to 
biopsies from healthy patients [24, 25] (Figure 3C) and 
was in full agreement with a previous report [29].
We also monitored the expression levels of other 
transcripts identified in uEVs. On the one hand, CMTM3 
expression, which was shown to be down-regulated in the 
ultracentrifugation uEVs (but not detected with Norgen 
extraction method), showed a significant reduction in 
PCa compared with BPH tissues, but this result was 
not reproduced in publicly available PCa datasets 
and exhibited only a modest trend in PCa cell lines 
(Supplementary Figure S3A–S3C). On the other hand, 
our housekeeping genes RPL6 and EEF1A1 showed no 
consistent alterations throughout the same analytical 
layout (Supplementary Figure S3A–S3C). 
We next ask whether the reduction of CDH3 
expression observed in PCa could be extrapolated to other 
urogenital cancers. Data mining analysis was performed 
in bladder and renal cancer datasets (www.oncomine.
org, [30]). Although there was certain consistency in the 
alteration of CDH3 expression within the same tumor type, 
the directionality of the alterations was not preserved among 
the different tumor types (Supplementary Figure S3D). 
In order to address whether gene expression 
alterations in CDH3 could be translated in a decrease in the 
protein expression, we took advantage on publicly available 
initiatives for immunoreactivity analysis. Proteinatlas 
(www.proteinatlas.org, [31–35]) allows the visualization 
of immunohistochemistry (IHC) staining in a wide array 
of tissues. There was data available for CDH3 staining 
with high quality IHC-specific antibodies. Importantly, 
the staining in normal prostate epithelia corroborated the 
staining of basal prostate epithelial cells, in agreement 
with reports in this and other epithelial tissues [29, 36, 37] 
(Figure 3E, middle panel and Supplementary Figure S3F). 
As predicted, CDH3 expression was decreased in PCa 
specimens. This result was particularly evident in tumor 
samples with adjacent non-neoplastic tissue (Figure 3D). 
Interestingly, CDH3 sub-cellular distribution was altered 
in tumor cells, with a predominant loss of membrane 
immunoreactivity (Figure 3D).
We next asked the molecular cues leading to the 
down-regulation of CDH3 in PCa. On the one hand, we 
studied the genomic and epigenetic changes occurring 
in CDH3 locus. The genomic analysis showed frequent 
shallow deletions of CDH3 in four independent PCa 
datasets (Figure 4A, [24, 25, 38, 39]). Moreover, 
epigenetic analysis of CDH3 promoter indicated increased 
methylation in PCa and a correlation between the 
methylation status of the locus and the transcript abundance 
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(Figure 4B, 4C; [38, 39]), in line with a previous report 
[29]). On the other hand, we evaluated the association 
of CDH3 expression with well-known upstream 
regulators. Tp63 is a basal prostate epithelial marker 
which is down-regulated in PCa specimens [40–42], 
and that has been reported to regulate CDH3 expression 
[43]. We found a strong correlation between the mRNA 
expression of Tp63 and CDH3 in prostate specimens, 
which suggests that transcriptional regulation of this 
cadherin downstream p63 is at play in PCa (Figure 4D). 
Altogether, our results indicate that genomic loss, 
transcriptional regulation and promoter methylation 
contribute to the down-regulation of CDH3 in PCa. 
DISCUSSION
Extracellular vesicles including exosomes have 
been detected and characterized in urine [2, 44, 45]. 
These vesicles vary in composition and are associated 
with different diseases [12, 46]. Importantly, recent 
evidence suggests that PCa might exhibit alterations in 
the composition of uEVs [12, 47, 48]. The majority of 
Figure 2: Transcriptomic analysis of uEVs reveals transcripts with differential abundance in BPH and PCa. 
(A) Representative analysis of RNA size distribution obtained from the Bioanalyzer analysis of uEV preparations. n = 4–6. (B) Venn 
diagram depicting the number of unique transcripts identified in each experimental condition (n = 4 for BPH and n = 6 for PCa). 
(C) Transcripts exhibiting a presence-absence pattern in BPH and PCa. The transcripts shown complied with the requirements of being absent 
in one condition and with a minimum presence of 75% of cases in the other. Detection p-value is presented, where a limit was established in 
p < 0.01 in the microarray analysis (significant conditions are highlighted in pink or green in BPH and PCa, respectively). (D) Detection of 
ultracentrifugation-purified candidate uEV transcripts by qRTPCR. Detection was established as consistent amplification in the technical 
settings employed in the assay. n = 7 for BPH and n = 9 for PCa. (E) Transcript abundance of CDH3 relative to GADPH (left) and RPL6 
(right) in Norgen-purified uEVs-associated RNA samples. n = 6–7 for BPH and n = 18 for PCa. FU: fluorescence units. S: seconds. Error 
bar represents s.e.m. a.u. = Arbitrary units. Statistic test: Mann Whitney U test (E).
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Figure 3: CDH3 expression is reduced in PCa specimens. (A) CDH3 expression in tissue biopsies from BPH and PCa. CDH3 
expression relative to GAPDH is shown. n = 14 for BPH and n = 15 for PCa. (B) CDH3 expression in a panel of metastatic prostate cancer 
cell lines (black bars) and benign immortalized prostate cell lines (grey bars) relative to beta-Actin. n = 3. (C) CDH3 expression in two 
PCa datasets (Taylor PCa n = 150, normal n = 29; Grasso PCa n = 76, normal n = 12). (D) Representative images of immunohistochemical 
detection of CDH3 protein in PCa. Middle panel corresponds to a normal area and right panel to high grade PCa (HG PCa). Data source: 
Human Protein Atlas. Statistic test: Mann Whitney U test (A), Student t test (C).
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the studies are carried out comparing healthy individuals 
with PCa patients. It is worth noting that there is an 
increasing incidence of BPH in association with age [14], 
and the interference that this might introduce to biomarker 
identification is poorly understood. To address this 
question, we have performed a transcriptomics analysis 
comparing the mRNA content of uEVs from patients with 
BPH or PCa. The results reveal that urine from these two 
groups have significant alterations in vesicle number. 
Little is known about alterations in EV production in 
different pathologies as compared to the nature of its cargo 
and this aspect warrants further investigation. Importantly, 
we found a markedly different transcriptomics profile 
in uEVs from BPH and PCa. We were able to reduce a 
whole genome analysis (which revealed 1336 transcripts 
detected in uEV preparations) to two candidate transcripts 
(CMTM3 and CDH3) with decreased abundance in PCa. 
Interestingly, the miniaturization of the assay employing 
an alternative purification method revealed that CMTM3 
detection is sensitive to the approach used. This suggests 
that the detection of uEV transcripts might be affected 
by the uEV purification protocol and calls for further 
refinement and characterization of the selectivity and 
specificity of the uEV isolation methods. 
Placental cadherin (P-Cad or CDH3) has been widely 
studied in cancer [37, 49–59]. This protein regulates cell-cell 
adhesion processes and cellular differentiation. Interestingly, 
both oncogenic and tumor suppressive activities of this gene 
have been described in tissue-specific manner [37, 49–59]. 
We observe that CDH3 mRNA levels are down-regulated 
in PCa. This is coherent with preliminary observations 
at the protein level. It has been suggested that CDH3 is 
down-regulated and exerts tumor suppressive functions in 
hepatocellular carcinoma [50] and a prior study reported 
changes of CDH3 in PCa [29]. Our data suggest that CDH3 
may be exerting tumor suppressive activities in PCa.
Figure 4: Evaluation of the molecular events accounting for CDH3 down-regulation in PCa. (A) Analysis of the genomic 
alterations in CDH3 locus in four PCa databases (Taylor n = 93, Grasso n = 61, TCGA n = 258, Broad n = 56). (B and C) Promoter 
methylation analysis from TCGA database evaluating methylation in CDH3 locus (B) n = 49 for normal tissue, n = 101 acinar PCa and 
n = 196 for PCa) and the correlation between methylation status and CDH3 mRNA expression (C) n = 294). (D) Correlation analysis 
between CDH3 and Tp63 expression in two independent datasets. (Grasso, n = 49; Taylor, n = 131; primary tumors). Statistic test: Student 
t Test (B); Pearson´s coefficient (R) (C, D).
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We show that the regulation of CDH3 expression in 
PCa occurs at multiple levels. On the one hand, genomic 
and epigenetic analysis strongly suggests that deletion 
and methylation of the locus accounts for changes 
in expression. On the other hand, we find potential 
regulations at the level of upstream transcriptional 
regulators. Prior studies showed that CDH3 is a basal 
epithelial cell marker [29, 37]. Interestingly, Tp63, 
an upstream regulator of CDH3 [36], presents similar 
behavior to our gene of interest. Tp63 localizes to basal 
epithelial cells and is down-regulated in PCa [40–42, 60]. 
Our correlation analysis in public PCa supports the notion 
that p63 is a transcriptional upstream regulator of CDH3.
Of note, immunoreactivity analysis has provided 
preliminary evidence of mis-localization of CDH3 in PCa 
cells compared to non-tumoral counterparts, Interestingly, 
this alteration is also observed in other cancers and is 
associated to poor prognosis [59].
Altogether, our data show multiple means 
of regulation (genomic loss, DNA methylation, 
transcriptional regulation, and protein mis-localization) 
that could potentially lead to the alteration of CDH3 
function in PCa.
The function of EVs in cell communication and 
cancer aggressiveness has emerged in the past years [61, 62]. 
While their use as source of biomarkers is under intense 
investigation, there is limited evidence about their 
potential role as readouts of the tumoral genetic alterations 
[9]. This study informs about the properties of uEVs to 
reflect genetic alterations in the tumor of origin. We 
find that the decrease in abundance of CDH3 in uEVs 
is coherent with mRNA changes in the prostate tumor 
cells. This data opens new avenues in the non-invasive 
characterization of genetic alterations in PCa using uEVs, 
with the consequent potential for patient stratification.
MATERIALS AND METHODS
Patient samples and cell lines analysis
All urine samples were obtained from the Basque 
Biobank for research (BIOEF, http://www.biobancovasco.
org, Basurto University Hospital) upon informed consent 
and with evaluation and approval from the corresponding 
ethics committee (CEIC code OHEUN11-12 and 
OHEUN14-14). Inclusion criteria: For BPH patients, 
samples were obtained from cases with normal PSA, 
with symptomatic alterations (polyuria, distress), and 
that were scheduled for surgery. For PCa cases, samples 
were obtained from patients with primary localized 
cancer diagnosed de novo and that were scheduled for 
radical prostatectomy. Urine (40–100 ml) was collected 
by spontaneous urination between 8–10 AM, in fasting 
conditions. Patient information, tumor characteristics 
and urine volume is described in Supplementry Table S1. 
For prostate tissue specimens, samples were prepared and 
diagnosed as described in [16]. Cell lines were cultured as 
described in [17] and RNA was harvested in conditions of 
exponential growth.
Urine extracellular vesicle purification
uEV isolation by ultracentrifugation was performed 
as described in [16]. Briefly, urine was centrifuged at 
2000 × g for 5 min to remove cell debris and filtered 
through 0.22 μm pore-filter before frozen at −80°C. For 
uEV isolation sample was thawed and subjected to two 
sequential centrifugations of 11500 × g for 30 min and 
second 118000 × g for 90 minutes. The pellet containing 
uEVs was resuspended in 150 μl of cold PBS and frozen 
for later processing. RNase treatment was not performed 
unless otherwise specified.
Western blot
Western blot was performed as described [18], using 
CD26 (Abcam, Cambridge, UK), CD63 (clone H5C6; from 
Developmental Studies Hybridoma Bank, Iowa, US), CD13 
(clone 3D8; from Santa Cruz Biotechnology Inc.), FLT1 
(clone 18; from BD Biosciences) and AQP2 (Sigma-Aldrich) 
antibodies.
Transmission electron microscopy (TEM) 
analysis
For cryo-electron microscopy, uEV preparations 
were directly adsorbed onto glow-discharged holey 
carbon grids (100 Holey carbon film of Cu with mess 
200; Quantifoil®, Germany). Grids were blotted at 95% 
humidity and rapidly plunged into liquid ethane with 
the aid of VITROBOT (Maastricht Instruments BV, 
The Netherlands). Vitrified samples were imaged at 
liquid nitrogen temperature using a JEM-2200FS/CR 
transmission cryo-electron microscope (JEOL, Japan) 
equipped with a field emission gun and operated at an 
acceleration voltage of 200 kV.
Size analysis and size distribution
Size distribution within uEV preparations was 
analyzed by nanoparticle-tracking analysis (NTA) by 
measuring the rate of Brownian motion using a NanoSight 
LM10 system (Malvern, U.K.), which is equipped with 
a fast video capture and particle-tracking software. 
NTA post-acquisition settings were kept constant for all 
samples, and each video was analyzed to give the mean, 
mode, and median vesicle size, as well as an estimation of 
the concentration [19]. For each preparation, two videos of 
30 seconds each were taken. For each video, at least 200 
tracks were completed in post-capture tracking analysis.
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Transcriptomic analysis
Total RNA isolation from uEV was achieved 
by RNeasy columns (Qiagen, Inc). The integrity, size 
and quantification were evaluated in RNA Pico Chips 
(Bioanalyzer; Agilent Technologies). For transcriptomic 
analysis of mRNA-associated uEVs, Illumina whole 
genome (HumanHT-12_V4.0; DirHyb, nt) method was 
used as reported [20]. cRNA synthesis was obtained out of 
2–25 ng of Total RNA, with TargetAmp™ Nano-g™ Biotin-
aRNA Labeling Kit for the Illumina® System (Epicentre, 
Cat# TAN07924) and subsequent amplification, labelling 
and hybridization were performed according to “Whole-
Genome Gene Expression Direct Hybridization” 
Illumina Inc.’s protocol, except the hybridization 
cRNA concentration, which was 285 ng instead of the 
standard 750 ng. Raw expression data were background-
corrected, log2-transformed and quantile-normalized 
using the lumi R package [21], available through the 
Bioconductor repository. Probes with a “detection 
p-value” lower than 0.01 in at least one sample were 
regarded as detected.
Retrotranscription and quantitative real time 
PCR analysis
To extract RNA from uEVs isolated by 
ultracentrifugation, we employed miRCURY™ RNA 
Isolation Kit Cell & Plant (Exiqon). In average, 1.5e7 
vesicles were used per retrotranscription reaction. In 
addition, a set of samples was extracted by Norgen 
Biotek Exosomal RNA purification kit, following 
the manufacturers’ instructions. For cell lines, RNA 
was extracted using NucleoSpin® RNA isolation kit 
from Macherey-Nagel (ref: 740955.240C). cDNA 
was synthesized from 0.1–1 µg of RNA using 
Superscript III (Life Technologies) following the 
manufacturer’s recommendations. For prostate tissue 
samples, RNA was extracted as reported in [16]. 
Quantitative Real Time PCR (Taqman qRTPCR) was 
performed as previously described [18]. Universal 
Probe Library (Roche) primers and probes employed 
are detailed in Supplementary Table S2. β-ACTIN 
(Hs99999903_m1) and GAPDH (Hs02758991_g1) 
housekeeping assays were from Applied Biosystems and 
showed similar results.
DNA methylation
Raw intensity CDH3 DNA methylation was 
extracted from The Cancer Genome Atlas dataset (https://
tcga-data.nci.nih.gov/tcga/) based on Illumina’s 450K 
methylation array. Data analysis from normal tissues 
(n = 49), prostate carcinoma (n = 196) and acinar prostate 
carcinoma (n = 101) were included. A three step-based 
normalization procedure was performed using the lumi 
[21] package available for Bioconductor [22], under 
the R statistical environment [23], consisting in color 
bias adjustment, background level adjustment and 
quantile normalization across arrays, as specified in [21]. 
Methylation level (β-value) for each of the 485, 577 CpG 
sites was calculated as the ratio of methylated signal 
divided by the sum of methylated and unmethylated signals 
plus 100. After normalization step, probes related to X and 
Y chromosomes were removed as well as those containing 
a SNPs with a frequency > 1% (1000 Genome project) 
in the probe sequence or interrogated CpG site.
Bioinformatics analysis and statistics
The following statistical analysis were employed:
Database normalization: all the datasets used for 
the data mining analysis were downloaded from GEO and 
subjected to background correction, log
2
 transformation 
and quartile normalization. In the case of using a 
pre-processed dataset, this normalization was reviewed 
and corrected if required.
For CDH3 genomic analysis, data from PCa patients 
with copy number alteration information in Taylor [24], 
Grasso [25], Broad/Cornell [26] and Robinson [27] et al. 
datasets was extracted from cbioportal.org. 
Correlation analysis
Pearson correlation test was applied to analyze 
the relation between paired genes. From this analysis, 
Pearson’s coefficient (R) indicates the existing linear 
correlation (dependence) between two variables X and Y, 
giving a value between +1 and −1 (both included), where 
1 is total positive correlation, 0 is no correlation, and −1 
is total negative correlation. The p-value indicates the 
significance of this R coefficient.
Statistical analysis
Data represent mean ± s.e.m. of pooled experiments 
unless otherwise stated. For data mining analysis, ANOVA 
test was used for multi-component comparisons. Student T 
test or Mann Whitney U test for two-group parametric or 
non-parametric comparisons, respectively. The confidence 
level used for all the statistical analyses was of 0.95 (alpha 
value = 0.05). Two-tail statistical analysis was applied for 
experimental design without predicted result and one-tail 
for validation experiments.
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The metabolic co-regulator PGC1α suppresses
prostate cancer metastasis
Veronica Torrano1,18, Lorea Valcarcel-Jimenez1,18, Ana Rosa Cortazar1, Xiaojing Liu2, Jelena Urosevic3,
Mireia Castillo-Martin4,5, Sonia Fernández-Ruiz1, Giampaolo Morciano6, Alfredo Caro-Maldonado1, Marc Guiu3,
Patricia Zúñiga-García1, Mariona Graupera7, Anna Bellmunt3, Pahini Pandya8, Mar Lorente9,
Natalia Martín-Martín1, James David Sutherland1, Pilar Sanchez-Mosquera1, Laura Bozal-Basterra1,
Amaia Zabala-Letona1, Amaia Arruabarrena-Aristorena1, Antonio Berenguer10, Nieves Embade1,
Aitziber Ugalde-Olano11, Isabel Lacasa-Viscasillas12, Ana Loizaga-Iriarte12, Miguel Unda-Urzaiz12,
Nikolaus Schultz13, Ana Maria Aransay1,14, Victoria Sanz-Moreno8, Rosa Barrio1, Guillermo Velasco9,
Paolo Pinton6, Carlos Cordon-Cardo4, JasonW. Locasale2,19, Roger R. Gomis3,15,19 and Arkaitz Carracedo1,16,17,20
Cellular transformation and cancer progression is accompanied by changes in the metabolic landscape. Master co-regulators of
metabolism orchestrate the modulation of multiple metabolic pathways through transcriptional programs, and hence constitute a
probabilistically parsimonious mechanism for general metabolic rewiring. Here we show that the transcriptional co-activator
peroxisome proliferator-activated receptor gamma co-activator 1α (PGC1α) suppresses prostate cancer progression and metastasis.
A metabolic co-regulator data mining analysis unveiled that PGC1α is downregulated in prostate cancer and associated with
disease progression. Using genetically engineered mouse models and xenografts, we demonstrated that PGC1α opposes prostate
cancer progression and metastasis. Mechanistically, the use of integrative metabolomics and transcriptomics revealed that PGC1α
activates an oestrogen-related receptor alpha (ERRα)-dependent transcriptional program to elicit a catabolic state and metastasis
suppression. Importantly, a signature based on the PGC1α–ERRα pathway exhibited prognostic potential in prostate cancer, thus
uncovering the relevance of monitoring and manipulating this pathway for prostate cancer stratification and treatment.
The metabolic switch in cancer encompasses a plethora of discrete
enzymatic activities that must be coordinately altered to ensure the
generation of biomass, reductive power and the remodelling of the
microenvironment1–4. Despite the existence of mutations in metabolic
enzymes5, it is widely accepted that the main trigger for metabolic
reprogramming is the alteration in cancer genes that remodel the
signalling landscape2. Numerous reports provide evidence of the
pathways regulating one or a few enzymes within ametabolic pathway
in cancer. However, the means of coordinated regulation of complex
metabolic networks remain poorly documented.
Master transcriptional co-regulators of metabolism control a
variety of genes that are in charge of remodelling the metabolic
landscape, and their impact in cellular and systemic physiology has
been studied for decades. It is worth noting that these co-regulators,
1CIC bioGUNE, Bizkaia Technology Park, Building 801A, 48160 Derio, Bizkaia, Spain. 2Department of Pharmacology and Cancer Biology, Duke Cancer Institute, Duke
Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina 27710, USA. 3Oncology Programme, Institute for Research in Biomedicine
(IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona 08028, Catalonia, Spain. 4Department of Pathology, Icahn School of Medicine at
Mount Sinai, New York, New York 10029, USA. 5Department of Pathology, Fundação Champalimaud, 1400-038 Lisboa, Portugal. 6Department of Morphology, Surgery
and Experimental Medicine, Section of Pathology, Oncology and Experimental Biology, University of Ferrara, 44100, Italy. 7Vascular Signalling Laboratory, Institut
d’Investigació Biomèdica de Bellvitge (IDIBELL), Gran Via de l’Hospitalet 199-203, 08907 L’Hospitalet de Llobregat, Barcelona, Spain. 8Tumour Plasticity Team,
Randall Division of Cell and Molecular Biophysics, King’s College London, New Hunt’s House, Guy’s Campus, London SE1 1UL, UK. 9Department of Biochemistry and
Molecular Biology I, School of Biology, Complutense University and Instituto de Investigaciones Sanitarias San Carlos (IdISSC), 28040 Madrid, Spain.
10Biostatistics/Bioinformatics Uni, IRB Barcelona, Parc Científic de Barcelona, 08028 Barcelona, Spain. 11Department of Pathology, Basurto University Hospital,
48013 Bilbao, Spain. 12Department of Urology, Basurto University Hospital, 48013 Bilbao, Spain. 13Computational Biology, Memorial Sloan-Kettering Cancer Center,
New York 10065, USA. 14Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). 15Institució Catalana de Recerca i Estudis
Avançats (ICREA), 08010 Barcelona, Spain. 16Ikerbasque, Basque Foundation for Science, 48011 Bilbao, Spain. 17Biochemistry and Molecular Biology Department,
University of the Basque Country (UPV/EHU), PO Box 644, E-48080 Bilbao, Spain. 18These authors contributed equally to this work. 19These authors jointly supervised
this work.
20Correspondence should be addressed to A.C. (e-mail: acarracedo@cicbiogune.es)
Received 2 November 2015; accepted 13 April 2016; published online 23 May 2016; DOI: 10.1038/ncb3357
NATURE CELL BIOLOGY VOLUME 18 | NUMBER 6 | JUNE 2016 645
© 2016 Macmillan Publishers Limited. All rights reserved
ART ICLES
P = 6.057 × 10–14 P = 7.64 × 10–10
5.5
6.0
6.5
7.0
7.5
N PT Met
–3
–2
–1
0
0 30 60 90 0 30 60 90 0 30 60 90
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
D
FS
 (%
)
Low
High
Low
High
Low
High
Low
High
Low
High
Low
High
Time (months) Time (months) Time (months)
0 25 50 75 100 125 0 25 50 75 100 125 0 25 50 75 100 125
D
FS
 (%
)
P = 0.66 
V
ar
am
b
al
ly
 e
t 
al
.
Percentage of alteration
a b
c
0 10 20 30 40 50 60
HDAC2
CRTC1
HDAC5
SIRT1
RB1
NCOR1
HDAC4
HDAC7
KAT2B
NCOA1
NCOA3
MED1
CRTC2
NCOA2
PGC1B
CRTC3
NCOR2
NRIP1
HDAC3
KAT2A
HDAC9
HDAC1
PGC1A
Upregulation 
Downregulation 
La
p
oi
nt
e 
et
 a
l.
To
m
lin
s 
et
 a
l.
G
ra
ss
o 
et
 a
l.
P = 0.0194
P = 0.0211
P = 0.0001
P = 0
P = 0.2445
P = 0.005
P = 0.0012 P = 0.0039
P = 0.0007
∗ 
∗ 
∗ 
∗ 
∗ 
∗ 
∗ 
∗ 
∗ 
(m
ed
ia
n 
ce
nt
re
d
)
Lo
g 2
 m
R
N
A
Lo
g 2
 m
R
N
A
Lo
g 2
 m
R
N
A
(m
ed
ia
n 
ce
nt
re
d
)
Lo
g 2
 m
R
N
A
Lo
g 2
 m
R
N
A
Lo
g 2
 m
R
N
A
(m
ed
ia
n 
ce
nt
re
d
)
(m
ed
ia
n 
ce
nt
re
d
)
Ta
yl
or
 e
t 
al
. 
TC
G
A
 
∗ 
PGC1A HDAC1 PGC1B
P = 0.101
P = 0.0479 P = 0.301 
P = 0.003
0
10
20
30
40
Robinson
et al.
Taylor
et al.
Grasso
et al.
PT
Mets
In
ci
d
en
ce
 o
f
sh
al
lo
w
 d
el
et
io
ns
0/0
41/118
2/109
7/19
0/11
14/50
d e
Taylor et al.
N PT Met
Lapointe et al.
P = 0.0191
P = 0.054
–2.5
–2.0
–1.5
–1.0
–0.5
0
0.5
PGC1A
6.5
7.0
7.5
8.0
8.5
9.0
–3
–2
–1
0
1
2
3
–0.5
0
0.5
N PCa
HDAC1
11.6
11.8
12.0
12.2
12.4
12.6
12.8
13.0
–0.5
0
0.5
1.0
1.5
–0.8
–0.6
–0.4
–0.2
0
0.2
0.4
–0.5
0
0.5
N PCa
PGC1B
5.0
5.5
6.0
6.5
7.0
7.5
–2
–1
0
1
N PCa
Figure 1 PGC1A is downregulated in prostate cancer. (a) Frequency of
alterations (differences greater than twofold versus mean expression of non-
tumoral biopsies) in the expression of 23 master co-regulators of metabolism
in a cohort of 150 PCa patients22. ∗P<0.05, statistically different expression
of the indicated gene in PCa (n= 150) versus normal (n= 29) patient
specimens (according to Supplementary Fig. 1A). (b) Gene expression levels
of PGC1A, PGC1B and HDAC1 in up to four additional PCa data sets
(N, normal; PCa, prostate cancer). Sample sizes: Tomlins et al.23 (N, 23;
PCa, 52); Grasso et al.21 (N, 12; PCa ,76); Lapointe et al.18 (N, 9;
PCa, 17); and Varambally et al.24 (N, 6; PCa, 13). (c) Association of
the indicated genes with disease-free survival (DFS) in two PCa data sets
(low: first quartile distribution; high: fourth quartile distribution. Sample
sizes: TCGA provisional data19,20, primary tumours n=240; Taylor et al.22,
primary tumours n= 131. (d) PGC1A expression in normal prostate (N),
primary tumour (PT) and metastatic (Met) specimens in the Taylor and
Lapointe data sets18,22. Sample sizes: Taylor (N, 29; PT, 131; Met, 19)
and Lapointe (N, 9; PT, 13; Met, 4). (e) Incidence of PGC1A shallow
deletions in three independent data sets (Robinson et al.25, Taylor et al. and
Grasso et al.). Points outlined by circles indicate statistical outliers (d). Error
bars represent minimum and maximum values (b,d). P, P value. Statistical
tests: two-tailed Student’s t-test (a,b), Kaplan–Meier estimator (c) and
ANOVA (d).
through their capacity to interact and regulate diverse transcription
factors, exhibit a unique capacity to control complex and extensive
transcriptional networks, making them ideal candidates to promote
or oppose oncogenic metabolic programs.
The tumour suppressor PTEN is a negative regulator of cell growth,
transformation and metabolism6–9. PTEN and its main downstream
pathway, PI(3)K, have been extensively implicated in prostate cancer
(PCa) pathogenesis and progression10–12. This tumour suppressor
is progressively lost through the progression of PCa, and complete
loss of PTEN is predominant in advanced disease and metastasis8.
Genetically engineered mouse models (GEMMs) recapitulate many
of the features of PCa progression. However, the molecular and
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Figure 2 Combined deletion of Pgc1a and Pten in the murine prostate
epithelia results in prostate cancer progression and dissemination.
(a) Schematic representation of the genetic cross and the time of
analysis. (b,c) Comparison of anterior prostate lobe weights (when both
anterior lobes were analysed, the average weight was calculated and
represented) between genotypes. n=number of mice; pc, prostate-specific
allelic changes; +, wild-type allele; −, deleted allele; WT, any given
genotype resulting in the lack of deletion of Pgc1a or Pten alleles.
(d) Histopathological characterization of the prostate (HGPIN, high-
grade prostatic intraepithelial neoplasia) in the indicated genotypes.
(e) Quantification of the frequency of metastatic lesions in lymph
nodes and liver of Pten-KO (5) and DKO (9) mice. (f) Representative
histological images (×200 magnification) of lymph nodes with (right) and
without (left) metastasis in the indicated genotypes. (g) Representative
immunohistochemical detection (×200 magnification) of Pan-cytokeratin
(panCK)- and androgen receptor (AR)-positive cells in metastatic lymph nodes
of DKO mice. Pten-KO, Ptenpc−/− Pgc1apc+/+; DKO, Ptenpc−/− Pgc1apc−/−.
NS, not significant; ∗∗P < 0.01. H&E, haematoxylin–eosin. Error bars
indicate interquartile range (b,c). Statistical test: two-tailed Mann–Whitney
U-test (b,c).
metabolic bases for PCa metastasis remain poorly understood13–16.
Indeed, complete loss of PTEN in the mouse prostate does not result
in metastasis11, in turn suggesting that additional critical events are
required in this process.
In this study, we designed a bioinformatics analysis to interrogate
multiple PCa data sets encompassing hundreds of well-annotated
specimens. This approach allowed us to define a master regulator of
PCa metabolism that is crucial for the progression of the disease. Our
results identify the peroxisome proliferator-activated receptor gamma
co-activator 1 alpha (PGC1α) as a suppressor of PCa metastasis. This
transcriptional co-activator exerts its function through the regulation
of oestrogen-related receptor alpha (ERRα) activity, in concordance
with the activation of a catabolic program and the inhibition of
PCa metastasis.
RESULTS
A bioinformatics screen identifies PGC1A as a metabolic
co-regulator associated with prostate cancer progression
We approached the study of PCa metabolism applying criteria to
ensure the selection of relevant master regulators that contribute to
the metabolic switch. We focused on transcriptional co-regulators
of metabolism17 that were consistently altered in several publicly
available PCa data sets18–24, and were associated with reduced time
to recurrence and disease aggressiveness. We first evaluated the
expression levels of the metabolic co-regulators in a study comprising
150 PCa specimens and 29 non-pathological prostate tissues (or
controls)22. The analysis revealed 10 co-regulators in the set of
study with significant differential expression in PCa compared with
non-neoplastic prostate tissue (Fig. 1a and Supplementary Fig. 1A).
NATURE CELL BIOLOGY VOLUME 18 | NUMBER 6 | JUNE 2016
© 2016 Macmillan Publishers Limited. All rights reserved
647
ART ICLES
We next extended this observation to four additional data sets18,21,23,24
in which there were available data for non-tumoral and PCa tissues.
Only the alteration in PPARGC1A (PGC1A), PPARGC1B (PGC1B)
and HDAC1 expression was further confirmed in most or all sets
(Fig. 1b and Supplementary Fig. 1B). Among these, PGC1A was the
sole co-regulatorwith altered expression associatedwithGleason score
(Supplementary Fig. 1C,D) and disease-free survival (Fig. 1c).
To rule out the possibility that cellular proliferation could
contribute to the alteration of metabolic regulators, we carried out an
additional analysis in which we compared the expression of PGC1A
in PCa versus a benign hyper-proliferative condition (benign prostate
hyperplasia or BPH). The results corroborated that the decrease in
PGC1A expression is associatedwith a cancerous state rather thanwith
a proliferative condition (Supplementary Fig. 1E).
We observed that the expression of PGC1A was progressively
decreased from primary tumours to metastasis (Fig. 1d and
Supplementary Fig. 1F). Strikingly, genomic analysis revealed
shallow deletions of PGC1A exquisitely restricted to metastatic PCa
specimens19–22,25 (Fig. 1e), in full agreement with the notion that there
is a selective pressure to reduce the expression of this transcriptional
co-activator as the disease progresses.
From our analysis, PGC1α emerges as the main master metabolic
co-regulator altered in PCa, with an expression pattern reminiscent of
a tumour suppressor.
Pgc1a deletion in the murine prostate epithelium promotes
prostate cancer metastasis
PGC1α has been widely studied in the context of systemic
metabolism26, whereas its activity in cancer is just beginning to
be understood27–33. To ascertain the role of PGC1α in PCa in vivo,
we conditionally deleted this metabolic co-regulator in the prostate
epithelium34, alone or in combination with loss of the tumour
suppressor Pten11 (Fig. 2a–d and Supplementary Fig. 2A,B). Pgc1a
deletion alone or in the context of Pten heterozygosity did not result
in any differential tissue mass or histological alteration, which led
us to conclude that it is not an initiating event (Fig. 2b,d). However,
compound loss of both Pten and Pgc1a resulted in significantly larger
prostate mass (Fig. 2c), together with a remarkable increase in the
rate of invasive cancer (Fig. 2d). Histological analysis of the prostate
revealed the existence of vascular invasion in double-mutant mice
(DKO), but not in Pten-deleted (Pten-KO) prostates (Supplementary
Fig. 2C). PGC1α regulates the inflammatory response, which could
influence and contribute to the phenotype observed35. However,
we did not observe significant differences in the infiltration of
polymorphonuclear neutrophils and lympho-plasmacytic infiltrates
in our experimental settings (Supplementary Fig. 2D). PGC1α
has been also shown to induce angiogenesis in coherence with
the induction of vascular endothelial growth factor (VEGF)-A
expression36. Pgc1a status in our GEMMs did not alter VEGF-A
expression and microvessel density (Supplementary Fig. 2E,F). We
therefore excluded the possibility that regulation of angiogenesis or
inflammation downstream of PGC1α could drive the phenotype
characterized in this study.
PCa GEMMs faithfully recapitulate many of the features of the
human disease37. A reduced number of mouse models with clinically
relevantmutations show increasedmetastatic potential13–16. Strikingly,
histopathological analysis of our mouse model in the context of
Pten loss revealed that DKO mice—but not Pten-KO counterparts—
presented evidence of metastasis, which was estimated in 44% to
lymph nodes and 20% to liver (Fig. 2e,f and Supplementary Fig. 2G).
Metastatic dissemination was in agreement with the observation of
pan-cytokeratin (panCK)- and androgen receptor (AR)-positive PCa
cell deposits in the lymph nodes of DKO mice (Fig. 2g). Of note,
33% of Pten-KO mice presented small groups of panCK-positive
cells in lymph nodes (without metastatic lesions; Supplementary
Fig. 2H), suggesting that even if these cells are able to reach the
lymph nodes, they lack capacity to establish clinical metastasis.
Interestingly, bone analysis revealed disseminated groups (but not
clinical metastasis) of panCK-positive cells in DKO but not in Pten-
KO mice (Supplementary Fig. 2I–K). Analysis of a small cohort of
Ptenpc−/−; Pgc1apc+/− mice demonstrated that heterozygous loss of
Pgc1a is sufficient to promote aggressiveness, vascular invasion and
metastasis (Supplementary Fig. 2L–N). This observation supports the
notion that single-copy loss of PGC1A (as observed in metastatic
human PCa specimens, Fig. 1e) could be a key contributing factor to
the metastatic phenotype.
The cooperative effect observed in our mouse model between loss
of Pten and Pgc1a was supported by the direct correlation of the
two transcripts in patient specimens and the association of PGC1A
downregulationwith PTEN genomic loss (TCGAprovisional data19,20,
Supplementary Fig. 2O).
In summary, our results in GEMMs and patient data sets formally
demonstrate that the downregulation of PGC1α in PCa is an
unprecedented causal event for the progression of the disease and its
metastatic dissemination.
PGC1α suppresses prostate cancer growth and metastasis
To characterize the prostate tumour suppressive activity of PGC1α, we
first evaluated its expression level in well-established PCa cell lines38.
Using previously reported PGC1α-positive and -negative melanoma
cells28, we could demonstrate that PCa cell lines lack detectable
expression of the transcriptional co-activator at the protein level
(Fig. 3a). In agreement with this notion, PGC1α silencing in these
cells failed to impact on the expression of its well-established targets39
(Supplementary Fig. 3A). Importantly, through the analysis of publicly
available data sets22, we could demonstrate that the transcript levels
of PGC1A in metastatic cell lines are comparable to those observed
in human metastatic PCa specimens and vastly reduced compared
with PGC1α-positive melanoma cells (Fig. 3a and Supplementary
Fig. 3B). Despite our efforts to optimize the detection of the protein
with different commercial antibodies, we could not identify an
immunoreactive band that would correspond to PGC1α, in contrast
with other reports40,41. Yet, we cannot rule out that in non-basal
conditions, stimulation of other factors such as AR41 or 5′ AMP-
activated protein kinase (AMPK)40 could lead to the upregulation and
allow detection of PGC1α in PCa cells.
Owing to the lack of PGC1α detection in PCa cellular systems,
we aimed at reconstituting the expression of this gene to levels
achievable in the cancer cell lines previously reported28. By means
of lentiviral delivery of inducible Pgc1α and doxycycline titration,
we reached expression levels of this protein in three PCa cell lines
(AR-dependent—LnCaP—and independent—PC3 and DU145)
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Figure 3 PGC1α exhibits tumour and metastasis suppressive activity in PCa
cell lines. (a) Analysis of PGC1α expression by quantitative rtPCR (top
histogram) and western blot in a panel of prostate cancer cell lines (technical
duplicates are shown), using melanoma cell lines as positive (MeWo)
and negative (HT114, HS294T and A375) controls (n=3, independent
experiments). (b) Representative experiment of PGC1α expression in PC3,
DU145 and LnCaP cell lines after treatment with 0.5 µgml−1 doxycycline
(Dox) (similar results were obtained in three independent experiments).
(c) Relative cell number quantification in Pgc1α-expressing (+Dox, pink) and
-non-expressing (−DOX, black) cells. Data are represented as cell number
at day 6 relative to −Dox cells (n= 12 in PC3; n= 7 in DU145; n= 3
in LnCaP, independent experiments). (d,e) Effect of Pgc1α expression on
anchorage-independent growth (d; n=3, independent experiments) and BrdU
incorporation (e; n=3, independent experiments) in PC3 cells. (f) Evaluation
of tumour formation capacity in xenotransplantation experiments (n=7mice;
two injections per mouse). (g) Schematic representation of metastasis assay
through intra-cardiac (IC) injection. (h,i) Evaluation of metastatic capacity
of Pgc1α-expressing PC3 cells using IC xenotransplant assays (n=8 mice
for −Dox and n=6 for +Dox). Luciferase-dependent signal intensity (upper
panels) and metastasis-free survival curves (lower panels) of PCa cells in
lungs (h) and limbs (i) were monitored for up to 28 days. Representative
luciferase images are presented, referring to the quantification plots. In
hind limb photon flux analysis, the average signal from two limbs per
mouse is presented. Images (i) and (ii) depict tibia or lung photon flux
images from specimens that are proximal to the median signal in −Dox
and +Dox, respectively. (j) Schematic representation of bone metastasis
assay through intra-tibial (IT) injection. (k) Evaluation of the metastatic
capacity of Pgc1α-expressing PC3 cells using IT xenotransplant assays
(n= 7 mice). Photon flux quantification at 20 days (upper panel) and
incidence of metastatic lesions at the end point (lower panel). Representative
luciferase images are presented, referring to the quantification plots. For
photon flux analysis, the average signal from two limbs per mouse is
presented. For incidence analysis, mice with at least one limb yielding
luciferase signal >50,000 units were considered metastasis-positive. Images
(i) and (ii) depict tibia photon flux images from specimens that are proximal
to the median signal in −Dox and +Dox, respectively. +Dox, Pgc1α-
induced conditions; −Dox, Pgc1α-non-expressing conditions; BrdU, bromo
deoxyuridine; a.u., arbitrary units. Error bars represent s.e.m. (c–e) or
minimum and maximum values (h,i,k). Statistical tests: two-tailed Student’s
t-test (c–e), one-tailed Mann–Whitney U-test (h,i,k (upper panels)), log-rank
test (f,h,i (lower panels)) and Fisher’s exact test (k, lower panels). ∗P<0.05,
∗∗P<0.01, ∗∗∗P<0.001. Statistics source data for Fig. 3k are provided in
Supplementary Table 9. Unprocessed original scans of blots are shown in
Supplementary Fig. 8.
NATURE CELL BIOLOGY VOLUME 18 | NUMBER 6 | JUNE 2016
© 2016 Macmillan Publishers Limited. All rights reserved
649
ART ICLES
0 10 20 30 40
Metabolic pathways
Citrate cycle (TCA cycle)
Parkinson's disease
Oxidative phosphorylation
Alzheimer's disease
Huntington's disease
Pyruvate metabolism
Cardiac muscle contraction
Propanoate metabolism
Glyoxylate and dicarboxylate metabolism
Valine, leucine and isoleucine degradation
Glycolysis/gluconeogenesis
Drug metabolism (cytochrome P450)
Metabolism of xenobiotics by cytochrome P450
Fatty acid metabolism
Glutathione metabolism
0 5 10 15 20
ACADM
ACSL4
ACAT1
MPC2
MPC1
IDH3A
SDHA
SUCLA2
CLYBL
GOT1
ISCU
ETFDH
GSTM4
NNT
SOD2
ATP1B1
TP53INP2
IH
D3
A FH
SU
CL
A2
0
0.5
1.0
1.5
2.0
2.5
AT
P1
B1
GS
TM
4
IS
CU
LA
M
B2
SD
HA
AC
AT
1
AC
AC
B
AC
SL
4
SU
CL
A2 FH
0
2
4
6
8
10
12
∗∗
∗
∗∗∗
∗∗∗
∗∗
∗
∗
∗∗∗
∗
∗
KEGG
–Log2(adjusted P value) a
∗∗ 
∗ 
∗ 
∗∗ 
∗∗∗ 
∗∗∗ 
∗∗ 
∗∗ 
∗∗ 
∗ 
∗∗ 
∗∗ 
∗ 
Fold change relative to –Dox 
∗ 
FA metabolism
Pyr metabolism
TCA; TCA-related
ETC
ROS scavenger
∗∗∗ 
∗ 
∗ 
∗∗
–Dox +Dox Pten-KO DKO 
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
∗∗
Others
b
c d
Figure 4 PGC1α induces a metabolic transcriptional program. (a) KEGG
(Kyoto Encyclopaedia of Genes and Genomes) analysis of the transcriptional
program regulated by PGC1α. The dotted line indicates P = 0.05. (b–d)
Validation of microarray by quantitative rtPCR in PC3 TRIPZ–HA–Pgc1α
cells (b, n=3 for TP53INP2, SOD2, NNT, GSTM4, ETFDH, GOT1, CLYBL,
SUCLA2, MPC1, MPC2, ACAT1 and ACSL4; n= 4 for ATP1B1, ISCU,
SDHA, IDH3A and ACADM; independent experiments; data are normalized
to the −Dox condition, represented by a black dotted line), xenograft
samples (c, −Dox n=11 tumours; +Dox n=6 tumours) and prostate tissue
samples from Pten-KO and DKO mice (d, n=7 mice). +Dox, Pgc1α-induced
conditions; −Dox, Pgc1α-non-expressing conditions; Pten-KO, Ptenpc−/−
Pgc1apc+/+; DKO, Ptenpc−/−, Pgc1apc−/−. ROS, reactive oxygen species; ETC,
electron transport chain; TCA, tricarboxylic acid cycle; Pyr, pyruvate; FA, fatty
acid. Error bars indicate s.e.m. (b) or interquartile range (c,d). Statistical
tests: one-tail Student’s t-test (b); one-tail Mann–Whitney U-test (c,d).
∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001.
equivalent to that observed in the PGC1α-expressing melanoma
cell line MeWo (Fig. 3b and Supplementary Fig. 3C,D). Next, we
evaluated the cellular outcome of expressing PGC1α in PCa cell
lines. Interestingly, expression of Pgc1α in this context resulted
in a reduction in bi-dimensional and three-dimensional growth
(Fig. 3c,d and Supplementary Fig. 3E), cellular proliferation
(Fig. 3e and Supplementary Fig. 3F) and cell cycle progression
(Supplementary Fig. 3G). Of note, we excluded the possibility that
doxycycline treatment could influence the result of the growth analysis
(Supplementary Fig. 3H). The Pgc1α phenotype was recapitulated
in vivo, where ectopic expression of this gene decreased tumour
formation and growth (Fig. 3f and Supplementary Fig. 3I–K). In
agreement with the GEMM data, we did not observe a contribution
of angiogenesis to the phenotype (Supplementary Fig. 3L–N).
We observed in GEMMs that Pgc1a loss resulted in metastatic
dissemination (Fig. 2). We next sought to study whether Pgc1α
expression could oppose a pre-existing metastatic phenotype. To this
end, we carried out xenotransplant assays in immunocompromised
mice using luciferase-expressing Pgc1α-inducible PC3 cells. Intra-
cardiac injection of these cells (Fig. 3g) revealed that Pgc1α expression
blunted metastatic growth in the lung, and led to a remarkable
decrease in bone colonization (Fig. 3h,i). As an additional approach,
we sought to analyse metastatic tumour re-initiation capacity by
means of local injection of PCa cells at the metastatic site. As PCa
exhibits an osteotropic nature42, we carried out intra-tibial injection
of cells and the appearance of tumour masses in the bone was
monitored43 (Fig. 3j). The results demonstrated that PGC1α exerts
a potent anti-metastatic activity both in bone tumour mass and
metastatic lesions (Fig. 3k). These data provide evidence of the anti-
metastatic potential of PGC1α.
PGC1α determines the oncogenic metabolic wiring in prostate
cancer
PGC1α regulates gene expression through the interaction with
diverse transcription factors26. To define the transcriptional program
associated with the tumour suppressive activity of PGC1α, we
performed gene expression profiling from Pgc1α-expressing versus -
non-expressing PC3 cells. We identified 174 probes with significantly
altered signal encoding genes predominantly related to functions
such as mitochondrial catabolic programs and energy-producing
processes26,44 (Supplementary Table 1 and Fig. 4a), which we
validated by quantitative real-time PCR (rtPCR) (Fig. 4b–d and
Supplementary Fig. 4).
To demonstrate that the tumour suppressive activity of PGC1αwas
indeed accompanied by a global metabolic rewiring, we carried out
integrativemetabolomics.We analysed cell line, xenograft andGEMM
tissue extracts using liquid-chromatography high-resolution mass
spectrometry (LC–HRMS). LC–HRMSmetabolomics and subsequent
biochemical assays confirmed that oxidative processes such as fatty
acid β-oxidation (Fig. 5a–d and Supplementary Fig. 5A–C and
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Figure 5 PGC1α induces a catabolic metabolic program. (a–c) Untargeted
LC–HRMS analysis of differential abundance in metabolites involved in
fatty acid catabolism in Pgc1α-expressing PC3 cells (a, n=4, independent
experiments), xenografts (b, −Dox n=8 tumours; +Dox n=4 tumours) and
GEMMs (c, Pten KO n=3 mice; DKO n=5 mice). (d) Evaluation of the
dehydrogenation of tritiated palmitate (readout of fatty acid β-oxidation) in
Pgc1α-expressing PC3 cells (n= 6, independent experiments). (e) Effect
of Pgc1α expression on the abundance of tricarboxylic acid cycle (TCA)
intermediates measured by LC–HRMS in PC3 cells (n= 4, independent
experiments). (f) Effect of Pgc1α expression on TCA intermediates (mass
isotopomer abundance) after stable 13C–U6-glucose labelling in PC3 cells
(n=3, independent experiments). (g) Oxygen consumption rate (OCR) in
PC3 Pgc1α-expressing cells (n= 7, independent experiments). (h) Basal
mitochondrial ATP production in PC3 cells following Pgc1α expression
(n=20 for −Dox and n=10 for +Dox conditions, independent experiments).
(i) LC–HRMS quantification of ATP abundance in xenografts (left panel,
−Dox n=8 tumours; +Dox n=4 tumours) and GEMMs (right panel, Pten-KO
n=3 mice; DKO n=5 mice). (j) Effect of Pgc1α expression on palmitate
paired mass isotopomer abundance after stable 13C–U6-glucose labelling in
PC3 cells (n=3, independent experiments). (k) Schematic representation
of the main findings of the study. Pyr, pyruvate; AcCoA, acetyl CoA; OAA,
oxaloacetate; Mal, malate; Fum, fumarate; Succ, succinate; Cit, citrate;
ETC, electron transport chain; FA, fatty acids. a.u., arbitrary unit. Error
bars indicate s.e.m. (a,d–h,j) or interquartile range (b,c,i). Statistical tests:
two-tailed Student’s t-test (a,d–h,j); one-tail Mann–Whitney U-test (b,c,i).
∗P<0.05,∗∗P<0.01, ∗∗∗P<0.001.
Supplementary Tables 2–5) and tricarboxylic acid cycle (TCA, Fig. 5e
and Supplementary Fig. 5D) were increased in response to Pgc1α
expression. To quantitatively define the use of glucose in the TCA
cycle, we carried out stable 13C–U6-glucose isotope labelling. This
experimental approach provided definitive evidence of the increased
oxidation of glucose in the mitochondria in Pgc1α-expressing cells
(Fig. 5f). This metabolic wiring was consistent with elevated oxygen
consumption (basal and ATP-producing) and ATP levels following
Pgc1α expression (Fig. 5g–i and Supplementary Fig. 5E–I and
Supplementary Tables 2–5).
We next reasoned that over-activation of mitochondrial oxidative
processes would lead to decreased anabolic routes. On the one hand,
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we monitored the incorporation of carbons from 13C–U6-glucose
into fatty acids (through the export of citrate from TCA to the
cytoplasm45 and conversion to acetyl CoA that is used for de novo
lipid synthesis). Interestingly, we found a significant decrease in 13C
incorporation into palmitate (reflected as 13C carbon pairs) when
Pgc1α was expressed (Fig. 5j and Supplementary Fig. 5J). On the
other hand, we monitored lactate production as a readout of aerobic
glycolysis or ‘the Warburg effect’2, which has been associated with
the anabolic switch. As predicted, Pgc1α-expressing cells exhibited
reduced extracellular lactate levels (Supplementary Fig. 5K). Of note,
lactate production and respiration were unaltered by doxycycline
challenge in non-transduced PC3 cells (Supplementary Fig. 5L,M).
Taken together, our data provide a metabolic basis for the tumour
suppressive potential of PGC1α in PCa, according to which this
metabolic co-regulator controls the balance between catabolic and
anabolic processes (Fig. 5k).
An ERRα-dependent transcriptional program mediates the
prostate tumour suppressive activity of PGC1α
We next aimed to identify the transcription factor that mediated the
activity of PGC1α, and hence we performed a promoter enrichment
analysis. The results revealed a predominant abundance in genes
regulated by ERRα (Fig. 6a). We corroborated these results with
Gene Set Enrichment Analysis (GSEA; normalized enrichment
score= 2.02; nominal P value= 0.0109)46. This transcription factor
controls a wide array of metabolic functions, from oxidative processes
to mitochondrial biogenesis44. We have shown that PGC1α is
indeed capable of regulating functions attributed to ERRα, such as
mitochondrial oxidative metabolism (Figs 4 and 5 and Supplementary
Figs 4 and 5). In addition, we observed that Pgc1a expression led
to increased mitochondrial volume (Supplementary Fig. 6A). To
ascertain the extent towhich the growth inhibitory and anti-metastatic
activity of PGC1α required its ability to interact with ERRα, we took
advantage of a mutant variant of the co-activator (PGC1αL2L3M) that
is unable to interact with this and other nuclear receptors46,47. The
expression of PGC1αL2L3M in PC3 cells (Supplementary Fig. 6B) failed
to upregulate target genes, to reprogram oxidative metabolism, to
inhibit cell growth, and, importantly, to suppress bone metastasis
in intra-tibial xenografts (Fig. 6b–f and Supplementary Fig. 6C).
To further discriminate between PGC1α functions that depend
on ERRα or other nuclear receptors, we undertook a targeted
silencing approach, and we transduced Pgc1α-inducible PC3 cells
with an ERRα-targeting or a scramble short hairpin RNA (shRNA;
Supplementary Fig. 6D). In coherence with the L2L3M mutant
data, ERRα silencing partially blunted the effects of Pgc1α on gene
expression and cell growth (Fig. 6g and Supplementary Fig. 6H). In
vivo, silencing of ERRα in the presence of the ectopically expressed
transcriptional co-activator resulted in a significant increase in bone
metastasis incidence from 40% (in Pgc1α-expressing cells transduced
with scramble shRNA) to full penetrance (Fig. 6h). Of note, the
requirement of ERRα for the effect of PGC1αwas recapitulated in vitro
with a reverse agonist of the transcription factor, namely XCT79048
(Supplementary Fig. 6F–I).
It is worth noting that other metabolic pathways have been
suggested to sustain the metastatic phenotype. Oxidative stress
has been shown to limit metastatic potential in breast cancer
and melanoma29,49. PGC1α regulates the expression of antioxidant
genes, and the enhancement of mitochondrial metabolism can lead
to the production of reactive oxygen species28,29,49 (ROS; Fig. 4b
and Supplementary Table 1). We therefore tested whether ROS
production was modified in our experimental settings and if it could
contribute to the phenotype observed.Mitochondrial and cellular ROS
production were not consistently altered by Pgc1α expression in vitro
(Supplementary Fig. 6J). In addition, lipid peroxidation (which serves
as a readout of ROS production) was unaffected in our xenograft study
(Supplementary Fig. 6K). These results are coherent with the inability
of antioxidants to rescue the proliferative defect elicited by Pgc1α
(Supplementary Fig. 6L).
Our data provide a molecular mechanism by which ERRα
activation downstream of PGC1α promotes a metabolic rewiring that
suppresses PCa proliferation and metastasis.
A PGC1α–ERRα transcriptional signature harbours prognostic
potential
We have shown that reduced PGC1A expression in PCa exhibits
prognostic potential (Fig. 1c). As our data demonstrate that
transcriptional regulation downstream of ERRα is key for the
tumour suppressive activity of this co-activator, we reasoned that the
association of PGC1α with aggressiveness and disease-free survival
should be recapitulated whenmonitoring ERRα target genes (Fig. 7a).
We started the analysis from the list of genes positively regulated
by PGC1α in our cellular system (153 genes, Fig. 7b). As predicted,
the analysis in two independent patient data sets confirmed that the
average signal of the PGC1α gene list was positively correlated with
time to PCa recurrence (Fig. 7c). In addition, we observed a decrease in
the expression of the aforementioned gene list associated with disease
initiation and progression (Supplementary Fig. 7A). Importantly,
comparable results were obtained when we performed the analysis
with the subset of ERRα-target genes within the PGC1α gene set
(73 genes, Supplementary Table 6 and Fig. 7b,d and Supplementary
Fig. 7B). We next sought to curate the gene list to consolidate a
prognostic PGC1α-ERRα gene set.We therefore focused on genes that
exhibited a strong correlation with PGC1A in patient data sets. We
selected genes that were significantly correlated with the co-activator
(R> 0.2; p< 0.05) in at least three out of five studies. The results
unveiled a PGC1α transcriptional signature in patients consisting
of 17 genes, most of which exhibited decreased expression in PCa
versus BPH, and were further downregulated in metastatic disease
(Supplementary Table 7 and Supplementary Fig. 7C,D). Nearly 60%
of these genes were regulated by ERRα (10 genes out of 17) and
were selected for further analysis as a PGC1α–ERRα curated gene
set (Supplementary Table 7). The results revealed reduced PGC1α–
ERRα curated gene set expression as the disease progressed (Fig. 7e).
We next analysed the association of the PGCα–ERRα curated gene
set with disease recurrence. To this end, we compared patients
harbouring primary tumours with ERRα curated gene set average
signal values in the first quartile (Q1, termed signature-positive)
versus the rest (Q2–Q4). Patients with signature-positive tumours
exhibited reduced disease-free survival in two independent data sets
(Fig. 7f). A hazard ratio of 4.2 (Taylor) and 17.8 (TCGA) was
defined for signature-positive patients, whereas signature-negative
individuals presented reduced risk of recurrence, with a hazard ratio
652
© 2016 Macmillan Publishers Limited. All rights reserved
NATURE CELL BIOLOGY VOLUME 18 | NUMBER 6 | JUNE 2016
ART ICLES
0
50
100
NS P = 0.025
N
or
m
al
iz
ed
 p
ho
to
n
flu
x 
(h
in
d
 li
m
b
s)
NS P = 0.03
100
80
60
40
20
0
100
80
60
40
20
0
H
in
d
 li
m
b
 le
si
on
 in
ci
d
en
ce
 (%
)
H
in
d
 li
m
b
 le
si
on
 in
ci
d
en
ce
 (%
)
H
in
d
 li
m
b
 le
si
on
 in
ci
d
en
ce
 (%
)
L2L3M–DoxL2L3M–Dox L2L3M–DoxL2L3M+DoxL2L3M+Dox L2L3M–Dox L2L3M+Dox L2L3M+Dox
NS
WT–DoxWT–Dox WT+DoxWT–Dox WT+DoxWT+Dox WT–Dox WT+Dox
1010
109
108
107
106
105
104
103
102
E
x 
vi
vo
 p
ho
to
n 
flu
x 
(h
in
d
 li
m
b
s)
109
108
107
106
105
104
103
102
106
105
104
103
102
100
101
E
x 
vi
vo
 p
ho
to
n 
flu
x 
(h
in
d
 li
m
b
s)
P = 0.0006
0
20
40
60
80
100
a
0 5 10 15 20 25 30 35 40 45
TGACCTY_V$ERR1_Q2
TGACCTTG_V$SF1_Q6
V$SF1_Q6
V$ER_Q6_02
GATTGGY_V$NFY_Q6_01
GGGCGGR_V$SP1_Q6
V$ERR1_Q2
V$NFKAPPAB65_01
V$ER_Q6_01
V$CREL_01
V$DR4_Q2
V$TAXCREB_01
ID
H3
A
AT
P1
B1
AC
AT
1
IS
CU
GO
T1
AC
AD
M
0
5
10
15
$
∗∗∗
∗
∗
∗∗ ∗∗
$
$$
$
Fo
ld
 c
ha
ng
e 
fr
om
 –
D
ox
∗
∗
$$
$
WT+Dox
L2L3M+Dox
b
–Log2 (adjusted P value) 
350
300
250
200
150
100
50
0
0
20
40
60
80
100
120 350
300
250
200
150
100
50
0
NS
c d
∗∗
R
el
at
iv
e 
ce
ll 
nu
m
b
er
0
20
40
60
80
100
120
R
el
at
iv
e 
ce
ll 
nu
m
b
er
O
C
R
 (p
m
ol
 m
in
–1
)
O
C
R
 (p
m
ol
 m
in
–1
)
∗
NS
e
P = 0.01
NS
Basal OCR2D growth
+Dox
g
∗∗∗
∗∗∗
$
R
el
at
iv
e 
ce
ll 
nu
m
b
er
2D growth 
h
ERRα shRNA +Dox
SC shRNA +Dox
ERRα shRNA –Dox
SC shRNA –Dox
–Dox+Dox–Dox
f
(i)
(ii)
Colour bar
Min = 1.5 × 106
Max = 2.4 × 109
Colour bar
Min = 3.0 × 105
Max = 2.4 × 109
ERRα shRNA +Dox
SC shRNA +Dox
(i)
(ii)
Figure 6 An ERRα-dependent transcriptional program mediates the tumour
suppressive activity of PGC1α. (a) Promoter enrichment analysis of the
PGC1α transcriptional program. The red dotted line indicates P = 0.05.
(b–d) Effect of Pgc1αWT (WT) or Pgc1αL2L3M (L2L3M) induction on the
expression of the indicated genes (b, quantitative rtPCR; n=8 for IDH3A;
n= 4 for ATP1B1; n= 3 for ACAT1, ISCU, GOT1 and ACADM genes,
independent experiments; data are normalized to each −Dox condition,
represented by a black dotted line), relative cell number by crystal violet
(c, n=7, independent experiments) and oxygen consumption rate (d, OCR,
n=5, independent experiments). (e,f) Evaluation of the metastatic capacity
of PC3 Pgc1αWT (WT)-expressing (upper panels) or PC3 Pgc1αL2L3M (L2L3M)-
expressing (lower panels) cells using intra-tibial xenotransplant assays
(e, photon flux quantification; WT, n= 6 mice; L2L3M, n= 7 mice, two
hind limbs per mouse; f, incidence of metastatic lesions presented as
histograms). Representative luciferase images are presented referring to the
quantification plots. For photon flux analysis, average signal from two limbs
per mouse is presented. For incidence analysis, mice with at least one
limb yielding luciferase signal >50,000 units were considered metastasis-
positive. Images (i) and (ii) depict tibia photon flux images from specimens
that are proximal to the median signal in −Dox and +Dox, respectively.
(g) Relative cell number quantification following ERRα silencing in Pgc1α-
expressing PC3 cells. Data are represented as cell number at day 4 relative
to −Dox cells (n=3, independent experiments). (h) Evaluation of metastatic
capacity of Pgc1α-expressing PC3 cells transduced with SC shRNA or ERRα
shRNA using intra-tibial implantation for 14 days (n=8 mice; two injections
per mouse; incidence of metastatic lesions presented as histograms). For
photon flux analysis (left panel), average signal from two limbs per mouse
is presented. For incidence analysis (right panel), mice with at least one
limb yielding luciferase signal >50,000 units were considered metastasis-
positive. +Dox, Pgc1α-induced conditions; −Dox, Pgc1α-non-expressing
conditions. NS, not significant; SC, Scramble; OCR, oxygen consumption
rate. Error bars represent s.e.m. (b–d,g) or minimum and maximum values
(e,h). Statistical tests: one-tailed Student’s t-test (b–d,g); one-tailed Mann–
Whitney U-test (e,h (left panel)); Fisher’s exact test (f,h (right panel)).
∗ or $P<0.05, ∗∗ or $$P<0.01, ∗∗∗P<0.001. Asterisks indicate statistical
difference between −Dox and +Dox conditions and dollar symbols between
Pgc1αWT and Pgc1αL2L3M or SC shRNA and ERRα shRNA. Statistics source
data for Fig. 6e,h are provided in Supplementary Table 9.
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Figure 7 The PGC1α transcriptional program is associated with prostate
cancer recurrence. (a) Schematic summary of the ERRα-dependent regulation
of the PGC1α transcriptional metabolic program and its association with PCa
progression. Dashed PGC1α outline represents a decrease in abundance.
(b) Venn diagram showing the distribution of PGC1α target genes, ERRα
target genes (from Supplementary Table 6) and genes correlated with
PGC1A expression in PCa patient specimens (from Supplementary Table 7).
(c,d) Correlation between time to recurrence and the average signal of the
genes within the PGC1α-upregulated gene set (c) or the PGC1α-dependent
ERRα-upregulated gene set (d) in the indicated data sets (Taylor22 n=27;
TCGA provisional data set19,20 n=8). Each dot corresponds to an individual
patient specimen. (e) Representation of the average signal of the genes within
the PGC1α–ERRα curated gene set (Supplementary Table 7) in normal tissue
(N; Taylor n=29 and Grasso21 n=12), primary tumour (PT; Taylor n=131
and Grasso n=49) and metastasis specimens (Met; Taylor n=19 and Grasso
n=27), in two independent data sets. Each dot corresponds to an individual
patient specimen. (f) Association of the PGC1α–ERRα signature with disease-
free survival in the indicated patient data sets (Taylor n= 131; TCGA
provisional data set n=240). Q1 indicates patients with signature signal
within the first quartile of primary tumours (Q1) in the corresponding data
set. HR, hazard ratio. Error bars indicate interquartile range. Statistical tests:
Pearson’s coefficient (R) (c,d), ANOVA (e), Student’s t-test (e) and Kaplan–
Meier estimator (f). ∗∗P < 0.01; #P > 0.05. Asterisk indicates statistical
difference versus N; hash indicates statistical difference versus PT.
of 0.23 (Taylor) and 0.05 (TCGA). Furthermore, the frequency of
patients with signature-positive signal values was absent or low in the
normal prostate group and further increased in metastasis compared
with primary tumours (Supplementary Fig. 7E). Taken together,
ERRα-regulated metabolic transcriptional program is associated
with the activity of PGC1α in PCa. This interplay is conserved
in patient specimens and defines a gene signature that harbours
prognostic potential.
DISCUSSION
In this study we provide a comprehensive analysis of master
transcriptional co-regulators of metabolism in PCa. Through the use
of human data mining analysis, GEMMs and cellular systems, our
study presents evidence demonstrating that PGC1α exerts a tumour
suppressive activity opposing PCa metastasis. Interestingly, three out
of ten significantly altered co-regulators (PGC1A, PGC1B and NRIP1,
Fig. 1a) in the Taylor22 PCa data set (two out of three consistently
altered throughout databases, Fig. 1b) converge in the regulation of
a common transcriptional metabolic program, led by ERRα (ref. 44),
and that is associated with the phenotype observed in this study. These
data strongly suggest that such pathway is of critical importance for
the control of aggressiveness properties in PCa. Indeed, our results
demonstrate that a gene set composed of ERRα target genes that are
under the control of PGC1α expression is progressively downregulated
in PCa and metastatic disease, and presents prognostic potential for
the identification of patients at risk of early recurrence.
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The study of the tumour suppressive potential of Pgc1α in
mouse models allowed us to characterize a clinically relevant PCa
GEMM presenting enhanced metastatic dissemination. PGC1α is
added to the shortlist of genetic events that drive metastasis in this
model13–16, and the first to be explicitly linked to the regulation of
the metabolic switch. Overall, our finding is of importance for the
future study of the requirements for PCa metastasis and therefore for
therapeutic purposes.
The sole alteration of PGC1α expression in PCa has a profound
impact on the oncogenicmetabolic switch50. These data are in linewith
the reported activities of this protein inmetabolism andmitochondrial
biogenesis26. Of note, despite the widely accepted fact that the reported
metabolic switch50 has comparable consequences in all cancer
scenarios, the study of PGC1α in other tumour types has also revealed
a selective pressure towards oxidative processes27–29. Previous work
from others and us defined PGC1α signalling as a selective advantage
for breast cancer and melanoma cells4,27–29,51. The contribution of this
co-activator to cellular proliferation differs between tumour types and
experimental systems, promoting growth inmelanoma28 but irrelevant
to breast cancer cells29. Interestingly, in breast circulating tumour
cells, PGC1α expression supportsmetastatic capacity29. Themolecular
pathways regulating these diverse biological features converge in the
activation of ERRα and peroxisome proliferator-activated receptors
(PPAR). Whereas PPAR activation mediates the increase in fatty acid
β-oxidation4, ERRα is responsible for the overall increase in oxidative
metabolism and mitochondrial biogenesis44. Similarly, the activation
of an antioxidant transcriptional program has been suggested to
contribute to anoikis and cancer cell dissemination in a PGC1α-
dependent and independent manner27,28,49,52. In PCa, however, we
demonstrate that the oxidative metabolic program elicited by PGC1α
prevents tumour growth and metastatic dissemination, in the absence
of overt changes in ROS production, inflammatory response or
angiogenic signals. These findings support the notion that the optimal
metabolic wiring for tumour growth and metastasis might differ
depending on the tumour type, the mutational landscape of the
tumour and, potentially, the microenvironment. This would lead to
opposite activities of PGC1α depending on the cancer setting, from
metastatic promoter29 to metastasis suppressor (as we demonstrate in
the present work).
In summary, our study identifies PGC1α as a master regulator of
PCametabolism that opposes the dissemination of the disease. There-
fore, a PGC1α-regulated ERRα-dependent transcriptional program
might open new avenues in the identification of metabolic transcrip-
tional signatures that can be exploited for patient stratification and the
use of metabolism-modulatory therapies. 
METHODS
Methods and any associated references are available in the online
version of the paper.
Note: Supplementary Information is available in the online version of the paper
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METHODS
Reagents. 3-[4-(2,4-Bis-trifluoromethylbenzyloxy)-3-methoxyphenyl]-2-cyano-N -
(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)acrylamide (XCT 790), etomoxir (ETO),
doxycycline hyclate (Dox), oligomycin, N -acetyl-cysteine (NAC) and manganese
(III) tetrakis (4-benzoic acid)porphyrin chloride (MnTBAP) were purchased
from Sigma.
Cell culture. Human prostate carcinoma cell lines LnCaP, DU145 and PC3
were purchased from Leibniz-Institut DSMZ - Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH, who provided an authentication
certificate. None of the cell lines used in this study were found in the database of
commonly misidentified cell lines maintained by ICLAC and NCBI Biosample.
Cells were transduced with a modified TRIPZ (Dharmacon) doxycycline-inducible
lentiviral construct in which the RFP and miR30 region was replaced by HA–
Flag–Pgc1a (ref. 51) or HA–Flag–Pgc1aL2L3M (ref. 47). Lentiviral shRNA constructs
targeting PGC1A (TRCN0000001166) and ESRRA (TRCN0000022180) were
purchased from Sigma and a scramble shRNA (hairpin sequence: 5′-CCGGCA
ACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTG-
3′) was used as the control. For ESRRA shRNAs, the puromycin resistance cassette
was replaced by the hygromycin cassette from pLKO.1 Hygro (Addgene Ref. 24150)
using BamHI and KpnI sites. Melanoma lines were provided by M. D. Boyano53
and A. Buqué and purchased from ATCC. Cell lines were routinely monitored for
mycoplasma contamination and quarantined while treated if positive.
Animals. All mouse experiments were carried out following the ethical guidelines
established by the Biosafety and Welfare Committee at CIC bioGUNE and The
Institutional Animal Care and Use Committee of IRB Barcelona. The procedures
employed were carried out following the recommendations from AAALAC.
Xenograft experiments were performed as previously described54, injecting 106
cells per condition in two flanks per mouse. PC3 TRIPZ–HA–Pgc1a cells were
injected in each flank of nude mice and 24 h post-injections mice were fed with
chow or doxycycline diet (Research diets, D12100402). GEMM experiments were
carried out as reported in a mixed background11,14,55,56 (where the founder colony
was cross-bred for at least three generations before the expansion of experimental
cohorts to ensure a homogenous mixed background). The PtenloxP and Pgc1aloxP
conditional knockout alleles have been described elsewhere11,34. Prostate epithelium-
specific deletion was effected by the Pb–Cre411. Mice were fasted for 6 h before
tissue collection (9:00–15:00) to prevent metabolic alterations due to immediate
food intake.
For intra-tibial and intra-cardiac injections BALB/c nude male mice (Harlan)
of 9–11 weeks of age were used. Before the injections, PC3 Tripz–HA–Pgc1a (WT,
L2L3M, SC shRNA, ERRα shRNA) cell lines were pre-treated for 48 h with PBS or
doxycycline (0.5 µgml−1). Mice injected with cells treated with doxycycline were
also pre-treated for 48 h with 1mgml−1 of doxycycline in drinking water. After
the injections this group of mice was left on continuous doxycycline treatment
(1mgml−1 in drinking water). Before the injections mice were anaesthetized
with a mixture of ketamine (80mg kg−1) and xylazine (8mg kg−1). For intra-tibial
injections, 1×104 cells were resuspended in a final volume of 5 µl of cold PBS and
injected as described previously57. For intra-cardiac injections 2× 105 cells were
resuspended in a final volume of 100 µl of cold PBS and injected as described
previously57. After the injections, tumour development was followed on a weekly
basis by BLI using the IVIS-200 imaging system from Xenogen. Quantification
of bioluminescent images was done with Living Image 2.60.1 software. The
development of metastasis was confirmed by examining in vivo or ex vivo (following
necropsy) bioluminescent images of organs of interest (metastasis positivity in
lesion incidence analysis was defined as tibias with luciferase signals greater than
50,000 units). When comparing cell lines independently transduced with the
luciferase-expressing vector (Fig. 6h), photon flux values per limb were presented as
normalized signal (corrected by basal signal, obtained within 24 h after injection):
Normalized photon flux = (day 14 signal/day 0 signal) × 1,000. For metastasis-
free survival curves, a metastatic event was scored when the measured value of
bioluminescence bypassed 1/10 of the day 0 value.
Patient samples. All samples were obtained from the Basque Biobank for research
(BIOEF, Basurto University hospital) on informed consent and with evaluation and
approval from the corresponding ethics committee (CEIC code OHEUN11-12 and
OHEUN14-14).
Cellular, molecular and metabolic assays. Cell number quantification with crystal
violet58 was performed as referenced. Soft agar assays were performed as previously
described (INSERT REF 60) seeding 5,000 cells per well in 6-well plates.
Western blot was performed as previously described51. Antibodies used: PGC1α
(H300; Santa Cruz Biotechnology sc-13067; dilution 1:1,000); ERRα (E1G1J; Cell
Signaling no. 13826; dilution 1:1,000); β-actin (clone AC-74; Sigma no. A 5316;
dilution 1:2,000); GAPDH (clone 14C10; Cell Signaling no. 2218; dilution 1:1,000);
HSP90 (Cell Signaling; no. 4874; dilution 1:1,000).
RNA was extracted using the NucleoSpin RNA isolation kit from
Macherey-Nagel (ref: 740955.240C). For patients and animal tissues a Trizol-
based implementation of the NucleoSpin RNA isolation kit protocol was used as
reported previously59. For all cases, 1 µg of total RNA was used for cDNA synthesis
using qScript cDNA Supermix from Quanta (ref. 95048). Quantitative real-time
PCR (rtPCR) was performed as previously described51. Universal Probe Library
(Roche) primers and probes employed are detailed in Supplementary Table 8.
β-ACTIN (Hs99999903_m1; Mm0607939_s1) and GAPDH (Hs02758991_g1,
Mm99999915_g1) housekeeping assays from Applied Biosystems showed
similar results (all quantitative rtPCR data presented were normalized using
GAPDH/Gapdh).
Fatty acid oxidationwas performed as previously described51. Lactate production
was measured as referenced60 using the Trinity Biotech lactate measurement kit.
Oxygen consumption rate (OCR) was measured with an XF24 extracellular flux
analyser (Seahorse Bioscience)61. Briefly, 50,000 cells per well were seeded in anXF24
plate, and OCR measurements were normalized to cell number analysed by crystal
violet. Cells were initially plated in 10% FBS DMEM media for 24 h, and 1 h before
measurements, the medium was changed to serum- and bicarbonate-free DMEM,
with glutamine and glucose (10mM).Mitochondrial stress test was carried out using
the following concentration of injected compound: oligomycin (1 µM).
For mitochondrial ATP assays, 50,000 PC3 and DU145 cells were plated onto
13-mmcoverslips and transfectedwith amitochondrial-targeted luciferase chimaera
(mtLuc). Cells were perfused in the luminometer at 37 ◦C with KRB solution
containing 25 µMluciferin and 1mMCaCl2 and supplementedwith 5.5mMglucose.
Under these conditions, the light output of a coverslip of transfected cells was in
the range of 5,000–20,000 c.p.s. for the luciferase construct versus a background
lower than 100 c.p.s. Luminescence was entirely dependent on the presence of
luciferin and was proportional to the perfused luciferin concentration between
20 and 200 µM.
Mitochondrial morphology was assessed by using a cDNA encoding
mitochondrial matrix-targeted DsRed (mtDsRed). Cells were seeded onto 24-mm-
diameter coverslips (thickness between 0.16–0.19mm) (Thermo Scientific) and
24 h later cells were transfected with 2 µg mtDSred (Lipofectamine LTX reagent;
Invitrogen). mtDsRed expression was assessed 36 h later. All of the acquisitions
were performed with a confocal Nikon Eclipse Ti system and fluorescent images
were captured by using NisElements 3.2.
Lipid peroxidation based on MDA detection was assayed in xenograft samples
following the manufacturer’s instructions (MAK085 Sigma-Aldrich).
ROS production was determined by Mitosox and DCF staining as
previously described62.
Histopathological analysis. After euthanasia, histological evaluation of a
haematoxylin and eosin (H&E)-stained section from formalin-fixed paraffin-
embedded tissues of the following organs was performed: prostate gland, lymph
nodes, long bones from lower limbs and other solid organs such as lungs and liver.
Following the consensus reported previously63, prostate gland alterations were
classified into four categories: gland within normal limits; high-grade prostatic
intraepithelial neoplasia (HGPIN); HGPIN with focal micro-invasion; and invasive
carcinoma. Lymphovascular invasion was assessed in all cases wheremicro-invasion
foci or invasive carcinoma were observed.
Lymph node metastasis and the presence of groups of PCa cells in bone marrow
were determined after haematoxylin–eosin (H&E) staining (lymph nodes) and
immunohistochemical identification of cytokeratin (CK) and androgen receptor
(AR)-expressing cells using a panCK rabbit polyclonal antibody (Dako) and AR
rabbit polyclonal antibody (Santa Cruz Biotechnology, sc-816) (lymph nodes and
bone marrow). In the case of bone marrow, cases were classified as ‘dissemination
negative’ when none or few scattered (fewer than five) CK-expressing cells were
identified and ‘dissemination positive’ when more than five or small groups of these
cells were observed.
To assess the inflammatory component in the prostate tissues we performed a
semiquantitative analysis in the glandular and the stromal areas separately for each
of the specimens. We first determined the type of inflammatory cell present in each
tissue compartment: polymorphonuclear neutrophils versus lympho-plasmacytic
infiltrates. Then we performed a quantification of these cells using the following
score system: 0—no inflammatory cells, 1—few cells, 2—moderate amount of cells
and 3—high amount of cells. Scores in between were also determined as 0.5, 1.5 and
2.5. If both types of cell were present in one compartment, we chose the highest as
the final score.
Proliferation was assessed in paraffin-embedded xenografts samples by
using Ki67 antibody (MA5-14520, Thermo Scientific). Microvessel density
was determined and quantified in GEMMs and xenograft samples by the
immunodetection of CD31 (rabbit anti-CD31; Ref. ab28364 Abcam).
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Metabolomics. Liquid-chromatography high-resolution mass spectrometry
(LC–HRMS) metabolomics and stable isotope 13C–U6-glucose labelling was
performed as reported previously64–66. Briefly, for LC–HRMS metabolomics,
PC3 TRIPZ–HA–Flag–Pgc1a cells treated or untreated for 72 h with 0.5 µgml−1
doxycycline were plated at 500,000 cells per well in 6-well plates, and grown
maintaining the doxycycline regime for 42 h before collection. For stable isotope
13C–U6-glucose labelling experiments, 24 h after seeding cells were washed and
exposed to media with serum, without glucose and pyruvate and supplemented
2mM 13C–U6-glucose. After a further 16 h, cells were washed and another
13C–U6-glucose pulse was performed for 2 h before collection.
Transcriptomic analysis. For transcriptomic analysis in PC3 TRIPZ–HA–Flag–
Pgc1α cells, the Illumina whole-genome -HumanHT-12_V4.0 (DirHyb, nt) method
was used as reported previously67.
Promoter enrichment analysis was assessed with the Transcription Factors
(TFs) data set from MSigDB (The Molecular Signature Database; http://www.
broadinstitute.org/gsea/msigdb/collections.jsp). TheTFs data set contains genes that
share a transcription factor-binding site defined in the TRANSFAC (version 7.4,
http://www.gene-regulation.com) database. Each of these gene sets was annotated
by a TRANSFAC record. A hypergeometric test was used to detect enriched data
set categories.
The GSEA was performed using the GenePattern web tool from the Broad
Institute (http://genepattern.broadinstitute.org). The list of PGC1α-upregulated
genes ranked by their fold change was uploaded and analysed against a list of ERRα
target genes46. The number of permutations carried out was 1,000 and the threshold
was 0.05.
Bioinformatic analysis. For database normalization, all of the data sets used for the
data mining analysis were downloaded from GEO, and subjected to background
correction, log2 transformation and quartile normalization. In the case of using a
pre-processed data set, this normalization was reviewed and corrected if required.
Frequency of alteration of metabolic co-regulators (Fig. 1 and Supplementary
Fig. 1A): expression levels of the selected co-regulators were obtained from the
data set reported by Taylor et al.22. A matrix containing signal values and clinical
information was prepared to ascertain the up- or downregulation.We computed the
relative expression of an individual gene and tumour to the expression distribution
in a reference population (patients without prostate tumour or metastasis). The
returned value indicates the number of standard deviations away from the mean
of expression in the reference population (Z-score). Using a fold change of +2 and
−2 as a threshold, we determined the number of samples from the cancer data set
that were up- or downregulated. P values were calculated by comparing the means
of normal of cancerous biopsies.
For quartile analysis in disease-free survival, patients’ biopsies from primary
tumours were organized into four quartiles according to the expression of the gene
of interest in two data sets. The recurrence of the disease was selected as the event
of interest. The Kaplan–Meier estimator was used to perform the test as it takes into
account right-censoring, which occurs if a patient withdraws from a study. On the
plot, small vertical tick marks indicate losses, where a patient’s survival time has
been right-censored. With this estimator we obtained a survival curve, a graphical
representation of the occurrence of the event in the different groups, and a P value
that estimates the statistical power of the differences observed.
For PGC1A genomic analysis, data from prostate cancer patients with copy
number alteration information in Taylor22, Grasso21 and Robinson25 et al. data sets
were extracted from cbioportal.org. Percentage of shallow deletions of primary
tumours and metastatic patients was calculated separately.
For correlation analysis, the Pearson correlation test was applied to analyse
the relationship between paired genes. From this analysis, Pearson’s coefficient (R)
indicates the existing linear correlation (dependence) between two variables X and
Y , giving a value between +1 and −1 (both included), where 1 is total positive
correlation, 0 is no correlation, and −1 is total negative correlation. The P value
indicates the significance of this R coefficient.
Statistics and reproducibility. No statistical method was used to predetermine
sample size. The experiments were not randomized. The investigators were
not blinded to allocation during experiments and outcome assessment. Unless
otherwise stated, data analysed by parametric tests are represented by the mean
± s.e.m. of pooled experiments and median ± interquartile range for experiments
analysed by non-parametric tests. n values represent the number of independent
experiments performed, the number of individual mice or patient specimens.
For each independent in vitro experiment, at least three technical replicates were
used (exceptions: in western blot analysis technical replicates are presented, in
untargetedmetabolomics two technical replicates were used and for 13C–U6-glucose
isotope labelling one technical replicate was used) and a minimum number of
three experiments were performed to ensure adequate statistical power. For data
mining analysis, ANOVA test was used for multi-component comparisons and
Student’s t-test for two component comparisons. In the in vitro experiments, normal
distribution was confirmed or assumed (for n<5) and Student’s t-test was applied
for two-component comparisons. For in vivo experiments, aswell as for experimental
analysis of human biopsies (from Basurto University Hospital) a non-parametric
Mann–Whitney exact test was used, without using approximate algorithms to avoid
different outcomes of statistics packages68. To this end, we applied the formulae
described69 for small-sized groups and Graphpad Prism for large-sized groups. In
the statistical analyses involving fold changes, unequal variances were assumed.
For contingency analysis, Fisher’s exact test was used for two-group comparison
(metastasis incidence) and Chi Square when analysing more than two groups
(analysis of PGC1α–ERRα signature frequency in PCa human specimens). The
confidence level used for all the statistical analyses was of 95% (alpha value= 0.05).
Two-tailed statistical analysis was applied for experimental design without predicted
result, and one-tail for validation or hypothesis-driven experiments.
Accession numbers and data sets. Primary accessions: the transcriptomic data
generated in this publication have been deposited in NCBI’s Gene Expression
Omnibus and are accessible through GEO Series accession number GSE75193.
Referenced accessions: Grasso et al.21, GEO: GSE35988; Lapointe et al.18,
GEO: GSE3933; Taylor et al.22, GEO: GSE21032; Tomlins et al.23, GEO: GSE6099;
Varambally et al.25, GEO: GSE3325.
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Supplementary Figure 1 A, Expression of 23 metabolic co-regulators in 
Taylor1 dataset (N: normal; PCa: prostate cancer). B, Expression of 7 
metabolic co-regulators from figure 1a in four additional prostate cancer 
datasets (N: normal; PCa: prostate cancer). In Varambally2 dataset gene 
expression levels are presented in Log2. In Tomlins3, Grasso4 and Lapointe5 
datasets gene expression levels are presented in median centred Log2. C-D, 
Association of PGC1A expression with Gleason score in TCGA provisional 
data6,7 (C) and Taylor1 datasets (D). E, Analysis of PGC1A expression 
in benign prostatic hyperplasia (BPH) and PCa specimens from Basurto 
University Hospital cohort (qRTPCR, BPH n= 14 patient specimens and 
Cancer n=16 patient specimens). F, PGC1A expression in normal prostate 
(N), primary tumour (PT) and metastatic (Met) specimens in Grasso 
dataset4. Points outlined by circles indicate statistical outliers (A, C, D and 
F). Error bars represent minimum and maximum values (A, B, C, D and F) or 
median with interquartile range (E). Statistic test: two-tailed Student T test 
(A, B), two-tailed Mann Whitney U test (E) and ANOVA (C, D and F).
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Supplementary Figure 2 A, Analysis of Pten and Pgc1a gene expression 
in GEMMs of the indicated genotype (Ptenwt Pgc1awt n=3 mice; Pten pc-/- 
Pgc1apc+/+ n=7 mice; Ptenpc+/+ Pgc1apc-/- n=6 mice; Ptenpc-/- Pgc1apc-/- 
n=12 mice; data is normalized to Gapdh expression). B, Age comparison 
between experimental cohorts (n as in Figure 2d). C, Quantification 
of prostate tissue with histological vascular invasion signs in Pten KO 
(2 mice) and DKO mice (9 mice) (limited to mice with invasive signs). 
D, Histological analysis of inflammatory signs (stromal and glandular 
infiltration) in Pten KO and DKO mice (Pten KO, n=7 mice; DKO, n=12 
mice). E Quantification of Vefga mRNA expression in Pten KO and DKO 
mice (Pten KO, n=7 mice; DKO, n=6 mice; data is normalized to Gapdh 
expression). F, Quantification of microvessel density (MVD) (dot plot, 
left panels) and representative images of CD31 immunodetection (right 
panels) in Pten KO and DKO mice (Pten KO, n=3 mice; DKO, n=5 mice). G, 
Representative haematoxylin and eosin staining depicting liver metastasis 
in DKO (bar=500µm). H, Incidence of small groups of Pan-cytokeratin 
(Pan-CK) positive cells in the lymph nodes of Pten KO mice (6 mice). I-J, 
representative immunohistochemical detection (200X) of Pan-CK positive 
cells in the bone marrow (BM) of Pten KO and DKO (I) and androgen 
receptor (AR) in the bone marrow of DKO (J) (bar=100µm). Pink arrows 
indicate immunoreactive cells. K, Quantification of BM dissemination 
frequency (Pten KO, 6 mice; DKO, 8 mice). L-M, Histopathological 
characterization of the prostate tissue (L) and frequency of vascular 
invasion signs (M, only in mice with invasion signs) in Ptenpc-/-, Pgc1apc+/- 
mice (3 mice). N, Frequency of metastatic lesions in lymph nodes (LN), 
liver and lung of Ptenpc-/-, Pgc1apc+/- mice (3 mice). O, Correlation between 
PGC1A and PTEN gene expression in prostate cancer specimens (left panel) 
and the association of PTEN genomic loss to PGC1A gene expression (right 
panel), in TCGA provisional dataset. pc, prostate-specific allelic changes; 
+, Wildtype allele; -, deleted allele; wt: any given genotype resulting in the 
lack of deletion of Pgc1a and Pten alleles. Pten KO = Ptenpc-/-, Pgc1apc+/+; 
DKO = Ptenpc-/-, Pgc1apc-/-. Stdv: standard deviation of the mean. All error 
bars represent median with interquartile range. p = p-value. a.u: arbitrary 
units. Statistic tests: one-tailed Mann-Whitney U test (A, B), two-tailed 
Mann-Whitney U test (D, E and F); ANOVA (O, right panel); Pearson´s 
coefficient (O, left panel). *p < 0.05, ***p < 0.001. 
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Supplementary Figure 3 A, mRNA expression of PGC1A, ACO2 and HADHA 
by qRTPCR in PC3 cells transduced with scramble shRNA (shSC) or PGC1A-
targeting shRNA (shPGC1A) (n=3). B, PGC1A expression in normal (N, 
n=29), primary tumour (PT, n=131), metastasis (Met, n=19) specimens 
and metastatic cell lines. Data is shown as Log2 mRNA expression. C, 
Densitometry of PGC1α protein expression in MeWo (endogenous) and 
PC3 TRIPZ-HA-Pgc1α (ectopic) cell lines, relative to β-Actin (n=3, 
independent experiments). D, Effect of Pgc1α induction (+Dox) on ACO2 
mRNA expression in PC3 (n=4, independent experiments), DU145 (n=7, 
independent experiments) and LnCaP cells (n=3, independent experiments). 
E-F, Effect of Pgc1α expression on anchorage-independent growth (E, n=3, 
independent experiments) and BrdU incorporation (F, n=3, independent 
experiments) in DU145 cells. G, Effect of Pgc1α expression on cell cycle 
progression in PC3 cells (n=4, independent experiments). H, Effect of 
doxycycline treatment (0.5µg/ml) on cell growth of non-transduced PC3 
cells (n=3, independent experiments). I-J, Pgc1α protein expression and 
cell proliferation by Ki67 immunoreactivity in xenograft samples from Fig. 
3f (- Dox n=14 tumours, + Dox n=6 tumours). K, mRNA expression of ACO2 
and HADHA in xenograft samples from Fig. 3f. (- Dox n=9 tumours, + Dox 
n=6 tumours). L-M, Analysis of VEFGA mRNA expression upon Pgc1α 
induction in PC3 cells (L, n=4, independent experiments) and xenograft 
samples (M, - Dox n=9 tumours and + Dox n=6 tumours). N, Quantification 
of microvessel density (MVD) in xenograft samples (- Dox n=9 tumours 
and + Dox n=7 tumours). Right panels show representative CD31 staining 
micrographs. Error bars indicate s.e.m (A, C, D, E, F, G, H, L) and median 
with interquartile range (J, K, M, N). Statistic tests: two-tailed Student T test 
(A, B, C, D, E, F, G, H, L) and one-tailed Mann-Whitney U test (J, K, M, N). 
*p < 0.05, **p < 0.01, ***p < 0.001.
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Supplementary Figure 4 A-B, Validation of the microarray by qRTPCR in 
DU145 (n=4, independent experiments) and LnCaP (n=3, independent 
experiments) TRIPZ-HA-Pgc1a cells. Gene expression values relative 
to - Dox cells are represented (reference - Dox gene expression values are 
indicated with a dotted line) C, mRNA expression of PGC1α target genes in 
doxycycline-treated (0.5µg/ml) non-transduced PC3 cells (n=3, independent 
experiments). Error bars represent s.e.m. Statistic test: One tail Student T 
test. *p < 0.05, **p < 0.01, ***p < 0.001.
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Supplementary Figure 5 A, Analysis of differential abundance in metabolites 
involved in fatty acid catabolism by untargeted LC-HRMS in DU145 
TRIPZ-HA-Pgc1α cells (n=4, independent experiments). B-C Evaluation 
of the dehydrogenation of 3H-palmitate (readout of β-oxidation) in DU145 
cells upon Pgc1α expression (B, n=3, independent experiments) and, 
in doxycycline-treated (0.5µg/ml) non-transduced PC3 cells (C, n=3, 
independent experiments). Values relative to - Dox cells are presented. D, 
Effect of Pgc1α expression on citrate abundance measured by LC-HRMS 
metabolomics in DU145 cells (n=4, independent experiments). E-F, ATP-
producing OCR (upon complex V inhibition by oligomycin injection) in 
PC3 (E, n=3, independent experiments) and DU145 (F, n=3, independent 
experiments) cells upon Pgc1α expression. G, Basal mitochondrial ATP 
production in DU145 cells upon Pgc1α expression (n=10, independent 
experiments). H-I, LC-HRMS quantification of ADP (H) and AMP (I) 
abundance in PC3 Pgc1α (n=4, independent experiments), DU145 Pgc1α 
(n=4, independent experiments), xenografts (- Dox n=8 tumours; + Dox n=4 
tumours) and GEMMs (Pten KO n=3 mice; DKO n=5 mice). J, Quantification 
of area under the curve (AUC, relative to - Dox) of Palmitate labelling from 
13C-U6-Glucose in PC3 TRIPZ-HA-Pgc1α cells (data related to Fig. 5j, 
n=3, independent experiments). K, Determination of extracellular lactate 
in PC3 TRIPZ-HA-Pgc1α cells (n=3, independent experiments). L-M, 
Lactate production (L) and OCR (M) in doxycycline-treated (0.5µg/ml) non-
transduced PC3 cells (n=3, independent experiments). Error bars represent 
s.e.m., except xenograft and GEMM data in H-I, that represent median 
with interquartile range. Statistic tests: two tailed Student T test (A, B, C, 
D, E, F, G, H (PC3 and DU145), I (PC3 and DU145), J, K, L, M) and one 
tailed Mann Whitney U test (H (Xenografts and GEMMs), I (Xenografts and 
GEMMs)). *p < 0.05, **p < 0.01, ***p < 0.001.
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Supplementary Figure 6 A, Analysis of mitochondrial morphology 
(mitochondrial volume) in PC3 cells upon Pgc1α expression (n=5, 
independent experiments). B, Expression of PGC1αWT and PGC1αL2L3M 
in PC3 cells after treatment with 0.5 μg/ml doxycycline (Dox) (a 
representative experiment with technical replicates is presented, similar 
results were obtained in three independent experiments). C, Basal 
mitochondrial ATP production in PGC1αWT and PGC1αL2L3M PC3 cells 
(n=11, independent experiments). D, Expression of Pgc1α and ERRα 
in doxycycline-treated PC3 TRIPZ-HA-Pgc1α cells transduced with sh-
scramble (shSC) or shERRα (a representative experiment with technical 
replicates is presented, similar results were obtained in three independent 
experiments). E, mRNA expression of PGC1α target genes in doxycycline-
treated PC3 TRIPZ-HA-Pgc1α cells transduced with shSC or shERRα 
(n=4 for ACAT1 and n=5 for IDH3A, ATP1B1, ISCU, GOT1 and ACADM; 
independent experiments). F-I, mRNA expression of PGC1α target genes (F, 
n=3 for ACAT1 and n=4 for ATP1B1 and IDH3A; independent experiments), 
cell number (G, n=4, independent experiments), basal oxygen consumption 
(H, n=3, independent experiments) and basal mitochondrial ATP production 
(I, n= 7 for - Dox + XCT790; n=8 the rest; independent experiments) in 
vehicle (Veh) or XCT790-treated Pgc1α-inducible PC3 cells. J, Evaluation 
of cellular (DCF) and mitochondrial-specific (Mitosox) ROS production in 
Pgc1α-expressing PC3 (left panel; n=4, independent experiments) and 
DU145 (right panel; n=6, independent experiments) cells. K, Evaluation 
of lipid peroxidation in xenograft tissues from Fig. 3f (- Dox n=4 tumours; 
+ Dox n=5 tumours). L, Effect of the indicated antioxidant treatments 
on cell number (relative to day 0) of Pgc1α-expressing PC3 cells (n=3, 
independent experiments). DCF: 2’,7’-dichlorodihydrofluorescein. n.s.: not 
significant. Error bars represent s.e.m. (A, C, E, F, G, H, I, J, L) or median 
with interquartile range (K). Statistic tests: two tailed Student T test (A, C, 
E, F, G, H, I, J, L) or one tailed Student T test (comparison between + Dox 
conditions in C, E, F, G, H, I) and two tailed Mann-Whitney U test (K). */$ 
p < 0.05, **/$$ p < 0.01, ***/$$$ p < 0.001. Asterisks indicate statistic 
between - Dox and + Dox conditions (unless represented otherwise) and 
dollar symbol between either, vehicle (Veh) and XCT790-treated Pgc1α-
expressing cells, shSC and shERRa-transduced Pgc1α-expressing cells or 
Pgc1αWT and Pgc1αL2L3M.
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Supplementary Figure 7 A-B, Representation of the average signal of genes 
within the PGC1α-upregulated gene set (A) (Fig. 7b, blue circle) and within 
the PGC1α-dependent ERRα-upregulated gene set (B) (Fig. 7b, yellow 
circle, Table S6) in the indicated datasets1,4,6,7, in normal (N; Taylor n=29 
and Grasso n=12), primary tumours (PT; Taylor n=131 and Grasso n=49) 
and metastasis (Mets; Taylor n=19 and Grasso n=27). C, qRTPCR mRNA 
expression analysis of PGC1α target genes from C, in benign prostatic 
hyperplasia (BPH) and PCa specimens from Basurto University Hospital 
cohort (BPH n=14 patient specimens; Prostate cancer n=16 patient 
specimens). D, Expression of the indicated genes (from Supplementary Table 
7) in different disease states (N: normal, Lapointe n=9, Taylor n=29 and 
Grasso n=12; PT: primary tumour, Lapointe n= 13, Taylor n=131 and Grasso 
n=49; Met: metastasis, Lapointe n=4, Taylor n=19 and Grasso n=27) in 
three PCa datasets1,4,5. E, Representation of “PGC1α-ERRα Q1 signature” 
frequency within different tumour types (N: normal; PT: primary tumour; 
Met: metastasis) in two datasets1,4 (Taylor: N, n=29; PT, n= 131; Met, n=19; 
Grasso: N, n=12; PT, n=49; Met, n=27). Error bars represent s.e.m. (A, B), 
median with interquartile range (C) and maximum and minimum (D). Statistic 
tests: Statistic tests: ANOVA (A, B, D); two tailed Student T test (A, B), one 
tailed Mann Whitney U test (C), Chi Square (E). Asterisks in A, B indicates 
statistics between normal and metastasis and hash between primary tumours 
and metastasis. p: p-value. */# p < 0.05, **/## p < 0.01, ***p < 0.001.
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Supplementary Figure 8 Unprocessed blots. A, Western blot 
corresponding to Figure 3a. B, Western blot corresponding to Figure 
3b. C, Western blot corresponding to Supplementary Figure 3I. D, 
Western blot corresponding to Supplementary Figure 6B. E, Western blot 
corresponding to Supplementary Figure 6D. Precision Plus Protein™ 
Dual Color Standards (Ref #1610374) markers was used in A-D. Pink 
Pre-stained protein ladder, Nippon Genetics, Cat.No. MWP02, was 
used in E.
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Table titles and legends
Supplementary Table 1 Gene expression profiling in PC3 TRIPZ-HA-Pgc1α cells (Doxycycline vs. No Doxycycline, (0.5µg/ml). 
Supplementary Table 2 Untargeted LC-HRMS metabolomic profiling in PC3 TRIPZ-HA-Pgc1α cells (Doxycycline vs. No Doxycycline, (0.5µg/ml).
Supplementary Table 3 Untargeted LC-HRMS metabolomic profiling in DU145 TRIPZ-HA-Pgc1α cells (Doxycycline vs. No Doxycycline, (0.5µg/ml).
Supplementary Table 4 Untargeted LC-HRMS metabolomic profiling in xenograft-derived tissues (from PC3 TRIPZ-HA-Pgc1α cells) upon induction of Pgc1α 
expression (Doxycycline diet vs. chow). 
Supplementary Table 5 Untargeted LC-HRMS metabolomic profiling in GEMM-derived prostate tissues (Ptenpc-/-, Pgc1apc-/- vs. Ptenpc-/- , Pgc1apc+/+). 
Supplementary Table 6 Definition of ERRα signature within the PGC1α gene list. Genes included in the TGACCTY_V$ERR1_Q2 dataset or identified in the 
study by Stein et al (STEIN_ESRRA_TARGETS8) were considered as ERRα targets. 
Supplementary Table 7 List of Pgc1α-regulated genes in PC3 (Supplementary Table 1) that show significant and consistent correlation with PGC1A in human 
prostate cancer datasets (R>0.2; p<0.05) in at least three out five datasets.
Supplementary Table 8 List of primers and probes (Universal Probe Library, Roche) used in qRTPCR.
Supplementary Table 9 Statistics source data for animal experiments reported in Fig. 3k, and Fig. 6e, h. All data are organized into different sheets and 
named based on the corresponding figure/panel numbers.
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